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ABSTRACT
The safe and timely introduction of milk feeding is a fundamental part of neonatal care for
preterm and low birth weight infants. Yet enteral feeding in such infants presents significant
challenges for the neonatologist. Data from randomised controlled trials are sparse and there
is limited evidence to guide clinical practice. Opinion about optimum feeding regimens
varies considerably and this variation in opinion is likely to be reflected in similar variation
in clinical practice. Different approaches to feeding appear to carry different risks and
benefits and serious adverse clinical outcomes may accompany extremes of practice in this
area.
Much of the uncertainty around practice in enteral feeding has been engendered by
inconsistent results from research studies. Most studies have centred upon necrotising
enterocolitis (NEC), a serious and devastating bowel disease that primarily affects preterm
infants. Mortality from NEC is high. The aetiology of the condition remains elusive and is
likely to be multifactorial, but early and rapid enteral feeding has been implicated. In
contrast, delayed feeding necessitating prolonged use of central venous catheters and
parenteral nutrition may increase susceptibility of preterm infants to severe systemic
infection. The potential role of enteral feeding in the development ofNEC is of great interest
because unlike many other factors, it is amenable to change. However, only through well-
designed trials of different practice will optimum strategies for feeding in high-risk infants
begin to emerge. The design of acceptable and feasible clinical trials that fall within the
known margins of safety is challenging. As studies of neonatal feeding practice would
probably need to take place on an international basis to provide sufficient numbers of
outcomes, disparities in practice between different countries may serve only to increase this
challenge. An understanding of the variation in practice, the factors influencing this variation
and the effects on feed-related outcomes is necessary to inform further research.
There have been few recent detailed reports relating to opinions about feeding of preterm
infants. No previous study has explored the relationship between available research
evidence, clinician opinion and clinical practice. The subject of this thesis is a two-part
observational study, conducted in the United Kingdom (UK) and Canada. A questionnaire
survey sent to neonatal clinicians sought to investigate current opinion and reported practice
with respect to enteral feeding of infants born at less than 30 weeks of gestation and/or
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1501 g birth weight in the UK and Canada. This survey was complemented by a detailed
retrospective review of the medical and nursing records of infants admitted to fifteen UK and
three Canadian neonatal units. Opinions of neonatal clinicians were described and factors
influencing feed-related decisions were explored. Analysis of infant feeding data allowed
comparison and contrasting of different practices and exploration of short-term neonatal
outcomes that may be related to or influenced by variation in practice.
Questionnaire responses of 302 clinicians and feeding data from 670 infants were analysed.
The results of the study confirmed wide variation both in opinion and in clinical practice
across almost all aspects of enteral feeding. This was evident between and within neonatal
units and between the two countries. Reported availability and clinicians' awareness of
written guidelines to assist in decision-making were also extremely variable. The study
demonstrated that a large number of factors appear to influence feeding practice, but that
these, too, differ between countries. The most consistent influence affecting the advancement
of enteral feeds was the presence of signs consistent with actual or suspected intra-abdominal
pathology such as NEC. Occurrence of proven NEC and associated mortality were within
previously reported ranges.
The effects of variation on necrotising enterocolitis and other important clinical outcomes
are not known. Important gaps in knowledge remain with respect to the rate of feed
advancement and the relationship between therapeutic interventions and NEC. Further
research is required and should be directed towards defining optimum feeding strategies that
maximise benefits in terms of growth and neurodevelopment, whilst minimising morbidity
and mortality associated with NEC and infection.
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Enteral feeding of preterm and very low birth weight infants presents significant challenges
for neonatologists. Current opinion about optimum feeding regimens varies considerably.
Sources of variation are many: timing of introduction of milk feeds, type of milk used, rate
of progression to full milk feeds, frequency of feeds; feeding by bolus or continuous
methods, the use of minimal enteral feeding regimens and management of feed intolerance.
It is therefore highly likely that this variation in opinion is reflected in equally wide variation
in clinical practice, both between and within neonatal units (NNUs) worldwide.
In clinical decision-making about preterm infant feeding, there are many factors to consider.
Different approaches to feeding appear to carry different risks and benefits and careful
evaluation of these is required. Serious but conflicting clinical risks may accompany
extremes of practice in this area.
Much of the uncertainty around optimal methods of feeding has been engendered by
inconsistent results from research studies. Most studies to date have centred upon necrotising
enterocolitis (NEC), a serious and life-threatening bowel disease that primarily affects
preterm infants. The potential influence of the timing of introduction and advancement of
enteral feeds in the development of this disease is a major concern for clinicians in
neonatology. However, recruitment of infants is often a challenge for interventional research
studies in neonatal medicine, due to the difficulties of approaching parents for consent at a
very stressful time and the relatively small numbers of preterm infants. Although there is
now a substantial amount of published work on the subject of enteral feeding, much of this
was carried out a considerable number of years ago. This, together with small numbers of
subjects, makes results difficult to interpret. In addition, many of the interventional and
epidemiological studies have been carried out in North America, where data from larger
numbers of infants are available than in the United Kingdom (UK). Many British clinicians
have regarded these studies as having little relevance for them since some study
interventions have borne little resemblance to current UK trends in practice.
A pilot survey of feeding practice conducted in Scottish NNUs was the subject of Dr Elaine
Boyle's dissertation for a MSc in Epidemiology' 2 and confirmed wide inter-unit variation in
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both opinion and practice of clinicians in the feeding of infants born between 23 and 32
weeks of gestation. It was not large or detailed enough to explore the relationships between
feeding practices and important outcomes such as the incidence of NEC and the occurrence
of catheter related sepsis.
Optimum strategies for feeding in high-risk infants can only be identified from the results of
well-designed trials of different practice. However, given the current disparities in practice, it
is challenging to design trial protocols that will be acceptable to large numbers of clinicians
and feasible to carry out, that fall within the known margins of safety and that examine the
most appropriate major outcomes. Large international multicentre trials usually yield more
reliable and generalisable results than small, single-centre studies. However, as studies of
neonatal feeding practice would probably need to take place on an international basis to
provide sufficient numbers of outcomes the variation in clinical practice in different
countries of the world will make the study design and feasibility even more challenging.
This observational study, carried out in NNUs in the UK and Canada, aimed to examine the
evidence base for early enteral feeding of preterm and low birth weight infants. In the light
of this published literature, it aimed to describe opinions of neonatologists with regard to
enteral feeding, document the approaches used, identify any extremes of practice and
consider how short-term nutritional outcomes and the occurrence of NEC relate to this
practice.
1.1 Hypothesis
It was anticipated that this survey would demonstrate very limited availability of written
feeding guidelines and wide variation in many aspects of feeding practice in neonatal units in
the UK. A further specific hypothesis was that enteral feeds would be introduced later and
advanced more slowly in Canadian neonatal units than UK units.
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CHAPTER 2
AIMS AND OBJECTIVES OF THE RESEARCH
2.1 General Aims
To describe the variation in opinion and clinical practice in UK and Canadian NNUs with
respect to the enteral feeding of preterm and very low birth weight infants and to assess the
relationship between feeding interventions and important short-term outcomes, with
particular reference to NEC, in order to inform subsequent trials.
2.2 Specific Objectives
1. To determine factors that influence UK and Canadian clinicians' decision-making
with respect to the initiation, progression and discontinuation of enteral feeds in
infants who are born at less than 30 weeks of gestational age or with a birth weight
of less than 1501 grams.
2. To describe clinical practice in UK and Canadian NNUs with respect to enteral
feeding in infants who are born at less than 30 weeks of gestational age or with a
birth weight of less than 1501 grams.
3. To explore the relationships between different approaches to enteral feeding, short-
term nutritional outcomes and NEC in infants who are born at less than 30 weeks of
gestational age or with a birth weight of less than 1501 grams.
4. To identify areas of practice worthy of further investigation.
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CHAPTER 3
BACKGROUND AND REVIEW OF THE LITERATURE
The aim of this literature review is to summarise the available background knowledge related
to enteral feeding of preterm infants and the benefits and risks, associated with feeding
practice in the clinical setting. In view of the large number of themes of interest and
relevance to this area of clinical practice, a comprehensive systematic review of the literature
in each of these domains is beyond the scope of this thesis. The following review is therefore
a careful review of the published literature describing research into feeding practice in
preterm neonates and its associated complications, primarily NEC. Literature searches for all
sections were carried out using Medline for the years 1966 to the present date via Pub-Med.
Search terms used were "infant, premature", "infant, newborn" "infant feeding", "enteral
nutrition", "breastfeeding", "human milk", "breast milk", "human milk fortifier"
"enterocolitis, necrotizing", "gastro-oesophageal reflux", "feed advancement", "feed
interval", "preterm formula", "feed intolerance", "patent ductus arteriosus", "blood
transfusion" and "indomethacin". Searches were limited to "human" and to the age range
"newborn; birth to one month" and to literature published in the English language. Titles of
all references retrieved were reviewed and the relevant papers examined. Additional
references were identified from reference lists of these papers.
3.1 Pathophysiology of NEC
Despite extensive basic science and clinical research over many years, the pathogenesis of
NEC remains poorly understood. The disease is predominantly one of newborn infants and
produces severe necrosis of the intestine. NEC has not been described in stillborn infants3
and therefore it is presumed that at least some factors leading to development of the disease
are acquired after birth. The newborn gut, and in particular the preterm gut, appears to be
susceptible to a number of important pathogenic mechanisms that have been proposed as
important factors involved in the development of the pathological features of NEC.
However, the complex events predisposing infants to NEC are thought to be multifactorial
and have not yet been clearly defined.
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3.1.1 Role of hypoxia-ischaemia
Ischaemia of the gut has long been implicated in the development ofNEC. Histopathology of
resected portions of gut from infants with the disease demonstrates coagulative necrosis, a
feature of ischaemic damage. Early epidemiological studies ofNEC noted a higher incidence
of the disease in mature infants suffering a significant perinatal asphyxial insult4"6. These
findings led to the hypothesis that asphyxia in such neonates produces the "diving reflex",
which describes redistribution of blood flow to the brain and heart, leaving the intestine and
other organs relatively hypoxic. This was thought plausible, in that the most common site for
NEC in the bowel is the ileocolic region, which is situated at a distance from the superior
mesenteric artery, from which it receives its blood supply via smaller branches. NEC in term
infants tends to develop early in life, supporting the hypothesis that hypoxia-ischaemia may
play a primary role; however, other clinical studies have failed to show an association
between asphyxia and NEC3 7 8. Many animal models ofNEC have been developed based on
this concept of ischaemic aetiology and are currently used despite the conflicting evidence9.
In preterm infants, the disease develops later, suggesting that there may be a different
mechanism for the ischaemic changes seen. Although it is accepted that ischaemia has a role
in the pathogenesis ofNEC, it is not thought to be the primary factor promoting disease.
3.1.2 The immature intestinal circulation
Regulation of the intestinal circulation depends on the peptide, endothelin-1 (ET-1), which
has a vasoconstrictor effect10, and on nitric oxide (NO), a vasodilator". Intestinal production
ofNO develops in utero in response to nitric oxide synthase, produced by the endothelium;
production increases in the postnatal period promoting vasodilatation to cope with the large
blood flow demands of the maturing newborn intestine. Thus, any endothelial damage may
disrupt this process, leading to reduction in blood flow and tissue oxygenation. Studies have
shown that premature neonates with NEC have decreased activity of nitric oxide synthase,
supporting the hypothesis that disturbance in this mechanism may, at least in part, be
involved in the development ofNEC12.
ET-1 has also been linked to NEC where an ischaemic insult has been followed by
reperfusion13. In this situation, constriction of the intestinal vessels was observed in the gut
of immature, but not older individuals. In a study that used a neonatal rat model, animals
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were exposed to artificial milk feeding, hypothermia and hypoxia, factors that have been
associated with NEC. This produced a reduction in gut blood flow which was greater in rat
pups that developed NEC14.
3.1.3 Immaturity of intestinal barrier function
One of the most important functions of the intestinal epithelium is to provide a barrier
between the gut lumen and the rest of the body. The mature gut uses a number of defence
systems, both physical and chemical, to protect it from effects of potentially damaging
antigens and colonisation with pathogenic bacteria.
Multiple components contribute to the physical barrier. Tight junctions between intestinal
cells help to form a mechanical barrier and production of mucus from goblet cells provides
further protection. Effective peristaltic propulsion of gut contents avoids stasis and
overgrowth of bacterial pathogens. All these systems are immature, even in term infants and
correspondingly more so in the preterm neonate, making them particularly vulnerable to gut
pathology. Studies have shown that gut permeability is increased in preterm infants during
the first two days of life, which may render the gut susceptible to damage from pathogenic
bacteria or other injurious insults, although permeability decreases by six days of life15.
Increased permeability is more obvious in infants with NEC16. Epidermal growth factor
(EGF) is also important in the function of the intestinal barrier by enhancing proliferation of
intestinal epithelial cells in response to injury. Decreased levels of EGF have been noted in
preterm infants with NEC17.
Antimicrobial peptides, lysozyme and phospholipase A2 are secreted from Paneth cells in
the crypts of the intestinal wall. These contribute to the biochemical barrier of the gut by
regulating the presence and type of bacteria within the intestine18. Antimicrobial peptides
have antimicrobial activity against many different organisms, including bacteria, fungi and
viruses19 20. The role of these chemical defences in protection against NEC has not been fully
explored in preterm neonates.
It is likely that disruption of these normal protective mechanisms in the gut may predispose
to injury and that immature systems may be at greater risk from such damage, which may
lead to invasion of pathogenic bacteria with subsequent harmful inflammatory changes.
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3.1.4 Role of infection
An infective aetiology has been suggested for NEC and clinically, severe NEC is often
almost indistinguishable from overwhelming sepsis in the preterm neonate. The pathological
changes of NEC in the intestine only occur postnatally and it has not been identified in
stillborn infants, where the gut is sterile3. Although most cases are sporadic, outbreaks and
clusters of cases have been reported, in patterns typical of infectious diseases21"23. Although
many cultures taken from infants with NEC are negative for bacteria, organisms have been
isolated in blood and stool cultures, sometimes at times of outbreaks, lending further support
to this hypothesis24 25. Yet no specific organism has been consistently implicated in the
pathogenesis of NEC and the majority of cases do not occur in clusters, making it unlikely
that NEC is primarily an infectious disease. However, some viral gastrointestinal illnesses
present with clinical signs that are difficult to differentiate from those of NEC suggesting
that, although the causes may be different, the final pathway in the pathogenesis may be
similar in the two conditions26 27. Increased occurrence of gastrointestinal illness during
outbreaks ofNEC or NEC-like illness have been noted in overcrowded NNUs, which might
be more in keeping with a disease of viral aetiology28.
However, the likelihood that bacteria play an important role in the pathogenesis of NEC is
suggested by the finding of intestinal intramural gas, presumably caused by bacterial
fermentation, in many infants with the disease. Bacterial colonisation of the intestine in the
healthy neonate begins after birth and the gut may become colonised with both beneficial
and harmful bacteria. The process occurs in four phases and is influenced by a number of
factors including the mode of delivery and postnatal feeding. Infants delivered vaginally tend
to establish gut colonisation earlier than those delivered by caesarean section, due to
exposure to a range of bacteria within the vagina and on the perineum. In the first phase, the
predominant organisms found in the gut are those from the mother, such as streptococci and
coliform bacteria29. Thereafter, during establishment of milk feeds, anaerobic bacteria more
suited to the intestinal environment begin to emerge, including bifidobacteria, which are
found in higher numbers in breast fed infants than formula fed infants. Bifidobacteria
outnumber enterobacteria by around 7 days of age. As solid feeds are introduced, numbers of
Bacteroides increase and other organisms such as Clostridia and enterobacteria become more
evident. Changes in the gut flora of breast fed infants are more dramatic at the onset of
weaning than those in formula fed infants, since large numbers of aerobic bacteria and
bacteroides are seen earlier with formula feeding30. By one year of age, the gastrointestinal
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flora resembles that of adults. In very low birth weight infants, the pattern of gut colonisation
is somewhat different. Enterobacteria and streptococci continue to be the dominant
organisms for a longer time, with much smaller numbers of bifidobacteria emerging than in
term infants29. However, a recent study showed higher levels of bifidobacteria and
lactobacillus than had been seen previously and the authors speculate that this may have
been related to the early use of unpasteurised breast milk31. Within the context of abnormal
gut colonisation, the predominant organisms also tend to be virulent32 33. This phenomenon is
probably related to the intensive care environment, where the use of broad spectrum
antibiotics is common, nasogastric tubes form part of routine care, drugs affecting gastric
acidity are often administered and the introduction of enteral feeds tends to be delayed34.
Abnormal gut colonisation may therefore play a significant part in the pathogenesis ofNEC
and this is supported by a number of studies. Hoy et al examined 752 stool samples from 90
infants during a period when 7 definite episodes of NEC were identified35. All episodes
followed the introduction of nasogastric feeding; enterobacteria were isolated from the stools
of 4 cases before the onset of disease and 4 species of Clostridia were isolated from one. A
later study also noted the presence of Clostridia in 3 neonates who later developed NEC, but
no controls, leading them to suggest that early colonisation with this organism may
predispose to the disease36. Bjorkstrom et al found significantly increased cultures of
Klebsiella, Pseudomonas and Proteus in NEC cases than in infants without NEC31.
The mechanism by which abnormal gut colonisation may contribute to the pathogenesis of
NEC is not fully understood, but may be is related to the immaturity of the immune response
to bacteria.
3.1.5 Immunity and inflammation
Toll-like receptors (TLRs) are transmembrane proteins located on the surface of host defence
cells, which recognise pathogen-associated molecules including glycoproteins,
lipopolysaccharides and nucleic acids. TLRs are present in intestinal cells and this means
that they may be able to detect, within the lumen, components of bacteria such as
lipopolysaccharide within the bacterial cell wall, resulting in the activation of an
inflammatory cascade37. Immature intestinal cells exhibit an exaggerated inflammatory
response when this system is activated38.
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Platelet-activating factor (PAF) is a phospholipid inflammatory mediator. When given
experimentally to animals, it produces signs similar to those seen in infants with NEC and it
has been shown to produce extensive intestinal injury in a piglet model of NEC39. Levels of
PAF have been noted to be higher in preterm infants with NEC by a number of researchers
and levels may be indicative of severity of the disease40"42. PAF increases in the blood and
stools of infants affected by NEC and also in response to enteral feeding, which has been
suggested as an important factor in the development of the disease38. PAF acetylhydrolase
(PAF-AH), the enzyme that degrades PAF, is present at only low levels in newborn infants
during the first few weeks of life, which may increase susceptibility to the damaging actions
ofPAF4j. PAF-AH is present in breast milk, which is thought to be protective against NEC44.
Increased levels of inflammatory cytokines such as tumour necrosis factor-alpha (TNF-a),
interleukin (IL)-l and IL-6 have been seen in infants with NEC and may reflect severity of
disease42 45 46. Conversely, levels of anti-inflammatory mediators such as IL-10 are low in
preterm infants, indicating that there may be some loss of protection against inflammation in
this group47 48.
Many inflammatory and anti-inflammatory mechanisms are involved in the immune
response to bacterial insult. It appears that immaturity of these immune systems contributes
at different levels to render the preterm neonate susceptible to a variety of insults, which may
then lead to a pathway culminating in the pathological signs of NEC. The pathogenesis of
the disease is therefore likely to be related to a complex interplay between these mechanisms
that has yet to be fully elucidated.
3.1.6 Genetic predisposition to NEC
Increasingly, genetic variation is being identified as a major factor in predisposition of
individuals to disease states. A single change in the DNA code in a gene (single nucleotide
polymorphism (SNP)) can alter the expression and function of that gene. Although this effect
may be small, it may be sufficient to alter susceptibility to disease. There is a genetic
component to preterm birth itself. Black women are more likely to deliver prematurely than
white women; women who have had one preterm birth are more likely to deliver preterm
again and recurrent preterm birth is seen in different members of the same family.
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Researchers have therefore investigated genetic predisposition as a possible factor in the
occurrence of NEC in neonates. Since regulation of the circulation and inflammatory
responses are thought to be important in the development ofNEC, genetic variation, relating
to either of these systems, may make it more likely that an infant will develop the disease.
A recent study has investigated SNPs in the carbamoyl phosphate synthetase (CPS) 1 gene.
CPS regulates production of L-arginine, which is a precursor of nitric oxide (NO).
Deficiency in arginine may therefore be implicated in mucosal injury. This small case-
control study showed that there was an increasing linear trend in incidence of NEC with the
number of variant alleles in the CPS 1 gene49. The retrospective nature of the study and the
absence of data for other risk factors for the disease precluded further analysis to determine
whether this genetic variation is an independent risk factor for NEC.
Genes involved in the inflammatory process have been more extensively investigated,
although this type of research remains in its infancy. A recent study examined the influence
of SNPs in the pattern recognition receptors TLR4, CD 14 and caspase-recruitment domain
15 (CARD 15), all of which are involved in binding of lipopolysaccharide. However, they
found no association between genotype and prematurity, sepsis or NEC50. Nucleotide
oligomerization domain 2 (NOD2) is another pattern recognition receptor that has been
studied. CARD15/NOD2 is involved in the innate immune response and is expressed by
intestinal cells. Mutations have been associated with sepsis in VLBW infants51 and with
Crohn's disease52. However, it does not appear to be involved in the pathogenesis of NEC53.
A number of variations in cytokine encoding genes have been investigated, including TNFa,
IL-6 and IL-10. Most studies have shown only modest, if any association between genetic
variants and NEC and results have not been consistent between studies54"56.
Although results of studies investigating the role of genetic variation in NEC have been, for
the most part, negative, it is likely that this will continue as a rapidly expanding area of work
in the future and may provide additional insight into the pathogenesis of this disease.
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3.2 Clinical presentation and classification of NEC
Necrotising enterocolitis is certainly not a new disease entity. It is thought that it was
probably first described by Genersich in 1891 who wrote of a 45 hour old premature baby
who died within 24 hours following vomiting, abdominal distension and cyanosis57.
However, further and more detailed descriptions first began to emerge in the 1960s. Mizrahi,
in 1965, reported on 18 preterm neonates, bom between 1953 and 1963, who developed a
disease characterised by "necrotizing enteritis...with fibrinoid necrosis of the mucosa
(involving) the lower ileum or the ascending and transverse colon or both, with frequent
ulcerations, pseudomembranous inflammation, complicated at times by perforations and
pneumatosis"58. Of the 18 infants reported by Mizrahi, some went on to develop a "shock¬
like" state and of the whole group, only two infants survived.
In 1975, Santulli et al reported their experience of the disease in 64 infants over a period of
almost 20 years57. They concluded that there were different severities of the disease and that
the incidence of the most severe manifestation of the disease or "fully developed" disease
was "relatively low".
In 1978, Bell et al proposed a method of clinical staging based on clinical and radiological
criteria (Table 3.1) to indicate the severity of disease in infants at the time of diagnosis of
NEC59. This was in recognition of the fact that there appeared to be a very wide spectmm of
disease, ranging from the mild form to a very fulminant and rapidly progressive disease.
They derived this classification from a study involving 48 infants evaluated and treated for
NEC in 1974 and 1975. These infants were bom between 26 and 40 weeks of gestation
(mean 33 weeks). All ten infants with Stage I disease survived and they therefore felt that it
was more relevant to calculate the mortality for those with Stage II or Stage III disease; the
mortality that they believed could be ascribed to NEC was 6/38 (15%). It was unclear
whether those infants that were classified with Stage I disease had early NEC that responded
completely and rapidly to treatment, or whether they had never, in fact, had NEC. In
contrast, those with the most fulminant form of the disease responded poorly to treatment,
whether medical or surgical. The authors concluded that NEC should be treated early and
vigorously using medical therapies, reserving surgical intervention for those failing to
respond or with complications such as gut perforation.
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Clinicians and researchers have used Bell's staging criteria59 (Table 3.1), since it was first
proposed, to guide management, monitor the occurrence and standardise reporting of the
condition. One recognised modification to the staging system by Walsh et al, published in
1986 (Table 3.2), particularly distinguished infants in whom bowel perforation complicated
the disease60. This classification subdivides Bell's original categories and adds guidance on
appropriate treatment for each stage.
Table 3.1: NEC staging system based upon historical, clinical and
radiographic data59
Stage I a. Any one or more historical factors producing perinatal stress
(suspect) b. Systemic manifestations - temperature instability, lethargy, apnoea,
bradycardia
c. Gastrointestinal manifestations - poor feeding, increasing pre-gavage
residuals, emesis (may be bilious or test positive for occult blood), mild
abdominal distension, occult blood may be present in stool (no fissure)
d. Abdominal radiographs show distension with mild ileus
Stage II a. Any one or more historical factors
(definite) b. Above signs and symptoms plus persistent occult or gross gastrointestinal
bleeding; marked abdominal distension
c. Abdominal radiographs show significant intestinal distension with ileus;
small bowel separation (edema in bowel wall or peritoneal fluid),
unchanging or persistent "rigid" bowel loops, pneumatosis intestinalis,
portal vein gas.
Stage III a. Any one or more historical factors
(advanced) b. Above signs and symptoms plus deterioration of vital signs, evidence of
septic shock or marked gastrointestinal hemorrhage
c. Abdominal radiographs may show pneumoperitoneum in addition to
others listed in lie
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3.3 Incidence of NEC
NEC principally affects preterm infants and is one of the major causes of morbidity and
mortality in this group worldwide. However, in studies where comparisons have been made,
marked variations in incidence have been described between NNUs. When studies from
different parts of the world are considered, there appears to be even more variation in
occurrence of the disease between different countries.
The British Paediatric Surveillance Unit (BPSU) reported a study conducted in 1993-946'.
This study was based on criteria defining two grades of disease. Grade I was defined as those
cases having at least two of the following criteria: pneumatosis intestinalis; abdominal
distension or an abdominal x-ray showing gaseous distension or frothy appearance of the
bowel lumen, or both; bloody stool; lethargy, hypotonia, apnoeic episodes or a combination
of these three features. Grade II was defined as cases having features of Grade I disease with,
in addition, one or more of the following: abnormal bleeding in response to trauma or
spontaneous bleeding; abdominal tenderness or rigidity; mucosal tissue in the stool;
peripheral white cell count <100 x 109/1 or free gas in abdomen or portal vein gas on x-ray.
"Confirmed" cases were those where gas was present in the bowel wall or portal tract on
abdominal x-ray or if a diagnosis of NEC was confirmed at surgery or post mortem
examination. Using these definitions, 300 infants met the criteria for either Grade I or Grade
II disease and of these, 185 had confirmed disease. Sixty-five percent of cases had birth
weight <1500g. The estimated incidence of confirmed NEC reported by the BPSU in the
UK, at this time, was 0.23 per 1000 live births and 2.1 per 1000 admissions to NNUs. The
proportion of babies with confirmed NEC that died was 28%, with overall mortality being
highest in the smallest babies. The study did not consider inter-unit variation in the incidence
of disease.
Geffers et al reported the incidence ofNEC as part of a prospective surveillance system for
hospital acquired infection in very low birth weight (VLBW) babies in Germany,
commenced in 200062. NEC was included in this survey in view of the clustered nature of
many cases, indicating a potential infective aetiology. They defined NEC as
histopathological evidence of NEC or at least one characteristic radiographic abnormality,
plus at least two of the following in the absence of any other explanation: vomiting,
abdominal distention, residual gastric volumes prior to feeding, persistent microscopic or
gross blood in stools. Characteristic radiological features included pneumoperitoneum,
pneumatosis intestinalis, and unchanging 'rigid' loops of small bowel. By the time of
reporting in 2005, 52 NNUs had been surveyed for periods ranging from 1 to 5 years, with
the inclusion of 8677 VLBW infants. They reported that 3.5% of babies developed NEC
giving incidences of 1.1 per 1000 patient days in babies <1000g and 0.6 per 1000 patient
days in larger babies. The addition of participating units at various stages during the period
covered by the study may have introduced bias into the study results, depending on the size
and type of units involved and the gestational ages and severity of illness of the babies for
whom they provided care. Certainly, methodology of this kind would preclude any
comparison of rates between German NNUs because of differences in the time over which
data was collected. The proportion of 3.5% is somewhat lower than that quoted for a number
of other developed Western countries and may be subject to question in the light of these
factors, but this study provides the only available recent epidemiological data for NEC in
Germany.
Data from neonatal intensive care units within the Canadian Neonatal Network in 1996-97
were obtained to examine variation in clinical practice and outcomes, including NEC63.
Trained research assistants collected these data prospectively, from the medical records of
mothers and babies, as part of the larger study involving 19,507 infants admitted to NNUs in
Canada. NEC was defined for the purposes of this study according to Bell's criteria for Stage
II disease or greater. It was further classified as "medical" disease (clinical signs and
symptoms of disease, with pneumatosis seen on X-ray) or "surgical" disease, requiring
histological evidence of NEC from a specimen taken at surgical intervention. The incidence
ofNEC in 3,692 very low birth weight (VLBW) babies (i.e. birth weight <1500g) was 6.6%,
again with the highest rates in the smallest babies64. The crude incidence of NEC in this
cohort ranged from 0% to 13.3%, with one NNU reporting no NEC during the period of
study. The authors do not report on mortality. Differences in NEC rates between units were
not statistically significant before or after adjustment for baseline population risks and illness
severity. Data collection methods in this study appear to have been robust but it is interesting
to note the 0% incidence in one NNU with 93 admissions ofVLBW babies. Reasons for this
might include either under-reporting of the disease or a true difference in incidence, perhaps
generated by differences in clinical practice or population, or a chance finding.
Data from the United States of America (USA) have shown a similar incidence of NEC to
the Canadian study. In 1991, Uauy et al reported the incidence ofNEC in 8 NNUs belonging
to the National Institute of Child Health and Development (NICHD)7. They studied 2681
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infants weighing <1500g born during an 18-month period between 1998 and 1999 and
classified NEC according to the modified Bell's staging. In their analysis, "suspected NEC"
was used to describe stages IA and IB and "proven NEC" was used to describe stage IIA and
more advanced stages; they used the term "perforated NEC" to describe stage IIIB. One of
the study objectives was to examine variation in rates of the disease between centres. The
overall prevalence of proven NEC was 10.1%, with a further 17.2% of infants falling into the
category of suspected NEC. Mortality in this group for Stage III NEC was 50%. Rates of
NEC differed between centres from 3.9% to 22.4%. The authors speculated that this might
relate to differences in clinical practice rather than population differences, but were unable to
show this conclusively due to limited numbers of subjects.
A further NICHD study, conducted between 1998 and 2001, studied 11,072 infants with
birth weight below 1500g surviving for 12 hours or more after birth in 19 units65. Of these
infants, 7.1% went on to develop NEC overall, with the figure rising to 11.4% in babies with
birth weight of < 750g. Modified Bell's staging criteria were used for classification of
disease in this study. Stages IA and IB were defined as "suspected" NEC. Stages IIA, IIB or
IIA were defined as "proven, no surgery" and Stage IIB disease was defined as "proven,
surgery". In this study, the incidence of NEC varied from 4.26-11.25% (p<0.0001) between
centres. Mortality was not discussed.
In 2000, also in the USA, Holman et al estimated rates of NEC as defined by the
International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) code
777.5 (necrotizing enterocolitis in fetus or newborn)66. They obtained data from hospital
discharge records from the Kids' Inpatient Database produced for the Healthcare Cost and
Utilization Project sponsored by the Agency for Healthcare Research. Since data were
anonymised, the analysis was based on hospital admission episodes and final discharge/death
data rather than infants, to avoid bias due to inter-hospital transfers and associated duplicate
counting of infants. This study revealed that approximately 1 per 1000 live births was given
a diagnosis ofNEC during their neonatal hospitalisation. As in previously described studies,
the largest proportion of affected babies was among those of very low birth weight.
Mortality rates were high (15.2%). They also examined rates of NEC according to
geographical regions, but observed no statistically significant differences.
In 2002 the Vermont Oxford Network (VON), comprised of 331 NNUs in North America
and 31 units in a total of 17 other countries, reported data from 1991-1999 for the 362
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participating NNUs67. Only 39 of the participating units, however, were involved in data
collection for the full 9-year period. Rates ofNEC remained relatively steady among infants
<1500g throughout the whole 9-year period, ranging from 6.0% to 7.1% when considering
all participating units and from 6.2-8.4% when considering only those units that participated
for the whole time. Although these estimates do not represent population-based data, the
VON database collects data from widely varying and geographically diverse areas in
developed countries and is likely to be representative of clinical practice in the USA and
other Western countries and these results are in line with other large sequential studies in the
USA.
Trends in rates of NEC have also been explored in Australia. Luig et al reported a
retrospective population-based study utilising prospectively collected data from the New
South Wales Neonatal Intensive Care Unit Study database68 69. They examined data from
three epochs: 1986-1987, 1992-1993 and 1998-1999. Units joining the group at any point
included in this total time period were excluded to ensure integrity of data. NEC was defined
as clinically suspected NEC plus at least one of the following: abdominal wall cellulitis and
palpable abdominal mass, pneumatosis intestinalis, portal vein gas, persistence of a rigid
dilated bowel loop seen on serial x-rays, or diagnosis at surgery or post mortem examination.
In contrast to the studies from the USA, this Australian study showed decreasing incidence
of proven NEC across the three epochs (9%, 10% and 5% respectively for the three periods
(p<0.001)), in spite of significantly increasing numbers of surviving ELBW infants.
However, this did not translate into a reduction either in the numbers requiring surgery or in
overall mortality rates for the condition. The authors were unable to show any parallel trends
with respect to changes in clinical practice or population that might account for this finding.
3.3.1 Limitations in reporting of the incidence of NEC
A major challenge in monitoring the incidence of NEC lies in the inconsistency of the
definitions used by different research groups, in spite of the availability of the staging system
introduced by Bell59 and since modified. It is clear from the above studies that definitions are
poorly standardised between studies. Although in most research the criteria used are based
on those included in either the original or the modified staging, they differ in detail, making
interpretation of multiple studies difficult and combination of results inappropriate. Some
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groups, for example the BPSU in their report, have chosen to devise a separate and different
classification of disease for the purpose of their study61.
With increasing experience in the care of VLBW and extremely low birth weight (ELBW)
infants, significant limitations of Bell's staging system have been recognised. Firstly, there is
a lack of specificity in the classification of stage I, or "suspected" NEC. Systemic diseases of
any kind, and in particular those of infectious aetiology, may produce any or all of the
manifestations that Bell describes. Temperature instability, episodes of apnoea and episodes
of bradycardia are frequently seen with systemic sepsis and "localising" features such as
abdominal distension and increased residual volumes on gastric aspiration can often more
appropriately be attributed to intestinal ileus secondary to severe systemic illness. This
imprecision creates the potential for misclassification of disease with the likelihood of
overestimation of the occurrence of NEC. This has led most researchers to consider only a
diagnosis of Stage II or III NEC as significant or indicative of proven disease. Where data
collection occurs prospectively, this is probably a reasonable approach, but in retrospective
studies or those for which the attribution of disease status relies upon coding of diagnosis at
discharge, the accuracy of data collection is less predictable, being dependent on
retrospective interpretation of the clinical condition. In addition, restriction of investigations
to confirmed Stage II or III NEC does not allow consideration of the impact of Stage I
disease on treatment and outcome of infants.
Secondly, a further limitation has recently led researchers and clinicians to question the
appropriateness of using Bell's staging ofNEC in the current and more "modem" climate of
neonatal medicine26. With advancing knowledge and skills, the survival of extremely
preterm and ELBW babies has increased significantly. With this increasing survival, changes
in patterns of disease have been noted and a condition that may previously have been
attributed to NEC, according to Bell's criteria, has emerged as an entirely separate entity.
Spontaneous intestinal perforation (SIP) was first described in detail in a case series by
Aschner et al in 198870. In SIP, there is perforation of the bowel wall, usually in the ileum,
but without pathological features consistent with NEC and generally carrying a better
prognosis. SIP has probably occurred for a long time, but the incidence appears to have
increased substantially in recent years, probably at least in part due to the more widespread
use of drugs such as steroids and non-steroidal anti-inflammatory drugs. Lack of recognition
of this condition and therefore a tendency to ascribe a diagnosis of NEC to any bowel
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perforation in an immature infant may also feature as an important source of error in the
challenging task of determining the incidence ofNEC in the preterm population.
Differences in reporting methods may also contribute to difficulties associated with
collection of accurate data on NEC. The BPSU study relied on reporting of cases by
clinicians to a central body. Since under-reporting is common in surveys of this kind, it is
possible that their results may represent an underestimate of the true impact of the disease in
the UK. Accuracy in retrospective data collection is challenging. Routine prospective
population-based collection of details of diagnosis is probably the most robust means of
obtaining accurate and complete data, but for a condition such as NEC which, although
extremely important clinically, is a rare outcome, very large populations will be required to
produce data over a substantial time span to allow meaningful rates to be obtained. This is
particularly so with NEC, since disease rates appear to fluctuate significantly with time and
location. The large databases in the USA such as the NICHD and VON databases are
probably best placed to be able to provide such data. However, although these are large
populations, given the variation between different countries, their data will not necessarily be
generalisable to other areas of the world and the confounding introduced by cultural and
economic differences may preclude comparison between countries.
Nevertheless, despite inconsistencies in definition and potential for the introduction of error,
most studies support the conclusion that NEC is an important disease with consistently high
rates of morbidity and mortality and one in which changing trends in neonatal care have
failed to make a significant impact either in reducing incidence or improving outcomes.
3.4 Risk factors associated with the development of NEC
Given the high rates ofmorbidity and mortality associated with NEC, it is not surprising that
much effort has been directed towards attempts to identify causal factors in this condition
and towards ways of preventing or reducing the burden of neonatal disease. In spite of this,
the aetiology of NEC has remained obscure and there are likely to be multiple contributing
factors involved. A host of risk factors, pertaining both to the babies' clinical condition and
to neonatal interventions, has been proposed as a result ofmultiple observational studies.
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There appear to be two distinct patterns in the occurrence of NEC. Clusters of cases or
"outbreaks" have been observed leading researchers to explore in detail the concept of an
infective cause for the disease. However, this by no means accounts for all cases and many
seem to have a sporadic pattern. The majority of epidemiological studies have chosen to
focus on the identification of clinical risk factors that are commonly associated with NEC.
Although all studies agree that the most consistent factor associated with NEC is
prematurity, this alone does not account for all cases. Around 10% of cases ofNEC occur in
term born infants although the risk of disease is far lower than in the preterm and may reflect
different pathogenetic mechanisms. A discussion of NEC in term infants is beyond the scope
of this thesis.
The age at which preterm neonates develop NEC is extremely variable, with a tendency
towards somewhat later onset in the most preterm babies compared with larger and more
mature preterm neonates. This variability in the time of onset suggests that it is not only
predisposing conditions present at or soon after birth, but also later environmental factors or
clinical interventions that may promote development of disease. Several factors have been
identified that may represent "iatrogenic" aspects contributing to the disease process.
The evidence for each of the risk factors that are considered potentially important in preterm
and VLBW infants will be considered in detail in the following sections.
3.4.1 Gestational age and birth weight
More than 90% of cases of NEC occur in preterm infants. Studies have consistently shown
that this is the most important risk factor. There is a strong relationship between birth weight
and gestational age and most researchers have chosen to analyse their study results by birth
weight. This may lead to inclusion of some babies that are small for their gestational age.
This and the fact that many studies were conducted some years ago when survival in babies
of the lowest gestational age was less common, means that many included babies are more
mature than those on whom the greatest concern now focuses.
A number of studies have suggested that not only is prematurity an important factor in the
development of NEC, but that it may be the only significant risk factor. Although these
studies examined the influence of other factors that had previously been implicated in the
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pathogenesis of NEC, they were unable to confirm relationships with any other risk factors
other than gestation and/or birth weight. Stoll et al used a case control design to study 35
babies with NEC and 98 controls71. Babies were matched for birth weight and the mean
gestational age was 31 weeks in both groups. This study found that NEC was commoner in
the smallest, least mature and sickest babies. The overall incidence in the group was 6 per
1000 live births, rising to 66 per 1000 live births in infants with birth weight of <1500g. The
age at onset of the disease was inversely proportional to gestational age at birth. They
suggested that prematurity was the greatest risk factor and hypothesised that smaller babies
who have been most unwell develop NEC later possibly due to ongoing insults to the
maturing gut on recovery from acute illness after birth. In 1987, De Curtis et al performed a
study of 27 cases and 54 weight-matched controls72. Their results confirmed these findings
and they were unable to show a significant association with any other risk factors. Both
studies included mature infants and had limited power to detect differences.
Kanto and Lui conducted similar case control studies but included only low birth weight
preterm infants73 74. They too found that the occurrence ofNEC was inversely related to birth
weight and gestational age and were unable to identify other risk factors. Lui et al also noted
an inverse relationship between gestational age and the time of presentation with the disease.
Guthrie et al retrospectively analysed data from 98 NNUs within the Pediatrix Medical
Group Inc. across the USA75. Included infants were inborn babies between 23 and 34 weeks
of gestation. Using logistic regression, they analysed prospectively identified risk factors for
NEC by univariate analysis and found a number to be significant. However, when included
in multivariate analysis adjusted for birth weight, many lost significance and they concluded
that birth weight was the most important factor. They also examined cases according to
whether they were treated medically or surgically and showed that surgically treated babies
were more likely to be of lower birth weight and gestational age than conservatively treated
infants. Sharma later showed that the clinical presentation of NEC and management by
surgeons also differ with gestational age76.
Palmer examined the confounding effects of both birth weight and gestational age. They
found these to be similar and chose to report their analysis by birth weight4, dividing their
study groups according to birth weight above or below 1500g. Interestingly, their results
suggested that risk factors for NEC might vary with gestational age; smaller babies with
events or conditions leading to prolonged hypoxia were at greater risk, whereas in larger
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babies, the most common risk factor was hypoxia at birth. Beeby studied babies born at <36
weeks of gestation in a case control study of 74 infants matched for gestational age and also
found differences between more and less mature infants77. In infants born between 25 and 29
weeks of gestation (n=35) they were unable to identify any risk factors other than
prematurity, suggesting that this group are at risk of NEC purely by virtue of their gestation
at birth. In contrast, more mature infants (n=8) all had identifiable predisposing factors of
asphyxia or intrauterine growth restriction. Luig and Lui looked at a group (n=178) of even
less mature babies with NEC69. They showed that incidence of and mortality from NEC both
increased with lower gestational age. The proportion of the disease in babies of 24-27
weeks' gestation was 6.6%, falling to 2.6% in babies born between 28 and 31 weeks of
gestation. In the more mature preterm group, the only risk factor identified was surgical
treatment of patent ductus arteriosus, whereas the less mature infants were more likely to
have risk factors associated with NEC. However, these risk factors were common in all the
smaller infants.
Whilst all studies have considered gestational age and/or low birth weight as a major risk
factor for NEC, results have been conflicting regarding the contribution of other risk factors
in development of the disease in association with prematurity. Some have suggested that
other risk factors cannot be identified. If gestational age were the only contributing factor in
NEC, it might be expected that the incidence of the disease would be rising in line with
increasing survival of extremely preterm infants. However, Luig and Lui showed that, in
their cohort of infants bom at 24-28 weeks of gestation, the incidence of NEC decreased
steadily over time, despite increasing survival of high-risk infants or low gestational age68 69.
There were many potential risk factors that were not considered in this study and it seems
more likely that declines in the incidence of NEC were related to changes or advances in
care over the study period. Overall, the evidence suggests that prematurity is the most
consistent and important risk factor, but that there may be many other contributing factors
necessary for the development of NEC and influencing the severity of the disease. Since
NEC is a relatively rare outcome and the presence of multiple and variable risk factors is
common in most sick preterm babies, the true influence of gestational age per se is almost
impossible to determine with certainty and this probably accounts for the conflicting results
seen in the studies.
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3.4.2 Intrauterine growth restriction
3.4.2.1 Assessment of intrauterine growth at birth
In the first trimester and early part of the second trimester of pregnancy, foetal growth is
characterised mainly by increasing cell numbers. During the later stages, this changes and
the fetus enlarges primarily by increase in cell size. By the time of the last trimester fat,
muscle and connective tissues are laid down. By far the largest proportion of weight gain
takes place during the latter half of pregnancy. Disturbance or slowing of this process can
occur for a number of reasons such as placental insufficiency or maternal illness, leading to
the birth of a baby that is smaller than would be expected at full term, when taking into
account the normal range of weights for male and female infants.
Intrauterine growth restriction (IUGR), previously known as intrauterine growth retardation,
has been defined in a number of ways, with the commonest definition being that of birth
weight below the tenth percentile on the growth chart. Others have taken it as birth weight
falling less than two standard deviations below the mean; this corresponds approximately to
the level of the third percentile. For the purposes of this study, the first of these definitions
was used. The term "growth restriction" is frequently used interchangeably with the term
"small for gestational age". However, this is not strictly correct, since the latter group may
contain infants who are constitutionally small because they have small parents. Other infants
may be small because of their ethnic origin. Many of these babies for whom it is "normal" to
be small may fall below the tenth centile on the growth chart. However, such babies are at no
greater risk either during pregnancy or during the perinatal period than larger normally
grown infants. This is in contrast to those infants for whom their small size represents the
result of an intrauterine insult and a significantly increased risk of early morbidity and
mortality. The limitations of growth reference charts can be clearly appreciated, but it would
not be feasible to take account of every eventuality when devising such a reference source.
Measurement of intrauterine growth and the implications of different rates of growth became
a topic of interest in the 1960s78 and it was noted that babies with poor intrauterine growth
were at high risk of having congenital anomalies79 80. An increased mortality rate in these
infants was confirmed in other cohorts81 82. This early work focused mainly on mortality in
infants born at term. Later studies investigated morbidity within this group.
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3.4.2.2 Abnormal antenatal umbilical artery Doppler studies and NEC
Prenatally, studies of Doppler waveform velocities in the umbilical artery are commonly
used as an obstetric measure of fetal wellbeing in high-risk pregnancies. These studies may
show varying degrees of increased placental vascular resistance, ranging from reduced end
diastolic flow in the umbilical artery to absent (AEDF) or even reversed end diastolic flow
(REDF), which have a strong association with fetal compromise and chronic hypoxia.
Foetuses affected by such placental insufficiency usually display poor in utero growth. The
finding of AEDF or REDF on antenatal Doppler studies will prompt most obstetricians to
intervene and deliver the preterm baby in view of the high risk of intrauterine demise.
Depending on the stage of gestation, lesser degrees of compromise may be monitored for a
period of time, especially if it is thought that risks of prematurity are greater than the risk of
intrauterine death in the growth restricted fetus. Although improved obstetric services have
led to more frequent monitoring of antenatal umbilical Doppler velocities in high-risk
pregnancies, these studies are not performed in all pregnancies, and in some centres this
investigation is not available at all. Therefore this information is not currently available for
all preterm deliveries, even where IUGR may have been identified on fetal measurement.
Chronic hypoxia associated with poor placental perfusion results in a redistribution of blood
flow in the fetus to preserve cerebral circulation. This often leads to asymmetrical growth in
the affected fetus with the head circumference being proportionately greater than expected
for the birth weight, so-called "brain sparing". Flackett et al, in a retrospective review of data
from Doppler studies in growth restricted fetuses, showed that this preservation of cerebral
perfusion resulted in decreased blood flow in the descending aorta83. Aortic blood flow
velocity was significantly more severely impaired with increasing growth restriction.
Kempley et al, in 1991, investigated the hypothesis that these prenatal haemodynamic
disturbances persist into the postnatal period by studying superior mesenteric artery (SMA)
and coeliac axis blood flow velocity in infants with antenatally diagnosed growth
restriction84. Compared with control infants matched for weight and gestational age at birth,
these infants showed reduced abdominal blood flow velocities, but no difference in cerebral
blood flow velocities, suggesting that this is the case. Differences were most marked in
infants with antenatal AEDF and only a slow recovery was seen during the first seven days
of postnatal life. A later study by Maruyama showed similar results85.
A number of studies86"88 have shown an association between IUGR and the postnatal
development ofNEC in preterm infants, while others have failed to demonstrate this. Garite
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et al, by retrospective analysis of a large dataset including more than 1000 growth restricted
neonates, showed an increased risk of NEC in infants born at 25-32 weeks of gestation88.
Gilbert et al, also in a retrospective review showed a significant increase in NEC that was
confined to infants of more than 34 weeks of gestation87. However, this study only included
infants who survived to one year of age, so it is possible that this will have overlooked some
immature infants with NEC who may have died from this or other complications of extreme
prematurity. Simchen et al, in a smaller retrospective study, found a trend towards increased
NEC in growth-restricted infants86. In contrast, Pena et al did not show any increase in NEC
related to IUGR89.
Further studies have looked more closely at the relationship between abnormal antenatal
Doppler studies and NEC. Again results have proved conflicting. Adiotomre et al, in a
retrospective review of 60 infants did not find any increased association between NEC and
AEDF90. Hackett et al analysed the history and neonatal outcome where Doppler studies
were carried out in pregnancies and birth weight was below the 10th centile83 . A greater
proportion of babies where there had been AEDF developed NEC. Malcolm et al in a case
control study of 25 high-risk pregnancies with absent or reversed end diastolic umbilical
artery flow showed a similar relationship and concluded that this was an independent risk
factor for NEC91. Other retrospective studies by Karsdorp, Kirsten, Soregaroli and Miiller-
Egloff found no statistically significant difference between groups with abnormal and
normal Doppler studies92"95. Many of these studies have included small numbers of infants
and therefore lack power to detect a real difference between the study groups. A meta¬
analysis96 of 14 studies examining the risk of NEC in infants where Doppler studies have
been abnormal showed an increased risk with absent or reversed end diastolic flow in the
umbilical artery or aorta. Since this meta-analysis, two further studies have been published.
Kamoji et al included 206 infants in a retrospective analysis of infants with NEC in whom
information about antenatal Doppler studies was available97. This showed a highly
significant association, after adjustment for gestation at birth and birth weight between
abnormal Doppler studies and infants with either suspected or definite NEC. There was a
twofold increase in stage II or III (confirmed) NEC in those with abnormal Dopplers, but this
was not statistically significant. The most recent study to address this question was a
prospective multicentre study in which 404 fetuses were assessed antenatally with umbilical
artery Doppler studies98. Thirty-nine neonates developed NEC. The authors were unable to
demonstrate any correlation between worsening antenatal Doppler study results and the
development ofNEC, which might be expected if the relationship were causal.
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One common thread running through many of the studies of antenatal Dopplers and NEC is
that, because obstetricians usually deliver infants when fetal compromise becomes severe,
infants with absent or reversed end diastolic flow tend to be more preterm and of lower birth
weight than their growth-restricted counterparts with normal Doppler studies. It is therefore
possible that the higher rates of NEC in these babies may be related to the recognised risk
factors of gestation and birth weight.
3.4.3 Enteral feeding
The observation that more than 90% of infants developing NEC have received some form of
enteral feeding3 has led to scrutiny of feeding practices in an attempt to investigate whether a
causal relationship exists. A review of the available literature pertaining to enteral feeding in
preterm infants reveals substantial changes in practice over time for virtually every aspect of
feeding. Changes have occurred gradually in response both to mounting evidence from
research and to changes in the population of babies cared for in the newborn period with
increasing survival of smaller and more immature infants.
3.4.3.1 Withholding of enteral feeds
When neonatal care of premature babies was in its infancy, the practice of allowing a period
of starvation was common. This arose, not from concerns about the development of
gastrointestinal disease, but from fears of respiratory compromise due to aspiration ofmilk".
In view of the observed irritant effect of aspirated milk, the usual practice, on introduction of
enteral feeds, was for water or glucose to be administered orally or via nasogastric tube,
depending on the maturity of the infant. Bauman questioned this indication for the starvation
of infants in I960100, randomly allocating infants admitted to the NNU to receive sterile
dextrose-saline solution nasogastrically either before 6 hours of age or after 36 hours. He
was, however, unable to demonstrate a clear beneficial effect on respiratory morbidity in
either group. A further study by Wennberg et a/101 showed that early feeding resulted in less
jaundice and weight loss and that administration of a glucose solution led to improved
glucose levels compared with sterile water feeds. Other concerns developed about the
possible effect of a prolonged period of nutrient starvation on brain growth and development.
As nasogastric feeding and other nursing techniques improved, anxieties about the likelihood
of aspiration of milk lessened and attention turned to whether milk feeds could be given
safely within the first hours of life. Smallpeice and Davies demonstrated earlier regain of
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birth weight, reduced hypoglycaemia and hyperbilirubinaemia in 111 infants fed undiluted
human breast milk102. Wu confirmed these findings in infants fed in the first hours of life
with formula milk103.
Most of these studies were undertaken in babies of >1500g and >34 weeks of gestation in an
era when it was said that babies with a birth weight of <1000g "almost invariably die"102.
With rapidly improving methods of neonatal intensive care in subsequent years leading to
survival of the smallest preterm babies and increasing documentation of cases of NEC57 58,
the type of feeds to be given, the timing and methods of introducing enteral feeds once more
became controversial.
3.4.3.2 Type of feed
(a) Breast milk or formula milk?
For infants bom at or near term, there is overwhelming evidence that breast milk has
important benefits, both in the long and short term. These relate to the immuno-protective
effects of breast milk. Immunological components of breast milk are lactoferrin, secretory
IgA and lysozyme, which are thought to protect against infection. Breast-feeding in this
group is associated with reduction in gastrointestinal illness104 and infection105, protection
against later atopic conditions such as asthma and eczema106 107 and beneficial effects on
cognitive development108. Long-term developmental effects are thought to be related to long
chain polyunsaturated fatty acids, which are components of human milk, but not of cow's
milk.
Studies comparing feeding with maternal breast milk or preterm formula milk in preterm and
LBW babies have been fewer and none are randomised 109. Follow-up of a large group of
infants participating in a trial of glutamine supplementation provided an opportunity for
Vohr et al to assess developmental outcomes in relation to early feeding110. Children
receiving any, as opposed to no breast milk scored more highly on Bayley Scales of Infant
Development (BSID) at 18 months of age. Takana et al, in Japan, recently studied the
relationship between breast-feeding and cognitive function in a small group of preterm
infants, of whom 10 received >80% breast milk in the first 4 weeks of life and 8 received
<80% breast milk111. They found a significant difference at 5 years of age in head
circumference and some cognitive skills in those receiving more breast milk. However, the
study included only small numbers and did not consider confounding factors, such as
maternal education, postnatal environment and parenting behaviours, all of which may
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influence child development. Although these studies are observational rather than
randomised, the results are supportive of the hypothesis that similar effects to those in
mature infants also exist in preterm infants. However, Furman et al were unable to
demonstrate an effect on developmental outcome in 98 infants due to breast milk after
adjusting for confounding factors112.
Most studies in preterm and LBW infants have concentrated on short-term outcomes
including NEC and neonatal infection. Although NEC undoubtedly occurs in infants fed
exclusively on breast milk, observational studies have indicated that breast milk may confer
some protection against the disease. Lucas and Cole, in 1990, used two parallel, randomised
studies involving 926 infants to assess the role of different types ofmilk in the development
of NEC113. Infants in three centres received preterm formula or pooled donor breast milk and
groups were stratified according to whether maternal breast milk was also provided. This
allowed comparison of donor milk and preterm formula as sole nutrition or as supplements
to maternal breast milk. In a further two centres, infants were similarly randomised to
receive either preterm or term formula in addition to breast milk, if provided. They observed
no difference in the incidence of NEC between infants given pooled donor breast milk, or
maternal breast milk, but there was significantly more confirmed NEC seen in the formula
milk groups, with these differences remaining significant after adjustment for confounding
factors. The risk of disease was also higher in exclusively formula-fed infants compared with
those fed some breast milk in addition to formula. Benefits increased with decreasing
gestational age114. Lucas et al later demonstrated benefits in terms of later development at 18
months115, assessed using BSID and increased verbal intelligence quotient scores in boys at
7-8 years of age1'5.
A number of more recent observational studies have also reported decreased rates of NEC
and/or sepsis with breast milk feeds compared with formula. Furman et al prospectively
studied 119 VLBW infants and showed significantly lower rates of infection in the first
month of life in infants who received >50ml/kg per day of maternal milk compared with
those receiving less117. In this study, there was no effect on incidence ofNEC, but the sample
size would have been inadequate to detect a difference in this. Whilst birth weight, ethnicity
and gender were considered in analysis, severity of illness was not taken into account.
Schanler et al studied babies of <30 weeks of gestation whose mothers intended to breast¬
feed118. Infants were randomly allocated to supplementation with donor milk or preterm
formula if maternal milk was insufficient; 29% received only maternal breast milk and 21%
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changed from donor breast milk to preterm formula because of poor weight gain. Intention to
treat analysis showed a significant difference between those who only received maternal
milk and the other groups, with maternal milk-fed infants having fewer episodes of infection
and/or NEC and shorter hospital stay. No such differences were seen between the donor milk
and formula groups, indicating that maternal milk may confer benefits over donor breast
milk. Meinzen-Derr et al have recently analysed further data from 1272 infants involved in
their randomised trial of glutamine supplementation to investigate the effects of human milk
on the combined outcome of NEC and death119. In this group, after adjusting for multiple
confounding factors, increases in the cumulative amount of human milk fed were associated
with decreasing risk ofNEC or death, suggesting a dose-response relationship.
Comparison of the effects of breast milk and formula are fraught with difficulties. Feeding
method is highly dependent on maternal wishes and supply ofmaternal breast milk and these
factors cannot be manipulated or controlled. There are many other important factors that may
be associated both with feeding practices and with outcomes. Some of these are dependent
on the clinical condition of the infant, some relate to differing opinion and practice among
clinicians and others to maternal characteristics, such as socioeconomic status and education
level, which are known to influence breast-feeding rates. Since NEC is a relatively rare
disease, large numbers are likely to be necessary to demonstrate differences between groups
of infants, even with rigorous controlling for confounding factors. The numbers of babies at
highest risk ofNEC are small and even studies of national data may be inadequate to provide
definitive results. In addition, geographical variation and waxing and waning in incidence of
the disease further complicate the issue. Another difficulty lies in achieving results from
"pure" groups, since the majority of infants receive a combination of breast milk and
formula, due to problems encountered by many mothers in expressing sufficient breast milk
for the nutritional and volume requirements of their babies, particularly in the first few days
of life. Current recommendations120 favour breast milk as the most appropriate form of
enteral feeding for preterm infants and in view of the known immunological benefits it is
unlikely that randomised trials will ever be conducted.
(b) Maternal breast milk or donor breast milk?
A substantial number of mothers of preterm infants either do not wish, or are not able to
provide breast milk. The clear benefits of breast milk have led to the provision of third party
donated breast milk by human breast milk banks121. Currently, there are 17 established breast
milk banking facilities in the UK, 11 in the USA, and 1 in Canada, with further banks under
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development. Milk distributed by such banks is pooled donated milk usually originating
from mothers of term infants. Differences in content of term milk compared with preterm
milk may be important when considering the value of donated breast milk for preterm
infants. Milk constituents may also be affected by the degree of prematurity. Concern about
transmission of infection through breast milk mandates processing of donated milk using
pasteurisation. However, pasteurisation, whilst eliminating the risk of transmission of
bacteria and viruses such as the Human Immunodeficiency Virus (HIV), also affects some of
the nutritional and immunological components of the milk.
Long chain polyunsaturated fatty acids (LCPUFAs), in particular docosahexaenoic acid
(DHA), appear to be important for early cognitive and visual development 122 l23. Humans
cannot synthesise these fatty acids and therefore the fetus depends on placental transfer
during the final trimester of pregnancy, which is a period of rapid growth, brain development
and deposition of adipose tissue. For the extremely preterm infant, LCPUFAs must be
provided in enteral feeds. A systematic review by Bokor et al examined differences in fatty
acid content between term and preterm human milk124. This review identified five
longitudinal studies comparing content ofmilk from mothers delivering at 25 to 30 weeks of
gestation or at >37 weeks123'129. Three of these studies showed higher levels either of DHA
or its intermediaries in preterm human milk compared with term milk126128 l29. This is most
likely to be explained by the fact that mothers delivering prematurely have accumulated
stores of LCPUFAs, but placental transfer has not occurred. The authors speculate that
adaptive mechanisms, designed to provide for the ex utero needs of a preterm infant, may
play a part, but this is an untested hypothesis. These results suggest that maternal milk, rather
than donated breast milk may confer benefits for the preterm baby.
Differences in levels of immunoglobulin have been shown in several studies. Barros et al
observed higher levels of IgA, IgG and IgM in colostrum collected from 17 mothers of
preterm babies compared with that of 18 delivering at term although they noted similar
profiles in milk from mothers of full term growth restricted infants130.
Lepage et al showed differences in calorie, nitrogen and fatty acid content of milk produced
by mothers at 26-31 weeks of gestation compared with later preterm gestations131. Anderson
et al also showed higher calorific and protein content in preterm compared with term milk,
based on 24 hours of expressed breast milk (EBM)132. Gross et al, in a small study including
26 mothers, confirmed higher protein levels in preterm expressed milk, compared with EBM
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from mothers delivering at term, but showed no difference in calorie content between the
groups133. Conflicting results may be due to variability in milk composition between
individuals, differing gestational ages and/or small numbers in the studies, but there is a
paucity of further work and large studies in this area.
Schanler directly compared the composition of milk from mothers who had delivered
preterm with pooled donated breast milk l34. This study showed significantly higher nitrogen
content initially in preterm mothers' milk, with gradually decreasing levels that approached
those of the donated milk after two weeks. Mean calcium content was also higher in preterm
mothers' milk. However, the author was unable to conclude from this work whether these
findings would translate into growth-related benefits for the premature infant. A recent study
examined calorie content of 415 samples of donor breast milk from 273 mothers and showed
this to be 19kcal/oz, compared with an accepted average value of 20kcal/oz for term breast
milk135. In view of the increased metabolic demands of preterm babies, the authors suggest
that this may not be sufficient to meet these demands without the use of breast milk fortifier.
The process of pasteurisation is known to affect the immunological components of breast
milk. Koenig et al analysed samples of raw and pasteurised colostrum from 101 mothers
delivering at different gestations, both preterm and term136. In this study, protein, lysozyme,
IgA and IgG concentrations were all significantly reduced by pasteurisation. However, the
authors concluded that appreciable amounts of protein and IgA were retained, particularly in
preterm milk, that might reasonably be expected to provide some benefit to the preterm baby
though this is likely to be less than mother's own untreated milk.
Four randomised trials113137~139, all conducted before 1985, have considered the role of donor
breast milk feeding compared with formula milk in the prevention of NEC. None found
statistically different rates of NEC between the groups. A more recent meta-analysis of
results of these studies revealed a lower incidence in the groups fed with donor milk140.
However, this should be interpreted with caution in view of differences in the population and
management of preterm infants at the time of these studies compared with current neonatal
care. A further single centre study reported in 2005 by Schanler et al included infants bom at
23 to 29 weeks of gestation. Infants were randomised to receive either donor milk (n=81) or
preterm formula (n=92) if supplementation of mother's own milk was required"8. In this
study, 21% of the infants given donor milk were changed to preterm formula
supplementation because of poor weight gain. NEC occurred in 6% and 11% of babies
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respectively for the donor and formula milk groups, which did not represent a statistically
significant difference. The authors concluded that the study did not provide evidence of any
short-term advantage of donor milk over preterm formula for extremely preterm infants, but
that further larger studies examining long-term outcomes may be warranted.
Differences in constituents between maternal breast milk and pooled donated milk may have
an important impact on health and development, but randomised comparison between
exclusive feeding with mother's own milk versus exclusive feeding with donated breast milk
would not be ethically acceptable. At the present time, third party donated breast milk is not
universally available and its use in the UK is determined by policies of individual NNUs,
additional cost implications associated with provision of a milk banking service, accessibility
of milk banking facilities, supply of donor milk and acceptability of the process to mothers
of preterm infants.
(c) Term or preterm formula?
In circumstances where mothers of preterm babies cannot, or are unwilling to express breast
milk and donated milk is not available, an alternative artificial feed must be used. The
composition of term formula milk is based on the composition of human breast milk
produced by mothers of term infants, whereas preterm formula is specifically designed to
meet the additional nutrition and growth needs of a preterm infant. Preterm formula products
contain, in particular, higher amounts of protein and carbohydrate than term formulas. The
lactose content of preterm milks is reduced to avoid the risk of lactose intolerance by the
immature gut. The calorie content of preterm formula is around 80kcal/ 100ml, compared
with term formulas in which the energy content is around 60-70 kcal/ 100ml.
Infants given preterm formula are more able to achieve rates of growth comparable to those
in utero'41 l42. There have been few trials comparing the effects of feeding preterm or term
formula to preterm infants. Lucas et al performed two parallel, randomised trials to examine
the effects of early feeding on long term outcomes143. In the first, they randomised preterm
infants to receive either donor breast milk or preterm formula and in the second, either term
or preterm formulas either as a supplement to breast milk (n=264) or sole diet (n=160). This
was continued until the infants reached a weight of 2000g and thereafter the parents and
clinicians determined feeding. Infants in the second trial who received preterm formula had
better gain in weight and head circumference144. At 18-month follow-up, those who had been
fed with preterm formula had significantly higher scores for both mental and motor
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development and developmental impairment was higher in the term formula group143. The
same group of infants was later followed up at the age of 7.5 to 8 years to assess long-term
growth and development. At this stage, no effect of the early diet on growth was found,
suggesting that improvement in early nutrition is not reflected in improved long-term growth
parameters146. However, particularly in boys, improved cognitive outcomes were seen in the
group fed preterm formula and the incidence of cerebral palsy was less in this group"6.
Despite these apparent advantages of preterm formula over term formula in the absence of
expressed milk, concern exists over whether it is the optimal milk with which to feed
preterm neonates during the first weeks of life. Jadcherla and Berseth noted poor tolerance of
enteral feeds in infants fed with preterm formula compared with term formula and
investigated the effects of different formulas on intestinal motility147. Fifty-two preterm
infants who were receiving parenteral nutrition (PN) were randomly assigned to small
volume (24 ml/kg/day) supplemental enteral feeds for 10 days with either term or preterm
formula. Feeds were given in 4 hourly cycles, with continuous feeding for 2 hours and rest
for the next 2 hours. Motor activity was measured using manometry on the day of starting
enteral feeding (pre-test) and again 10 days after repeated enteral feeding (post-test). A
subgroup of infants was fed both types of formula during the pre-test. Gut responses were
similar between the groups in the fasting state. All infants demonstrated a change in motor
activity at the onset of enteral feeding, but the response differed with the type of formula.
Infants fed term formula showed an increase in contractile activity when feeding
commenced; in contrast, those fed preterm formula showed a decrease in motor activity,
which was greatest at 60-90 minutes of feeding. Similarly, in infants where both types of
milk were given sequentially, motor activity was increased initially in response to term
formula, but this was followed by a decrease with preterm milk. By the time of the post-test
responses were similar in both groups. Of the 9 infants who experienced feed intolerance
during the study period, 7 were in the preterm formula group. Feed intolerant babies went on
to establish full enteral feeding later (22 v 11 days). Neither of these results reached
statistical significance due to the small number of babies. The authors speculated that these
differences related to the different composition of the feeds and principally the higher fat and
carbohydrate content in preterm formula. Feeds containing high levels of carbohydrate and
fat content have also been shown to inhibit gut motility and gastric emptying in adults148.
It appears that both beneficial and non-beneficial effects exist with the use of preterm
formula in infants where breast milk is not available. In practice, the choice of which type of
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formula to use probably rests with the clinician, with decision-making likely to be based on
his or her interpretation of this data in the absence of a large body of research evidence.
Potential long-term benefits of improved developmental outcome are indeed attractive, but
may appear less convincing if weighed against the risk of longer duration of central venous
parenteral feeding and potential for life-threatening infection that may be associated with
this.
(d) Hydrolysedprotein formula
Grulee and Sanford first highlighted a link between formula feeding and the development of
infantile eczema in 1936149. Since this time, efforts have been directed towards reducing the
risk of allergy in babies by modification of feeding. The use of protein hydrosylate formulas
for infant feeding was first introduced with the aim of preventing and treating cow's milk
allergy in term infants. A recent systematic review of the literature identified 2 studies
comparing early feeding with hydrolysed formula and breast-feeding150 15and 16
comparing prolonged feeding with either extensively or partially hydrolysed formula and
cow's milk formula152"'66. Studies comparing human milk and hydrolysed formula found no
difference in the incidence of allergy, but these were only short-term trials. Meta-analysis of
trials comparing hydrolysed protein formula with cow's milk formula showed a significant
reduction in early allergy, but this failed to reach significance when the incidence of allergy
at 2 years was considered. Studies included in the analysis were small and heterogeneous
with respect to definitions of allergy and atopy was not always confirmed with allergy
testing. Most studies152"154 156-159 162 163 165166 recruited infants at high risk for allergy based on
family history. Two recruited healthy term babies150 164 and only three studies enrolled
preterm and/or low birth weight infants155 160 161. No adverse effects were found in term
infants, but preterm infants were at increased risk of poor weight gain when fed hydrolysed
formula. The authors concluded that there was insufficient evidence to recommend
hydrolysed formula feeding above exclusive breast-feeding for the prevention of allergy or
food intolerance, but that limited evidence exists that supplementation with hydrolysed
formula in preference to cow's milk formula may be of benefit in infants at high risk of
allergy who cannot be exclusively breast fed.
Hydrolysed formula use has also been suggested to improve early tolerance of enteral feeds
in preterm infants where breast milk is unavailable. In a study of 36 infants, Riezzo et al
randomised infants who were taking full feed volumes by bottle to receive either standard
preterm formula or hydrolysed formula and measured gastric electrical activity and gastric
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emptying time167. There was no significant difference between the groups for either
parameter. Although infants receiving hydrolysed formula had less episodes of vomiting,
this difference was not significant. Mihatsch et a! studied 15 preterm infants taking full
enteral feeds including up to 20% of their feed volume as maternal breast milk in a
randomised crossover study168. The first formula was fed for 5 days before changing to the
second for a further 5 days. Carmine red was used to stain the milk on days 4-9 of the study
and the time from feeding the dye until its appearance in the nappy was recorded as the
transit time. Transit time was shorter in infants fed hydrolysed protein formula (9.8 hours v
19 hours). There were no differences in the number of episodes of vomiting or the gastric
residual volumes representative of feed intolerance.
3.4.3.3 Minimal enteral nutrition
Surges in the gut hormones, motilin, gastrin and enteroglucagon have been demonstrated in
response to enteral feeding during the early postnatal period169. These physiological
responses occur in both term and preterm infants and are thought to be an important element
of adaptation after birth, stimulating trophic changes in the structure and function of the
neonatal gut in preparation for extrauterine nutrition. The fact that these responses were not
seen in infants that had not received milk feeds led to investigation of the hypothesis that
enteral feeding is essential for normal gut maturation in the newborn. Animal studies have
shown that hypotrophy of the gut occurs in neonatal rats who have received only PN for
even a small number of days170. Lucas first investigated the amount of enteral feed necessary
to induce postnatal gut hormone responses171. The results of his study suggested that
volumes of breast milk equating to 1ml/hour for 24 hours was sufficient to induce significant
hormonal surges and that by the time a total of 96ml had been given, hormonal responses
were maximal. The authors concluded that "the first few millilitres of milk to enter the gut
may constitute a potent stimulus to gut development which could then precede the
attainment of full enteral feeding", whilst recognising that such small feed volumes were not
adequate from a nutritional point of view. Berseth and colleagues demonstrated that gut
motility differed between term and preterm infants, but that infants born as early as 25 weeks
of gestation showed changes in the motility of the small intestine in response to infusion of
milk feed172. They also showed that infants given early milk feeds showed enhanced
maturation of gut motor responses and increased production of gastrointestinal peptides
compared with those in whom feeding was delayed. Early milk feeding was also associated
with improved feed tolerance and earlier achievement of full enteral feeding173174.
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The practice of early administration of small volumes of milk alongside PN with the aim of
promoting normal intestinal structural and functional development has been variously
referred to as minimal enteral feeding, minimal enteral nutrition (MEN), gut priming, trophic
feeding and hypocaloric enteral feeding and these terms have been used interchangeably in
studies. Several randomised trials have been conducted to investigate the effects of minimal
enteral nutrition, compared with fasting, on important feeding-related outcomes175"183. These
have been small, single-centre studies and have used slightly different definitions of MEN.
Initiation of MEN started between day 1 and day 4 of life; volumes given ranged from
lOml/kg/day to 25ml/kg/hour; frequency of feeding ranged from hourly to 4 hourly and the
duration of MEN continued for between 7 and 14 days. One study continued MEN until
ventilation was discontinued176"178 and another until umbilical artery catheters were
removed184. In most cases, MEN was given as EBM or formula, but two studies excluded
breast fed infants175 l79. In all trials, controls received no milk and all infants received PN
during the period of study. A Cochrane review reported a meta-analysis of these trials185.
This did not show any significant difference between infants receiving MEN and those that
did not in the time to achieve full enteral feeding or NEC. No statistically significant
differences were found in mortality, short-term measures of growth or hospital stay between
the two groups.
Two recent studies have addressed other specific outcomes with respect to MEN. Weiler et
al assessed bone mass at term corrected gestational age in infants bom between 24 and 32
weeks of gestation who were fed MEN of 12ml/kg/day186. In this randomised trial, MEN was
commenced either before or after 72 hours of life and typically between 2 and 6 days. The
authors showed a significant increase in bone mineral content in infants receiving MEN
compared with those that only received PN. However, this small study included only 27
infants and there were a number of deviations from the intended protocol, so it is possible
that the positive result may represent a type 1 statistical error. Henderson et al used a case-
control study design to examine the relationship between enteral feeding regimens and
NEC187. Cases were infants born at less than 37 weeks of gestation with NEC, diagnosed
according to modified Bell's criteria. Controls were matched for gestational age. Although
the mean time of commencing feeds (cases 2.9 days v controls 2.8 days) did not differ
between the two groups, cases diagnosed with stage II/III NEC received shorter duration of
MEN (<1 ml/kg/hour) than controls (3.3 days v 6.2 days).
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One randomised trial is often cited in support of the protective effects of prolonged small
feeding volumes against NEC188. Berseth et al randomised 141 preterm infants to receive
either minimal feeds of 20ml/kg/day for 10 days or increasing feeds, advancing by
20ml/kg/day from the time at which enteral feeds were introduced, which was determined by
the attending neonatologist. A sample size calculation a priori had determined that
recruitment of 250 infants would be required to detect a decrease in incidence ofNEC from
12% to 4% with a power of 0.8 at the 5% significance level. Unfortunately, the study was
discontinued early because of a significantly higher rate of NEC in the group assigned to
advancing feeds (10% v 1.4% (P<0.03)), determined by a one-tailed Fisher's exact test. The
combined outcome ofNEC and death showed no statistically significant difference between
the groups. Although the authors did not specifically state the age of starting enteral feeds,
the data published suggested that the mean day on which enteral feeds were introduced was
around the tenth day of life. This implies that all babies experienced a period of starvation,
in contrast to most studies of MEN, in which enteral feeds are introduced during the first
week of life. The authors' conclusion that prolonged use of small enteral feedings reduces
the risk ofNEC has been questioned and it is clear that caution is necessary in interpretation
of these results189.
None of the studies of MEN has assessed long-term outcomes and none attempted to
determine either the optimal time for starting minimal enteral nutrition or the duration for
which minimal enteral feeding should be given.
In the absence of conclusive evidence for the practice of MEN, researchers have sought to
determine current practice among clinicians. A survey of Australian neonatologists in 2001
yielded a response rate of 70% (56/80) 19°. Of the respondents, 80% prescribed trophic
feeding for infants born at 27 weeks of gestation and less. Reported volumes given were 1 -
30ml/day or 10-30ml/kg/day. Approximately half of the clinicians would continue MEN for
2-3 days, whereas the remaining half would continue for 5-15 days. Results of a North
American survey, conducted in 2006 were recently reported191. This survey was distributed
to neonatologists, neonatal nurse practitioners and dieticians, with a response rate of 23%
(176/775). The majority of respondents indicated that they prescribed MEN and continued
this for longer in the smallest babies. The duration ofMEN reported varied between 0 and 10
days. This reported variation suggests that lack of evidence has led to a wide range of
clinical practice with respect to the use ofMEN. In spite of positive results in physiological
studies and the now widely held view that MEN may be beneficial for high risk infants,
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objective data remains limited, uncertainty exists about how best to achieve positive effects
and further studies are warranted to guide clinical practice.
3.4.3.4 Timing of introduction of enteral feeds
The timing of initiation of enteral feeding in preterm neonates is dependent on many factors
related to inherent features of individual babies such as gestational age at birth, birth weight
and severity of illness but also to preferences of clinicians. However, the success in
establishing early feeding is also related to the structure and function of the preterm gut,
which differs from that ofmore mature infants and adults192.
Aspects of gut maturation have been studied in preterm infants, with much of the research
examining development of gut motility and the intestinal response to feeding. Berseth
characterised gut motility in 31 infants who had never been fed, using continuous
manometry192. The gestational age of the infants ranged from 25-42 weeks and studies were
carried out 12 hours before the introduction of enteral feeds. Term born infants showed
similar patterns of gut activity to those demonstrated in adults, consisting of three phases: (i)
periods of quiescence, (ii) irregular activity and (iii) periods of regular phasic propagating
activity, also known as migrating motor complexes (MMCs). In contrast, MMCs were not
present in the majority (19/23) of preterm infants and when they occurred were of lesser
amplitude than in term infants. A further study using similar methods in 36 infants examined
the response to initiation of continuous, slow formula feeding172. Results showed increases in
motility from the fasting state in both term and preterm infants that were not significantly
different, suggesting that infants as immature as 25 weeks of gestation are able to respond to
enteral feeds. The effect of timing of introduction of enteral feeds in preterm infants was
studied, using manometry and measurement of intestinal peptides, in a group of 27 ventilated
infants of whom 14 received early (postnatal day 3-5) formula feeds and 13 received late
(day 10-14) feeds173. These infants were more mature, with gestational ages of 32 ± 1 weeks.
An initial study was performed before enteral feeds up to day 5 of life, a second at 10 days
and a final study after a further 10-14 days. Feeds were commenced at 1ml/hour and
advanced daily by l-2ml/hour until a daily volume of 120ml/kg was achieved. Results
showed significant differences in intestinal motor activity, but not in intestinal peptide
activity between the groups at the time of the first study. At the time of study 2, early fed
infants showed better organisation of gut motor activity and increased gut hormone and
peptide activity compared with those fed late. By the third study period, results were the
same in both groups, with 75% of babies showing distally migrating MMCs. Early feeding
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led to earlier establishment of full enteral feeds (day 17 versus day 31 (P<0.01)) earlier oral
feeding (day 35 versus day 47 (P<0.05)) and shorter hospital stay (38 v 55 days (p<0.05)).
Late fed babies also showed greater feed intolerance than the infants fed early. This study
suggests that earlier introduction ofmilk feeds is beneficial for promoting maturation of the
gut and moreover, that delaying feeding may hinder gut development and adversely affect
clinical outcomes such as growth. Later studies showed similar advantages in introducing
milk, rather than water feeds in preterm infants, indicating that nutritional feeding is
important in the process of gut maturation after birth174 193.
Other studies and trials investigating the effect of early and late introduction of feeds on
clinical outcomes in less mature babies have been diverse with respect to timing and
volumes of feeds administered. In all studies, infants were given PN until attaining adequate
enteral feed volumes. Slagle and Gross randomly assigned 46 preterm neonates of < 32
weeks and birth weight < 1500g either to receive milk feeds of 12ml/kg/day from day 7 or to
starve for a further 10 days before advancing feeds on day 18 of life194. The type of milk
given in this study was not standardised. Early fed infants showed better tolerance of feeds
and had shorter duration ofPN.
A number of researchers have sought to determine whether timing of initiation of feeds plays
a role in the development of NEC. All studies have been small and many observational.
LaGamma et al used a scoring system to identify "sick" infants at risk of NEC195. These
infants were assigned, at the discretion of the attending clinician, to receive no milk feeds for
two weeks (n=20) postnatally or to receive incremental dilute formula or breast milk feeds
during this time although it is unclear exactly when enteral feeds were started in the early
feeding group. In this study, infants receiving no enteral feeds had a higher rate of NEC
(60%) than those given milk in addition to PN (22%). The authors came to the conclusion
that "early, dilute, incremental oral feedings that are gradually advanced may serve to protect
the human gut". However, given the small numbers included in the study and the
retrospective design, it would not have been possible to detect differences in the occurrence
of NEC with certainty. A further small study by the same research group attempted to define
an optimal time for introducing feeds196, assigning high risk babies to starting enteral feeds
on day 1 (n=18) or day 7 (n=20) of life, progressing from sterile water, to dextrose 2.5%, to
dilute milk feeds and finally to full strength feeds over seven days. Feeds were advanced
after seven days. The incidence of NEC in this high-risk group was similar regardless of
feeding (5/17 early v 6/17 late fed infants) but, as in the previous study, there was
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insufficient power to detect a true difference. Dunn et al randomised 39 ventilated infants of
<1500g birth weight with UACs to commence enteral feeds of 15-20ml/kg/day of dilute
formula at 48 hours or 10 days of life175. The attending clinician decided rates of feed
advancement after 10 days. Infants fed early in this study showed earlier attainment of full
enteral feeds and required less days of phototherapy for jaundice. This small study was also
unable to detect a statistically significant difference in rates of NEC between the early and
late fed groups (5% and 16% respectively). A case control study by McKeown et al
examined records of 59 pairs of infants matched for race, date of birth and birth weight197.
Their analysis revealed that the number of infants developing NEC who had been fed prior
to diagnosis was significantly greater than the number of controls fed during the same
period. In the NEC group, enteral feeds had been commenced significantly earlier than in
controls (mean 5.1 (SD2.2) v 7.7 (5.1) days (P<0.01)). This remained significant after
controlling for birth weight and risk score.
Only two randomised controlled trials, one published only in abstract format, have addressed
this issue. Davey et al randomised 62 infants with low UACs to early (median 2 days) or late
(median 5 days) introduction of feeds198. Feeds were of whey, breast milk or diluted formula
using identical feed volumes and rates of advancement. There were no significant
differences in morbidity between the groups, but infants receiving early feeds were evaluated
less for sepsis and received less days of PN. The authors concluded that there was no
disadvantage to early feeding of preterm infants with low UACs. Khayata randomised only
12 infants to early (within 4 days of birth) or late (day 10) feeding with standard formula
milk199. This study reported no difference in weight gain between the groups, but did not
include NEC as an outcome.
Of note is the fact that feeding protocols in the studies discussed have used water, glucose
solution or formula feeds. Only a small number of babies in one small study received
maternal breast milk. Later studies have included infants fed EBM. Sisk et al recruited a
cohort of very low birth weight infants to examine the effects of early maternal expressed
milk (MEBM) feeds200. Formula milk was given only if the mother chose to formula feed or
had insufficient breast milk and enteral feeds were started when the infant was deemed stable
by the attending clinician. In this study 72% of infants started feeds within the first 3 days of
life and 97% within one week. Infants who received > 50% of their enteral intake as human
milk (n=156) within the first two weeks of life were significantly less likely to develop NEC
than those whose breast milk intake was <50% of the total (5/156 v 5/46). The authors
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concluded that the type of milk, rather than timing of introduction or volume given may be
more relevant when considering the effects of feeding on the incidence of NEC. In a large
cohort study of Norwegian infants of <1000g, Ronnestad examined the effects of very early
feeding with human milk201. Feeding was started within a few hours after delivery at
volumes of l-2ml every 2 or 3 hours, increasing by 0.5-lml every 6-8 hours. Feeds were
started on day 1 in 61%, by day 2 in 91% and by day 3 in 96% of enrolled infants. Clinical
signs suggestive of NEC were noted in 4%, with only 2.2% having radiological evidence of
pneumatosis intestinalis. Rates of late onset sepsis were reduced in infants who achieved full
feeds earlier, but no effect on sepsis was seen related to the time of commencing feeds.
However, this may be due to the fact that feeds were started early in most babies and 80%
had achieved full enteral feeds by 14 days of life. This study suggests that it may be possible
to feed infants with EBM considerably earlier than attempted in most studies without
complications.
Few studies have sought to determine the optimum time for introducing enteral feeds in
preterm infants in the current era of neonatal intensive care and none have been randomised.
Studies that have been conducted vary considerably with respect to type and timing of milk
feeds and whether static minimal feed volumes or progressively increasing volumes are
given. None had large enough sample sizes to detect a difference in the incidence of NEC
reliably. Variation appeared to stem from differing local practice between centres and
countries, differing interpretation of the published literature and likely differing experiences
and preferences of individual clinicians. Systematic reviews have suggested that further
work is necessary to inform clinical practice with respect to the introduction of either
minimal or progressive enteral feeds185 202. Although many individual NNUs may have
written local guidelines, given the paucity of robust evidence, no clear national or
international guidelines have been produced to assist clinicians in their daily practice.
However, recent papers203 204 have suggested that minimal enteral feeds of 5-20ml/kg/day,
using human milk where possible, should be started within the first one or two days of life.
3.4.3.5 Rate of advancement of enteral feeds
Whilst the introduction of small volume feeds is thought to enhance development of motor
activity in the preterm gut, it is clear that, at some point, these volumes must be increased to
establish full enteral nutrition adequate for growth. The aim of neonatal nutritional care in
high-risk infants is to achieve this as soon, but as safely as possible, without increasing the
rate of serious complications. It has been suggested that fear of NEC may interfere with
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consideration of other important outcomes, which may be both positive, such as growth, and
negative. Since the provision of early nutrition demands the use of parenteral feeding,
usually administered via central venous catheters, the risks of prolonging PN include
catheter-related complications such as septicaemia and less commonly, cardiac tamponade.
Complications of PN administration itself include liver impairment, cholestatic jaundice,
hyperlipidaemia, and electrolyte disturbances. Rapid advancement of enteral feeds, therefore
carries benefits, but it has also been associated with an increased risk ofNEC.
Book et al first compared two different rates of feeding in a retrospective study prompted by
an observed increase in NEC from 0.3% to 5.1%205. This showed that infants developing
NEC achieved full enteral feeds more rapidly (day 7) than those who did not (day 14) and
that the average daily feed volumes were twice as large in these infants. They then
randomised 29 infants to slowly increasing feeds (10ml/kg/24 hours) or rapidly increasing
feeds (20ml/kg/24 hours). Feeds were started at a mean age of 2.9 and 2.3 days respectively.
This prospective study was not able to detect a difference in rates of NEC between the
groups due to its very small sample size. The difference between slow and fast regimens was
small and in terms of today's practice, both may be regarded as slow or even minimal
feeding. Goldman further highlighted a possible link between feed volumes and NEC in
1980206. He observed a sharp increase in NEC in infants <2500g with a change in feeding
policy characterised by larger increases in feed volumes. However, this was a diverse group
of infants of varying birth weight, severity of illness and seven different types of formula
feed were used. In addition, increases in volumes were variable, with some as high as
60ml/kg/day, which represents much larger increases than seen in most other studies, or in
clinical practice today. The multicentre study by Uauy et al showed that, in a cohort of 2681
infants at risk of NEC, the most significant factor predicting the prevalence of NEC was
differences between centres7. They observed that infants who regained their birth weight
more quickly were at increased risk of Stage II and III NEC. Although they were cautious in
their interpretation of this observational study, they suggested that, amongst other factors,
aggressive fluid and feeding regimens might contribute to the prevalence ofNEC in VLBW
infants. McKeown et al, in a case control study found that the 59 cases were fed earlier, were
given full strength feeds earlier and were fed more rapidly than controls, with sicker infants
being more vulnerable197. They estimated infants fed with increasing volumes of more than
30ml/kg/day to have a 28-fold risk of developing NEC, but the 95% confidence interval for
this result is wide (OR 28.0 (CI 3.81-205.8)).
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There are few randomised controlled trials addressing the question of the rate at which
enteral feeds should be advanced. A major difficulty with randomised feeding trials is the
inability to use blinding, potentially introducing bias. This can be minimised by concealment
of the randomisation process, the use of strict study protocols and independent observers for
outcomes, such as radiological evidence ofNEC and by the use of intention to treat analysis.
Rayyis et al randomised 185 formula-fed infants with birth weight <1500g and gestational
age at birth of <34 weeks to slow feeding (20ml/kg/day increasing by 15ml/kg/day) or fast
feeding (35ml/kg/day increasing by 35ml/kg/day)207. MEN was not used in this study and
feeds were started on day 4 or 5 of life. Breast fed infants were excluded, as were those
requiring inotropic support, those with congenital heart disease, polycythaemia or
requirement for exchange transfusion. The trial used a defined protocol for the temporary
discontinuation of feeds based on gastric residual volumes and abdominal examination.
Independent radiologists performed reviews of all x-rays to diagnose NEC. The sample size
was based on 16% of infants expected to develop of NEC with fast feeding, and the
detection of a fall to 5% in the slow feeding group. No statistically significant difference was
seen in the incidence of Bell stage II or III NEC between the randomised groups (13% for
slow feeding v 9% for rapid feeding). Of note is the fact that neither group reached the
anticipated proportion of 16%, which had been observed prior to the trial and was used to
determine the power of the trial. Babies allocated to rapid feed advancement achieved full
enteral feeds by 11 days compared with 15 days in the slow group (P<0.001) although the
length of hospital stay was similar in the groups. Caple et al randomised 155 infants between
lOOOg and 2000g birth weight and <35 weeks of gestation at birth to either slow (increments
of 20ml/kg/day) or fast (increments of 30ml/kg/day) feeding208. Breast milk was used where
possible and this was similar (32-34%) in both groups. Criteria for stopping feeds were
defined a priori. The primary outcome for this study was the time to full enteral feeds of
150ml/kg/day and infants assigned to the faster feeding regimen achieved this 3 days earlier
than the slow group (P<0.01). They also had significantly fewer days of intravenous feeding
(P<0.01) and a shorter length of stay, although the latter difference was not statistically
significant. Three infants in the fast feeding group developed NEC compared with two in the
slow group, with an overall rate of 3.2%. The day of starting feeds was determined by the
attending clinicians and is not stated for either group. The study is also limited by the
researchers' decision to exclude babies weighing <lOOOg, their justification being that there
is often a delay in starting feeds in this group. Unfortunately, this group is the most
vulnerable and high-risk group for NEC and therefore the group for whom data is much
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needed. A meta-analysis of these three randomised trials was performed in 1999 and
showed a reduction in days to full feeds and days to regain birth weight209. However, the
small number of infants included and low overall rates of NEC with wide confidence
intervals meant that the effects of different feeding regimens on NEC could not be
determined with certainty. Much larger multicentre trials, preferably including infants at
highest risk, would be required to assess this important outcome. Authors of a more recent
Cochrane review in 2008 chose to analyse the role of slow advancement of feed volumes to
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prevent NEC in very low birth weight infants . In this review, the study by Book was
excluded because feeds in both groups were advanced slowly. Perhaps because of the
challenges associated with designing large randomised controlled trials of feeding practice, it
is interesting to note that only one additional small trial met the criteria for inclusion in this
review. Salhotra and Ramji included infants <1250g who were given 2-3 days of minimal
enteral nutrition of 5ml/kg/day before increasing to 15ml/kg/day followed by increments of
either 15ml/kg/day (n=26) or 30ml/kg/day (n=27)2". In this study, full enteral feeds were
defined as 180ml/kg/day and preset criteria for feed discontinuation were used. As with
previous studies, some of the infants at highest risk were excluded because of the need for
inotropic drugs or oxygen therapy. The mean gestational age and birth weight of included
infants were 33 weeks and 1050g respectively. Results showed that fast fed babies achieved
full feeds 5 days earlier (P<0.001) and had better weight gain but the study was not large
enough to detect any difference in NEC, which occurred in only two babies, both assigned to
rapid feed advancement. The Cochrane meta-analysis was unable to show evidence of
benefit with slow advancement of feeds, due to the same reasons identified in the earlier
review.
Substantial uncertainty remains regarding the optimum rate at which feeds should be
advanced in high-risk preterm infants. Studies have been small, methods and outcomes
different, and results inconclusive. Rapid advancement has consistently, but not surprisingly,
resulted in the earlier attainment of nutritional feed volumes and therefore reduced exposure
to the risks of PN. Short-term measures of growth have also been improved in this group.
Although observational data suggest that rapid feeding may be associated with an increased
risk of NEC, randomised trials to date have not confirmed this finding. However, in reality,
no trial has been performed that would have adequate power to demonstrate this difference.
No trial of the rate of feeding has examined longer-term outcomes, such as
neurodevelopmental outcome or later growth parameters. Most studies have centred on
formula-fed infants and there are few data indicating whether suggested risks of rapid feed
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advancement are similar in infants who are either exclusively or primarily fed EBM. Indeed,
it seems plausible that the optimum feeding regimens may be different depending on the type
of milk given, but this has not been adequately explored. Few extremely low birth weight or
severely ill neonates have been included in studies, and these are also groups for whom
feeding needs may be different. In spite of the challenges associated with large trials that
investigate uncommon outcomes, it is unlikely that these questions will be answered without
such research.
3.4.3.6 Standardised feeding regimens
The large variation in incidence of NEC has, over many years, led researchers to question
whether difference in "packages" of clinical care given to preterm neonates in neonatal
centres is important in causing or preventing the disease7. In many NNUs, local guidelines
have been introduced, based on available evidence, in an attempt to standardise management
in the hope of reducing NEC and improving outcomes for babies. A report of variations in
incidence of NEC in Canadian NNUs included 18,234 infants admitted to 17 neonatal
intensive care units between 1996 and 1997 showed no significant difference in risk-adjusted
incidence between units 64. However, one unit included in this study reported no NEC among
910 admissions during this period. It is possible that this finding over a two-year period was
as a result of chance, particularly since the incidence of NEC is known to fluctuate with
time. However, the same centre also reported that they had no cases in the five-year period
preceding the study. This led the authors to conclude that "it may be possible to reduce the
incidence of NEC through selected practice changes" although the study did not specifically
collect data on feeding practices within the NNUs. Wiedmeier et al documented the
incidence of NEC in three units over a four-year period, during which one of the three
centres experienced a rate of 14.5%, compared with 2.3% in each of the other two centres212.
This study examined demographic data, maternal and infant characteristics and a number of
areas of clinical practice, including feeding of infants to try to explain this difference. Their
analysis revealed that feeding practice in the centre with the highest incidence was clinician-
dependent, whereas the other centres used detailed written feeding guidelines. They also
showed an increased incidence in black infants, although the number of such infants was
small in all centres. Although ethnicity and the number of outbom infants varied between
centres, they were not thought to account for the differences in NEC. Feeding schedules in
the two hospitals with low incidence were most notably similar in their greater use of human
milk and this may reflect the protective role of breast milk as shown in previous studies.
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However, other authors have postulated that standardised feeding guidelines may play an
important role in the prevention ofNEC in preterm infants.
In 1978 Brown and Sweet reported their experiences following the introduction of a new
"cautious" feeding regimen for preterm infants213. They described in detail their slowly
progressive feeding schedule, which they believed had "virtually eliminated" NEC from the
unit over a four-year period compared with their previous feed management. Spritzer later
reported similar findings in a sequential study before and after the introduction of a more
cautious feeding regimen for infants <2000g214. Their management of infants at high risk for
NEC changed from a first feed of 20-40ml/kg/day of full strength formula, given at the
discretion of the neonatologist, increasing by 20-40ml/kg/day. The later regimen involved
withholding feeds for one week before giving diluted formula at 20ml/kg/day, increasing by
20ml/kg/day. With this change, they saw a dramatic and prolonged reduction in NEC from
around 13% to zero over a seven-year period. Kamitsuka et al retrospectively reviewed
records of infants over a six-year period during which a standardised feeding protocol was
introduced215. Prior to this, feeding practices varied for babies of >1250g although smaller
infants were already fed according to a defined protocol. When developing the protocol, they
considered the time of starting feeds, rate of advancement and concentration of feeds and
devised different protocols for three groups of infants according to birth weight: (A) 1250-
1500, (B) 1501-2000g and (C) 2001-2500g. The groups were starved for at least 72, 48 or 24
hours respectively and longer if clinically indicated. First feeds were of either breast milk or
diluted formula, changing on day 4 of feeds to full strength. Daily feed volumes were
increased by no more than 20ml/kg/day and full feeds were established for the groups in 10,
9 or 8 days. During the non-standardised period, 4.8% (23/477) of infants developed definite
NEC, compared with 1.1% (5/467) after introducing the regimen (P=0.0006). The difference
in babies fed with breast milk was less marked, with the reduction being 60%. However, a
significantly greater proportion of babies received breast milk in the second part of the study
period, which may also have influenced the rates of NEC. Patole et al also report virtual
elimination ofNEC over a period of 5 years with standardised feeding introduced because of
participation in controlled trials compared with a historical cohort of babies216. Only one case
ofNEC was seen after introducing standardised feeding, compared with six deaths attributed
to the disease in the previous five-year period. The components of the new feeding regimen
were not substantially different from the clinical practices in the unit beforehand, except for
the management of feeds in infants with haemodynamically significant patent ductus
arteriosus (PDA), but they were unable to comment on whether this factor might have
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influenced NEC rates independently. Premji et al used a before-and-after matched cohort
study to assess the benefits of a clinical practice guideline for feeding in infants <1500g217.
Matching was performed for birth weight and gestational age in 100 babies in line with an a
priori sample size calculation based on pilot data. In contrast to other studies, the results
showed no statistically significant differences between the groups for time to full enteral
feeds, day of commencing feeding, feed intolerance, days of receiving PN or the incidence
ofNEC.
The largest study to address the value of standardised guidelines is reported by Kuzma-
O'Reilly et al on behalf of the Vermont Oxford "Got Milk" focus group218. This group
developed guidelines for potentially better practice for feeding based on eight evidence-
based criteria for the initiation and advancement of enteral and parenteral nutrition and
monitoring of feed-related outcomes. These were instituted in three participating centres, all
of which were involved in the guideline development. Membership of the VON permitted
benchmarking of these unit outcomes against other member centres. Following
implementation of the guidelines, the group showed reduction in the time to starting feeds
and achieving full feeds, increased use of breast milk as the first feed and earlier initiation of
parenteral feeding. There was a reduction in NEC from 16% to the VON mean of 6%.
Patole and de Klerk performed a systematic review of some of these observational studies219.
Although there was significant heterogeneity between the included studies (P<0.001), they
performed a meta-analysis. Inclusion of all studies213"219 revealed that the risk of NEC was
reduced by 87% (Pooled risk ratio 0.13 (95% CI 0.03-0.5) following introduction of a
standardised regimen. A second meta-analysis of studies that included VLBW infants215 218
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suggested a smaller reduction of 47%, with the study by Patole et al showing the
largest effect. Exclusion of this study from the analysis reduced heterogeneity between the
studies to a level that was not significant and this analysis suggested an overall reduction in
risk of NEC of 29% associated with the introduction of any standardised feeding regimen.
The authors conclude that standardised feeding regimens may represent "the single most
important tool to prevent/minimise NEC".
It is difficult to interpret data from such studies reliably. The included studies were
conducted over a period ofmany years, during which neonatal care has progressed, in terms
of both the population requiring intensive care and the treatments available to clinicians.
Many of these factors may influence changing outcomes. The use of before-and-after
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analysis is also subject to confounding within individual studies due to other local changes in
clinical practice, patient population and staff over time. Caution should therefore be
exercised in attributing reduction in adverse outcomes entirely to the introduction of a new
policy. Since differences in the policies existed between the studies, this implies that, rather
than content of the policy being the most important factor, the mere existence of a unit
guideline influenced outcome. This is difficult to explain. Unfortunately, none of these
studies showed evidence ofmonitoring of strict compliance with the policy and it cannot be
assumed that adherence was universal.
3.4.3.7 Fortification of breast milk
Whilst there are many clear benefits to feeding with breast milk, human breast milk does not
provide sufficient protein, sodium, calcium or phosphate to fully meet the nutritional needs
of the preterm infant221. The nutritional content of milk from mothers delivering preterm is
similar to that of term milk by 3 or 4 weeks after birth, a time of very high nutritional
demand for the baby, considerably in excess of that in a healthy term baby222. Inadequate
nutrition at this time can have long-term effects on growth and development. Low mineral
intake in infants fed solely on breast milk places them at risk of decreased semm phosphate
levels, increased calcium levels and increased alkaline phosphatase (ALP) activity compared
with infants fed preterm formula, which is specifically designed to meet these needs223.
Osteopenia of prematurity is common in preterm infants due to delayed feeding and lack of
active movement and this is further exacerbated by inadequate intake of essential minerals.
Protein content is variable in breast milk and may also be inadequate. In practice, one
potential response to this situation is to change from breast milk to formula feeding, but this
approach deprives high-risk infants of the beneficial effects of breast milk and is
unacceptable to many mothers who wish to establish breast-feeding at later stage. To
overcome this, methods of fortification based on cow's milk have been developed for
addition to human milk, the most commonly used being powders containing multiple
nutrient components including protein, fat, minerals, electrolytes, vitamins and trace
elements224.
Growth in infants fed fortified human milk does not reach the rates seen in formula fed
infants. Schanler et al compared infants receiving either fortified breast milk or preterm
formula225. Infants receiving fortified breast milk showed better tolerance of feeds and
attained full enteral feeds earlier, although both groups attained full oral feeding at a similar
time. This group also experienced significantly lower rates of NEC than the formula group
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(1.6% v 13% (P<0.01)). However, rates of growth in these babies were significantly lower
than in the formula fed group. The authors concluded that the benefits of feeding with human
milk fortifier (HMF) outweighed the disadvantage in growth.
Several studies made additional comparisons between preterm formula, fortified breast milk
and unfortified breast milk. These studies were diverse with respect to entry criteria,
volumes of milk given, components and amounts of the fortifier used, and outcome
measures. Most evaluated growth in some way and some included measurements of bone
mineral content. Human milk in all studies was either mother's own milk or donor breast
milk, depending on availability. Carey analysed data from 18 infants of birth weight <1500g,
randomised to one of three groups: human milk with or without fortification or preterm
formula226. Fortification included protein, calcium and phosphorus. The milk protein content
differed between the groups but energy content was similar. The study protocol continued
for around one month. This small study showed increased weight gain (g/kg/day) in the
groups fed fortified human milk or formula compared with infants receiving only unfortified
breast milk. Both human milk groups showed low phosphate levels and high ALP levels
compared with formula fed infants. Venkataraman studied 24 infants <1500g in a similar
study and also showed raised ALP levels with feeding of non-fortified human milk, but not
in the other groups227. Outcomes were evaluated after 2 weeks. This study also measured
bone mineral content by direct photon absorptiometry and found this to be lowest in the non-
fortified human milk group and highest in the formula fed group. Weight gain was not
measured. In a study by Modanlou et al, 30 very low birth weight infants were assigned to
similar groups and were evaluated at the time of discharge or when the weight had reached
1800g228. Their HMF contained additional protein, calories and minerals. This study also
showed poorer weight gain (g/day) and slower increase in head circumference in infants fed
unfortified human milk, but the authors were unable to show a difference in bone mineral
content between the randomised groups. Nicholl and Gamsu used a HMF containing protein,
carbohydrate, calcium, phosphorus, minerals and vitamins in a study randomising 52
infants229. Weight gain (g/kg/day) was highest in the formula fed infants and similar in both
groups receiving human milk. Linear growth was measured using changes in lower leg
length velocity and this was significantly greater in infants fed preterm formula or fortified
human milk that those given human milk alone. Ronnholm studied 44 infants, randomised to
receive unfortified human milk versus supplementation with either protein, fat or both230.
This study showed increased gain in weight and length in the protein-supplemented groups
and a decrease in protein levels in the group fed unfortified human milk, suggesting that
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protein, rather than calorie content, is the most important factor influencing weight gain.
Kashyap analysed data from 42 infants between 900 and 1750g birth weight, given mother's
own milk either with or without supplementation containing protein, calcium, phosphorus
and sodium231. A third group comprised infants who received supplemented donor breast
milk. The results showed increased weight gain in the supplemented human milk groups
compared with the unsupplemented group, but ALP levels did not differ. The degree of
weight gain was proportional to the amount of protein fed, supporting the hypothesis that
protein influences weight gain in these infants. Greer and McCormick included, in addition,
a group of infants that were fed a standard term infant formula in a study of 38 infants232.
They found that infants receiving either unfortified human milk or term formula took greater
volumes ofmilk than the other groups. However, when evaluated after 6 weeks, these groups
showed poorer weight gain (g/kg/day), poorer gain in length and head circumference and
reduced bone mineral content compared with the infants who had been fed with fortified
breast milk or preterm formula.
Others have examined the practice of using preterm formula as a supplement for human
milk. Gross, in a study of 2 phases, compared unfortified human milk with supplementation
using preterm formula after one week and supplementation using a powdered fortifier
containing calcium and phosphorus after 2 weeks233. When all groups were compared, there
was no difference between gain in weight, head circumference and length. However,
secondary analysis showed significant increases in all parameters in the group receiving
powdered fortifier compared with either of the other groups. After 5 weeks, there was no
difference in the change in bone mineral content between the groups, although all were
significantly less than those of healthy term babies. Interestingly, by the time of follow up at
44 weeks of gestation bone mineral content in these babies had increased to levels similar to
term infants. This led the authors to conclude that fortification of human milk may not be
necessary in healthy preterm infants, in view of the lack of evidence of long-term benefit.
Zuckerman compared unsupplemented human milk with supplementation with preterm
formula in 53 infants, only 20 of whom were followed up at 18 weeks after discharge234.
They observed no rickets, found no differences in weight gain or length between the groups
and concluded that supplementation of breast milk conferred no significant advantage over
human milk feeding. One study compared only two groups with mean gestational age of 33
weeks, receiving either fortified or unfortified human milk235. They saw an increase in bone
mineral content and faster return to birth weight in the fortified group. However, after
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regaining birth weight, the rates of increase in birth weight (g/kg/day) were similar in the
two groups and by 3 months of age, bone mineral content was similar.
A number of other studies chose to supplement the control group of unfortified milk fed
infants with minerals. Faerk looked at 127 infants of <32 weeks' gestation in 3 randomised
groups given human milk (mother's or donated) with added phosphate, human milk with
protein, calcium and phosphate or preterm formula236. This study showed increased weight at
term in the preterm formula group compared with the others, but no difference between the
groups for head circumference, length or bone mineral content. Polberger compared
supplementation of human milk with fat, protein or both and all included infants were also
given supplements of vitamins, folate, calcium and phosphorus237. From 4 weeks, iron was
also added. As shown in previous studies, growth was related only to the intake of protein.
Large differences were seen in the amount of milk produced by mothers, which also varied
in protein content. Wauben compared maternal breast milk supplemented with a
multicomponent fortifier or phosphate and calcium alone with preterm formula238. Weight
gain (g/kg/day) was similar in both groups fed human milk, but this was lower than those fed
formula. There was no difference in bone mineral content between the groups.
Only one study addressed longer-term effects of human milk fortification239. Lucas
randomised 275 infants of <1850g to receive fortification of maternal breast milk either with
a multicomponent fortifier or phosphate, sodium, potassium and vitamins. Infants whose
mothers were unable to produce sufficient breast milk were supplemented as necessary with
preterm formula. There were no differences in the rates of growth between all groups, but
those infants who received >50% of their intake as breast milk had increased weight gain
(g/kg/day) than those receiving less breast milk. When followed up at 18 months, the
fortified group attained higher scores on BSID, but this did not reach statistical significance.
The results of these studies are challenging to interpret because of the differences between
them. There were very few infants of birth weight <1000g included in any of these studies.
This is perhaps largely due to the fact that many were conducted when numbers of surviving
babies of extremely low birth weight and gestational age were fewer. Most of the studies
were also subject to large rates of attrition due to inadequate breast milk production, poor
feed tolerance or illness in the babies. For many studies, the number of infants for whom
data were analysed does not reflect the numbers that were initially recruited to the studies.
This might introduce some bias in favour of infants whose mothers were able to produce
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large quantities of breast milk and larger, healthier preterm neonates. The majority of these
studies have included small numbers of infants. Kushel and Harding performed a Cochrane
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systematic review of thirteen randomised controlled trials " comparing human
milk supplemented with multicomponent fortifier and unfortified human milk, including a
total of over 600 infants240. Meta-analysis of these trials showed small but statistically
significant increases in weight gain, head growth and linear growth in the infants fed
fortified milk compared with unfortified milk. They did not show an effect on ALP levels.
No short-term adverse effects were seen, although the small numbers and high attrition rates
in most studies imply that cautious interpretation of this finding is required. No long-term
advantage was found, although this was not addressed by most studies.
There has been concern clinically about feed tolerance in infants given fortified milk,
although the definition of feed intolerance on which this may be based presents challenges.
The Cochrane systematic review showed a trend towards increased feed intolerance, but this
was not statistically significant240. Moody et al compared infants fed fortified human milk
with infants fed unfortified human milk241. The mean gestational age and birth weight were
27 weeks and 1065g respectively and the infants received fortifier from 22 days of age.
Although fortified infants had more episodes of gastric residual volumes >2ml/kg and more
episodes of vomiting, this did not translate into a difference in the number of hours for which
feeds were stopped, delay in attaining full feeds or hospital discharge. One of the proposed
mechanisms for feed intolerance is delayed gastric emptying associated with the use of
fortifier. Several studies have examined this, using paired studies of infants who were fed
fortified and unfortified milk. McClure and Newell, in a study of 22 low birth weight infants
found no influence on gastric empting242. Infants' median weight was 1495g and gestation
31.5 weeks; tests were carried out at 6-67 postnatal days. Gathwala used similar
methodology in 25 babies with a mean gestational age of 34 weeks and birth weight of
1900g243. They also found no effect of fortification on gastric emptying. In contrast, Ewer
and Yu found, in paired studies in 11 infants, that gastric emptying was slower in 10 of the
11 infants when fed fortified, as opposed to unfortified breast milk. These were less mature
infants with median gestational age of 28 weeks and birth weight of 1090g. Given the effects
of maturation on gut motility, it is possible that the conflicting results were due to the
different gestational ages of infants studied. However, a recent study in 20 VLBW infants
with mean gestational age of 29 weeks, found that although gastric emptying was reduced in
infants when they were fed fortified milk, this did not reach statistical significance244.
68
Some studies have included NEC as an outcome. In a prospective cohort study, Hallstrom
studied risk factors for NEC in 140 infants245. Stage I-III NEC developed in 18.6% and
severe (stage II-III) NEC in 8.6%. On logistic regression, the use of breast milk fortifier was
significantly associated with all types ofNEC (OR3.85, 95% CI 1.29-11.5 (P=0.016), but not
with severe NEC. However, the infants developing severe NEC were significantly more
immature and small than the rest of the NEC group. In their randomised trial, Lucas et al
observed a non-significant trend (P=0.12) towards increased NEC in infants receiving
fortified milk239.
Increase in the osmolality of feeds has been suggested as a possible precipitating factor in
NEC246. Jocson et al showed that the storage for 72 hours of fortified human milk increased
the osmolality by approximately 4%. Others have since investigated the osmolality of
fortified milk before and after storage for 24 hours. De Curtis showed that, with the
exception of those containing only protein, addition of fortifiers rapidly increased the
osmolality and a further increase was seen after storage247. Yigit also reported increased
osmolality and found that it was highly variable between samples, but the time at which it
was measured was not standardised 244. Another study measured osmolality at 20 minutes
and found a significant increase, but no additional change was seen at 6 hours248. Osmolality
may vary with different types of formula and it is possible that this change may have
different effects depending on the maturity of infants. No study has specifically examined
this in a large group of infants.
Previously, HMFs have been derived from cow's milk. A recent development lies in the
production of a new exclusively human milk-based fortifier, derived from screened human
donor milk. Only one trial has so far studied this product249. 207 infants of birth weight 500-
1250g were randomised to receive human milk-based fortifier when the enteral intake was
either 40ml/kg/day or lOOml/kg/day or bovine milk-based fortifier when the enteral intake
was lOOml/kg/day as a supplement to maternal or donor breast milk. Comparison between
both human milk groups and the bovine fortifier revealed a lower incidence of NEC and
surgical NEC in the human milk-based fortifier groups, both separately and combined. The
reduction in NEC was 50% and for surgical NEC approached 90%. A statistically significant
difference was found for the combined outcome of death and NEC (P=0.02). All cases
requiring surgery were in the group fed bovine milk-based formula. The authors suggest that
an exclusive diet of human milk may be important for protection. In one of the groups,
fortification was started earlier and was tolerated well, which may have implications for
69
earlier and more appropriate weight gain. In addition, all infants in this study were less
mature than in many other studies, so results may be more applicable to the current
population of high-risk neonates. This may therefore represent an important advance in the
enteral feeding of preterm babies.
3.4.3.8 Feeding preterm growth restricted infants
In view of the conflicting evidence with respect to NEC in growth-restricted infants,
uncertainty exists about how enteral feeding should be introduced in these infants. This has
led to the use of very heterogeneous feeding strategies among neonatologists. Research in
this field reflects this uncertainty.
Several studies have looked at postnatal intestinal motility and tolerance of feeds in infants
with abnormal Doppler studies. Robel-Tillig et al prospectively studied 124 infants with
birth weight of less than 1500g25°. This study found that 38/42 (88%) infants with prenatal
haemodynamic disturbances had signs of intestinal motility problems including later
tolerance of feeds and delayed passage of meconium, although none developed classical
signs of NEC. These infants also had reduced blood flow velocity in the SMA supporting
the hypothesis that poor gut perfusion may contribute to observed gut motility disturbances.
Enteral feeding in these infants was started "as early as possible, but not before the 12th hour
of life", but no further detail is provided about exact timing of introduction of feeds or the
rate of increase in the two study groups. Miiller-Egloff et al also showed slower progression
of feeds in infants with severe prenatal Doppler abnormalities in infants who received
minimal enteral feeds of 18-16ml/day of breast milk or diluted preterm formula from the first
day of life and where feed intolerance was defined as gastric residuals of > 3ml or 50% of
feeding volume, whichever was greater94 25°. Mihatsch studied a group of growth-restricted
infants and found no differences in the age at starting feeds, time to achieve full feeds or the
age at full feeds251. However, in this study, initial enteral feeds were of glucose 5% in the
first hours of life, with milk feeds started only when the infant had passed meconium,
according to the NNU's protocol for feeding all VLBW infants. Prenatal umbilical Doppler
studies were performed in only 55% of infants; where these were abnormal or there was
brain sparing, feeds were started later. The authors concluded that no special feeding
protocol for growth-restricted infants was necessary. Murdoch et al performed postnatal
Doppler studies of the SMA on the first postnatal day in 64 infants and demonstrated a
positive association between NEC, which occurred in 10 infants, and high-resistance flow in
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the SMA252. In this study, enteral feeding was delayed by 5-7 days in infants who had AEDF
or REDF on antenatal Doppler studies.
The uncertainties that exist with respect to enteral feeding in growth-restricted infants are
similar to those for appropriately grown preterm infants. Flowever, the observation that
IUGR infants seem to be at special risk of developing NEC, together with evidence that gut
perfusion may be disturbed postnatally in these infants has made many clinicians feel that
enteral feeding may play an even more significant part in either reducing or increasing this
risk. The research studies described above illustrate the range of strategies that may be
adopted in feeding these babies in the absence of conclusive evidence. In a review article,
Dorling reports results of a survey of hospitals in two English health regions, which showed
marked variation in clinical practice in commencing enteral feeds and suggested that
abnormal antenatal Doppler studies made delaying feeds more likely96. The Abnormal
Doppler Enteral Prescription Trial253 conducted in the UK, completed recruitment in 2009.
This trial randomised babies bom at up to 34 weeks of gestation, in whom antenatal Doppler
studies had shown AEDF or REDF, to start enteral feeds "early", on day 2 of life or "late" on
day 6 of life. The primary outcome measures are the age at which full feeds of 150ml/kg/day
are sustained for 72 hours or more and NEC. It is anticipated that the results of this important
and large randomised trial will clarify which of these regimens is preferable in these infants.
However, the trial does not address the question of whether the introduction of feeds the first
day of life is appropriate in such infants, although it is likely that some clinicians use this
approach with MEN. In addition, given the inconsistent availability of Doppler studies in
many centres, uncertainty will remain as to whether results of this trial are applicable to
growth-restricted infants in whom results of Doppler studies are not available or in those
where results have not shown absent or reversed end diastolic flow.
3.4.4 Umbilical vessel catheterisation
Catheterisation both of the umbilical vein and artery are common practices in neonatal care.
The insertion of indwelling umbilical catheters in high-risk preterm neonates facilitates
monitoring of physiological parameters, administration of fluids and PN and minimises the
need for invasive blood sampling. Cochran et al first documented both benefits and
complications in 1968254. However, the use of such techniques has been controversial for
many years because of reports suggesting an increased incidence of NEC in babies with
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umbilical catheters in place. There are two positions considered acceptable for the placement
of the tips of umbilical arterial catheters (UACs). "High" catheters are usually placed so that
the tip lies in the descending aorta above the diaphragm and below the left subclavian artery.
Low catheter tips lie above the aortic bifurcation and below the renal arteries.
Uncertainty has existed about the risks associated with placement of the catheter tips,
duration of use and the concurrent administration of feeds via the enteral route. Many reports
documenting these concerns about the use of umbilical catheters date back to the period
when exchange transfusion was regularly and often repeatedly performed via the umbilical
vein in neonates with haemolytic disease due to rhesus incompatibility. At this time,
umbilical venous catheters (UVCs) were placed without radiological confirmation of optimal
placement. Castor et al described spontaneous gut perforation in two mature infants
following exchange transfusion and speculate that altered haemodynamics, together with
local bowel wall factors may be contributing factors255. Touloukian et al described further
cases of babies with clinical signs of enterocolitis after exchange transfusion and, in the
same paper, also reported an experimental piglet model of exchange transfusion using
umbilical catheters, documenting a dramatic rise and fall in portal venous pressure with the
potential to lead to angiospasm256. Both authors noted the similarity of clinical and
histological features in these babies to those in preterm infants with NEC and postulated that
aetiological characteristics may be shared by the two conditions that may include
complications of UVC use255 256. Both also noted the tendency for UVCs to be placed
inadvertently within the portal vasculature, increasing the likelihood of associated
haemodynamic, thrombotic, embolic or septic complications.
A later study explored the effects of UACs on mesenteric blood flow in 12 clinically stable
infants using duplex Doppler sonography 257. These researchers showed a significant
increase in blood flow in the coeliac trunk on removal of the catheters, although there was no
evidence of thrombosis having occurred. They suggested that the presence of an UAC might
produce obstruction to the coeliac trunk and SMA, lending support to the hypothesis that
catheters increase the risk of NEC by reducing mesenteric blood flow in neonates. They
therefore recommended caution in the use of UACs in haemodynamically unstable newborn
infants.
Wigger, in 1970, reported the post mortem finding of significant thromboses in infants with
arterial (n=20) and venous (n=ll) umbilical catheters258. These infants had serious sequelae
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such as pulmonary embolus, hepatic and renal infarctions and in some cases death was
directly attributed to catheter-related pathology. Tyson later reported even higher rates in a
larger population of infants with UACs sited above the diaphragm259. Thirty-three infants of
56 that had UACs were found to have multiple thrombotic lesions in the aorta, representing
an increased risk of embolic damage to abdominal organs and 23 infants had mesenteric
thromboembolism. No infant without a catheter had thromboses, but in those with catheters,
thrombus formation was seen as early as 12 hours after inserting the catheter and the extent
of the disease increased with prolonged duration of catheterisation.
Bunton et al explored the hypothesis of umbilical catheterisation as a contributing factor to
the development of NEC in an epidemiological study260. They retrospectively reviewed
medical records of 17 infants with NEC and 45 control infants, matched for time of
admission, birth weight and the presence of haemolytic disease in 5 infants diagnosed with
NEC. Their analysis revealed that the presence of umbilical catheters, duration of use of the
catheters and frequency of catheter-related complications were all significantly increased in
infants who developed NEC. In infants receiving exchange transfusion, they did not show
any difference that could be attributed to the procedure. The authors were cautious about
directly attributing NEC to umbilical catheterisation, since NEC did not develop until 2-29
(mean 13) days after removal of the catheters. Of note, also, is the fact that this group was a
small and heterogeneous group of infants, with widely varying gestational age and birth
weight. Only 5 (29.4%) infants studied were of very low birth weight (<1500g) and a further
7 (41%) were of a gestational age of >35 weeks suggesting that predisposing factors to
disease may have varied within the group. Others have demonstrated an association between
umbilical catheterisation and NEC. Smith et al, in a study of 17 infants with NEC and 49
controls showed that 35% of infants with the disease, compared with only 6% of controls
had an UAC in situ (P<0.01)261. However, this group was similarly heterogeneous in terms
of birth weight, gestational age and underlying pathology. In a larger study, Palmer et al
reported on cases ofNEC identified in the UK in 1981 and 1982 as part of a UK surveillance
scheme comprising eight centres 4. Sixty-two cases and 97 controls were included. Logistic
regression analysis showed an independent effect associated with catheterisation of the
umbilical artery, but not the umbilical vein. The associated relative risk was estimated as
18.1 in infants with birth weight <1500g, independent of the effect of birth weight. However,
umbilical catheters are most commonly used in infants with respiratory disease and on
further analysis, its association with NEC was not independent of respiratory distress in these
infants.
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Other epidemiological studies have failed to find any relationship between umbilical
catheterisation and NEC8 7172 74 77 245 262. The most recent epidemiological study of association
was a retrospective review by Guthrie et a! of an administrative database comparing infants
who did and those who did not develop NEC75. Univariate analysis showed the use of both
umbilical and venous catheters to be significantly related to NEC, but when closer
examination with multivariate analysis including birth weight was performed, the effect was
no longer present and there was an apparent protective effect of umbilical catheterisation.
The authors were unable to provide any explanation of this finding and indeed it is difficult
to think of any plausible reason why this effect should be seen.
Later studies have focused on the group of infants known to be at highest risk of NEC by
virtue of their low gestational age and birth weight. It therefore appears likely that earlier
studies demonstrating a significant relationship were subject to error due to small numbers
and heterogeneous study groups. It is possible that the findings may be more related to
relatively high numbers of mature infants undergoing exchange transfusion in these studies
and misplacement of the catheters with ensuing haemodynamic complications causing an
ischaemic effect on the bowel. In recent years, the necessity of exchange transfusion has
decreased substantially due to advances in antenatal care and the ability to provide
intrauterine transfusion in foetuses with severe haemolytic disease. In addition, it is now
routine practice to ascertain catheter positions radiologically prior to using umbilical
catheters to withdraw blood or infuse fluids, so it is unlikely that this finding will be
replicated in any future studies to identify risk factors for NEC.
A number of researchers have conducted studies to determine the optimal placement of
umbilical catheters to avoid potential complications. A Cochrane Review of this subject was
published in 2000263, including five studies264"268. Four of these were randomised controlled
trials265"268. All studies reported on the incidence of NEC, but it was a rare outcome with
reported rates of only 3.9% with high catheters and 2.9% with low catheters, which did not
represent a statistically significant difference between the groups on meta-analysis.
However, Barrington comments that, although this does not necessarily mean that there may
not be a clinically significant effect, given the low incidence of NEC overall, it is unlikely
that further studies will be performed with sufficient power to detect a clinically significant
difference263. In this meta-analysis, duration of usage was improved and vascular
complications reduced with high catheters, leading to the recommendation that high
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catheters should be preferentially used where possible.
The fact that almost all infants who develop NEC have started enteral feeding prior to the
onset of disease has led particularly to caution in introducing enteral feeds in the presence of
an umbilical catheter. However, there have been surprisingly few studies specifically
focusing on this aspect of clinical practice. Lehmiller and Kanto first explored the
relationship between umbilical catheterisation, thrombotic disease, enteral feeds and NEC in
197 8269. In this study of 30 post mortem examinations, mesenteric thromboembolism,
apparently caused by umbilical catheters, were seen in 12 of 16 infants with NEC. Ninety-
four percent of these infants had been fed enterally before developing NEC. Although the
authors found significant relationships between thromboembolism and NEC and between
feeds and NEC, there was no statistically significant association between enteral feeds and
thromboembolism, except in those infants who had received enteral feeds whilst a UAC was
in place. They hypothesised that thrombus caused by the UAC formed intermittent emboli,
which were then increased in the presence of increased postprandial blood flow associated
with milk feeds. Moreover, they suggested that the effects of ischaemic damage caused by
this mechanism would then be exacerbated by the increased metabolic demands of
processing feeds in the gut. These findings supported a hypoxic-ischaemic cause for NEC
and might explain the increased risk associated with feeding.
Only one clinical trial has since examined this issue. Davey et al randomised preterm infants
with UACs placed in the low position to receive feeds while the catheter was in place (n=29)
or after it had been removed for 24 hours (n=31)198. They found no increased risk ofNEC or
other morbidities in the early feeding group and these infants required PN and percutaneous
central venous catheters for shorter periods of time, potentially reducing their risk of
systemic sepsis. They concluded that there appeared to be no disadvantage to feeding stable
preterm infants in the presence of a low-positioned UAC. However, since NEC is a rare
event, this study would have been grossly underpowered to detect a difference had NEC
been chosen as a primary outcome measure. Instead, they chose more common, but much
less specific, signs of feeding difficulties necessitating discontinuation of enteral feeds as
outcome measures representative of NEC risk. Since such feed intolerance is non-specific
and may be associated with other illnesses as well as NEC, this may not be the most
appropriate approach in a small study.
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In 2003 Tiffany et al published results of a survey in the USA investigating NNU practice
with respect to concurrent use of umbilical catheters and enteral feeds and perceptions of
complications associated with this approach. NEC was highlighted by 18% of respondents as
a complication related to UVC use270. Thirty-seven percent reported regular practice of some
feeding with a UVC, 51% some of the time and a further 12% never practised this. Less
common was the practice of more complete enteral feeding with a UAC in place, with 24%
regularly and a further 44% sometimes doing this. With respect to UAC placement and
concurrent feeding, small feed volumes would be given most of the time by 30%, some of
the time by 49% and never by 22%. Complete feeding and concurrent use of a UAC was
never practised by 49% of respondents. NNUs that never initiated enteral feeding with
umbilical catheters in place reported waiting around 12 (0-24) hours after removal of the
catheter before starting feeds. The brief structured questionnaires in this survey were sent to
NNU directors to obtain a representative response from each unit. The response rate was
70% and no attempt was made to elicit reports of variation between clinicians within any
single unit. It is possible that, had this been explored, the range of responses might have been
more varied. A further survey was conducted in Australia in 2004 designed to document
feeding practices190. 56 neonatologists, representing a response rate of 70%, completed this
survey. Almost 18% responded that a UVC should be removed prior to starting enteral
feeding and 23% would remove a UAC prior to feeding. 67.9% and 66% respectively
disagreed with this approach and 10-14% of respondents were uncertain.
Despite conflicting results and limitations of many of the studies considering umbilical
catheterisation and NEC, their influence on clinical practice can be seen. Current
recommendations are that UVCs should be placed in the inferior vena cava and UACs in the
high position. However, the optimum duration of use to minimise complications remains
uncertain. The use of both UVCs and UACs remains controversial, particularly when
considering the importance and safety of feeding whilst maximising benefits associated with
catheter use and the relationship between catheters and NEC remains unproven. It is likely
that there is substantial variation in the interpretation of the available evidence on this
subject and probable that this is reflected in varying clinical practice.
3.4.5 Blood Transfusion
Anaemia is common in premature infants in part due to the well-recognised anaemia of
prematurity and exacerbated by the need to perform repeated blood sampling for
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investigations to monitor these infants whose total blood volume is small. Neonates
frequently receive multiple blood transfusions, both in the early days or weeks after birth and
later when, although their clinical condition is generally more stable, they may nevertheless
become progressively and profoundly anaemic and are sometimes symptomatic from this.
There have been reports linking blood transfusion with the occurrence of NEC. McGrady et
al noted an outbreak of NEC that appeared to be directly associated with blood
transfusion271. They reported a cluster of cases and compared with a group of control infants,
infants with NEC were significantly more likely to have received a blood transfusion shortly
before developing the disease, although they do not specify the length of time between the
two events. Their analysis does not implicate early feeding, the use of umbilical catheters or
exchange transfusion as risk factors in this epidemic setting, distinguishing their cases from
previous reports centred on endemic occurrence of the disease4 260 261. They proposed volume
homeostatic mechanisms as important potential contributing factors. Bednarek et al also
examined the relationship between NEC and transfusion practice, finding no association
between the two272. Importantly, however, this analysis was performed according to centres
with differing transfusion policies, rather than individual babies and no reference was made
to the timing of onset of NEC or transfusion administration in this study. In addition,
although they reported progressively decreasing incidence of NEC across units that were
"high, middle and low transfusers", these results may be confounded by the unreported
differences in severity of illness in babies receiving transfusions.
Mally et al reported an association between transfusion and NEC in a group of preterm
infants who had progressed from the acute stages of their prematurity-related illness to a
more stable condition where care is centred mainly on feeding, growth and preparation for
hospital discharge273. Anaemia of prematurity can be a significant problem in such babies
and transfusions continue to be commonplace, even in the absence of acute illness. They
noted a high rate of severe NEC in these babies and chose to examine risk factors in all
babies with NEC during a 17-month period. During this time the overall rate ofNEC in the
NNU was 1.8% and in infants <1000g was 10%. Six cases developed within 48 hours of
blood transfusion in otherwise stable neonates and 11 cases developed that were not closely
temporally related to transfusion. The median intervals between transfusion and onset of
disease were 19 (range 12-38) and 180 (range 96-312) hours respectively. Infants who
developed NEC following transfusion were all fully fed on enteral feeds compared with 9%
in the non-transfusion associated group, and had no central vascular catheters, in contrast to
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91% of the non-transfusion group who had catheters in place. None of the recently
transfused infants, but 45% of those who had not recently been transfused was ventilated.
These factors and the later onset of disease (32±7 compared with 11±7 days of life) lend
credence to assertion that these infants were clinically stable prior to transfusion. All
received their transfusions electively for anaemia of prematurity. The NEC in the recently
transfused babies was particularly fulminant with pneumatosis intestinalis developing in all,
compared with 70% in the other group and mortality was 50% compared with 35%. The
authors discuss possible mechanisms to account for this phenomenon and suggest that
factors concerned with storage of blood for transfusion may play a part. Red blood cell
characteristics may be altered with storage, making them less deformable and hence more
susceptible to trapping in the microcirculation, which might give rise to vascular lesions;
oxygen transfer capacity may also be reduced, potentially leading to hypoxic injury. Factors
within the infants themselves may also play a part and it is of note that all were anaemic;
although there was no overt difference between the groups in occurrence of apnoea, the
authors suggest the possibility of occurrence of low-grade gut ischaemia that might be
exacerbated by repeated mild apnoeic episodes related to anaemia. They conclude that their
study did not provide sufficient information to determine a cause for transfusion related
NEC, and that it is likely that several factors may be responsible, related both to the infant
and to the transfused blood itself.
In the light of suspicion that gut disease may be precipitated by blood transfusion, opinion
has varied about whether feeding during transfusion might worsen the risk. A recent study
by Krimmel et al sought to examine the influence of blood transfusion on mesenteric blood
flow in the presence and absence of enteral feeding in 22 preterm infants bom at 25 to 32
weeks of gestation274. All were receiving enteral feeds of at least 60ml/kg/day. The normal
postprandial response is an increase in mesenteric blood flow and blood flow velocity.
Doppler flow studies of the SMA were performed sequentially pre-feed and post-feed,
before and after blood transfusion in two groups of infants randomised either to have feeds
given or withheld during transfusion. Infants who had previously had NEC and those
experiencing feed intolerance at the time of the study were excluded and the study group was
stratified by weight of above or below 1250g. Those of higher weight were transfused later
in life and for a lower level of haemoglobin than larger babies. Doppler studies in infants
>1250g showed an increase in peak and mean blood flow velocity in response to feeding
when anaemic, but not after transfusion. This effect was not seen in smaller infants who
displayed no response to feeding prior to transfusion. Following transfusion, neither group
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exhibited a change in blood flow in response to feeding. The authors hypothesised that larger
infants may be at greater risk of NEC secondary to transient gut hypoperfusion post
transfusion. The study found no difference between the groups based on whether they were
fed during transfusion, or whether feeds were of breast milk or formula and the authors
interpret these findings as indicating that feeding during transfusion is probably a safe
practice. However, since the study was not designed to investigate NEC as an outcome
measure, cautious interpretation and extrapolation of these results to clinical practice is
required. Nevertheless, this recent work by Krimmel supports the observations made and
hypothesis suggested made by Mally et al that larger and more mature infants with anaemia
of prematurity may be more vulnerable to the haemodynamic effects of transfusion, putting
them at an increased risk ofNEC273.
In the absence of clear recommendations, practice relating to blood transfusions has been
extremely diverse and results of clinical studies and trials examining practice have been
conflicting. Bednarek et al highlighted significant variation between NNUs in an
observational study of six centres272. This variation was not related to case mix in terms of
birth weight or severity of illness of babies included. Bell et al, in a randomised trial
including 100 infants, attempted to clarify whether transfusion practice according to
haemoglobin levels should be restrictive (transfusing at lower levels of haematocrit) or
liberal (transfusing at higher levels of haematocrit)275. Results showed an increase in the
number of transfusions in the liberal group, but a greater incidence of adverse neurological
outcomes in the group transfused at lower levels.They concluded that a more liberal
transfusion policy may be more appropriate. A similar randomised controlled trial in more
than 400 infants with birth weight of <1000g did not support these findings. In this study,
Kirpalani et al showed little evidence of benefit in using a restrictive policy based on
haemoglobin levels during the whole of the neonatal hospital stay, but found that these
infants received significantly more transfusions, which might theoretically increase risks of
transfusion-related complications276. They showed no difference in secondary outcomes of
the trial, including NEC and concluded that a restrictive policy was equally effective and did
not increase morbidity. Their follow-up of 93% of the original cohort at 18-21 months did
not show any difference in a composite outcome of death and neurodisability277. However,
post hoc analysis revealed worse cognitive outcomes in the restrictive group (P=0.016),
lending some support to the view that the more liberal approach of transfusing at higher
haemoglobin levels may be more beneficial, although cautious interpretation of unplanned
post hoc analyses is advisable. Failure to define clearly a preferred strategy means that there
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may still be considerable variation in opinion and practice. There is clearly a need for further
research to define safe levels at which infants should be transfused and elucidate the factors
that may link blood transfusion and NEC particularly in more mature very low birth weight
babies in order to guide clinical management and optimise transfusion strategies. There has
been no recent documentation of current transfusion practice or its relationship to the
development ofNEC.
3.4.6 Patent ductus arteriosus (PDA) and its management
The relationship between the presence of PDA, its management and the development of
NEC has been discussed for many years. PDA is often seen in sick preterm neonates and
NEC is also commonest in this group, so the two conditions are likely to occur together. The
presence of a PDA has been suggested as a risk factor for NEC, with the likely mechanism
being the flow ofblood from mesenteric arteries into the aorta and through the PDA, leading
to reduction of perfusion in the intestine. Recent research in preterm baboons showed that
the presence of a PDA limited the ability of the animal to increase blood flow to the intestine
postprandially, supporting this theory278. However, none of these animals developed NEC.
Van de Bor et al found that in a cohort of over 1300 babies <32 weeks or <1500g birth
weight, the incidence of PDA was 10.7%, and those with PDA were more likely to develop
NEC than those without PDA, even after adjustment for gestational age and birth weight279.
A later study also showed PDA to be an independent risk factor for the development of
NEC280. Milner showed that NEC in the presence of a PDA was associated with higher rates
of mortality281. Treatment of PDA might therefore be reasonably expected to reduce the
incidence ofNEC in these babies. Two methods of treatment are currently available: surgical
ligation or medical treatment with a cyclooxygenase inhibitor, most commonly
indomethacin. Each of these treatments carries risk. Surgical management may be
complicated by problems with anaesthetic administration, intra-operative difficulties or post¬
operative haemodynamic instability or infection. Medical closure of PDA is often attempted
first if therapy is deemed necessary. However, indomethacin has been associated with renal
impairment, hyponatraemia, thrombocytopenia, spontaneous intestinal perforation and
gastrointestinal bleeding. Indomethacin use has also been associated with an increased risk
ofNEC. It is known to reduce mesenteric blood flow and it is suggested that, in the presence
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of a PDA, indomethacin may further compromise perfusion of the bowel . A systematic
review of randomised controlled trials, performed in 2002, was unable to demonstrate an
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increased risk of NEC with the use of prophylactic indomethacin in preterm infants284.
However, most of the studies included in this review were small and confidence intervals
were wide for the results; however, the largest randomised trial to date showed no difference
in the incidence ofNEC with prophylactic therapy285.
Although prophylactic indomethacin confers some short-term benefits, no long-term
beneficial effects have been demonstrated and this strategy has not been widely adopted,
with indomethacin now more usually given for treatment of PDA that is thought to be
haemodynamically significant. Grosfeld et al examined the rates of NEC in a group of
babies with significant PDA treated with indomethacin286. 35% developed NEC, compared
with 13% in infants without PDA. Rates of perforation were also higher and both findings
were statistically significant. However, the two groups of infants were matched only for birth
weight and gestation and it is possible that other differences, particularly in severity of
illness, might have contributed to the difference in findings. Since the condition of SIP has
relatively recently been identified as a separate entity from NEC then it may be that some of
the increased rates of perforation were as a result of this, rather than more severe NEC. The
authors do not discuss this. Fujii performed a retrospective study in 65 infants <27 weeks of
gestation and birth weight <800g287. Infants were treated for PDA either prophylactically or
after 48 hours of life, when it became clinically significant. In this study, the rates of NEC
were similar with early or later treatment, but the group receiving prophylaxis had a
significantly increased rate of perforation. They speculate that this may have been caused by
high rates of antenatal steroid administration resulting in increased prostaglandin synthase
inhibiting effects due to the drug combination. In contrast, O'Donovan, also retrospectively
reviewed records of 224 very low birth weight infants treated for significant PDA with either
indomethacin, surgical ligation or both288. The incidence of NEC was similar in all groups;
SIP was reported separately and was also similar between the groups. Dollberg, in a
population-based study, found that although PDA was an independent risk factor for NEC,
this risk was not increased by the use of indomethacin therapy280.
There have been no randomised controlled trials addressing the question of optimum
management of PDA. In the absence of this evidence, medical treatment, surgical ligation
and no treatment probably lie within the boundaries of current clinical practice. Conflicting
study results and small study sizes limit interpretation of the possible effects of different
management strategies on the incidence ofNEC. In view of the perceived close link between
enteral feeding and NEC, it is likely that this too influences feeding practice and anecdotal
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reports suggest that some clinicians manipulate feeds differently either because of the
presence of or treatment for PDA. The effects of feeding during treatment with indomethacin
have not yet been determined.
3.5 Feed tolerance and feeding methods
Underpinning the issue of achieving full enteral nutrition in preterm neonates is the need to
attain adequate nutritional volumes of milk. It is clear that a very preterm baby's gut is not
sufficiently mature to be able to deal with full enteral feeding from birth and evidence is
conflicting about how best to achieve this in the safest, but quickest way. Whether or not a
baby's feeding progresses satisfactorily may be related to a large number of factors, many of
which have been previously discussed. Others may relate to the method by which the feed is
administered. There is still little to guide clinicians wishing to determine whether their
chosen feed strategy and feeding method is correct for an individual baby. Regular
assessments of the baby's clinical condition and abdominal examination may alert the
attending neonatologist to obvious or imminent gastrointestinal pathology. However, it may
be considerably more challenging to determine whether a baby is "content" with the rate at
which feeding is progressing, or whether larger or smaller volumes may be more
appropriate. The terms "tolerance" and "intolerance" of feeds are frequently used terms to
attempt to describe this, yet definition of either is difficult.
3.5.1 Gastric residual volumes
In preterm neonates establishing enteral feeding in the first weeks of life, it is common for
gastric residual volumes to be assessed prior to feeding. Contents of residual volumes
include milk from previous feeds, saliva and gastric secretions. In babies who do not have
abdominal signs suggestive of pathology, the amount and colour of residual volumes are
often used as a measure of feed tolerance. Increased residual volumes aspirated from the
stomach before a feed are often regarded as a sign of intolerance or as an early sign of
gastrointestinal disease such as NEC. On the basis of these gastric residuals, feeds are
temporarily discontinued in an attempt to avert or minimise the consequences of NEC,
should it develop. If NEC does not ensue, then feeds are restarted some time later. This is
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perceived as safe feeding practice, yet for an extremely small baby, multiple or prolonged
omission of feeds may represent significant reduction in nutrition.
Malhotra studied gastric residual volumes in 50 healthy preterm babies, some of whom
received PN to supplement milk feeds289. Gastric residual volumes decreased during the first
week of life as feed volumes increased and were less in babies placed prone (24.2 ±10.2%),
than in those lying in the supine position (12.8 ± 4.3%). Mean gastric residuals were less in
babies receiving a greater proportion of their feed via the enteral route, supporting the
findings of others that enteral feeding enhances gut motility. This study found no difference
in gastric residual volumes between infants fed human or formula milk. Mihatsch et al,
within a randomised controlled trial of infant formulas, studied the relationship between the
volume and colour of gastric residuals and feeding tolerance in 99 extremely low birth
weight infants in the fist two weeks of life290. Infants were fed every two hours with human
milk where available or formula starting at 12ml/kg/day and increasing by this amount daily
if the infant had received >50% of the daily volume in the previous 24 hours. Specified
gastric residual volumes were regarded as acceptable for different birth weights: <750g, up
to 2ml; 751-1000g, up to 3ml. Where volumes were less than specified, the full feed was
given; where residual volumes were greater, the feed volume given was made up to that of
the intended feed volume; where residual volumes exceeded the feed volume, milk was
withheld. Feeding was not influenced by hypotension, mild abdominal distension, infection,
indomethacin therapy or the colour of the residual. 59 infants advanced feeds according to
the study protocol. There was no relationship between the mean residual volume and feed
volume at 14 days. Most residuals were milky in colour and green or bloodstained residuals
did not influence feeding volumes, in the absence of other clinical signs. The authors
suggested that residual volumes of <2-3ml did not indicate feed intolerance. No increase in
residual volumes was seen infants developing NEC. In a further study by the same research
group, gastric residual volumes of up to 5ml/kg were tolerated without adverse effects168.
Cobb used a case control study design in 51 VLBW infants to compare residual volumes in
infants with and without NEC291. Each case was matched with 2 controls that had never had
feeds withheld for more than one day. The total residual volumes as a percentage of total
feed volumes were increased in NEC cases compared with controls and the maximum
residual volumes were increased prior to development of NEC. There was a non-significant
trend to lower total feed volumes in the NEC group after 6 days of feeding, suggesting worse
feed tolerance. The authors suggested that residual volumes of >3.5ml or 33% of the feed
volume may be associated with an increased risk of NEC. However, controls were selected
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because they had not shown feed intolerance. This choice may have excluded many babies
who experienced feed intolerance for other reasons, yet did not go on to develop NEC and
the effect of this would be to exaggerate the differences between the groups, making
interpretation of the results more difficult. In addition, the use of total residual volumes is
not helpful for clinical practice, where decisions must be made based on the day-to-day feed
tolerance of babies. Bertino recently published results of another case control study
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including over 800 infants" , accepting residual volumes as suggested by Mihatsch et al .
The overall incidence of NEC was low (2.2%). Mean maximum residual volumes were
greater in infants with NEC and the percentage of haemorrhagic residuals was greater, but
percentage of bile-stained residuals was similar between the groups. Although larger
volumes were noted in cases of NEC, this study did not attempt to quantify a volume at
which residuals may predict NEC, but Bertino suggested that early bloodstained residuals
might be important. Neu and Zhang, in a review article, suggest factors that might indicate
feed intolerance and increased risk of intra-abdominal pathology293. With respect to gastric
residual volumes, they suggest that volumes of >3ml/kg should prompt consideration of
temporary discontinuation of feeds pending further assessment.
Another area of recent work is investigation of the role of amylin, a potent inhibitor of
gastric emptying, in feed intolerance. Kairamkonda et al showed that serum amylin is
increased in preterm infants with feed intolerance compared with those tolerating increasing
feed volumes294. However, gastric emptying was not measured in these infants. This work is
in its infancy and confirmation of these results and mechanisms is necessary. However, it is
possible that with time, this will represent a measurable indicator of feed intolerance in
preterm infants.
Currently, there is no established guidance about the assessment of feed tolerance, although
most clinicians accept that gastric residual volumes are probably the best measure available
at present. Further research is required to elucidate the relationship between gastric residual,
their type and volume, feed tolerance and the development of NEC. Until such information is
available, it is likely that clinical practice will encompass widely ranging differences. There
are no published data documenting the gastric residual characteristics on which clinicians
base their decision-making with respect to temporary discontinuation of feeds.
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3.5.2 Continuous or bolus feeding
Preterm infants require a period of nutritional support using tube feeding before they become
mature enough to take suck feeds, either from the breast or bottle. Feeds may be given either
as intermittent bolus feeds or as continuous feeds. Both are associated with theoretical risks
and benefits. Intermittent bolus feedings are considered more physiologically appropriate, as
they promote cyclical surges of gut hormones needed for gut maturation295. Conversely,
delayed gastric emptying in the preterm neonate may render the babies less able to cope with
larger gastric volumes ofmilk296.
Toce alternately assigned 53 babies <1500g to continuous or intermittent 3 hourly
nasogastric feeding for a minimum of 7 days until transfer to another unit, establishment of
suck feeding or a maximum of 28 days297. Feed intolerance was defined as suspicion of
NEC, increased gastric residuals or withholding of feeds for 16 hours or more. Feeding
method did not predict changes in head circumference, total protein level or bilirubin level.
Continuous feeding was associated with increased weight gain in infants with birth weight of
1000g-1249g, but not in heavier babies. Three infants experienced more than 3 episodes of
feed intolerance or NEC (2 continuous; 1 intermittent) and were regarded as study failures.
In this study, intermittently fed infants had a non-significant increase in apnoeic episodes.
Continuously fed infants had a slight increase in feed intolerance, which reached
significance only in babies of 1000g-1249g. However, numbers were small and infants
achieving suck feeds before 7 days were excluded from analysis. Since these infants
presumably tolerated feeds well, this may have artificially exaggerated problems in the
remaining group. Akintorin also observed more apnoeic episodes in intermittently fed babies
and increased residuals in those fed continuously but overall feed tolerance did not differ
between the groups298. Silvestre compared feeding methods in 82 VLBW infants and found
comparable weight gain, head circumference, time to reach full enteral feeds and length of
hospital stay between the groups299.
In a randomised trial of gut priming in 171 infants (gestational age 26-30 weeks), Schanler
also compared continuous and intermittent feeding182. This study found significantly less
feed intolerance, defined as increased gastric residuals, and increased weight gain associated
with intermittent feeding. Dollberg also found 2-3 hourly intermittent feeding to be superior
to continuous feeding in a randomised trial of 28 infants, a result which was contrary to their
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original hypothesis300. Infants tolerated continuous feeds less well and took significantly
longer to reach full feeds (P <0.03).
In contrast, other studies have found continuous feeds to improve outcomes. Rojahn, in a
retrospective analysis of records of 45 VLBW infants, found that babies attained full feeds of
120 or 150ml/kg/day more rapidly when fed continuously, and attributed this to larger
volumes being tolerated in this group during the first few days of life301. Dsilna et al
randomly assigned 70 infants <1200g and 24-29 weeks of gestation to continuous or
intermittent feeds302. Continuously fed infants achieved full enteral feeds earlier than bolus
fed infants and this effect was most marked in the smallest infants <850g.
A systematic review of all studies was unable to detect a difference between the two
methods of feeding in terms of time to full enteral feeds, but was unable to reliably assess
risks and benefits that may be associated with either method from the data available303. In all
studies considered, intermittent enteral feeds were given every three hours. It is possible that
more frequent bolus feeding may have different effects and that infants may display different
tolerance to feeds depending on the interval between them. Given the lack of evidence for
superiority of one method of feeding over another, it is likely that clinical practice is based
on personal preference and policies in NNUs. There are no published data indicating which
method is most commonly used in current practice or how frequently bolus feeds are given
when this method is used.
3.5.3 Nasogastric or transpyloric feeding
In view of the delayed gastric emptying in preterm infants, it has been suggested that feeding
directly into the upper bowel may improve feed tolerance and ensure more reliable delivery
of milk feeds into the area where absorption takes place. In addition, nasojejunal feeding
may reduce the risk of reflux through the gastro-oesophageal valve and its potential
complications, the most serious of which is milk aspiration.
Rhea and colleagues first described their experience with transpyloric feeding of infants,
including preterm neonates in 1973 304. They found no evidence of gastrointestinal or surgical
complications and concluded that it was a safe and easy method of feeding. Cheek and
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Straub, in the same year, reported a study of 10 term and 36 preterm neonates who were fed
by this method without serious complications305.
Wells and Zachman first compared transpyloric feeding with nasogastric feeding in 18
VLBW infants, alternately assigned to the each method. Transpyloric feeds were given
continuously and nasogastric feeds every 3 or 4 hours. They encountered no problems and
found that infants fed via the nasojejunal route had faster initial weight gain, regaining their
birth weight earlier than nasogastrically fed infants306. Van Caillie and Powell studied 11
VLBW infants comparing continuous nasogastric and nasoduodenal feeding307. Transpyloric
feeding resulted in higher caloric intake during the first week of life and earlier regain of
birth weight. Two episodes of aspiration occurred and both babies had their tubes placed in
the stomach at this time. The authors suggested that transpyloric feeding might be most
appropriate in the first two weeks of life.
However, subsequent studies have urged caution. Roy et al compared feeding methods in 18
healthy infants308. Both were tolerated well, but over half of the nasojejunal group were
found to have gastric residual volumes, suggesting reflux through the pylorus. There were no
significant differences in gain in weight or head circumference between the groups, although
there was a trend favouring nasogastric feeding. Stool frequency was increased with
nasojejunal feeding, as was stool fat content, raising concerns of possible decreased
absorption. A larger study of 44 infants found difficulties in passing nasojejunal tubes on
many occasions and no benefits from nasojejunal feeding, but infants fed by the nasogastric
route had higher calorie intake309. One infant in the nasojejunal group died following
aspiration and two following NEC, compared with only one death in the nasogastric group
from NEC. They concluded that possible risks of using transpyloric feeding outweighed
evidence of benefit. Pereira310, Laing3" and Macdonald312 also found greater complexity,
more complications and no significant benefits with transpyloric feeding compared to
nasogastric feeding. Complications of transpyloric feeding were extra radiation needed to
check tube position, aspiration and gastric bleeding. Systematic reviews of the randomised
trials comparing transpyloric versus gastric tube feeding in preterm infants found more
adverse effects and no benefits with transpyloric feeding and the authors were unable to
recommend this practice over gastric feeding.
In a retrospective review, the role of transpyloric feeding has recently been investigated in
apnoea associated with gastro-oesophageal reflux in preterm infants313. In 15 infants,
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transpyloric feeding was initiated at between 20 and 51 (mean 32) days of age for symptoms
associated with reflux. Twelve of these responded with a reduction in apnoeic episodes. A
further retrospective study also showed a reduction in apnoea and bradycardia thought to be
associated with gastro-oesophageal reflux314. Without a control group, and given the
spontaneous improvement in apnoea of prematurity with increasing age, it is not possible to
be sure that improvement was related to this intervention. However, transpyloric feeding
may have a role in reflux disease in older preterm infants and this warrants further
exploration.
Review of this evidence suggests that routine use of transpyloric feeding in preterm infants is
inherently more complex and may be associated with complications not seen with
nasogastric feeding. In addition, ascertainment of nasojejunal tube position may require
significantly more x-ray examinations. Anecdotal reports suggest that it is used currently in
NNUs, either routinely or in selected babies for management of refractory feed intolerance
or gastro-oesophageal reflux, although this has not been documented.
3.6 Gastro-oesophageal reflux in preterm neonates
Gastro-oesophageal reflux (GOR) is common in preterm infants; they lie horizontally, take
in relatively large quantities of milk feeds and have an immature, lax oesophageal sphincter.
Dhillon and Ewer conducted a survey to determine an estimate for the incidence of GOR in
preterm infants in UK neonatal intensive care units and found the incidence to be
approximately 22% in infants under 34 weeks of gestation315. However, they also found that
there was considerable inter-unit variation in both diagnosis and management. Indeed, the
significance of GOR is contentious issue in neonatal medicine. Many regard it as a
phenomenon that is physiological rather than pathological, whereas others believe that it is a
cause of significant morbidity. Indicators of reflux include regurgitation of feeds and
vomiting and these may, in some cases, be associated with aspiration of milk. Adverse
outcomes that have been linked to GOR include apnoea, exacerbation of chronic lung
disease, poor weight gain and prolonged hospital stay.
Apnoea occurring around the time of feeding is often attributed to GOR. Early case reports
described episodes of respiratory arrest in term born infants at 1-5 months of age, which
resolved after surgical treatment with fundoplication and suggested the link with GOR316.
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Herbst observed increased reflux, detected by oesophageal pH monitoring in 14 infants with
bronchopulmonary dysplasia (BPD) and recurrent apnoea and proposed an association
between GOR, aspiration and chronic lung disease317. Menon studied 10 infants with feed
regurgitation and showed that apnoea of both short and prolonged duration was more
frequent at times of feeding than at other times and concluded that the two were temporally
and perhaps causally linked318. However, Menon also observed that many regurgitation
episodes were not associated with apnoea.
Other researchers have sought to confirm a temporal relationship between GOR and apnoea
in preterm infants, using various methodologies. Jolley used 24 hour pH monitoring to
determine the occurrence of prolonged duration of reflux during sleep in 82 infants with
respiratory symptoms thought to be caused by GOR319. They found that this was a less
common occurrence in infants below 39 weeks than in those above 39 weeks and concluded
that it was probably unrelated to the development of BPD. De Ajuriaguerra found no
relationship between apnoea and GOR in a small study of 20 preterm infants using pH
monitoring320. Peter et al studied 19 preterm infants at a mean postnatal age of 26 days using
multichannel intraluminal impedance techniques (Mil), electrocardiogram, nasal air flow
and oxygen saturation monitoring321. Two thousand and thirty-nine episodes of apnoea were
observed, but the number occurring at times of reflux was similar to the number during
periods where infants did not experience reflux. There was no relationship even when reflux
reached the level of the pharynx. In a study of 6255 episodes of GOR detected on overnight
pH monitoring, Di Fiore and colleagues were also unable to detect a temporal relationship
with apnoea322. In fact, their results showed a decrease in apnoea in the periods following
reflux episodes, possibly due to increased arousal caused by the reflux. They were also
unable to show any effect of GOR on duration of apnoeic episodes. Bhat et al also
incorporated a comparison between prone and supine positioning in 20 preterm infants with
and without BPD at 36 weeks corrected gestational age323. There was no difference in the
number of apnoeic episodes in the BPD and non-BPD groups, and no relationship between
apnoea and GOR in either position.
These conflicting results may at least in part be related to the methods used for monitoring
the occurrence of reflux. Although carefully designed, these studies have chosen to use
either pH monitoring or the more recent technique ofMIL Continuous 24 hour oesophageal
pH monitoring has been frequently employed in the diagnosis and investigation of suspected
symptomatic reflux. Significant GOR is diagnosed when there is pH <4 for 10% of the
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monitoring period. The limitation of this method is its ability to detect only acid reflux
(pH<4) and alkaline (pH>7.5) reflux. Frequent milk feeds can buffer gastric acid and raise
the pH of gastric contents to a level where this would not be detected on pFI monitoring324
325. The advent ofMil has made detection of non-acid reflux possible. Electrical impedance
changes when fluid or air passes between electrodes at multiple sites, allowing the direction
of flow to be determined326. Simultaneous pH monitoring and Mil can now be performed,
allowing detection of both acid and non-acid GOR. Wenzl used this technique in 22 term
infants and observed 165 episodes of apnoea in 20 infants, 96% ofwhich lasted for less than
10 seconds327. There was an association between GOR and apnoea in this group. Almost
30% of all apnoeas were associated with GOR and one third of all apnoeas were within 30
seconds of an episode of reflux. However, almost 80% of these reflux episodes were non-
acidic. Only one published study to date has used this technology in preterm infants.
Corvaglia et al studied 26 preterm infants <32 weeks (range 25-32 weeks) of gestation who
were receiving full enteral feeds and experiencing recurrent apnoeic episodes328. Using
simultaneous pH monitoring, Mil and polysomnography, infants were monitored for two 3-
hour periods postprandially. Apnoea was considered related to GOR if it occurred within 30
seconds before or after a reflux episode and pathological if it lasted for 5 seconds or more
and was accompanied by bradycardia. Reflux was identified on 1065 occasions, 382 by pH
monitoring and 683 on MIL Apnoea was identified on 1136 occasions and of these, 154
episodes were related to GOR. The frequency of apnoea during the 1-minute period around
the onset of GOR was significantly greater than the frequency during the total period free of
GOR. However, there was variability between individual infants, with some appearing to be
more susceptible to apnoea associated with GOR than others.
The evaluation of GOR in preterm neonates is fraught with difficulty and differences in
practice and opinion are many, in the face of conflicting evidence. Making the correct
diagnosis is a challenge in itself, with the most common diagnostic test having recognised
limitations and more sophisticated technology having significant resource implications; this
in a condition for which there is no agreement about either the clinical significance of the
condition or need, efficacy and safety of available treatments. Yet the diagnosis ofGOR and
the use of pharmacological treatment appear to be common. Responses to the postal survey
by Dhillon and Ewer in the UK indicated that non-pharmacological treatments for reflux,
such as positioning, were used alone in 54% of units and in 46% drug treatments were also
used 3'5. A recently published retrospective analysis of 1598 extremely low birth weight
infants in the USA reported that 24.8% of them were discharged with medications to treat
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reflux 329. However, there was significant variation in practice between centres, with rates
ranging from 2% to 90%. There are no recent published reports documenting the actual,
rather than reported use of anti-reflux medications in the UK.
3.6.1 Pharmacological management of GOR and feed tolerance
A number of different pharmacological therapies are used in the management of GOR in
neonates. These include feed thickeners, alginates, gastric acid inhibitors and prokinetic
agents.
3.6.1.1 Feed Thickeners
Thickening of infant feeds has been advocated for many years. The rationale behind this
practice is that the increased weight and viscosity of the feed will prevent reflux of stomach
contents into the oesophagus. Various agents have been used, including rice cereal, carob-
bean gum, carob-seed flour and sodium carboxymethylcellulose. Most studies have been
performed in older infants and young children, rather than in the newborn period and a
Cochrane review was unable to identify any randomised trials of the use of feed thickeners
in neonates 33°. Studies including preterm infants are even fewer. Since the natural history of
GOR is to resolve with maturity and changes in infant posture over time, results of non-
randomised trials in older infants should be interpreted with caution. Orenstein et al found
that vomiting and crying were reduced and sleeping time increased in infants of less than one
year of age 33'. However, reflux measured by scintigraphy did not decrease and infants
coughed more when fed thickened feeds. In a small, randomised trial of term infants, an
"anti-regurgitation" formula containing bean gum decreased regurgitation and reflux on pH
monitoring 332. A further multicentre study in term infants confirmed Orenstein's findings of
reduced regurgitation and improved sleep, but observed less coughing in infants fed with a
pre-thickened formula 333. Wenzl et al used a randomised crossover study of combined pH
monitoring and Mil to investigate the effect of feed thickening in a study of 14 healthy term
infants (mean age 42 ± 32 postnatal days) 334. Infants were fed alternately with a formula
with or without added carob bean gum. They observed reflux in all infants, with a total of
1183 episodes, of which 32% were acidic, 0.3% alkaline. In keeping with this group's other
studies326 327, the majority of reflux episodes were non-acid. There were 83 episodes of
regurgitation. They found a significant reduction in frequency and amount of regurgitation,
principally related to non-acid events. There was no difference in acid reflux.
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There are few reports of the use of feed thickeners in preterm infants, although their use may
be common in clinical practice 3I5. In a letter, Clarke and Robinson reported on two preterm
infants who died from NEC, having been treated for non-specific symptoms attributed to
GOR. They speculated that thickened feeds may have led to the development ofNEC either
by causing bowel obstruction and subsequent overgrowth of bacteria or by mucosal injury
associated with the high calorie density of the feed 335. Corvaglia et al sought to examine the
efficacy of thickened human milk in a crossover study in preterm infants, using combined
pH monitoring and MIL They found no reduction in reflux with feed thickening and the
study was discontinued after the recruitment of only 5 infants, in view of the suggestion of a
link with NEC as proposed by Clarke and Robinson. Although the evidence of an association
with NEC is scant and studies examining efficacy of feed thickening few and limited, these
authors and others caution against the use of feed thickeners in preterm infants, at least until
good feed tolerance has been achieved335"337.
3.6.1.2 Alginates
The antacid preparation most commonly used for the treatment of reflux in infants is
Gaviscon® Infant (Reckitt Benckiser Healthcare [UK] Ltd), which contains sodium and
magnesium alginate. Unlike Gaviscon® preparations for older children and adults, which
also contain bicarbonate to alter the pH of stomach contents and form a "foam raft" over the
stomach contents, the infant preparation probably acts as a feed thickener 338. Gaviscon has
not been extensively studied in neonates and most studies in infants have used preparations
available before the introduction of the infant preparation. Buts, in 1987, studied 20 infants
and children with GOR and found that reflux measured using 24 hour pH monitoring was
significantly reduced after treatment with Gaviscon compared with the placebo group338.
Forbes et al studied the effects of Gaviscon and metoclopramide in a group of 30 patients
with wide ranging ages (4 months to 17 years), but found no reduction in reflux episodes
with wither treatment 339. Miller also observed some improvement in reflux in infants
recruited in a general practice setting and treated with alginate preparation 34°. These studies
reported no adverse effects. However, previous reports have suggested that the use of
Gaviscon may be associated with intestinal obstruction caused by bezoars 341 342. These
reports have led to recommendation that it should not be administered concurrently with
other feed thickening agents 343 344.
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The most recent study used Gaviscon Infant and included 20 patients less than 12 months of
age, assessed with combined pH monitoring and Mil 345. Infants were monitored over a 24-
hour period during which there were six random administrations of Gaviscon Infant or
placebo. The results showed that, although there was a small decrease in reflux in infants
treated with Gaviscon Infant, this difference was not statistically significant. However,
others have suggested that the period of monitoring may have been insufficient to detect a
difference between the treatment and placebo 346. Although Gaviscon Infant preparations are
readily available, they are not recommended for infants of less than one year of age except
under the guidance of a medical practitioner. Evidence for either the safety or efficacy of
alginates in the preterm population is lacking.
3.6.1.3 Gastric acid inhibitors
Euler et al showed that gastric acid is produced during the first hour of life in both term and
preterm infants from 33 weeks of gestation347. Hyman et al characterised the nature of
gastric acid secretion in preterm infants348. This work showed wide variation in rates of acid
secretion between babies, but all demonstrated increasing secretion during the first four
weeks of life. This increase appears to be more related to postnatal than gestational age. By
six postnatal weeks, all infants were able to maintain a gastric pH of <4.0. Kelly et al later
demonstrated the presence of parietal cells in the developing stomachs of foetuses and
infants between 13 weeks of gestation and 21 weeks of postnatal age, suggesting that
mechanisms for gastric acid production may be present from this very early stage in
development349. Although studies have shown that much reflux in infants is non-acid,
positive results from pH monitoring in infants frequently lead to trials of treatment with
gastric acid inhibiting medications.
(a) H2 receptor antagonists
These drugs reduce gastric acid production by inhibiting the H2 receptors on gastric parietal
cells. Ranitidine is one of the most commonly used H2 receptor antagonists to treat GOR in
preterm infants, but has not been studied in randomised controlled trials in this group. In a
study of 10 infants treated with postnatal steroid therapy for BPD, ranitidine significantly
reduced gastric acidity and the authors suggested that it might be a useful adjunctive therapy
in such infants to prevent gastric perforation secondary to steroids. However, the subsequent
association of postnatal steroid therapy with later cerebral palsy has substantially decreased
the use of this in the management of BPD350. A further randomised trial of ventilated infants
in neonatal intensive care used prophylactic ranitidine and confirmed the reduction of stress-
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associated gastric mucosal lesions351. This trial did not report any adverse effects of
ranitidine therapy. However, Cothran found that increased gastric pH associated with the use
of ranitidine also increased rates of colonisation with pathogenic bacteria compared to
control infants who did not receive the drug 352. Guillet et al sought to determine whether
this effect on bacterial overgrowth was associated with the development of NEC 65. This
large study included VLBW infants and the rate ofNEC was 7.1% overall. They found that
both the incidence of NEC and the frequency with which H2 receptor antagonists were used
varied significantly between centres. A case control analysis of 787 infants with NEC and
2357 controls, matched for birth weight, race and centre, showed that the use of H2 receptor
antagonists was significantly associated with an increased incidence of NEC. Limitations of
this study included its retrospective design and the lack of information about aspects of
feeding practice, such as the use of breast milk and feeding regimens. They were also unable
to control for other potential confounding factors, such as the management of PDA.
Nevertheless, this study supported previous work showing that acidifying the milk feeds of
premature infants >1250g led to reduced bacterial colonisation and reduced incidence of
NEC, although this group reported a high (18%) baseline incidence of NEC prior to the
study 353. In the light of this evidence, it has been suggested that avoiding exposure to H2
receptor antagonists may be important in preventing NEC. A recent report of a retrospective
study has also linked an increased incidence of late-onset sepsis with ranitidine use in
neonatal intensive care, but this has not been explored further to date 354.
(b) Proton pump inhibitors
Proton pump inhibitors inhibit gastric acid secretion by inactivating the H+, K+ -ATPase
pump in parietal cells. Although widely used in adults, this group of drugs has only recently
been studied in the neonatal population 355. Moore et al assessed the effect of omeprazole in
64 irritable infants with GOR during the first year of life in a randomised controlled trial 356.
Although reflux was reduced in treated infants, symptoms remained unchanged in both
treatment and placebo groups, suggesting they may be coexistent, rather than related 357. A
randomised crossover study in 10 preterm infants, in whom conservative treatment for GOR
had been ineffective, used pH monitoring to evaluate the efficacy of omeprazole 358. This
study showed similar results, in that detected reflux episodes were significantly reduced, but
in spite of this effect, symptoms of vomiting, apnoea, bradycardia and irritable behaviour
persisted. Orenstein chose to investigate lansoprazole in a multicentre double-blind
randomised placebo controlled trial including 162 infants, of which 44 were preterm 359.
Identical numbers of infants in each group responded to treatment, in both the overall group
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and the preterm subgroup. Lower respiratory tract infections were commoner in the
treatment group, but it is possible that other factors, not attributable to lansoprazole may
have been important in these infants. Given the increasing evidence that this group of drugs
does not affect symptoms commonly attributed to GOR, its use in the management of this
condition must be questioned. In addition, neither the safety profile of proton pump
inhibitors in preterm infants, nor the long-term effects of treatment have yet been defined.
There have been no published reports of any association between proton pump inhibitor use
and NEC though, in the absence of evidence, it is possible that similar mechanisms may be
implicated in the future as those relating to H2 receptor antagonists.
3.6.1.4 Prokinetic agents
A small number ofprokinetic agents have been used in the newborn. Cisapride was effective
in decreasing GOR in preterm infants360 and was widely used, but the product license for this
drug was withdrawn in 2000 because of reports of sudden death due to cardiotoxicity3 .
Since this time, other prokinetics have been used increasingly.
(a) Metoclopramide
Metoclopramide is a dopamine antagonist, which enhances the gut's response to
acetylcholine and so increases gut motility and gastric emptying. A number of studies have
been conducted in older infants and children, but studies in preterm infants are few and
numbers included are small. Results of two small studies in the 1980s reported that
symptoms ofGOR were reduced with treatment without any increase in adverse effects362 363.
However, these observational studies included only 6 and 14 symptomatic infants
respectively. Kimball and Carlton retrospectively reviewed records of 132 preterm infants
treated with either cisapride or metoclopramide for GOR and associated apnoea 364. In this
study, neither drug reduced the frequency of apnoeic episodes; however, the retrospective
study design may have precluded the consideration of important confounding factors. A
recently published randomised, blinded, crossover trial used metoclopramide and ranitidine
in the treatment of bradycardia attributed to GOR in 17 preterm infants365. Results showed
that infants had significantly less bradycardic episodes during drug treatment than with
placebo. In a small study such as this, the finding may represent a type 1 statistical error.
However, the side effect profile of ranitidine in adults includes cardiac arrhythmias and the
authors suggested this as a potentially plausible explanation. A systematic review has been
published on the effects of metoclopramide on GOR in infants, although few preterm infants
were included 366. It concluded that there was insufficient evidence to either recommend or
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oppose the use of the drug for this indication. Substantial concern also exists about adverse
effects of metoclopramide. Severe extrapyramidal reactions are well recognised in adults.
Similar adverse effects have been noted in the paediatric population367 36S.
(b) Domperidone
Domperidone is a peripherally acting dopamine2-receptor antagonist with regulatory effects
on the motility of smooth muscle in the gut. It is widely used in adults as an antiemetic and
for relief of symptoms of GOR and it appears to have few adverse effects. Only a small
number of trials have evaluated the efficacy of domperidone in the newborn. A study of 15
infants aged 3 to 13 months reported in 1985 and found that postprandial reflux time
improved significantly369. They noted minimal adverse effects and concluded that
"domperidone is a useful and safe agent" for treatment of GOR in infants. However, it is
highly unlikely that a non-randomised study of this size would be sufficient to make
conclusive statements on safety of a therapy. Bines et al also observed improvement in GOR
in patients aged 5 months to 12 years, but only after 4 to 8 weeks of therapy in those with
chronic regurgitation and vomiting 37°. There was a large difference in the number of
episodes of reflux between the two groups on pH monitoring at the start of the study (69 and
16 episodes for treatment and placebo groups respectively) and study participants were of
widely varying ages, making interpretation of results difficult. Carraccio conducted a
randomised controlled trial in 80 children between one and 18 months of age371. GOR was
diagnosed radiologically and on pH monitoring and patients were reported to have
"considerably severe" symptoms, but these were not defined further. Randomisation was to
one of 4 groups, receiving placebo, domperidone alone, domperidone with alginate or
domperidone with magnesium and aluminium hydroxide. They observed no significant
improvement in symptoms with either domperidone alone or with alginate compared with
placebo. However, they observed improvement with combined domperidone and antacids
and concluded that this was a valid therapy for GOR in children. However, without
comparison between antacids with and without domperidone, this appears to be an over-
interpretation of the data.
Despite this very limited evidence of efficacy in infants, it is likely that domperidone is
being used routinely for the management of reflux in both term and preterm neonates, since
the use of anti-reflux medications is high in this group313 329. The efficacy of domperidone in
neonates is still being investigated. Cresi studied 26 infants using combined pH monitoring
and Mil 372. Term and preterm neonates were consecutively recruited and randomly assigned
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to treatment or control groups. Infants in the treatment group were given domperidone with
feeds at 8 and 16 hours after baseline monitoring. All infants were monitored for three
consecutive 8-hour periods. Significant increase in the frequency, but decreases in the
duration of reflux associated with feeds were observed in the group treated with
domperidone, but no difference in the measured pH between groups. The decrease in
duration of reflux suggests that domperidone has an effect on gastric emptying, but the
increase in frequency is difficult to explain. The authors postulate that these unexpected
findings may indicate that the response to prokinetic therapy may be different in the neonate
from that in older patients. Hegar et al compared domperidone with cisapride in a
randomised controlled trial in 20 infants 373. All infants underwent monitoring ofpH and also
ECG determination of normal QT interval. Parents of the infants kept daily diaries of
symptoms. The number of episodes of regurgitation decreased more during the first week of
treatment in the cisapride group, but this difference had disappeared by 2 and 3 weeks of
therapy. Differences in pH monitoring were not statistically significantly different between
the groups after one month of treatment, although the difference was greater with cisapride
than with domperidone and may represent a clinically significant difference. These authors
concluded that the two drugs were equally effective for regurgitation, but that cisapride was
more effective for GOR. They also stated that "domperidone has a better safety profile".
Of concern then, are recent reports of significant adverse effects with domperidone. Rocha
and Barbosa reported the occurrence of QT interval prolongation (as was previously
observed with and led to the withdrawal of cisapride) in association with the use of
domperidone in an infant374. Subsequently, two small studies have been published. Djeddi
studied 31 infants with a median gestational age at birth of 33 weeks (range 25-42) receiving
oral domperidone for GOR375. This study showed a significant difference between
gestational ages groups, with prolongation of the QT interval being associated with
domperidone administration in infants >32 weeks only, although none developed serious
arrhythmia. On the basis of this limited data, the authors suggested that use of the drug might
be considered in infants above this gestational age. Giinlemez enrolled 43 preterm neonates
born between 24 and 33 weeks of gestation treated with domperidone (mean postnatal age 32
days at start of treatment)376. All infants had normal electrocardiogram at baseline and two
infants developed prolonged QT interval during therapy. This was not statistically significant
and both resolved on discontinuation of the drug. However, these finding urge caution in the
use of the drug in preterm infants.
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(c) Erythromycin
Erythromycin is a macrolide antibiotic that increases gastrointestinal motility by acting as a
motilin receptor antagonist377. It has been proposed as a useful therapy to improve feed
tolerance in neonates. Results of studies have been conflicting and doses used have varied
between 1.0 and 12mg/kg 6 hourly; earlier studies generally used higher doses. Ng et al
showed that oral erythromycin was effective in reducing the time to establish full enteral
feeds in VLBW infants randomised to receive the drug (n=27) or placebo (n=29) from 14
days of life after feeds had been commenced during the first 5 days378. However, the authors
cautioned against the routine use of erythromycin in view of limited data about adverse
effects. Costalos and Nuntnarumit confirmed the prokinetic effects of erythromycin at doses
of 10-12mg/kg and the earlier establishment of enteral feeding in preterm infants in further
• • 379 380randomised controlled trials . Oei and Lui investigated the use of low dose (2.5mg/kg)
erythromycin from the time of the first feed to promote feed tolerance in 43 infants <32
weeks of gestation 381. Treated infants achieved full enteral feeds earlier than the placebo
group; this difference was statistically significant, suggesting that low doses may be
effective prophylactically. However, a study comparing low dose erythromycin with placebo
for the treatment of feed intolerance in 24 VLBW infants showed that although treated
infants reached full feeds earlier, the difference did not reach statistical significance. In
contrast to previous studies, El Hennawy et al were unable to show any beneficial effect of
erythromycin in a further small study involving 26 infants who did not achieve full feeds
within 8 days382. They were given 1.5mg/kg erythromycin with feeds or placebo for 8 days
after pH monitoring and manometry. This study did not find any difference in gastric
emptying, gut motility or transit times for feeds, and feeding outcomes were similar between
the groups, but the study failed to enrol the intended number of infants based on an a priori
sample size calculation. Aly et al recently studied 60 infants with feed intolerance
randomised to treatment with lmg/kg erythromycin 8 hourly or placebo383. Data from 49
infants were analysed, due to deaths within both groups of similar numbers of infants.
Erythromycin use was associated with significantly earlier achievement of full feeds and
decreased gastric residual volumes in infants >32 weeks of gestation, but not in less mature
infants.
Adverse effects appear to be uncommon with erythromycin, although it has been associated




Despite the now large numbers of trials that have been conducted in the use of erythromycin,
the results remain difficult to interpret because studies have been small and have used widely
differing doses of the drug in different populations, in addition to measuring different
outcomes. A systematic review of randomised trial concluded that there is insufficient
evidence to recommend the use of either high or low dose erythromycin for the management
of feed intolerance in preterm neonates.
3.7 Probiotics and prebiotics for the prevention of NEC
Whilst manipulation of feeding strategies and the avoidance of some of the factors thought to
be associated with the development of NEC have been proposed as means to reduce the
incidence of NEC, few postnatal interventions have been investigated. Intervention that
appear most promising to date are the addition of prebiotics or probiotics to enteral feeds.
Probiotics are live micro-organisms that can survive in the gastrointestinal tract and confer
benefit to the host387. Prebiotics are food supplements containing ingredients that selectively
stimulate the growth and activity of probiotic bacteria and probiotics are contained in human
milk. The mechanism by which NEC is thought to be prevented is colonisation of the gut
with beneficial bacteria such as bifidobacteria and lactobacilli, which in turn prevents
colonisation by pathogenic strains388. There are no randomised trials of prebiotics in preterm
infants, but a recent systematic review389 of probiotic therapy identified eleven trials 39°"400.
Meta-analysis suggested clear benefit in terms of reduction of all-cause mortality and
prevention of NEC. However, many of these studies were small and a number of different
organisms and dosing regimens were used. The authors concluded that evidence was
sufficient to warrant a change in practice to include the routine use of probiotics. Others have
felt that this response is premature and that further work is needed to determine the optimum
probiotic organism or combination of organisms, timing and duration of administration401402.
Concerns also exist about the possibility of cross-contamination within the NNU
environment, the potential for development of systemic sepsis with these organisms and the
long-term effects, which have not yet been examined403. In addition, few studies have
included the very smallest neonates, for whom the risk ofNEC is probably the greatest, and
therefore the effects in this extremely important high-risk group are relatively unstudied.
Further studies are in progress, which will help to answer such questions, but until these are
completed, decisions about the use of probiotics outside the context of clinical trials rests
with individual NNUs and clinicians.
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3.8 Discussion
A careful review of the research relating to feeding and influences on feeding practice in
preterm infants reveals a multitude of gaps in our current knowledge at every level. Much of
the published literature has attempted to address the subject of NEC, which accounts for
substantial mortality and morbidity in preterm infants and the management of which
undoubtedly poses an enormous challenge in the care of this population. Many studies have
been designed to clarify facts about disease processes and to inform clinical practice with a
view to improving outcomes. Basic science investigation, although active and continually
progressing, remains in its infancy and multiple studies have so far been unable to define
conclusively a cause for NEC. This is probably due partly to the apparently multifactorial
character of the disease, but may also reflect limitations in our current scientific and research
methods. It is likely that in coming years our knowledge will increase, but for the present
and the foreseeable future, we are faced with a number of potential areas to investigate, some
more likely to yield positive results than others, and some of which will almost certainly
prove to be "blind alleys".
While basic science progresses, so too does clinical medicine and few specialties are faster
growing than neonatology. Clinical researchers strive to understand and interpret results of
studies that are available, in an attempt to move ahead and translate these into clinical
studies, the results ofwhich might inform clinical practice. Faced with diverse opportunities
for research, clinical investigations attempting to determine safe, feasible and effective
strategies for managing a seemingly ever less mature newborn population, have been
prolific; this in spite of relatively limited robust data on which to base new work.
Unfortunately, in clinical studies there have been variations in populations, methodologies
and outcome measurements with subsequent conflicting results that have often served only
to confuse.
The research "gold standard" of the randomised double-blind placebo-controlled trial is not
easily attainable in the preterm neonatal population, due to small numbers of infants and
ethical issues surrounding research in the newborn period. Recruitment of adequate numbers
of infants needed to detect important outcomes such as NEC with certainty would probably
only be achieved through large international trials. Availability of funding for such
investigations is limited and amounts required would probably be prohibitive in many cases.
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In addition, clinical practice appears to be so variable that the logistic difficulties of
determining study protocols that are acceptable to all are considerable. There has recently
been a move towards large-scale international trials285 404 or simultaneous linked trials with
planned meta-analysis405 406, but such endeavours require immense collaborative effort and
take many years to complete. Although much needed, there have been no studies of this kind
relating to feeding practice in preterm neonates and none are reported to be planned or in
development. The current situation is therefore such that evidence from controlled trials
comes mainly from multiple small and heterogeneous studies. Meta-analysis has been
attempted in many areas to clarify overall findings from such studies, but few conclusions
have been drawn.
Partly as a result of challenges in performing randomised controlled trials, large studies of
feeding in preterm neonates have, for the most part, been observational in nature. This
renders them subject to criticism because of their inability to control many confounding
factors and to attribute securely cause-and-effect relationships between risk factors and
disease processes. Nevertheless, such studies analysing data from large databases or
networks have served as a springboard for much well designed interventional work, albeit
often in the form of small studies.
It is not surprising that researchers and clinicians alike are frustrated by the state of the
evidence with respect to preterm infant feeding. Many researchers, in published review
articles, have come to the reluctant conclusion that, in spite of multiple studies, evidence is
insufficient to make recommendations for best practice407"409. Others have made impassioned
pleas for available evidence to be acknowledged and for the results to be translated into
improved clinical practice at the cot side rather than further small studies being conducted410;
still others have found areas where evidence from good quality studies is completely
lacking330. For the clinicians delivering care, it is almost impossible to define best practice
and it is likely that this will lead to many practising "experience-based" or "opinion-based"
medicine rather than supporting evidence-based practice. For those who strive to base their
clinical practice on evidence, the dilemma is choosing the most appropriate evidence from
studies with conflicting results. The likelihood is that for any given area of practice a wide
variety of interpretations of evidence and personal preferences may influence the way in
which infant feeding is managed. Potentially, this may lead to either improved or less
favourable outcomes. However, if such diversity exists, it is possible that individual
clinicians or groups of clinicians within NNUs are not even aware of this.
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There are few detailed reports of opinions about feeding of preterm infants and no study has
examined the relationship between available research evidence, clinician opinion and clinical
practice. The cross-sectional survey reported in this thesis was intended to provide a
reference for current practice and to investigate areas where variation in practice may
influence neonatal outcomes and in particular NEC. Firstly, it aimed to survey current
opinion and reported practice of clinicians caring for premature and very low birth weight
newborn infants; secondly, it aimed to document current types of practice, intra- and inter-
unit variation with regard to feeding of preterm and very low birth weight infants in selected
units in the United Kingdom and Canada. It was necessary to use two different approaches in
order to achieve these aims. A semi-structured questionnaire was used to determine opinions
of senior neonatologists and paediatricians regularly involved in neonatal care. A
retrospective review of medical and nursing records of infants was chosen as the method of
obtaining data about current clinical practice. Included infants were those who had been born
at a gestational age of less than 30 weeks and / or a birth weight of 1500g or less.
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CHAPTER 4
INTRODUCTION TO THE SURVEY
4.1 Perinatal and neonatal care in the UK and Canada
Principles of delivery of health care are similar in both the UK and Canada in that there is a
universal health care system, with care being free for all at the point of delivery. However,
within neonatal and perinatal care, there are a number of important differences, in part due to
the general organisation of service delivery and in part to the huge difference in size between
the two countries. Some of these differences in the delivery of care may have the potential to
impact upon both pregnancy and neonatal outcomes.
The system for neonatal-perinatal care in Canada is highly regionalised. This system was
first proposed in 19704" and is now well established. Hospitals within the health care
regions are divided into three levels of care: level 1, normal newborn care; level 2, neonatal
high dependency care and level 3, neonatal intensive care. In this system, skills and
resources necessary to provide advanced neonatal care for the sickest and most premature
infants are concentrated within a relatively small number of large centres. Infants are
referred to whichever centre has the appropriate level of care to best meet their needs. This
centralisation of services means that mothers and babies who require or are likely to require
neonatal intensive care sometimes need to travel considerable distances before or after
delivery. Repatriation to a lower level unit nearer home will usually be arranged when the
baby's condition has improved sufficiently for intensive care facilities to be no longer
needed. Since the responsibility for organisation and delivery of care differs between
provinces, definitions for levels of care can also be variable and difficult to interpret. The
Fetus and Newborn Committee of the Canadian Paediatric Society have recently proposed
comprehensive guidelines for a common classification of levels of neonatal care in an
attempt to address this difficulty412.
The concept of restructuring in neonatal care has appeared more recently in England and
Wales. Traditionally, a range of care has been provided in most NNUs. Many smaller units
generally provide special care, but also have a limited capacity to offer neonatal intensive
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care to a small number of babies as necessary. In 2003, a Department of Health working
group produced a review of Neonatal Intensive Care Services413. Their report proposed the
introduction of a system of managed clinical networks with the aim of providing appropriate
perinatal and neonatal care as near to home as possible and avoiding the need for mothers
and babies to travel unacceptable distances. Four types of unit were defined with
corresponding levels of care: midwife-led units providing routine newborn care; level 1,
providing routine and special care; level 2, routine, special and high dependency care with
some providing short term intensive care if agreed within the network; and level 3 providing
routine, special, high dependency and intensive care. The British Association for Perinatal
Medicine (BAPM) defines levels of neonatal care in the UK (Table 4.1). Stages of
development and organisation of managed clinical networks currently vary across England
and Wales and the recommendations do not apply in Scotland. The early period of
reorganisation, transition and development that began in 2003 provided the backdrop for this
research project within the UK. Transfer of babies from level 3 units to lower level units is
common when intensive care is no longer needed. However, many level 3 units have special
care facilities to provide ongoing care for babies until discharge from hospital, avoiding the
need for transportation.
4.1.1 Staffing of NNUs
Staffing of NNUs and the duties carried out by different members of staff varies between
NNUs both within the UK and Canada and between the two countries. Medical training in
the UK was reorganised shortly after this study was carried out; this outline of training
structure therefore reflects the usual course of training for doctors in paediatrics and
neonatology at the time of the study.
Following undergraduate training, medical trainees in the UK completed one year of pre-
registration training before deciding the specialty of their choice. They then entered training
at the level of Senior House Officer (SHO), lasting for a minimum of 2 years, of which 6
months was spent in neonatal medicine. During this time, professional qualifications in
paediatrics would be obtained, allowing entry to the next level of training as a middle grade
doctor (Registrar). This comprised 2 years of further training in areas of paediatric medicine,
including a minimum of 4-6 months in neonatal medicine. For those wishing to specialise in
neonatology, this was followed by a minimum of 3 years of sub-specialty training, of which
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24 months was required to be spent in clinical neonatology, allowing opportunities for
trainees to pursue interests in research or other areas in the remaining time if desired,
although many spent the majority of time in clinical training. Trainees therefore, had
undergone a minimum of 5 years postgraduate training in the specialty before taking up a
senior position as a Consultant Neonatologist. In addition to training posts in paediatrics and
neonatology, some units also employ staff in non-training grades; these are usually at the
level of a middle grade doctor.
In Canada, following undergraduate studies, trainees spent 3 years in the junior grade of
Paediatric Resident, during which 3-4 months would be spent in neonatal medicine.
Following this, doctors wishing to specialise in neonatal medicine entered training as
Neonatal Fellows for a minimum of two years. Although this stage of training varied
between centres, most spent some time during each year of Fellowship training conducting
research, with research time increasing as training progressed. Following completion of sub-
specialist training, Canadian trainees are able to take a senior position as an Attending
Neonatologist (StaffNeonatologist).
Registered nurses with varying degrees of neonatal training form the mainstay of the nursing
workforce. However, in both the UK and Canada, the position of (Advanced) Neonatal
Nurse Practitioner (ANNP/NNP) has become a more prominent feature. These nurses
undergo additional training of 18 months to 2 years, enabling them to obtain many clinical
skills in common with doctors. Only a limited number of NNUs in both countries employ
NNPs and their numbers and roles within individual units are very variable. In larger units,
however, NNPs often function in a role similar to that of junior doctors and are closely
involved in day-to-day medical decision-making.
In Canada, in addition to medical and nursing personnel, other groups of professionals are
often employed in NNUs. Respiratory therapists (RTs), who are specifically trained in all
aspects of respiratory management of neonates, undertake much of the day-to-day
ventilatory management of infants. Also linked to units are neonatal dietician-nutritionists,
who are closely involved with the nutritional management of babies. Although common in
Canadian units, RTs do not exist in the UK and only a very small number of NNUs have
access to a specialist in neonatal dietetics.
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During this study period, therefore, large numbers of individuals with varying degrees of
experience and expertise are likely to have been involved in the care of babies in the units
surveyed. Whilst it is impossible to determine different levels of staffing and skill mix
associated with care of babies in this study, it is important to recognise that this is one of
many factors that may influence decision-making with respect to feeding.
Table 4.1: Levels of care defined by BAPM
Normal routine care Care of babies well enough to be at home but remain in hospital
because the mother needs support. This may include care of
mothers ofmature preterm infants or babies with minor or
common medical problems
Special care Continuing care for babies who require specialist support such as
tube feeding or care in incubators, for example well babies who
are maturing after preterm delivery or convalescing following
high dependency or intensive care
High dependency care Specialist cares for babies who, though not critically ill require
continuous support and observation for neonatal conditions.
Examples are preterm babies with recurrent apnoea spells, stable
babies receiving nasal CPAP or those receiving PN
Intensive care Critically ill babies who require continuous support for organ
failure and continuous observation, examples being babies who
require ventilation or very preterm babies with respiratory
distress syndrome
4.2 Ethics and consent
4.2.1 Research ethics approval
Research ethics approval for this work was sought from the Multicentre Research Ethics
Committee (MREC) in the UK. The research was approved in August 2004. Since the survey
was to be carried out by a single researcher, this approval was granted under supplementary
regulations. These regulations stated that where no local researcher is appointed, it was a
requirement only to inform relevant local research ethics committees, rather than to gain
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formal ethical approval for each centre involved. Copies of the survey protocol, study
documentation and MREC approval letters were therefore sent to each local committee for
information.
The survey protocol and documentation were submitted for consideration by the Research
Ethics Board of Hamilton Health Sciences / McMaster University in Canada in July 2005.
Approval was granted in August 2005. In Canada, there is no established system for ethical
approval of work involving collection of patient data to be undertaken on multiple sites. It
was therefore necessary to submit further individual and full applications to the Research
Ethics Boards for each centre to be involved. The regulations for ethical approval in Canada
stated that the Principal Investigator for any research study must be a registered Canadian
practitioner in a substantive post at the institution where the research was conducted. This
necessitated identification of and liaison with a staff neonatologist in each unit who was
willing to take responsibility for the survey in this capacity. Applications for ethical approval
were submitted to five hospitals in Ontario and Nova Scotia. However, due to limitations
caused by the time constraint of one year for the research in Canada, long distances between
centres and the duration of the application process, approval was obtained for only three
centres in Ontario.
4.2.2 Ethical Issues in clinical practice
The development of neonatology as a subspecialty of paediatrics has taken place in the
relatively recent past. Although research in the area is progressing and the body of
knowledge is growing rapidly, there remains a paucity of published evidence from well-
designed and conducted research in many areas. In such aspects of practice, those involved
in neonatal care must rely heavily on data from small studies or trials, supplemented by
knowledge from unit or personal clinical experience. The use of clinical guidelines and
frameworks for practice is becoming more widespread in NNUs, but is not yet universal.
Examination of the resulting variation in clinical practice can be considered to be a sensitive
issue, since there may be a risk of clinicians feeling vulnerable to criticism and comparison
of their personal practice with that of others. The information sheet circulated with the
questionnaire therefore contained a statement assuring clinicians that centres and participants
would be identified only by unique identification codes and that no specific comparisons
would be made between identified individual NNUs or practitioners. Although no explicit
107
written consent to take part in the survey was obtained, completion and returning of the
questionnaire were regarded as implied consent. The voluntary nature of participation was
highlighted. The information sheet was designed in accordance with guidance offered by the
Central Office for Research Ethics Committees (COREC) in the UK.
4.2.3 Consent for research in neonates
For interventional research in the newborn, it is essential to obtain explicit written informed
consent from parents before an infant can be included. The issues surrounding collection of
anonymised infant data are less clear. For retrospective data collection, research requiring
parental consent is limited by the ability of the researcher to locate and contact parents for
discussion of the research aims and requirements. This problem is magnified in work that
involves large numbers of infants who are no longer hospitalised and the inclusion of
multiple centres over wide geographical areas. The subject of parental consent for this
survey was carefully considered and was discussed with senior neonatologists and members
of ethical committees at an early stage in the planning of both the pilot and definitive
surveys. A requirement for fully informed consent from all parents of babies, both surviving
and those who had died, would almost certainly have rendered this survey impractical. It
would also have been likely to compromise the integrity of the work by introducing selection
bias. Since epidemiological research of this kind relies heavily on the completeness of data,
the approving research ethics bodies agreed that written parental consent was not required.
The approach was taken whereby all data were anonymised and no patient identifiable data
were removed from the hospital premises at any time.
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PART II




A semi-structured questionnaire was designed as a tool to examine the opinions and reported
practice of clinicians with respect to the initiation, progression and temporary
discontinuation of milk feeds in preterm and very low birth weight infants. It aimed to
determine the availability of written clinical practice guidelines on the subject of infant
feeding and clinicians' preferences for feeding strategies. Specifically, it included questions
to identity those factors that influence clinicians in their decisions about feeding preterm and
very low birth weight infants.
5.1 Piloting and peer review
There has been no recent work designed to address these questions and no previously
validated questionnaires or datasets suitable for modification. The questionnaire was
therefore constructed specifically for this research. A study piloting the use of a
questionnaire was carried out in Scotland in 2003'. This provided the opportunity to test the
methodology on a subset of the intended final population and to assess the feasibility of
performing a more extensive survey. Prior to the piloting of the clinician survey, the
questionnaire was administered informally to a small number of neonatologists who would
not be involved in the survey. They provided comments and feedback on the layout, length,
language, content, clarity and acceptability of the questionnaire and identified any
ambiguities or omissions. This peer-review process led to only minor changes in the wording
of the questionnaire. At this stage, questions on all potentially significant factors that might
be expected to affect either feeding practice or feeding-related outcomes were included. This
allowed identification of the most and least relevant factors and subsequent refinement of the
survey for more widespread use. For the pilot survey, face-to-face interview was chosen as
the most feasible method of administration and the method most likely to obtain the
maximum number of responses. This approach also provided clinicians with the opportunity,
during interview, to provide feedback on the content and administration of the survey. A
single researcher interviewed one consultant neonatologist in each of fifteen Scottish NNUs.
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Suggestions that were consistently made by respondents were then used to make
amendments when producing the subsequent version used for the current survey.
5.2 Questionnaire content
The content of the clinician questionnaire was modified firstly on the basis of experience
with using the questionnaire during piloting and secondly as a result of feedback from
clinicians taking part in the pilot survey.
Following analysis of the results of the pilot survey, it appeared that the list of factors chosen
as those that might significantly influence feeding practice was appropriate. Most of the
factors presented were considered to be a potential influence on decision-making by more
than 25% of clinicians. During the pilot survey, neonatologists had been given the
opportunity to identity any other areas they felt had been omitted. Many of them identified
one or more additional factors that might influence their practice. However, no more than
one clinician highlighted any single factor. It was therefore thought that the addition of a
number of other factors to the list might not yield a substantial number of additional
responses and that a lengthier list might serve to discourage participation. However, several
clinicians had felt that signs and symptoms of NEC should be included in the list. This had
previously been thought unnecessary, since it had been anticipated that there would be
consistent and unanimous agreement among neonatologists about discontinuation of feeds in
babies displaying symptoms of NEC. However, in view of this feedback, four further factors
were added: mild abdominal distension, severe abdominal distension, bloody stools and
abdominal tenderness. One other factor - blood transfusion - was also added since the
appropriateness of feeding infants during transfusion had been highlighted recently as a topic
of interest in professional internet discussion forum, "NICUnef'. Three factors that had been
included in the pilot survey were removed. 'Lack of MEBM' and Tack of any breast milk'
were considered inappropriate as answers to these questions might more closely reflect the
inconsistent availability of donor bank expressed milk rather than true clinician preference.
The third factor to be omitted in the definitive survey was 'patent ductus arteriosus'. This
was felt to be less discriminating than questioning about the administration of indomethacin
for treatment, since this was the more usual reason cited by clinicians for slowing or
discontinuing milk feeds in infants with patent ductus arteriosus.
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5.3 Survey participants
During training in paediatric and neonatal medicine, junior doctors frequently work in a
number of different departments and are therefore exposed to many different opinions and
practices for all aspects of care, including the feeding of infants. This exposure allows
development and shaping of an individual's own clinical practice. It is expected that by the
time of attaining a substantive position as a consultant or attending paediatrician or
neonatologist, a clinician will have had sufficient experience to have developed their views
to the extent where they would be able to give an informed opinion regarding aspects of
neonatal care. It was decided, therefore, that clinicians to be invited to take part in this
survey should be senior enough to have formulated individual opinions and be likely to have
been employed in the same NNU for a significant period of time. In the UK, all consultant
neonatologists and paediatricians regularly involved in the care of newborn infants were
approached. In Canada, all staff neonatologists working in Level 3 neonatal intensive care
units were included.
5.4 Layout and structure of the questionnaire
The questionnaire was first designed for use in the UK and consisted of five short sections,
labelled A to E for ease of reading. Section A included general questions to obtain
background information about the size of the NNU and type of care offered, including
availability of PN and DEBM. The subjects of initiation, progression and temporary
discontinuation of feeds were addressed in the following three sections (B, C and D
respectively) in the logical order in which these decisions would usually be taken in the
clinical situation. The layout of questions in each of these sections followed a similar pattern.
In each of the three sections, clinicians were asked about the availability firstly of general
and secondly, more specific written guidelines for feeding of preterm and low birth weight
babies on their NNU. It would be expected that centres with comprehensive feeding
guidelines would show less variation in practice, since personal opinion would be likely to
play less of a part in decision-making. For the initiation of feeds, the clinicians' views on the
optimum time for introduction of milk was sought, as well as opinion on the most suitable
type and volume of milk for this. Section C addressed the rate of progression to full enteral
feeds. Section D, addressed the temporary discontinuation of feeds and clarified criteria used
for this and personnel involved most often in the decision-making process.
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Section E addressed all specific single clinical factors previously identified as those
potentially associated with important or adverse outcomes related to preterm infant feeding.
Clinicians were asked to consider each factor with respect to initiation, progression and
discontinuation of feeds and to decide whether or not the presence of each factor influenced
decision-making on the NNU. Items on the list were clearly numbered from 1 to 30, with the
final section allowing clinicians to identify any factors they considered important, but not
included in the list.
Closed, structured questioning requiring Yes / No answers was used as far as possible to
facilitate comparison and quantitative analysis of the responses. Where this was not possible
because the range of responses was difficult to predict or likely to vary from one clinician to
another, doctors were asked to respond using their own words. Adequate free text space was
provided for this. It was hoped that this section might elicit some responses including factors
that would be repeated later in the questionnaire in the form of closed questions. The purpose
of this was to act as a measure of internal consistency. Similarly, some of the factors
included in Section E, such as "hypotension" and "use of inotropes" were closely related, as
are "vomiting" and "large aspirates". Similar responses to these questions would be
anticipated, since they are essentially measures of the same things and would also confirm
internal consistency.
The topic-based layout and wording of the questionnaire was intended to be as succinct and
simple as possible, whilst acknowledging that both the researcher and all respondents are
trained in the same discipline and are familiar with terminology and procedures in neonatal
medicine.
5.4.1 Adaptation of the questionnaire for use in North America
The layout and structure of the questionnaire used for Canadian neonatologists was identical
to that of the UK document. However, a number of minor revisions were necessary to adapt
the questionnaire for use in Canada to reflect transatlantic differences in terminology and
spelling. The main difference was in the terminology referring to neonatal staff personnel,




6.1 Identification of potential participants
6.1.1 United Kingdom
Contact details of consultant neonatologists in the UK were obtained from the Handbook of
the British Association of Perinatal Medicine (BAPM) after first informing the BAPM that
the survey was about to be circulated. Since many consultant paediatricians are not members
of the BAPM, but have significant input into neonatal care, further information was obtained
from the 2003 Handbook of the Neonatal Nurses Association, which lists neonatal and
special care baby units and provides names of clinicians associated with these units. Special
interests of consultants were checked using the Internet website www.specialistinfo.com.
Consultants who identified "neonatology", "neonates", "neonatal medicine" or "perinatal
medicine" as a special interest in their professional details were included in the distribution
list. Both publications that were used to compile the distribution list are freely available to
practising clinicians within neonatology. The website is accessible after registration and
independent verification of professional details. Although it was acknowledged that these
methods would be likely to identify some paediatricians who no longer work with the
newborn following reorganisation of services and workloads, it was felt to be important to
avoid exclusion of any who were potentially involved in neonatal care.
6.1.2 Canada
The Canadian Neonatal Network™ is a group of Canadian researchers who collaborate on
research issues relating to neonatal care. The Network was able to provide contact details of
NNU Medical Directors. Canadian NNUs have substantially more input from dedicated
neonatal dietician-nutritionists than is customary in UK units. It is usual for them, as well as
neonatologists, to make ongoing decisions and suggestions about feeding of high-risk
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infants. Similarly, neonatal dietician-nutritionists are significantly involved in the
development and implementation of feeding guidelines. Given this fundamental difference, it
was decided that questionnaires should be distributed to one neonatal dietician from each
NNU included in the survey. Members of the Neonatal Dieticians' Group in Canada were
able to provide a distribution list to facilitate contact with dietician-nutritionists.
6.2 Administration of the questionnaire
Clinicians interviewed during the piloting stage of the survey expressed the view that the
questionnaire might be appropriately administered by post or email in future surveys. Given
the much greater numbers of clinicians involved in the present work, this approach was
adopted. The questionnaire, together with a letter and information sheet about the aims of the
survey, was distributed by post to identified consultant neonatologists and paediatricians in
the UK. Stamped addressed envelopes were included for responses.
In Canada, NNU Medical Directors were approached by email via the Canadian Neonatal
Network, informing them of the survey and requesting permission to send the questionnaire
to neonatologists within the unit. The questionnaire and information sheet were then
distributed by email to clinicians, inviting responses by either email or post.
6.2.1 Non-responders
Following distribution of questionnaires by post to UK clinicians, a follow-up email was sent
to all those from whom a response had not been received within one month, together with a
request for any clinicians who felt that they had been inappropriately included in the mailing





In total, 854 questionnaires were distributed by post to clinicians in the UK between
September and December 2004 and to clinicians in Canada between May and September
2005. Of these, 740 (86.7%) recipients were neonatologists or paediatricians working in 175




Of the 740 UK clinicians who received questionnaires, 60 replied in writing, but indicated
that they believed they had been inappropriately included in the survey. Reasons given were:
retired (n=2), no longer in post (n=10) and no longer responsible for the care of preterm and
low birth weight newborn infants (n=48).
In an attempt to identify others who had not replied but may have been inappropriately
contacted, each NNU was telephoned to ensure that (i) the unit was still caring for infants
within the relevant gestational age and weight groups and (ii) each clinician still maintained
active participation in neonatal care. As a result of this, 7 NNUs (18 clinicians) were
identified as either having closed or discontinued care of infants <30 weeks of gestation. A
further 30 individual clinicians were identified as no longer being involved in the care of
infants <30 weeks' gestation and 7 clinicians had moved to other positions.
Therefore, in order to ensure that the dataset contained details only of clinicians who take a
significant part in neonatal care, 115 clinicians, to whom questionnaires had originally been
sent, were therefore excluded from the denominator data. Numbers of clinicians and reasons
for exclusion are shown in Table 7.1. This reduced the total number of clinicians that were in
the intended UK target population for questionnaire administration to 625. This figure was
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therefore used as the denominator when analysing UK questionnaire responses. These
clinicians worked in 168 NNUs.
Table 7.1: Reasons for exclusion of UK clinicians
Reason for exclusion Number of clinicians
No longer involved in neonatal care 96
Retired from clinical practice 2
Moved to another place of work 17
Total number of clinicians excluded 115
7.1.2 Canada
There were 114 questionnaires sent to clinicians working in Canadian NNUs. Contact details
for Canadian clinicians were obtained directly from the chief neonatologists of the units, so
it was therefore possible to confirm the status of doctors and dietician-nutritionists at this
time. All clinicians to whom questionnaires were distributed were employed in NNUs that
cared for infants within the relevant gestational and birth weight groups at the time of the
survey.
7.1.3 "Unit-based" responses
Several clinicians (19 neonatologists from 12 UK NNUs and 1 Canadian neonatologist)
requested to be considered in the analysis as part of a "unit response" rather than each
clinician within a unit being required to complete an individual questionnaire. Reasons given
for this on were (i) that unit guidelines for feeding were in place to which all clinicians
adhered and (ii) that the lead neonatologist would be most appropriately informed to be able
to give an opinion reflecting that of the whole clinician group.
Clinicians who suggested that they would prefer to submit a unit-based response were
contacted to re-emphasize the study aim of documenting intra-unit variability in opinion and
practice. However, all stated that they believed that feeding practice did not differ between
clinicians and that guidelines, where present, were closely followed. All declined to
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complete an individual questionnaire and said that one view would be likely to reflect those
of all clinicians.
Had the suggested approach been used, the opinions and reported practice of 55 clinicians
would have been reflected in responses from only 12 clinicians. This would be acceptable if
there was certainty that the views of all clinicians within a given unit would be identical;
however, it was felt that this would be unlikely. In order to test this, all completed
questionnaires from NNUs where one or more clinicians had requested that a unit-based
response should be accepted were examined. Completed questionnaires had been received
from more than one clinician (range 2-5) in four of the 12 NNUs. Detailed examination of
these questionnaires revealed that the responses were not identical in any case and were
substantially different in some. Table 7.2 shows the number of clinicians in these NNUs and
the number of questionnaires that were returned, together with the percentage of questions
that were answered in the same way by all responding clinicians. For one of the NNUs
where at least one clinician expressed the view that a unit response would be preferable, no
completed questionnaire was received. In view of this, only completed and returned
questionnaires from these units were included; all other clinicians were regarded as non-
responders.
Table 7.2: Agreement between questionnaire responses in units requesting
inclusion of unit-based responses
Total number of Number of completed Agreement between














7.2 Response rates and respondents
There were 277/625 responses (44.3%) from clinicians in the UK and 45/114 from Canada
(39.4%). Requests from 20 clinicians who did not complete the questionnaire, but wished to
be included based on a response from someone representing the whole unit, were excluded.
After exclusion of these clinicians, the total number of valid responses was 302 (40.9%) with
258 (85.4%) from UK clinicians and 44 (14.6%) from Canadian clinicians. The response rate
from UK clinicians was slightly higher than from Canadian neonatologists or dietician-
nutritionists and these are summarised in Table 7.3.
152 of the 191 NNUs involved in the survey returned at least one completed questionnaire
(79.6%). 135/168 (80%) UK units and 17/23 (74%) Canadian units returned at least one
questionnaire.
Table 7.3: Response rates by clinician groups
Number of Completed Response
clinicians questionnaires rate
UK neonatologists/ paediatricians 625 258 41.3%
Canadian neonatologists 98 39 39.8%
Canadian neonatal dieticians 16 5 31.2%
Total 739 302 40.7%
7.2.2 Characteristics of UK respondents
Of the 625 UK clinicians included in the survey, 354 (56.6%) were identified, on the internet
website 'www.specialistinfo.com' either as neonatologists or as paediatricians with a special
interest in neonatology. 203 (57.3%) of these clinicians completed and returned
questionnaires, accounting for 78.4% of all valid responses. This indicated that those
specialising in neonatal medicine were significantly more likely to respond (%2 test, P=0.006)
to this survey than were general paediatricians who had some, but not full time, commitment
to the neonatal service.
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7.2.3 Characteristics of Canadian respondents
In contrast to the UK system, in Canada there is little day-to-day "cross cover" between
paediatric and neonatal services by clinicians in NNUs that care for very low birth weight
infants on a regular basis. Only such units were contacted, therefore this negated the need to
clarify whether clinicians were spending all their time in neonatal care, as this is the norm
and all are regarded as specialists in neonatal medicine.
7.3 Availability of Parenteral Nutrition
Three hundred (99%) clinicians said that PN was available in their NNU. All Canadian units
had PN. Two respondents from two different UK units stated that it was not available.
However, one of these responses conflicted with the response of another clinician from the
same NNU that indicated the availability of PN.
7.4 Availability of Donor Expressed Breast milk
7.4.1 United Kingdom
All but one UK clinicians answered this question. Ninety-four (31%) clinicians, in total,
stated that donor expressed breast milk (DEBM) was available on their NNU. DEBM was
more widely available in the UK. There were positive responses from at least one clinician in
54/135 (40%) units. However, there were conflicting responses from 10/135 (7%) units,
suggesting that the true percentage of units having access to DEBM is probably somewhere
between 32% and 40%.
7.4.2 Canada
Only two neonatologists and one dietician, each from different NNUs in Canada said that
they had access to DEBM (7%). The dietician stated that it had become available to the
NNU only very recently; however, all responses from neonatologists in that unit indicated
that it was not available to them. With respect to the two other positive responses, one was
from a unit from which this was the only response; the other was in conflict with the
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responses of colleagues from the same NNU. These results suggest that DEBM was only
available in between 1 and 3 (6-18%) of the 17 Canadian units responding.
7.5 Use of Feeding Guidelines
Clinicians were asked to state whether their NNU had written guidelines for each of three
areas of feeding practice: (1) initiation of enteral feeds, (2) rate of advancement of enteral
feeds and (3) criteria for the temporary discontinuation of enteral feeds. They were also
asked (4) whether the unit routinely used a defined minimal enteral feeding regimen.
7.5.1 Initiation of enteral feeds
7.5.1.1 United Kingdom
256 UK clinicians answered the question about guidelines for the initiation of feeds. There
was at least one response from 134 NNUs. Of these, 58 NNUs were represented by a
response from a single clinician. From the remaining 76 units, at least two responses were
received (range 2-7). 134 (52%) clinicians answered that written guidelines were available
on their NNUs and 122 (48%) answered that guidelines were not available.
7.5.1.2 Canada
Forty-four clinicians from the 17 Canadian NNUs answered this question. Of these, 12
NNUs were represented by a response from a single clinician. From the remaining 5 units, at
least two responses were received (range 2-7). Thirty-six (82%) clinicians answered that
written guidelines were available on their NNUs and 8 (18%) answered that guidelines were
not available.
7.5.2 Advancement of enteral feeds
7.5.2.1 United Kingdom
Two hundred and fifty-five UK clinicians submitted a response about guidelines for the rate
of advancement of feeds. There was at least one response from 134 NNUs. Of these, 59
NNUs were represented by a response from a single clinician. From the remaining 75 units,
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at least two responses were received (range 2-7). One hundred and two (40%) clinicians
answered that written guidelines were available on their NNUs and 153 (60%) answered that
guidelines were not available.
7.5.2.2 Canada
Forty-three Canadian clinicians answered this question, with at least one response received
from each of the 17 NNUs. Of these, seven NNUs were represented by a response from a
single clinician. From each of the remaining 10 NNUs, at least two responses were received
(range 2-7). Thirty-nine (91%) clinicians answered that written guidelines were available on
their NNUs and 4 (9%) answered that guidelines were not available.
7.5.3 Temporary discontinuation of enteral feeds
7.5.3.1 United Kingdom
There were 252 responses from UK clinicians about temporary discontinuation of feeds.
There was at least one response from 133 NNUs. Of these, 59 NNUs were represented by a
response from a single clinician. From each of the remaining 74 units, at least two responses
were received (range 2-7). Only 42 (17%) clinicians answered that written guidelines were
available on their NNUs and 210 (83%) answered that guidelines were not available.
7.5.3.2 Canada
Forty-three clinicians from the 17 Canadian NNUs answered this question. Of these, 7
NNUs were represented by a response from a single clinician. From the remaining 10 units,
at least two responses were received (range 2-7). Twelve (30%) clinicians answered that
written guidelines were available on their NNUs and 31 (70%) answered that guidelines
were not available. Table 7.4 summarises the total number of positive responses received
from individual clinicians and the number ofNNUs that were represented.
7.5.4 Minimal Enteral Nutrition
7.5.4.1 United Kingdom
There were 254 responses from UK clinicians in 134 NNUs. There was at least one response
from all NNUs. Of these, 61 NNUs were represented by a response from a single clinician.
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From each of the remaining 73 units, at least two responses were received (range 2-7). 123
(48%) clinicians answered that their NNU used a defined minimal enteral feeding regimen
and 131 (51%) answered that it did not.
7.5.4.2 Canada
All clinicians returned a response to this question. Seven of the 17 NNUs were represented
by a single clinician's response. Between 2 and 7 responses were received from the other 10
units. Twenty-eight (64%) clinicians indicated that their NNU routinely used a minimal
enteral feeding regimen and 16 (36%) indicated that they did not.
Table 7.4: Positive (Yes) responses indicating the availability of written
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7.5.5 Intra-unit variation in responses
For Questions (1), (2), (3) and (4) there was more than one response from 86, 85, 84 and 83
NNUs respectively. There was substantial variation in responses between members of teams
within individual NNUs in the UK and in Canada. In NNUs from which more than one
response was received, these were conflicting >25% of the time for all questions and
approaching 50% of the time for the final question. Results are summarised in Table 7.5.
Where only one response was returned from a single clinician, based on the available data, it
could only be assumed that these responses correctly reflected the status of the NNUs at the
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time of the survey. For all units from which conflicting responses were received it is
uncertain as to whether guidelines were, or were not available at the time of the survey.
The survey results therefore suggest the following:
1. Guidelines for feed initiation may be available in between 42% and 64% of UK
NNUs and in between 59% and 88% of Canadian units.
2. Guidelines for the rate of advancement of feeds may be available in between 31%
and 48% ofUK units and in between 70% and 82% of Canadian units.
3. Guidelines for discontinuation of feeds may be available in between 10% and 23%
ofUK NNUs and in between 12% and 47% of Canadian units.
4. A defined minimal enteral feeding regimen is used routinely in between 39% and
63% ofUK NNUs and in between 41% and 76% of Canadian units.
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In addition to questions about the three main areas of feeding practice, clinicians were asked
whether their NNUs had any specific guidelines for the initiation or advancement of feeds in
any particular subgroups of babies. One hundred and nine clinicians stated that they had
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guidelines for initiation of feeds for one or more different subgroups of babies and 72 that
they had such guidelines for feed advancement. The types of babies were similar for both
aspects of feeding and the numbers of responses are summarised in Table 7.6. The most
common conditions for which guidelines had been developed were growth restricted babies
and those with abnormal umbilical antenatal doppler studies. Several clinicians indicated that
specific guidelines were available based on birth weight < 1500g, <1250g or <1000g, or
based on gestational age <24 weeks, <28 weeks, <30 weeks or <32 weeks. Others suggested
that guidelines were different according to "high risk" or "risk ofNEC", although these risks
were not defined. Most clinicians did not specify only one group of infants, but indicated
that a number of different specific guidelines were available in their units.
Table 7.6 Groups of babies for whom specific guidelines were available
Feed initiation Feed advancement
(No. clinicians) (No. clinicians)
Abnormal dopplers 51 24
IUGR 37 23
Based on birth weight 39 9
Based on gestational age 10 4
Birth asphyxia 8 3
High risk or risk of NEC 8 9
Risk of hypoglycaemia 7 1
Inotropic support 2 0
Surgical conditions 5 7
Polycythaemia 3 1
Umbilical catheters 1 0
Pharmacological paralysis 2 0
Delayed passage of meconium 1 1
Indomethacin 1 0
Sick 4 4
Based on SMA flow 1 1
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7.6 Introduction of enteral feeds
Clinicians were asked what they considered the optimal time for introducing breast milk
feeds where this is available and there is no specific contraindication to introducing enteral
feeds. 258 UK and 41 Canadian clinicians answered this question. The majority favoured the
early introduction of enteral feeds with more than 90% preferring to introduce milk within
48 hours of birth. Twenty (6.6%) considered that feeds should be started between day 3 and
day 7 of life. No clinician would delay the introduction of breast milk for a week or more in
the absence of specific contraindications (Table 7.7).




Day 1 150 (58%) 25 (57%) 175 (58%)
Day 2 88 (34%) 14 (32%) 102 (34%)
Day 3-4 17 (6%) 2 (4%) 19 (6%)
Day 5-7 1 (<1%) 0 1 (<1%)
> 7 days 0 0 0
No response 2 (<1%) 3 (7%) 5 (2%)
7.6.1 Delayed introduction of feeds, awaiting maternal breast milk
Clinicians were asked how long they felt it would be acceptable to delay the start of feeds
while awaiting MEBM. Responses were very variable and are summarised in Table 7.8;
there were three non-responders (1%), all from the UK. 15 (5%) clinicians from units where
donor breast milk was available would use this to introduce feeds when indicated.
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<24 hours 53 (20%) 19 (43%) 72 (24%)
< 48 hours 84 (33%) 10 (23%) 94 (31%)
< 3 days 40(15%) 11 (25%) 51 (17%)
< 4 days 13 (5%) 2 (4%) 15 (5%)
< 5 days 12 (5%) 0 12(4%)
< 6 days 1 (<1%) 0 1 (<1%)
< 7 days 6 (2%) 1 (2%) 7 (2%)
Would use donor milk 15 (6%) 0 15 (5%)
Would always await MEBM 9 (3%) 0 9 (3%)
Guided by parents' wishes 3(1%) 0 3 (<1%)
Variable periods, not specified 19 (7%) 1 (2%) 20 (7%)
No response 3 (1%) 0 3 (<1%)
7.6.2 Type of milk
It is accepted that when maternal breast milk is available, this is the milk of choice for the
introduction of feeds in preterm infants. In the absence ofMEBM, a number of choices are
available to the clinician. Clinicians were therefore questioned about their choice of milk to
use for preterm infants in circumstances where a mother is unable or does not wish to
express milk, or for whom breast-feeding is contraindicated. Responses for this question are
summarised in Figure 7.1. 19 (7%) clinicians from 12 NNUs said that donor breast milk
would always be available on their NNUs and that this would be their preferred choice in the
absence of maternal milk. A further 11 indicated that their choice would be different,
depending on whether the baby was considered "high risk or "low risk". These responses
indicated that high risk was based on criteria including birth weight < lOOOg or <1200g,
gestation <26 weeks, severity of illness or abnormal Doppler flow measured antenatally in
umbilical vessels. Of the clinicians who would usually use preterm formula, 11 would
consider the use of donor milk in high-risk babies, one would use term formula and five
would use a hydrolysed protein formula. Of those choosing a term formula for routine use,
four would give hydrolysed formula to high-risk babies.
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7.6.2.1 Intra-unit variation
There was more than one response to this question from 75/134 (56%) NNUs. Of these, 53
(71%) responses were in agreement about the preferred milk. From the remaining 16 units
(22 UK; 1 Canadian), there were two (n=22) or 3 (n=l) different responses. The most
common difference in opinion was a choice between preterm or term formula, which
occurred in 11 units. Preterm or hydrolysed formulas were the choices in four units (3 UK; 1
Canadian). In other units where there were differences (n=8), opinions were variable, with
preterm, term or hydrolysed formula each being chosen by one clinician, and donor breast
milk by another.












7.6.2.2 Initial feed volumes and frequency
Clinicians were asked to state the usual starting volume and frequency for enteral feeds
given to infants of <1500g birth weight and/or gestational age of <30 weeks in their NNUs.
294 (97.3%) clinicians provided responses to one or both parts of this question. Eight chose
not to answer and one provided information about volume, but not frequency of feeding. Ten
clinicians stated that their practice for both feed volumes and frequency was variable, but did
Preterm formula Term formula Hydrolysed formula DEBM
Milk preferred in the absence of MEBM
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not give reasons for this. A further 16 clinicians clarified that their practice varied depending
on the birth weight or gestation of the baby. There was, in addition, considerable variation in
responses, both in terms of actual volumes and frequencies reported and the way in which
they were quantified. Starting volumes were variably expressed in ml/feed, ml/hour,
ml/kg/feed or ml/kg/day. Frequently a range of volumes and frequencies was suggested.
Single feed volumes ranged from 0.1ml to 2ml and frequency of feeding ranged from every
12 hours to every hour. Hourly feeds were most commonly used, with 114 respondents using
this regimen. The range of responses is summarised in Tables 7.9 and 7.10. Table 7.10 also
shows the variation in feed volumes that would be administered in a 24-hour period and the
implication that this would have for the amount of enteral feed given to a preterm baby with
a birth weight of 750g, were these volumes and frequencies applied.
Table 7.9: Feed volumes and frequency
Feed volume No. clinicians Feed frequency No. clinicians
0.1-0.5 ml/feed 4 Hourly 114
0.5 ml/feed 54 1 - 2 hourly 10
0.5 - 1 ml/feed 38 1 - 3 hourly 2
1 ml/feed 79 1-4 hourly 6
1 - 2 ml/feed 7 2 hourly 30
2 ml/feed 2 2-3 hourly 4
0.5-1 ml/kg/feed 6 2-4 hourly 4
1 ml/kg/feed 29 2-6 hourly 1
3-10 ml/kg/day 3 3 hourly 10
10 ml/kg/day 4 3-4 hourly 4
10-20 ml/kg/day 12 4 hourly 27
20 ml/kg/day 9 4-6 hourly 5
12-24 ml/kg/day 1 6 hourly 13
20 - 40 ml/kg/day 2 2-12 hourly 2
30 ml/kg/day 1 6-12 hourly 4
60 ml/kg/day 18 12 hourly 4
60 - 90 ml/kg/day 2 Continuous 7
Dependent on gestational age 4
Dependent on birth weight 8
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Table 7.10: Feed volumes and intervals; range of responses
Feed volume Feed interval Expected feed
vol. /24 hours
Expected feed vol. /24
hours (750g infant)
0.1-0.5 ml/feed 4 hourly 2.4- 12 ml 2.4- 12 ml
0.5 ml/feed 1-12 hourly 1 - 12 ml 1 - 12 ml
0.5-1 ml/feed 1-12 hourly 1 - 24 ml 1 - 24 ml
1 ml/feed 1-12 hourly 2 - 24 ml 24 ml
1-2 ml/feed 2-12 hourly 2 - 24 ml 2 - 24 ml
2 ml/feed 2 hourly 24 ml 24 ml
0.5-1 ml/kg/feed 1 - 2 hourly 12-24 ml/kg 9-18 ml
1 ml/kg/feed 1-12 hourly 2-24 ml/kg 1.5-18 ml
3-10 ml/kg/day 1 - 4 hourly 3- 10 ml/kg 2.25-7.5 ml
10 ml/kg/day Hourly 10 ml/kg 7.5 ml
10 - 20 ml/kg/day 1-6 hourly 10-20 ml/kg 7.5- 15 ml
20 ml/kg/day Hourly 20 ml/kg 15 ml
12 - 24 ml/kg/day Not stated 12 - 24ml/kg 9- 18 ml
20 - 40 ml/kg/day 1 - 3 hourly 20 - 40 ml/kg 15-30 ml
30 ml/kg/day Not stated 30 ml/kg 22.5 ml
60 ml/kg/day 1 - 3 hourly 60 ml/kg 45 ml
60 - 90 ml/kg/day Not stated 60 - 90 ml/kg 45-67.5 ml
7.7 Factors influencing clinicians' decisions
Twenty-nine factors were chosen that had previously been suggested either as having an
influence on the occurrence ofNEC or as issues that were commonly taken into account by
clinicians when making decisions about initiation or advancement of enteral feeds. Twenty-
three of these factors were also likely to be associated with the temporary discontinuation of
feeds.
Factors included fell broadly into five categories:
1. Indicators of antenatal or perinatal foetal compromise (IUGR, abnormal antenatal
umbilical artery Doppler studies, evidence of perinatal asphyxia);
2. Indicators of severity of illness (hypotension, suspected systemic sepsis, acidosis,
use of inotropic support);
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3. Indicators of respiratory compromise (mechanical ventilation or nasal continuous
positive airways pressure (nCPAP), increasing oxygen requirement, recent
extubation, respiratory disease in a non-ventilated infant);
4. Indicators of abdominal pathology (abdominal distension, large or bilious gastric
aspirates or vomiting, blood in the stools or abdominal tenderness, failure to pass
meconium);
5. Other specific factors that have been associated with NEC or feed intolerance
(presence and position of umbilical catheters, sedation or pharmacological paralysis,
treatment with indomethacin, blood transfusion and polycythaemia).
Clinicians were asked whether each of the chosen factors would lead them to (i) delay
starting enteral feeds, (ii) slow the rate of increase of feeds and (iii) temporarily discontinue
enteral feeds. It is recognised that, in practice, decision-making about changes in approach to
the care of any individual baby will usually involve consideration of the condition of the
baby as a whole and the package of care offered. However, many feeding-related factors
have been suggested as significantly associated with important outcomes and as such may, in
isolation, influence the decisions taken. Clinicians were also given the opportunity to suggest
in free text, any other factors that they believed to be important in making such decisions.
Four clinicians clarified their response by stating that they would rarely make decisions
based on one factor in isolation, but after assessing the general condition of the baby.
Each of the factors included was considered important in decision-making by at least two
clinicians. Some factors were highlighted much more frequently and consistently than others
with the percentage of positive responses for an individual item ranging from 2-94%. In
addition, there were differences between opinions of UK and Canadian clinicians in some
areas. The responses are tabulated in Tables 7.11 to 7.14. Those factors that were considered
important by more than 50% of respondents in either country are discussed below.
7.7.1 Introduction of enteral feeds
7.7.1.1 Indicators of antenatal or perinatal fetal compromise
The majority (>75%) of clinicians indicated that they would delay feeding if there was
clinical evidence of perinatal asphyxia. However, 93% of Canadians would delay feeds,
compared with 75% in the UK (%2 test, P=0.007). UK clinicians were more likely than their
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Canadian counterparts to report delaying feeds on the basis of abnormal umbilical arterial
Doppler studies, and in particular if reversed end diastolic flow is seen (79% versus 41%; %2
test, P<0.001). Absent end diastolic flow was considered less important by both groups, but
the difference between the countries remained significant (58% compared with 32% (%2test,
P=0.001). Although abnormal antenatal umbilical Dopplers are closely related to IUGR, only
24% of clinicians overall indicated that they would delay introducing feeds because of IUGR
in isolation. The difference between the UK (22.1%) and Canada (34.1%) was not
statistically significant (x2test, P=0.125).
7.7.1.2 Indicators of severity of illness
Hypotension requiring inotropic support is a reasonable indicator of severe illness. Almost
90% of Canadian clinicians stated that they would do so in a hypotensive baby compared
with 65% UK clinicians (%2 test, P=0.002). Sixty-eight percent of Canadians versus 46% of
UK clinicians indicated that they would delay feeding if inotropic dmgs were required (%2
test, P=0.006). There was a smaller, but still statistically significant difference between the
two countries' clinicians in the case of suspected sepsis (x2test, P=0.044).
7.7.1.3 Indicators of respiratory compromise
Half of all Canadian respondents indicated that respiratory disease in a non-ventilated baby
was a reason to delay initiation of feeds compared with only 36% of UK clinicians. This
difference was not statistically significant.
Recent extubation was highlighted by just over 50% of clinicians. In addition, clinicians
were asked to indicate the length of time for which feeds would be withheld after extubation.
138 clinicians responded and durations for which feeds were withheld varied considerably.
The commonest responses were 2-4 hours (n=81) and 6-12 hours (n=44). However, 8
clinicians would delay for <2 hours and 2 clinicians for >24 hours. No other indicators of
respiratory illness were consistently identified by > 32% of clinicians in either group.
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Table 7.11: Reasons for delaying initiation of enteral feeds
No. (%) clinicians who would delay enteral
feeding
UK Canada (n=44) Total (n=302)
(n=258)
History of absent end diastolic flow 149 (57.8) 14(31.8) 163 (54.0)
History of reversed end diastolic 204 (79.1) 18(40.9) 222 (73.5)
flow
Evidence of perinatal asphyxia 193 (74.8) 41 (93.2) 234 (77.5)
Presence of UVC 44(17.1) 4(9.1) 48(15.5)
Presence of UAC 48(18.6) 9 (20.5) 57(18.9)
Position of UAC 33 (12.8) 6(13.6) 39(12.9)
Hypotension 168 (65.1) 39 (88.6) 207 (68.5)
Suspected systemic sepsis 116(45.0) 27 (61.4) 143 (47.4)
Sedation 7 (2.7) 6(13.6) 13 (4.3)
Nasal CPAP 15 (5.8) 6(13.6) 21 (7.0)
Respiratory disease (not ventilated) 92 (35.7) 22 (50.0) 114(37.7)
Acidosis 62 (24.0) 18 (40.9) 80 (26.5)
Pharmacological paralysis 74 (28.7) 28 (63.6) 102 (33.8)
Failure to pass meconium 30 (11.6) 5(11.4) 35(11.6)
Polycythaemia 51 (19.8) 3 (6.8) 54(17.9)
IUGR 57 (22.1) 15 (34.1) 72 (23.8)
Mechanical ventilation 47(18.2) 14(31.8) 61 (20.2)
Increasing inspired oxygen 64 (24.8) 10(22.7) 74 (24.5)
Treatment with indomethacin 79 (30.6) 32 (72.7) 111 (36.8)
Use of inotropes 118 (45.7) 30 (68.2) 148 (49.0)
Mild abdominal distension 54 (20.9) 4(9.1) 58(19.2)
Severe abdominal distension 243 (94.2) 41 (93.2) 284 (94)
Bloody stools 235 (91.1) 39 (88.6) 274 (90.7)
Abdominal tenderness 232 (89.9) 38 (86.4) 270 (89.4)
Large gastric aspirates 178 (69.0) 22 (50.0) 200 (66.2)
Bilious gastric aspirates 224 (86.8) 36(81.8) 260 (86.1)
Vomiting 159 (61.6) 32 (72.7) 191 (63.2)
Recent extubation 133 (51.6) 20 (45.5) 153 (50.7)
Blood transfusion 16 (6.2) 0 16(5.3)
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7.7AA Indicators of abdominal pathology
Potential indicators of abdominal pathology were the factors most commonly identified by
clinicians as likely to lead to a delay in the introduction of enteral feeds, with severe
abdominal distension, the presence of blood in the stools, abdominal tenderness and bilious
gastric aspirates each influencing >80% of clinicians in both the UK and Canada. Vomiting
would lead >60% of UK and Canadian clinicians to delay feeding. The presence of large
gastric aspirates was considered important by 69% of UK clinicians and 50% of Canadian
clinicians, representing a significant difference between the two groups (x2test, P=0.014).
7.7.1.5 Other factors
There were highly significant differences between the numbers of clinicians in Canada and
the UK who considered the use of indomethacin and the use of pharmacological paralysis as
reasons to delay the introduction of enteral feeding. Seventy-three percent of Canadian
clinicians would delay feeding with indomethacin, compared with 31% in the UK (y2 test,
P<0.001) and 64% compared with 29% would delay feeding in a baby treated with muscle
relaxants (%2 test, P<0.001). No data were obtained with respect to whether clinicians
favoured giving short or prolonged courses of indomethacin or whether it was used
prophylactically.
7.7.2 Progression of enteral feeds
7.7.2.1 Indicators of antenatal or perinatal fetal compromise
In babies where a clinical decision has been taken to begin enteral feeding, the most
commonly identified reason overall (81% clinicians) for slow advancement of feeds was a
history of reversed end diastolic flow on antenatal Doppler studies. However, in this and in
cases of absent end diastolic flow, clinicians in the UK were more likely to report a cautious
approach to feeding (86% and 70.5% compared with 52% and 41% respectively (%2 test,
P<0.001 for both)). Most Canadian (84%) and UK (70.5%) clinicians would advance feeds
more slowly if there was evidence of perinatal asphyxia. 61% of Canadian clinicians but
only 42% of UK clinicians indicated that they would feed more slowly in growth restricted
babies (%2test, P=0.028).
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7.7.2.2 Indicators of severity of illness
Overall, 55% would feed more slowly in hypotensive infants, with a slightly, but not
significantly increased tendency in Canada. 59% of Canadian, but only 40% UK clinicians
would do so if inotropic support were required (y2 test, P=0.027).
7.7.2.3 Indicators of abdominal pathology
Between 50% and 75% of clinicians would slow the rate of increase of feeds if the baby
displayed any of the signs of potential intra-abdominal pathology, and there was agreement
between groups from both countries. Large gastric residual volumes and vomiting were most
commonly identified.
7.7.2.4 Other factors
As seen with the introduction of feeds, there was a significant difference between clinicians
in the UK and those in Canadian units regarding the importance of treatment with
indomethacin when making feeding-related decisions, with 66% of Canadian, compared with
39.5% UK clinicians feeding more slowly (%2test, P=0.002).
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Table 7.12: Reasons for slowing the rate of increase of enteral feeds
No. (%) clinicians who would slow the







History of absent end diastolic flow 182 (70.5) 18 (40.9) 200 (66.2)
History of reversed end diastolic flow 222 (86.0) 23 (52.3) 245 (81.1)
Evidence of perinatal asphyxia 182 (70.5) 37 (84.1) 219 (72.5)
Presence of UVC 55 (21.3) 6(13.6) 61 (20.2)
Presence of UAC 71 (27.5) 9 (20.5) 80 (26.5)
Position of UAC 37 (14.3) 6(13.6) 43 (14.2)
Hypotension 135 (52.3) 30 (68.2) 165 (54.6)
Suspected systemic sepsis 119 (46.1) 20 (45.5) 139 (46)
Sedation 14 (5.4) 7(15.9) 21 (7.0)
Nasal CPAP 35 (13.6) 10 (22.7) 45 (14.9)
Respiratory disease (not ventilated) 91 (35.3) 21 (47.7) 112 (37.1)
Acidosis 49(19.0) 12 (27.3) 61 (20.2)
Pharmacological paralysis 63 (24.4) 20 (45.5) 83 (27.5)
Failure to pass meconium 74 (28.7) 8(18.2) 82 (27.2)
Polycythaemia 54 (20.9) 9 (20.5) 63 (20.9)
IUGR 109 (42.2) 27 (61.4) 136 (45)
Mechanical ventilation 53 (20.5) 8(18.2) 61 (20.2)
Increasing inspired oxygen 88 (34.1) 13 (29.5) 101 (33.4)
Treatment with indomethacin 102 (39.5) 29 (65.9) 131 (43.4)
Use of inotropes 103 (39.9) 26 (59.1) 129 (42.7)
Mild abdominal distension 134 (51.9) 20 (45.5) 154 (51.0)
Severe abdominal distension 161 (62.4) 27 (61.4) 188 (62.3)
Bloody stools 143 (55.4) 27 (61.4) 170 (56.3)
Abdominal tenderness 140 (54.3) 25 (56.8) 165 (54.6)
Large gastric aspirates 180 (69.8) 33 (75.0) 213 (70.5)
Bilious gastric aspirates 151 (58.5) 27 (61.4) 178 (58.9)
Vomiting 173 (67.1) 32 (72.7) 205 (67.9)
Recent extubation 66 (25.6) 7 (15.9) 73 (24.2)
Blood transfusion 16 (6.2) 0 16(5.3)
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7.7.3 Temporary discontinuation of enteral feeds
The only reasons commonly identified for discontinuing feeds by both groups of clinicians
were indicators of abdominal pathology and in particular, those signs that might be present
in a baby with suspected NEC. These included severe abdominal distension, bloody stools
and abdominal tenderness, which were identified by approximately 90% of clinicians in both
countries as reasons to discontinue enteral feeds. Bilious or large aspirates were also
regarded as indicators to stop enteral feeds, but by smaller numbers of clinicians in both
countries (73% and 82% respectively). The only other factor identified as an indication to
stop feeds was hypotension, by 52% of Canadian clinicians, but by only 34% in the UK (%2
test, P=0.028).
7.7.4 Significance of acidosis
Clinicians who indicated that acidosis would be an influencing factor in decision-making
were also asked to suggest a level of acidosis that they would consider significant. Eighty
(26%) responses suggested that acidosis would affect feed initiation, although less than three
quarters of these clinicians provided an opinion about significant levels of acidosis.
Similarly, although positive responses were received from 49 (16%) and 61 (20%) clinicians
respectively in response to questions about feed advancement and discontinuation
respectively, 40% and 30% of these respondents respectively did not offer opinions
regarding levels. Three UK clinicians suggested significant levels of acidosis, but indicated
that acidosis would not influence their decision-making.
Although less than 50% of clinicians stated that this was an important factor for any aspect
of feeding, there was variation between the responses received. This variation encompassed
differences in the measurements used to assess the degree of acidosis as well as differences
in the values considered significant. For each of the three aspects of feeding, there were
between eight and ten different responses regarding the level that might be used clinically as
a "cut-off point" to indicate significant acidosis; these are summarised in Table 7.13.
However, the most commonly used levels were a pH of <7.2 or 7.25. This was consistent
across the three areas of feeding practice and for both UK and Canadian subgroups.
137







































Figure 7.14: Reasons for temporary discontinuation of enteral feeds
No. (%) clinicians who would
discontinue enteral feeds
UK Canada Total %
(n=258) (n=44) (n=302)
Hypotension 87 (33.7) 23 (52.3) 110(36.4)
Suspected systemic sepsis 94 (36.4) 20 (45.5) 114(37.7)
Sedation 9 (3.5) 3 (6.8) 12 (4.0)
Nasal CPAP 5(1.9) 0 5(1.7)
Respiratory disease (not ventilated) 39(15.1) 5(11.4) 44(14.6)
Acidosis 41 (15.9) 8(18.2) 49(16.2)
Pharmacological paralysis 54 (20.9) 21 (47.7) 75 (24.8)
Failure to pass meconium 25 (9.7) 11 (25.0) 36(11.9)
Polycythaemia 13 (5.0) 0 13 (4.3)
IUGR 6 (2.3) 0 6 (2.0)
Mechanical ventilation 24 (9.3) 0 24 (7.9)
Increasing inspired oxygen 43 (16.7) 2 (4.5) 45 (14.9)
Treatment with indomethacin 45 (17.4) 18 (40.9) 63 (20.9)
Use of inotropes 71 (27.5) 18 (40.9) 89 (29.5)
Mild abdominal distension 30(11.6) 1 (2.3) 31 (10.3)
Severe abdominal distension 236 (91.5) 39 (88.6) 275 (91.1)
Bloody stools 233 (90.3) 41 (93.2) 274 (90.7)
Abdominal tenderness 230 (89.1) 40 (90.9) 270 (89.4)
Large gastric aspirates 188 (72.9) 33 (75.0) 221 (73.2)
Bilious gastric aspirates 214(82.9) 34 (77.3) 248 (82.1)
Vomiting 125 (48.4) 26 (59.1) 151 (50.0)
Recent extubation 113 (43.8) 15 (34.1) 128 (42.4)
Blood transfusion 25 (9.7) 0 25 (8.3)
7.7.5 Significance of gastric residual volumes
Clinicians indicating that large volume gastric aspirates would influence their decision¬
making were also asked to state the volume that they considered "large". Although this was
commonly identified as a reason for delaying introduction (66%), slowing advancement
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(70%) and discontinuing (73%) enteral feeds, responses to this part of the question were
fewer. Of those responding to the first part of each question, only 56%, 52% and 45% (113,
112 and 100 clinicians respectively for the 3 aspects of feeding) chose to state what they
perceived as "large". There was a great variation in responses with respect to volumes of
aspirate stated and how these were measured. Clinicians variably expressed volumes as
absolute volumes of between 1ml and 10ml, volumes over a time period (l-2ml/hour, 5-
10ml/4 hours) or by body weight (l-10ml/kg, ml/kg/day or ml/kg/hour). The most common
measure was expressed as a percentage of feed volumes given but this varied from 20% to
100% of the volume of milk given. There were over 30 different measures suggested, with
no single measurement identified by more than 22 clinicians. The most frequent responses
for all three questions were 2ml, 5ml, 50% and 100% of feed volume.
7.8 Decision-making with respect to feed discontinuation
Clinicians were asked to identify which groups of staff most often make decisions about
discontinuation of feeds in their NNU. Taking into account the differences in NNU
personnel and nomenclature between the UK and Canada, different lists were used for each
country. There were 256 responses from UK clinicians and 44 from Canadian clinicians.
7.8.1 United Kingdom
There was great variation in responses, with 18 different combinations of staff identified and
agreement between responses from only 6 UK NNUs. Bedside nurses alone were reported to
make most of the decisions by 36 individual clinicians, consultants by 12 clinicians and
middle grade doctors by 19 clinicians. However, combining responses from clinicians by
NNU indicated that in most NNUs (109/135 (80%)), decisions were taken by a combination
of nursing and medical staff. Consultants were said to be involved in decision-making in all
but one of these units. In 22/135 (16%), medical staff only were reported to make decisions
and in 5/135 (4%), nursing staff only. SHOs were the group of staff least often involved
(38/135 (28%)) and middle grade doctors most commonly (121/135 (90%)). Members of the
nursing staffwere involved in decisions to stop feeds in 114/135 (84%) units. Neonatal nurse
practitioners were involved in 55/135 (41%) units.
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7.8.2 Canada
In Canada, decisions were also most often made by a combination of medical and nursing
staff. Two units reported that the attending neonatologist made these decisions and no unit
reported that decisions were mostly taken by nursing staff alone. Nurses were involved in
decisions in 9/17 (53%) units and neonatal nurse practitioners in 11/17 (65%) units. Fellows
and residents were involved in 13/17 (76%) and 14/17 (82%) units respectively. Attending
neonatologists were involved in 14/17 (82%) units.
141
PART III






Data were collected for all babies born with a gestational age of <30 weeks and/or a birth
weight of < 1500g and admitted to selected NNUs within a defined period of time. The six
months between 1 February and 31 July 2004 was chosen, as all babies born during this time
period had been discharged from inpatient hospital care and therefore medical records would
be likely to be complete and available for detailed review. Collection of data was designed to
identify babies at highest risk of feeding-related complications, by virtue either of low
gestational age or of IUGR.
Following central ethics approval, neonatologists in all UK centres to be included in the
retrospective review of records were approached by letter in order to ascertain whether they
were willing for their neonatal unit to participate. When clinicians had confirmed their
intention for their unit to participate, the Fluman Resources department for each relevant
hospital trust was contacted, initially by telephone and then by letter to the appropriate
member of staff to establish the required procedures for obtaining permission to collect data
as an outside researcher entering the trust. Procedures and the time taken to meet
requirements varied considerably between trusts, with most requiring an honorary contract of
employment to be issued for the duration of the research within that location. In total,
seventeen UK trusts were approached. However, access for research was gained in only
fifteen, as one trust provided the contract too late for the research to be performed and
another was unwilling to allow the study to proceed without consent from all parents of
infants.
In Canada, similar processes were followed, but ethics approval was required for each single
centre. Although five centres were approached, the time-consuming nature of the ethics
approval process meant that only three centres could be included in the study.
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A local contact within the neonatal service in each participating centre was identified to
facilitate data collection. In some units, this was a neonatologist and, in others, an
administrative assistant or research nurse. In addition, these contacts were instrumental in
giving guidance about local processes for identifying eligible infants and obtaining the
relevant medical records. It was also necessary to arrange convenient times to visit the
neonatal units, when records would be available and when a suitable place on site could be
identified for review of the records. Medical and nursing records of all babies born with a
gestational age of <30 weeks and/or a birth weight of < 1500g and admitted to the selected
NNUs during this period of time were requested. All available paper and electronic medical
and nursing records and nursing charts for the whole of the neonatal hospital stay were
reviewed in detail by a single researcher (EMB). Data collection took place over a number of
days for each participating unit, at the convenience of both researcher and clinicians.
Feeding data were collected from birth until two weeks after the attainment of full enteral
feeds. Data for clinical conditions or areas of practice that might be expected to influence
feeding practice were also collected for this period of time, but no data were collected for
doses of drugs such as morphine and indomethacin. Analysis of the effects of these factors
on clinical practice was guided by the literature review and information from responses of
clinicians in the first part of the survey. Data items are listed in Appendix 3.
8.1.2 Data analysis
Data were analysed using SPSS for Windows Version 16.0.2 (SPSS Inc 1989-2007).
Comparisons of proportions were analysed using Chi-squared tests. Comparisons between
continuous variables were made using independent samples t-tests for normally distributed
data with presentation of means (SDs) or Mann Whitney U tests for non-parametric data,
presented with medians (interquartile ranges). Distributions of all continuous data were
examined for normality using graphical measures (histograms, normality plots) and Shapiro-
Wilk tests of normality. A number of variables were not normally distributed, including the
day of first feed and time to full feeds. In these cases where continuous variables were not
normally distributed, data were transformed for analysis using log 10 transformation to obtain
a more normal distribution. Data were presented as geometric means and variation between
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centres was analysed using one-way analysis of variance (ANOVA). Adjustments for
multiple comparisons were made using the Bonferroni method.
Relationships between variables were analysed using multiple regression analysis for
continuous outcome variables and binary logistic regression for binary categorical outcome
variables. Initially, univariate analyses were performed to assess the strength of relationship
between potentially relevant independent variables and outcome variables. Those that
showed an association (P <0.2) were entered into the multivariate regression models. This P
value was chosen to ensure that all those showing some association, even if not statistically
significant, would be included in further analysis. In all multivariate regression models,
independent variables were entered simultaneously. Variables were retained in the model if
they showed an independent association with the outcome variable (P<0.1). This P value
was chosen to ensure inclusion of all those factors with most significant associations. P
values of <0.05 were considered significant for all statistical tests.
All infants of <30 weeks of gestation were included in the study, whereas more mature
infants were only included if they met the study birth weight criterion of <1500g. This
allowed inclusion of some more mature, but growth-restricted babies and analysis of data by
either birth weight or gestation as appropriate. Inclusion criteria were the same for both
countries. For analyses according to gestational age or birth weight, babies were divided into
groups. For gestational age these groups were (i) <26 weeks+0 days; (ii) 26-27 weeks+6
days; (iii) 28-29 weeks+6 days, and (iv) > 30 weeks. Groups were selected to most closely
reflect clinical differences related to maturity and boundaries often chosen by clinicians
when considering the effects of immaturity. In order to reflect current reported practice with
respect to guidelines based on birth weight, the group was divided into three groups for some
of the analysis: (i) <1000g; (ii) 1000-1249g; (iii) >1250g.
8.2 Neonatal Units
Units included in the retrospective review were chosen based on a pragmatic approach. To
ensure that it would be feasible to complete data collection, units were chosen in parts of the
UK that were easily accessible and where accommodation was available for the researcher.
These fell into two main geographical areas - Scotland and the middle of England. Although
ideally the whole of the UK would have been included or a random sample selected from
145
across the whole country, this was judged to be impractical given the limited time available
for data collection. It is possible that this decision will have introduced an element of
selection bias because of regional training methods or guidelines. However, the units visited
were spread over a large geographical area and encompassed a number of different regions
for training and service provision. The area served by the units also comprised urban and
rural populations, minimising bias due to population characteristics. It is unlikely that there
are large systematic differences between these and the remaining regions of the UK that
were not included. It was also considered important that units of differing sizes were
included to produce a more representative sample.
NNUs that were included in Canada were those that were geographically accessible and
were able to grant ethical approval within the limited time available of one year. All three
NNUs were located in the region around Toronto in Ontario. It is acknowledged that these
three units may not be representative of neonatal practice throughout the whole of Canada.
However, the area served by these three NNUs is large and covers both urban and rural
regions.
8.3 Infants
A total of 701 babies were identified as having been born during the six-month period
chosen for the survey. The medical and nursing records of 695 babies in 18 NNUs (15 UK
units and 3 Canadian units) were examined. Data for a further six babies were not included
because data were not available. Reasons for this included inability to locate medical records
within the hospital and medical notes being needed by other authorities at the time they were
requested for review.
8.3.1 Exclusions
In total, 25 infants whose records had been reviewed were excluded from the final data
analysis. This was due either to crucial data being unavailable or to specific factors that
rendered the babies inappropriate for inclusion. The reasons for exclusion are detailed below.
Excluded infants were of significantly lower birth weight, were sicker as determined by
CRIB score and were more likely to die than included infants (Table 8.2).
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8.3.1.1 Exclusions due to gestational age andbirth weight
Both in the UK and in Canada, it is unusual for resuscitation to be initiated at birth for
infants born before 23 weeks of gestation or with a birth weight of less than 450g. One infant
in the group was born at 22 weeks and another at 21 weeks of gestation. A further two
infants were born with birth weight of less than 450g. All infants survived for only a short
time after birth and were never fed. Since these infants were felt not to be representative of
the preterm population generally cared for in NNUs in either country, all four infants were
excluded.
8.3.1.2 Exclusions due to congenital anomalies
Of the 695 babies included in the review, 17 (2.4%) had congenital anomalies. These are
listed in Table 8.1. Of these, three had recognised lethal anomalies and a further four had
major anomalies that would be likely to require early surgical management and therefore
would be expected to significantly affect feeding of these infants. Data for these seven
infants were therefore excluded from analysis.
8.3.1.3 Exclusions due to missing data
Birth weight was missing for one infant and gestational age at birth for another. These
infants were excluded, as further analysis would not be possible without this information.
For two infants, nursing charts documenting data relating to feed volumes for the whole of
the neonatal stay were unavailable. A further ten infants had substantial amounts of feeding
data missing from records due to being transferred from or to another hospital, making it
impossible to determine times of starting feeds or attaining full enteral feeds. These infants
were also excluded. Infants who were transferred, but for whom this information was
available were not excluded, but were not included in analyses where detailed information
about feeding volumes were required.
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Table 8.1: Types of congenital anomalies and exclusions
Nature of anomaly Number of babies affected Excluded
Unilateral absent radius 1 No
Ambiguous genitalia 1 No
Severe airway anomaly 1 Yes
Hydronephrosis 1 No
Choanal atresia I Yes
Congenital diaphragmatic hernia 1 Yes
Donohue syndrome 1 Yes
Hypoplastic left heart syndrome 1 Yes
Coarctation of aorta 1 Yes
Peters anomaly of the eye 1 No
Pierre Robin sequence (mild) 1 No
Trisomy 13 1 Yes
Trisomy 2 mosaicism 1 No
Trisomy 21 2 No
Cystic kidney(s) 2 No
Table 8.2: Comparison between included and excluded infants
Included Excluded Significance
n=670 n=25 (P value)
Birth weight (g) 1120 (913-1315) 1010(625-1150) 0.009
Gestation (weeks) 28 (27-30) 28 (26-31) 0.513
IUGR < 10th centile , n (%) 208 (31.0) 12 (48.0) 0.116
CRIB score 2(1-5) 6 (2-8) 0.005
5 minute Apgar score 9 (8-9) 8 (7-9) 0.297
Deaths, n (%) 75 (11.2) 7 (28.0) 0.02
Values for continuous variables presented as median (interquartile range);
Values for categorical variables are presented as n (%);
Mann-Whitney U testfor comparison between continuous variables;




9.1 Characteristics of study infants
Characteristics of the infants included in the study are summarised in tables 9.1 and 9.2.
There was a significant difference between the UK and Canadian groups of babies for
gestation at birth and a non-significant difference for birth weight and all other comparisons.
Table 9.1: Infant characteristics
Total
n=670 slld&w Canadan=219 P value






Gestation (weeks) 28 (27-30) 28 (27-30) 28 (27-30) 0.024
Male sex, n (%) 337 (50.3) 230(51.0) 107 (48.9) 0.662
IUGR < 10th centile,
n (%)
208 (31.0) 148 (32.8) 60 (27.4) 0.183
CRIB score 2(1-5) 2(1-4) 2(1-6) 0.401
5 minute Apgar 9 (8-9) 9 (8-9) 8 (7-9) 0.586
Deaths, n (%) 75 (11.2) 54(12.0) 21 (9.6) 0.431
Values for continuous variables presented as median (interquartile range);
Values for categorical variables arepresented as n (%>);
Test ofnormality (Shapiro-Wilk): P<0.001 for each variable;
Mann Whitney U testfor continuous variables; x testfor categorical variables.
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9.1.1 Gestational age
Gestational ages ofUK babies ranged from 23-37 weeks, with 10 babies born at >35 weeks,
whereas the range for Canadian babies was 23-34 weeks, with only five babies born after 32
weeks and none at >34 weeks; although the median gestational age was similar for both
countries, there was a significant difference between the two. There were only six infants
born before 24 weeks of gestation.
Table 9.2: Number and characteristics of infants by unit
Unit Country No. of infants Gestation (weeks) Birth weight (grams)
1 UK 56 28 (26-30) 1135 (916-1315)
2 UK 17 28 (27-29) 1090 (835-1335)
3 UK 6 29.5 (27-34) 1210 (1110-1480)
4 UK 30 28 (27-29) 1190(1027-1350)
5 UK 50 28.5 (27-30) 1130(887-1305)
6 UK 42 28 (27-30) 1187.50 (1053-1323)
7 UK 20 28 (26-30) 1140 (982-1252)
8 UK 43 28 (27-30) 1080 (955-1290)
9 UK 15 29 (28-30) 1210(1025-1365)
10 UK 59 29 (27-31) 1100 (858-1298)
11 UK 12 29 (25-30) 1172.50(1025-1437)
12 Canada 90 28 (27-30) 1145 (919-1334)
13 Canada 117 28 (26-29) 1040 (847-1307)
14 Canada 12 25.5 (24-28) 828.50 (597-1037)
15 UK 19 28 (25-32) 1056 (718-1456)
16 UK 13 28 (26-31) 1120 (1005-1390)
17 UK 20 29 (28-32) 1095 (1000-1287)
18 UK 49 28 (27-30) 1165 (857.50-1330.50)
Total 670
Birth weight and gestation presented as median (interquartile range)
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Table 9.3: Gestation by country
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Figure 9.1: Bar chart to show the proportion of babies in the UK and Canada




All infants with a birth weight <1500g were included, to represent the population of very low
birth weight infants. Since all infants of <30 weeks were also included, there were a number
of babies with birth weight >1500g. The majority (63%) of included babies had birth weights
between lOOOg and 1500g. There were a greater proportion of Canadian babies in the lowest
birth weight group.
Table 9.4: Birth weight by country
Birth Weight (g) <1000g 1000-1249g 1250-1499 >1500 Total
UK 134 157 147 13
n (%) (29.7) (34.8) (32.6) (2.9)
Canada 90 60 61 8
n (%) (41.1) (27.4) (27.9) (3.6)
9.2 Significant morbidities
Several babies suffered significant morbidities during their neonatal stay. These included
unilateral or bilateral intraventricular haemorrhage (IVH) and periventricular leukomalacia
(PVL), seizures, pulmonary haemorrhage, pneumothorax, retinopathy of prematurity,
chronic lung disease, defined as oxygen requirement persisting until 36 weeks of gestation
and necrotising enterocolitis. Table 9.5 shows the proportions of infants experiencing
morbidities. Some infants experienced multiple morbidities. Necrotising enterocolitis is not
included and is discussed in detail in a later section.
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Table 9.5: Infants experiencing significant morbidity in the UK and Canada
Condition UK Canada Total
(n=451) (n=219) (n=670)
Intraventricular haemorrhage
(unilateral or bilateral; highest grade)
Grade 1 41(9) 34(15.5) 75 (11.2)
Grade 2 25 (5.5) 14 (6.4) 39 (58.2)
Grade 3 6(1.3) 7 (3.2) 13(1.9)
Grade 4 22 (4.9) 10 (4.6) 32 (4.8)
Periventricular leukomalacia
Unilateral 6(1.3) 3(1.4) 9(13)
Bilateral 2 (0.4) 0 2 (0.3)
Seizures 8(1.8) 6 (2.7) 14 (2.1)
Pulmonary haemorrhage 21 (4.6) 6 (2.7) 27 (3.9)
Pneumothorax 18(4) 5 (2.3) 23 (3.4)
Retinopathy of prematurity
Stage 1 29 (6.1) 4(1.8) 33 (4.9)
Stage 2 18(4) 13 (5.9) 31 (4.6)
Stage3 4 (0.9) 1 (0.4) 5 (0.75)
Chronic lung disease 63 (14) 28(12.8) 91 (13.6)
Values arepresented as n (%>).
9.3 Initiation of enteral feeding
Feeding data for the first enteral feed were available for 629 (94%) infants. Forty-one (6%)
infants died before being fed (Table 9.6). Only one of six infants born before 24 weeks of
gestation survived to start enteral feeds, but all infants >29 weeks of gestation received some
enteral feed. As expected, infants who died before starting feeds were smaller and less
mature (Mann Whitney U test, P <0.001 for both) and had higher CRIB scores (P =0.001)
than survivors. Within this group, >55% were hypotensive and required UAC and inotropic
support, compared with <50% for the whole group overall. Sedation was used in 78%,
compared with 27% of the group overall and almost 20% of this group were acidotic,
compared with only 2% of the overall group, showing that these babies were sicker and
required more intensive care interventions.
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Table 9.6: Deaths before starting feeds by gestational age at birth
Gestation, 23 24 25 26 27 28 29 >30 Total
weeks (n) (6) (36) (43) (63) (82) (129) (100) (211) (670)
UK, n(%) 2 11 6 5 7 2 1 0 34
(67) (46) (24) (12) (13.5) (2.3) (1.5) (7.5)
Canada, n (%) 3 10 1 1 1 0 0 7
(100) (8) (4.8) (3.3) (2.3) (3.2)
Total, n(%) 5 12 6 6 8 3 1 0 41
(83) (33) (14) (9.5) (9.7) (2.3) (1) (6)
9.3.1 Factors affecting the initiation of feeds
In the clinician survey, the majority of clinicians indicated that they believed the optimum
time for introducing feeds was during the first 48 hours of life. It is therefore likely that
factors identified before birth or during the first two postnatal days will exert the greatest
influence on the timing of feed introduction. The occurrence of these factors during the first
three days of life in UK and Canadian infants is shown in Table 9.7. There are some marked
differences between the UK and Canada, with respect to the infants' condition and, more
significantly, the management of infants. Significant differences were found for abnormal
antenatal Doppler studies, the presence of abdominal distension, mechanical ventilation,
umbilical catheters and patent ductus arteriosus, the use of sedation and indomethacin. The
effects of these and other potentially important factors on the initiation of feeds are explored
in the following sections.
9.3.2 Type of milk used for introduction of enteral feeds
Of the 629 infants who survived to start enteral feeds 407 (64.7%) received MEBM, 132
(21%) preterm formula, 36 (5.7%) received term formula, 33 (5.2%) DEBM and 21 (3.3%)
hydrolysed formula for the first enteral feed (Figure 9.2). The use of MEBM for feed
initiation varied between 45% and 75% in Canadian NNUs and between 50% and 100% in
UK NNUs. In Canada, if MEBM was unavailable, all but one infant received preterm
formula and this infant was fed using term formula. In contrast, in similar circumstances in
the UK units, 24% received DEBM and where formula was used this was preterm (33.1%),
term (26.3%) or hydrolysed formula (15.8%) (Figure 9.3). The use of milks other than EBM
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for the first enteral feed was confined to the first five days of life in all but five infants, one
of whom received hydrolysed protein formula and four who received preterm formula.








Antenatal or perinatal compromise
Abnormal antenatal doppler studies 73 (10.9) 58(12.9) 15 (6.8) 0.027
Absent end diastolic flow 57 (8.5) 49(10.9) 8 (3.7)
Reversed end diastolic flow 16 (2.4) 9(2) 7 (3.2)
Asphyxia (diagnosis documented in 3 (0.4) 3 (0.7) 0 0.553
records)
Polycythemia 5 (0.7) 5(1.1) 0 0.278
Respiratory compromise
Mechanical ventilation 450 (67) 288 (63.9) 162 (74) 0.011
Nasal CPAP 310(46.3) 217 (48.1) 116(53) 0.273
Abdominal pathology
Presence of UAC 297 (44.3) 177 (39.2) 120 (54.8) <0.0005
Abdominal distension (mild) 47 (7) 43 (9.5) 4(1.8) <0.0005
Abdominal tenderness 1(0.1) 1 (0.2) 0 1.00
Bilious gastric aspirates 111 (16.6) 84(18.6) 27(12.3) 0.052
Other factors
Hypotension 124(18.5) 83 (18.4) 41 (18.7) 1.00
Use of inotropic drugs 124(18.5) 83 (18.4) 41 (18.7) 1.00
Use of opiate sedation 194 (28.9) 158 (35) 36(16.4) <0.0005
Acidosis 65 (9.7) 51 (11.3) 14(6.4) 0.06
Therapeutic paralysis 20 (2.9) 17 (2.7) 3 (0.9) 0.142
PDA 43 (6.4) 17 (3.8) 26 (11.9) <0.0005
Use of indomethacin 46 (6.8) 10(2.2) 36(16.4) <0.0005
Values are presented as n (%)
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Figure 9.3: Type ofmilk used when MEBM not used for first enteral feed




No infant in either country received transpyloric feeding at any time and all enteral feeds
were given by either nasogastric or orogastric tube. Of the 629 infants, 91% were fed using
bolus feeds. The remaining 9% received continuous feeding. Only three NNUs, all within the
UK, used continuous feeding. In two of these units, this method of feeding appeared to be
the norm, with over 90% babies fed in this way. In another smaller unit, 4/6 babies were
continuously fed.
Most infants (497/629 (79%)) received volumes of 0.5-1 ml for feeds for their first feeds. 8%
(53/629) received less than 1ml, 59/629 (9%) l-5ml and 21 infants received more than 5ml,
with the largest volume of 17ml fed to an infant of 36 weeks of gestation.
Data were available for the interval between feeds in the first two days after feed initiation
for 604/629 (96%) infants. Feeds were administered hourly in 45% and every two hours in
24%. Where feeds were given at one or two hourly intervals, this was maintained for several
days before increasing the interval between feeds with increasing postnatal age of the babies.
The remaining babies received feeds every 3, 4, 6, 8 or 12 hours and in these the time
between feeds was reduced more quickly, reaching intervals of one or two hours within a
small, but variable number of days. Correlation between the volume of first feeds
administered and birth weight, gestation and CRIB score were only weak (r=0.251, 0.351
and -0.151 respectively). There were similar weak correlations between feed interval and
these variables (r=0.314, 0.311 and 0.263 respectively). Figure 9.4 shows a box plot of feed
intervals by centre and this suggests both inter- and intra-unit variation that may be more
related to other factors such as centre or clinician preference.
9.3.4 Timing of introduction of enteral feeds
There were 274 (44%) infants who started feeds within the first 48 hours of life and a further
153 (24%) commenced on the third day. The remaining 32% received their first enteral feed
at between 4 and 14 days of life. The median (IQR) postnatal day on which enteral feeds
started was Day 3 (2-4) for the whole group. Data for the day of first feed were positively
skewed and were log transformed for further analysis. An independent samples t test was
performed to compare the mean time of first feed between countries and showed a
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significant difference; UK infants received the first feed 15% earlier than Canadian infants
(Table 9.8). Figure 9.5 shows a box plot of the day of first feed by centre. One-way ANOVA
was used to explore the differences in the geometric mean time to first feed between centres.
This showed a highly significant difference between the centres (Table 9.9)
Variation in the geometric mean day of first feed between groups of infants with different
gestational age and birth weight was examined using one-way ANOVA and showed a highly
significant difference between groups for both (Tables 9.10 and 9.11). Adjustments for
multiple comparisons were made using the Bonferroni method. Significant differences were
found between all gestational age (P <0.02 for each comparison) and all birth weight (P
<0.0001 for each comparison) groups.
Figure 9.4: Box plot to show feed interval by centre
~i—i—i—i—i—i—i—i—i—i—i—i—i—i—i—i—i—r
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Centre
Top and bottom ofboxes represent 25th and 75th percentiles; Bar represents median;
Whiskers represent smallest values that are not outliers or extreme values;0 represents
outliers; * represents extreme values
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Table 9.8: Comparison of day of first feed between UK and Canada




Day of first 2.63 3.08 0.85 0.001
feed (2.49, 2.77) (2.87,3.31) (0.78,0.93)
Independent samples t test; log10 transformed data






















zth i ycthTop and bottom ofboxes represent 25 7 and 75 percentiles; Bar represents median;
Whiskers represent smallest values that are not outliers or extreme values;° represents
outliers; * represents extreme values
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Table 9.9: One-way ANOVA for mean day of first feed by centre
Centre No. of infants Mean day of first feed* 95% CI P Value*
1 50 3.01 2.62,3.47 <0.0005
2 16 1.91 1.52,2.39
3 6 1.65 -1.19, 3.23
4 30 2.57 2.14, 3.09
5 47 2.20 1.90, 2.56
6 40 2.18 1.88,2.53
7 20 2.38 1.97,2.86
8 40 3.22 2.69,3.87
9 15 3.56 2.81,4.51
10 51 2.77 2.37, 3.25
11 10 3.72 2.62, 5.27
12 89 3.54 3.19,3.92
13 114 2.68 2.43, 2.96
14 9 4.59 3.10, 6.78
15 16 2.61 1.92, 3.55
16 12 3.82 2.43, 6.00
17 19 2.91 2.25, 3.77
18 45 2.33 1.94,2.79
*geometric mean; * Significance valuefor difference between groups
Table 9.10: One-way ANOVA for mean day of first feed by gestatio
Gestation No. Mean day of first feed* 95% CI P Value*
< 26 weeks 62 4.26 3.70,4.89 <0.0005
26-27 weeks 131 3.38 3.09, 3.69
28-29 weeks 225 2.86 2.69. 3.05
> 30 weeks 211 2.09 1.96,2.24
*geometric mean; * Significance valuefor difference between groups
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Table 9.11: One-way ANOVA formean day of first feed by birth weight
Birth weight No. Mean day of first feed* 95% CI P Value#
<lOOOg 191 3.6 3.38,3.91 <0.0005
1000-1249g 210 2.88 2.69, 3.08
>1250g 228 2.14 2.00, 2.28
*geometric mean; # Significance valuefor difference between groups
9.3.4.1 Associations with the time of initiation of enteral feeds
(a) All infants
Data for all babies surviving to start feeds were analysed using multiple regression to
examine other factors contributing to the variation in the time to starting enteral feeds.
Factors that were considered, but that did not show an association were asphyxia and blood
in the stools, but these were present in only two and four infants respectively. Abdominal
tenderness was recorded as being present in only one infant and this variable was therefore
not included. Mechanical ventilation, but not the use of nCPAP was significantly associated
with the time of feed initiation, but 72% of babies who received nCPAP were also ventilated
during the first 72 hours of life; nCPAP was therefore excluded from the model.
Independent variables were classified as present or absent during the first 72 hours of life.
The following were initially entered simultaneously into the regression model, together with
birth weight, gestation and CRIB score: IUGR, abnormal antenatal umbilical Dopplers,
umbilical catheters, hypotension, PDA, opiate sedation, acidosis, mechanical ventilation,
therapeutic paralysis, inotropic support, indomethacin, and bilious gastric aspirates. Birth
weight and gestation were highly correlated (0.676) and showed strong collinearity.
Hypotension and the use of inotropes were also highly correlated (0.772). Birth weight and
inotropes were retained as they showed a greater contribution to the model. Other variables
were retained in the model if they showed an independent association with the time to first
feed (P<0.1) This P value is conventionally used to ensure inclusion of those factors with
most significant associations.
Variables independently associated with the time to first feed were abnormal Dopplers,
opiate sedation, acidosis, mechanical ventilation, inotropic support, indomethacin and birth
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weight. Infants with higher birth weight were fed earlier and infants in whom other factors
were present started milk feeds later. This model accounted for approximately 34% of the
variation in time to first feed (r2 0.344; adjusted r2 0.337). The variable contributing most to
the model was birth weight (P<0.0005) (Table 9.12).
Since the availability of EBM (either MEBM or DEBM) at the start of feeds is also likely to
affect the timing of feeds, this was considered. Although data specifically for the availability
of EBM were not collected, the type ofmilk for the first feed was known for each baby. The
use of any EBM for the first feed was considered to reflect the availability of EBM. The
addition of this showed that this explained a further 6% of the variation (r2 0.407; adjusted r2
0.399; r2 change 0.063). The use of any EBM then became the most highly significant
contributor to the model, but all other variables remained significant.
In order to examine the effects of differences between countries, this was added to the
model. This resulted in a further significant change in overall effect, suggesting that the
country of hospitalization also contributes significantly to the variation in the model (r2
0.439; adjusted r2 0.430; r2 change 0.032). Infants in Canadian units were fed later than those
in UK units; all other effects remained significant.
9.3.4.2 Analysis by birth weight group
In order to examine more closely the effect of birth weight, further multiple regression
analyses were performed for each birth weight group. Variables were entered into the
regression models for each group according to the method previously defined.
(b) Birth weight <1000g (Table 9.13)
Abnormal Dopplers, the use of inotropes, indomethacin and CRIB score were significantly
associated with the time to first enteral feed. The use of inotropes was the largest
contributing variable and was associated with later feeding. Increasing CRIB score was
related to later feeding. This model explained less than 30% of the variation (r2 0.253;
adjusted r2 0.236). When the use ofEBM was added to the model, it contributed a highly
significant additional amount (r2 0.362; adjusted r2 0.343; r2 change 0.109) and the effect of
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abnormal Dopplers became non-significant. The addition of country did not contribute
significantly to the model (r2 0.364; adjusted r2 0.341; r2 change 0.002).
Table 9.12: Multivariate regression analysis to explore associations with
timing of first enteral feed
Independent variable Effect (%) 95% CI P value
Birth weight (kg) -1.48 -1.70, -1.28 <0.0005
Abnormal dopplers (yes/no) 1.22 1.09, 1.36 0.001
Opiate sedation days 1-3 (yes/no) 1.32 1.21, 1.44 <0.0005
Acidosis days 1-3 (yes/no) 1.24 1.10, 1.41 <0.0005
Mechanical ventilation days 1-3 (yes/no) 1.12 1.03, 1.22 0.008
Inotropic support days 1-3 (yes/no) 1.19 1.08, 1.31 <0.0005
Indomethacin days 1-3 (yes/no) 1.21 1.06, 1.39 0.005
EBM for first feed (yes/no) 1.40 1.30, 1.49 <0.0005
Country (UK/Canada) -1.26 -1.35, -1.16 <0.0005
Table 9.13: Multivariate regression analysis to explore associations with
timing of first enteral feed in babies <1000g
Independent variable Effect (%) 95% CI P value
Abnormal dopplers (yes/no) 1.15 1.04, 1.38 0.126
Inotropic support days 1-3 (yes/no) 1.44 1.25, 1.67 <0.0005
Indomethacin days 1-3 (yes/no) 1.35 1.11, 1.64 0.003
CRIB score 1.04 1.02, 1.06 <0.0005
EBM for first feed 1.48 1.28, 1.71 <0.0005
Country (UK/Canada) 1.05 -1.21, 1.09 0.468
(c) Birth weight 1000-1249g (Table 9.14)
IUGR, abnormal dopplers, and CRIB score were significantly associated with the time to
first enteral feed. However, this model explained less than 20% of the variation (r2 0.170;
adjusted r2 0.155). The effect of increasing CRIB score was the most highly significant
factor and was associated with later feeding. Unexpectedly, IUGR was associated with
earlier feeding. The effect added by the use of any EBM was significant (r2 0.248; adjusted r2
0.230; r2 change 0.078) and rendered the effect of abnormal Doppler studies non-significant.
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A further 4.9% of the variation was explained by the addition of country (r2 0.297; adjusted
r2 0.275; r2 change 0.049).
Table 9.14: Multivariate regression analysis to explore associations with
timing of first enteral feed in babies 1000-1249g
Independent variable Effect (%) 95% CI P value
IUGR (yes/no) -1.27 -1.49, -1.08 0.005
Abnormal dopplers (yes/no) 1.22 -1.03, 1.52 0.086
CRIB score 1.08 1.05, 1.11 <0.0005
EBM for first feed 1.43 1.24, 1.65 <0.0005
Country (UK/Canada) -1.29 1.5, 1.11 0.001
(d) Birth weight >1250g (Table 9.15)
Variables significantly associated with the time of initiation of feeds in this birth weight
group were IUGR, abnormal Doppler, sedation and acidosis. IUGR was unexpectedly
associated with early initiation of enteral feeds. The model explained just over 25% of the
variation in this group (r2 0.267; adjusted r2 0.254). The variable that showed the strongest
relationship was opiate sedation, which was associated with later feeding. The addition of
EBM to the model contributed a further 5.8% (r2 0.325; adjusted r2 0.310; r2 change 0.058).
The addition ofEBM resulted in the effect of abnormal dopplers becoming non-significant.
The addition of country to the model resulted in a statistically significant change (r2 0.355;
adjusted r2 0.337; r2 change 0.030).
Table 9.15: Multivariate regression analysis to explore associations with
timing of first enteral feed in babies >1250g
Independent variable Effect (%) 95% CI P value
IUGR (yes/no) -1.28 -1.44, -1.13 <0.0005
Abnormal dopplers (yes/no) 1.24 1.02, 1.57 0.067
Opiate sedation days 1-3 (yes/no) 1.54 1.32, 1.81 <0.0005
Acidosis days 1-3 (yes/no) 1.34 1.01, 1.79 0.045
EBM for first feed 1.31 1.17, 1.46 <0.0005
Country (UK/Canada) -1.21 -1.36, -1.08 0.002
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9.3.4.3 Minimal enteral nutrition
Of the 629 babies who survived to start enteral feeding, data on initial feed volumes were
missing for 11 (1.7%). 584 (92.8%) received at least one day ofMEN, defined as feeds of
<25ml/kg/24 hours prior to attempts to increase feed volumes. 423 (67%) received minimal
volumes for two or more days. Minimal nutrition volumes were started and maintained for
between 1 and 16 days (median (IQR) = 2(1,4) days) (Table 9.16).
There was a significant difference between UK and Canadian units in the number of days of
MEN given (Mann Whitney U test, P<0.001), with babies in the UK having shorter periods
ofMEN. In 32 (5%) infants, initial feed volumes were in excess of 25ml/kg/day and were
advanced immediately. Of these infants, 31 were from UK units, compared with only one
from a Canadian unit. This represents a highly significant difference between the countries
(P <0.001). Analysis of the characteristics of infants who received increasing feeds from the
time of feed initiation shows that they were of higher birth weight, more mature and less sick
than infants who received any MEN (Table 9.18).
The majority (84.4%) of babies progressed to increasing feed volumes after the period of
minimal nutrition. However, 97 (15.6%) infants had feeds discontinued for >24 hours after
commencing minimal feed volumes. All those infants who had feeds temporarily
discontinued were later given a further period ofMEN before volumes were increased. This
second period is not included in the results above for any baby. The commonest reasons
overall for discontinuing feeds during minimal feeding were the presence of bilious aspirates
(26 infants) and the introduction of indomethacin therapy (23 infants). Indomethacin was the
commonest reason among Canadian babies and was the indication on almost half of the
occasions where MEN was discontinued temporarily. In contrast, it was a much less
common reason in the UK where bilious aspirates, abdominal distension or large gastric
aspirates were more likely to result in feeds being discontinued. Further reasons for
discontinuation ofminimal feeding are detailed in table 9.17.
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Table 9.16: Number of days of minimal enteral nutrition






None 33 (8.1) 1 (0.5) 34 (5.5)
1 day 121 (29.8) 40(18.9) 161 (26)
2 days 113 (27.8) 33 (15.6) 146 (23.6)
3 days 58 (14.3) 38 (17.9) 96(15.5)
4 days 36 (8.9) 30(14.1) 66(10.7)
5 days 21 (5.2) 19(8.9) 40 (6.5)
6 days 11 (2.7) 20 (9.4) 31(5)
7 days 5(1.2) 15(7.1) 20 (3.2)
8 days 5(1.2) 4(1.9) 9(1.4)
9 days 3 (0.7) 6 (2.8) 9(1.4)
10 days 0 1 (0.5) 1 (0-2)
>11 days 0 5 (2.3) 5 (0.8)
Values are presented as n (%)
Table 9.17: Reasons for discontinuation ofminimal enteral nutrition
UK Canada Total
(n=52/406) (n=45/212) (n=97/618)
Bilious gastric aspirates 16(30.7) 10(22.2) 26 (2.7)
Indomethacin 2(3.8) 21 (46.7) 23 (23.7)
Abdominal distension / possible NEC 13 (25) 2 (4.4) 15 (15.5)
Large gastric aspirates 7(13.5) 6(1.3) 13 (13.4)
Re-ventilation 2(3.8) 1 (2-2) 3(3.1)
Blood-stained aspirates 1 (1-9) 0 1(1)
Blood transfusion 1 (1.9) 0 1(1)
Acidosis 1(1.9) 0 Kl)
Deterioration in clinical condition 5 (9.6) 4 (8.9) 9(1)
(Respiratory distress, seizures, pneumothorax,
pulmonary haemorrhage, cardiac arrest, sepsis)
Insufficient EBM 2(3.8) 1 (2.2) 3(3.1)
Not known 2 (3.8) 0 2(2)
Values arepresented as n (%)
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Table 9.18: Characteristics of infants receiving early advancing feeds
compared with those receiving MEN
Advancing feeds MEN P value
n=34 n=584
Birth weight (g) 1335 1127.5
(932.5-1462.5) (935-1315) <0.001
Gestation (weeks) 31.5 28
(29-34) (27-30) <0.001
CRIB score 2 11
(2-13) (2-14) <0.001
Values arepresented as median (IQR); Mann Whitney U testfor comparisons
9.3.4.4 Initiation of feeds in growth restricted babies
Of the 208 growth restricted babies, six died before being fed. The median (IQR) day to
starting feeds for growth-restricted babies was Day 2 (3-4), compared with Day 3 (2-4) in
babies whose birth weight was appropriate for their gestational age (AGA) at birth. This
difference was highly statistically significant (Mann Whitney U test, P <0.0005). Since it
would be expected that growth-restricted babies would be fed later than those who were not
growth-restricted, further evaluation was necessary to explain this finding. Examination by
gestational age (Table 9.19) shows that most of the babies with IUGR were in the highest
gestational age groups.
The distribution of data for the day of first feed in growth-restricted infants was highly
positively skewed and was not amenable to transformation; non-parametric tests were
therefore used to compare the timing of initiation of feeds between the UK and Canada. The
median day for starting feeds in UK growth-restricted infants was Day 2 (2-3), compared
with Day 3 (2-4) in Canadian infants, representing a statistically significant difference
(P=0.026). This is illustrated in the box plot in Figure 9.6. In contrast, there was no
difference between the countries for the day of starting feeds in appropriately grown infants
(Median (IQR) 3 (2-4) days for both; Mann Whitney U test P=0.107).
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Table 9.19: Number of IUGR babies by gestational age bands
UK Canada Total
(n=451) (n=219) (n=670)
<26 weeks 7(1.5) 3(1.4) 10(1.5)
26-27+6 weeks 11 (2.4) 12(5.5) 23 (3.4)
28-29+6 weeks 30 (6.6) 11 (5.0) 41 (6.1)
>30 weeks 100 (22.2) 34(15.5) 134(20)
Total 148 (32.8) 60 (27.4) 208
Values are presented as n (%)
Figure 9.6: Box plot to show the day of first feed in IUGR infants by
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9.4 Advancement of feeds
Fluid volumes administered to preterm infants increase over the first few days of life, with a
typical regimen starting at 60-1 OOml/kg/day on the first day depending on gestation and
increasing by 30ml/kg/day until 150ml/kg/day. Initially, some or this entire requirement is
usually given intravenously. After the introduction of enteral feeds, milk volumes are
increased and intravenous volumes simultaneously decreased until the total required volume
is given enterally. For the purpose of analysis, full enteral feeds were defined as
150ml/kg/day. During the first few days of life when feeds are being increased the
appropriate full fluid volume is expected to be less than 150ml/kg/day. If an infant was
deemed fit to receive this total required volume enterally and did not require
supplementation with PN, then the infant was considered to have achieved full enteral
feeding even though the volume administered may have been less than 150ml/kg/day.
Twenty infants died and a further 46 infants were transferred to other centres after starting
enteral feeds, but before reaching full enteral feeds. Complete paired data for the times of
starting feeds and attaining full feeds were therefore available for 563 (84.2%) infants. In a
further 12 cases nursing records for volumes of feed given were missing for some of the time
period during which feeds were advanced. Although information was available for the time
of initiation and attainment of full feeds, it was not possible to include these babies in more
detailed analysis of factors affecting feed advancement. Data for the type of feed given
whilst progressing to full feeds were available for 552 infants. Feeds were exclusively EBM
in 352 (64%) infants. In infants of <26 weeks of gestation, 82% received only EBM and this
proportion reduced to 68% in those of 26-29+6 weeks of gestation and further to 52% in
infants >30 weeks of gestation.
Figure 9.7 shows the median feed volumes given to infants during the first 14 days of life by
gestational age group. Overall, this shows that feed volumes started to increase earlier with
increasing gestational age at birth and were increased more rapidly across the groups with
increasing maturity. In infants of < 29 weeks of gestation, volume increases were similar
between the two groups for the first week of life. Further dividing the groups according to
country suggests that feeds were increased more slowly in all gestational age bands in
Canadian infants than in UK bom infants.
The median (1QR) day for attaining full enteral feeds was 1 1 (8-17 days) for the whole
group. Data for the time from first to full feeds were positively skewed and were log-
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transformed (Log 10) for further analysis. An independent samples t test was performed to
compare the time of attainment of full enteral feeds between UK and Canadian infants.
There was a highly significant difference between the countries with UK infants reaching
full feeds approximately 30% earlier than Canadian infants (Table 9.20).
Table 9.20: Comparison between the UK and Canada for the time of attaining
full enteral feeds







Day of reaching full feeds 8.20 12.09 0.68 <0.0005
(7.74, 8.68) (11.04,13.24) (0.61,0.75)
Time from first to full 10.05 14.50 0.69 <0.0005
feeds (days) (9.51,10.61) (13.29,15.82) (0.63, 0.76)
Independent samples t test; log10 transformed data
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Figure 9.7: Graphs to show the median volumes of enteral feed during the first
2 weeks of life by gestational age
Day of life
Figure 9.8 shows a box plot of the time from first to full feeds by centre. Examination of the
data identifies three infants with extreme values for the length of time to attain full feeds. All
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infants were from Canadian NNUs. Checking of the data showed these values to be both
correct and plausible and did not identify any special characteristics about the infants that
were not seen in at least some of the remaining infants. It was therefore thought that these
infants might reflect true variation in practice and that exclusion would lead to the loss of
valuable information. The independent samples t test was repeated after excluding these
variables and showed that the differences between the countries remained highly statistically
significant for the time from first to full enteral feeds (ratio of geometric means 0.70 (95%CI
0.63, 0.77; P<0.0005).
Examination of the time from first to full feeds showed that variances were unequal between
centres. A Kruskal Wallis test showed a highly significant difference between the centres (yj
74.33; df 17; P<0.0005). Median and IQR values for each centre are shown in Table 9.21.
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In order to identify whether differences in the time to attain full feeds existed
between infants of different gestational ages or birth weight, one-way ANOVA was
performed (Tables 9.22 and 9.23). There were significant differences, both for
gestation and birth weight. Post hoc analysis (using the Bonferroni approach for
multiple testing) showed that these differences were significant between all birth
weight groups. For gestation, differences were significant between all except the two
lowest gestational age groups for which the 95% confidence intervals overlapped.
Table 9.21: Median time from first to full feeds by centre
Centre No. of infants Median IQR P Value*
1 47 8 5-12 <0.0005
2 16 9 7-12
3 5 11 9.5-12
4 26 7 5-10
5 47 8 6-9
6 36 9.5 7-13
7 20 8 5-10
8 35 7 6-11
9 15 8 6-19
10 47 6 4-10
11 9 10 5.5-18
12 65 13 9-19
13 103 7 10-16
14 8 16 7.5-30.25
15 16 8 7-11
16 12 11.5 5.25-20
17 17 7 5.5-14.5
18 39 8 7-13
*Kruskal wallis testfor differences between centres
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Table 9.22: One way ANOVA for the time from first feed to full feeds by
gestation
Gestation No. Mean time from first to full feeds* 95% CI P Value
< 26 weeks 52 16.2 (13.91, 18.87) <0.0005
26-27 weeks 120 13.23 (12.09, 14.48)
28-29 weeks 198 9.30 (8.65, 10.03)
> 30 weeks 193 6.33 (5.89, 6.81)
*geometric mean
Table 9.23: One-way ANOVA for the time from first feed to full feeds by birth
weight
Birth weight No. Mean time from first to full feeds* 95% CI P Value
<lOOOg 174 12.68 (11.73, 13.70) <0.0005
1000-1249g 186 9.48 (8.69, 10.35)
>1250g 203 6.91 (6.41,7.46)
*geometric mean
9.4.1 Factors influencing the rate of advancement of enteral feeds
In their responses to the survey, clinicians identified a number of factors that would lead
them to progress feeds at a slower rate than usual. Some of these related to knowledge of
antenatal factors and others to the baby's clinical condition and management. Table 9.19
shows the proportions of babies affected by these factors and the number of days for which
they were present during the time of feed advancement. The number of days for each factor
was determined by its occurrence during all or part of a 24-hour period from the day of the
first enteral feed until the attainment of full feeds. Large gastric aspirates were defined as
aspirated volumes of >2ml, since this was the most commonly suggested volume by
clinicians in the survey. Data for the number of days of mechanical ventilation and UVC
were missing for two UK babies and for sedation for one UK baby. Other factors were
defined as either present or absent during the period of feed advancement. These are shown
in Tables 9.24a and 9.24b. Abdominal distension was defined as any period where
abdominal distension was documented by medical staff on clinical examination. Proven
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sepsis was defined as a positive microbiological culture obtained from a usually sterile body
fluid such as blood or cerebrospinal fluid (CSF). Positive blood cultures were identified from
laboratory results, which were available for 563 babies.
Canadian infants were ventilated for significantly longer than were infants in the UK. They
also had UVCs for longer and had more days on which large aspirates occurred. This
analysis confirmed the higher proportions of infants diagnosed and treated for PDA in
Canada compared with the UK. There were no differences between the countries for other
aspects of clinical management.
Table 9.24a: Occurrence of factors potentially influencing feed advancement
Number of babies Number of days
UK Canada All babies UK Canada P value
(n=375) (n=176)
Ventilation 126 (33.6) 104 (59) 5(2-13) 4(1-9) 7 (2-19) 0.001
nCPAP 205 (54.7) 115 (65.3) 4 (2-8) 4 (2-8) 5 (2-9) 0.149
UVC 98 (26.1) 116(66) 4 (2-6) 3 (2-4) 5 (3.25-7) <0.0005
UAC 113 (30.1) 93 (52.8) 3 (2-4) 3 (2-4) 2 (2-4) 0.413
Sedation 78 (20.8) 23 (13) 4(1-8.5) 5 (2-8) 3(1-11) 0.598
Paralysis 12 (3.2) 2(1.1) 2(1-3.25) 2(1-3.75) 2(1-3) 0.791
Inotropes 28 (7.5) 12(6.8) 2 (1-4) 2 (1-4) 2.5 (1-4) 0.965
Large aspirates 291 (77.6) 132 (75) 3 (2-6) 3 (2-6) 3 (2-4.75) 0.033
Bilious aspirates 169 (45) 90 (51.1) 2(1-3) 2(1-3) 2(1-3) 0.563
Number ofbabies arepresented as n (%>); Number ofdays arepresented as median (IQR)
Mann Whitney U testfor comparisons
Table 9.24b
UK Canada Total P value
(n=375) (n=176) (n=551)
Bolus feeds (yes/no) 325 (86.7) 176(100) 501 (90.9) 0.912
PDA (yes/no) 88 (23.4) 59 (33.5) 147 (26.7) 0.017
Indomethacin (yes/no) 58 (15.5) 68 (38.6) 126 (22.9) <0.0005
Abdominal distension (yes/no) 100 (26.7) 43 (24.4) 143 (25.9) 0.650
Proven sepsis (yes/no) 63/387 (16.2) 28(15.9) 91/563 (16.2) 1.0
Values arepresented as n (%>); x testfor comparisons
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9.4.1.1 Associations with the time from first feed until attainment of full feeds
(a) All infants
Complete data for the daily volumes of feed given were available for 551 surviving babies.
Data were analysed using multiple regression to examine factors, including birth weight that
potentially contributed to variation in the time taken to attain full enteral feeds. Variables
that were potentially relevant and were present during the time from starting feeds to
attaining full feeds were first analysed separately. Those which showed an association with
the time from first to full feeds (log 10 transformed data) on univariate analysis (P <0.2) were
entered into the multiple regression model. Two variables, abnormal Dopplers and bolus or
continuous feeding, were not significantly associated with the time to attain full feeds. All
other variables had highly significant relationships with the outcome. They were added
simultaneously to the model as follows: birth weight, gestation, number of days of
ventilation, CPAP, sedation, paralysis, large aspirates, bilious aspirates, UAC, UVC and
inotropes, together with the presence of PDA, use of indomethacin, abdominal distension,
proven sepsis, and significant events (pulmonary haemorrhage, pneumothorax or seizures).
The occurrence ofNEC before full enteral feed volumes were reached was also included and
was divided into Stage I and Stage II/III disease.
Variables independently associated with the time to first feed were gestation, the number of
days on which there were large aspirates, bilious aspirates, CPAP, mechanical ventilation,
UVC and inotropes, the presence of a PDA, abdominal distension, sepsis and stage I, but not
stage II/III NEC. This model accounted for 69% of the variation in the model. The variable
contributing most to the model was the presence of large aspirates (P<0.0001).
The number of days of MEN was not included in the initial regression model. Addition of
this variable resulted in explanation of a further 4.8% of the variation, but rendered the effect
of inotropes and UVC non-significant (r2 0.743; adjusted r2 0.737; r2 change 0.048). The
addition of country to the model led to a further small change and the final model explained
75% of the variation in the time from first to full feeds (r2 0.756; adjusted r2 0.75; r2 change
0.013). The effects of all other variables remained highly significant (P<0.001 for all; Table
9.25). Lower gestational age and either the presence of, or an increasing number of days of
all significant variables was associated with longer time to attain full feeds. The inclusion of
country confirmed that Canadian infants achieved full feeds later than UK infants and that
this was an independent effect.
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Some collinearity was detected in the model and this was explored. No two variables
included in the model were highly correlated and therefore no specific variable could be
identified which would be suitable for exclusion. Since the model was derived based on
clinical factors believed likely to contribute to variation, it was felt inappropriate to exclude
any variables arbitrarily. The factor that was responsible for collinearity was gestational age,
which was related to more than one other factor. Additional analysis was therefore
performed stratifying by gestational age to explore further the variation in the time to
achieve full feeds. In view of the small numbers of surviving infants in the lowest gestational
age band, the two lower bands were combined and analysis was performed for infants of <28
weeks, 28-29+6 weeks and >30 weeks of gestation
Table 9.25: Multivariate regression analysis to explore associations with the
time taken to attain full enteral feeds in all babies
Independent variable Effect (%) 95% CI P value
Gestation (weeks) -1.04 -1.06, -1.03 <0.0005
Large aspirates (no. days) 1.03 1.02, 1.04 <0.0005
Bilious aspirates (no. days) 1.05 1.02, 1.06 <0.0005
nCPAP (no. days) 1.01 1.00, 1.02 <0.0005
Inotropes (no. days) -1.01 -1.04, 1.02 0.448
UVC (no. days) 1.00 -1.01, 1.01 0.616
Ventilation (no. days) 1.02 1.01, 1.02 <0.0005
Abdominal distension (yes/no) 1.17 1.09, 1.24 <0.0005
PDA (yes/no) 1.12 1.04, 1.20 0.001
NEC Stage I (yes/no) 1.30 1.16, 1.49 <0.0005
Proven sepsis (yes/no) 1.15 1.06, 1.24 <0.0005
MEN (no. days) 1.06 1.05, 1.08 <0.0005
Country (UK/Canada) 1.19 1.12, 1.28 <0.0005
(b) Infants <28 weeks ofgestation
The following model explained more than 75% of the variation in the time to attain full feeds
in this gestational age band: bilious aspirates, nCPAP, ventilation, IUGR and proven sepsis
(r2 0.767; adjusted r2 0.757). The addition of the number of days ofMEN exerted an effect
that accounted for an additional small, but statistically significant amount of variation (r2
0.779; adjusted r2 0.768; r2 change 0.012; P=0.004). Although the addition of country did not
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significantly change the overall model, it rendered the effect of IUGR and MEN days non-
statistically significant and substantially increased the statistical significance of the use of
sedation (Table 9.26).
Table 9.26: Multivariate regression analysis to explore associations with the
time taken to attain full enteral feeds in babies of <28 weeks of gestation
Independent variable Effect (%) 95% CI P value
Bilious aspirates (no. days) 1.02 1.00, 1.05 0.017
nCPAP (no. days) 1.03 1.02, 1.03 <0.0005
Opiate sedation (no. days) 1.01 1.00, 1.02 0.011
Ventilation (no. days) 1.03 1.02, 1.03 <0.0005
IUGR 1.13 -1.04, 1.28 0.058
Proven sepsis 1.14 1.04, 1.25 0.005
MEN (no. days) 1.02 1.00, 1.03 0.054
Country (UK/Canada) 1.11 1.00,1.23 0.053
(c) Infants 28-29+6 weeks ofgestation
The exclusive use ofEBM was significantly associated with earlier attainment of full enteral
feeds. The presence of large gastric aspirates, bilious aspirates, respiratory support,
abdominal distension, mechanical ventilation and the diagnosis of stage I NEC during the
period of increasing feeds were all associated with later attainment of full feeds. This model
explained more than 60% of the variation in time to full enteral feeds (r2 0.647; adjusted r2
0.632). Addition of the number of days of MEN to the model resulted in explanation of a
further small portion of variation, and all other effects remained significant (r2 0.682;
adjusted r2 0.666; r2 change 0.034). The effect of adding country to the model was not
statistically significant (r2 0.683; adjusted r2 0.666; r2 change 0.002). The most highly
significant variables in the model were large aspirates and respiratory support with nCPAP
(Table 9.27)
(d) Infants >30 weeks ofgestation
In this gestational age stratum, inclusion of exclusive feeding with EBM, large aspirates,
bilious aspirates and abdominal distension resulted in a model that explained almost 50% of
the variation in the time taken to reach full feeds, but in which only large or bilious aspirates
and abdominal distension contributed significantly (P>0.05) (r2 0.503; adjusted r2 0.489; r2
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change 0.034). The addition of the number of days ofMEN contributed a further 11.8% to
the model (r2 0.620; adjusted r2 0.608; r2 change 0.118). The subsequent addition of country
increased the significance of the effect of exclusive EBM in the model and increased the
significance of the overall model by almost 3%. Unexpectedly, the use of EBM was
associated with later achievement of full feeds. All other variables were also related to later
feeding (Table 9.28).
Table 9.27: Multivariate regression analysis to explore the associations with
time taken to attain full enteral feeds in babies of 28-29 weeks of gestation
Independent variable Effect (%) 95% CI P value
Exclusive EBM -1.11 -1.23, -1.01 0.036
Large aspirates (no. days) 1.03 1.02, 1.04 <0.0005
Bilious aspirates (no. days) 1.04 1.01, 1.07 0.020
nCPAP (no. days) 1.03 1.02, 1.04 <0.0005
Abdominal distension (yes/No) 1.17 1.04, 1.32 0.01
UVC (no. days) 1.02 1.00, 1.04 0.045
Ventilation (no. days) 1.02 1.01, 1.02 <0.0005
Stage I NEC (yes/no) 1.56 1.28, 1.09 <0.0005
MEN (no. days) 1.06 1.03, 1.09 <0.0005
Country (UK/Canada) 1.06 -1.06, 1.19 0.311
Table 9.28: Multivariate regression analysis to explore associations with the
time taken to attain full enteral feeds in babies of >30 weeks of gestation
Independent variable Effect (%) 95% CI P value
Birth weight -1.02 -1.31, 1.26 0.869
Exclusive EBM 1.14 1.03, 1.25 0.009
Large aspirates (no. days) 1.07 1.05, 1.08 <0.0005
Bilious aspirates (no. days) 1.08 1.02, 1.13 0.003
Abdominal distension (yes/no) 1.24 1.09, 1.32 0.01
MEN (no. days) 1.11 1.07, 1.15 <0.0005
Country (UK/Canada) 1.24 1.11, 1.38 <0.0005
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9.5 Temporary discontinuation of feeds
Information about temporary discontinuation of enteral feeds was available for 557/609
surviving babies. Of these, 183 (32.8%) progressed from first to full feeds without any
periods during which feeds were withheld. The remaining 374 babies had feeds discontinued
for one or more hours. Table 9.29 shows that the largest proportion of babies had feeds
discontinued for less than 6 hours. However, more than a quarter had feeds withheld for a
period equivalent to three to seven days in total. In a small number of babies, feeds were
withheld for a total number of hours that was equivalent to two or three weeks.
Table 9.29: Number of hours of discontinued feeds
Number of hours Number (%) of babies
UK Canada Total
n (%) n (%) n (%)
0 130 (34.2) 53 (29.9) 183 (32.8)
1-6 60(15.8) 18(10.2) 78(11.6)
7-12 32 (8.4) 10(5.6) 42 (6.3)
13-24 41 (10.8) 17 (9.6) 58 (8.7)
25-48 36 (9.5) 20(11.3) 56 (8.4)
49-72 21 (5.5) 18(10.2) 39(5.8)
73-168 40(10.5) 26 (14.7) 66 (9.9)
169-240 11 (2.9) 5 (2.8) 16(2.4)
241-336 8(2.1) 2(1.1) 10(1.5)
337-504 1 (0.3) 5 2.8) 6 (0.9)
>505 0 3(1.7) 3 (0.5)
Total 380 177 557
Table 9.30 details the reasons why feeds were discontinued for part or all of a 24-hour period
during advancement to full feeds and the number of babies for whom feeds were omitted.
The table includes a number of the factors highlighted by clinicians in the survey as reasons
for slowing or discontinuing enteral feeds. The most frequently documented reason for
discontinuation of feeds was the presence of large gastric aspirates and this affected 37% of
the babies. Other factors indicative of possible intra-abdominal pathology were common
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reasons. Other non-specific indicators of clinical deterioration, sepsis, the need for
intubation, apnoea and respiratory distress also prompted discontinuation of feeds. A number
of babies had feeds omitted during blood transfusions, indomethacin treatment or procedures
or because of lack of availability of EBM. Other less commonly documented reasons were
PDA, large air aspirates, gastro-oesophageal reflux, loose stools, hypoglycaemia, seizures,
acidosis, surgery and fluid restriction, which each affected less than five babies. On 115
occasions in 46 babies, feeds were omitted for up to 24 hours, but no reason could be
determined from the medical or nursing records.
Analysis was performed using non-parametric tests to compare the numbers of hours for
which feeds were withheld according to the presence or absence of potentially influential
factors during the time from first feed to attaining full feeds. Infants who were treated for
Stage II or III NEC before reaching full feed volumes were excluded from the analysis, as
withholding of feeds is part of therapy for the disease. This showed that treatment with
indomethacin, sepsis or other significant event, the need for ventilation, nCPAP or inotropes,
opiate sedation and the presence of umbilical catheters during this period were all highly
significantly associated with an increase in feed discontinuation (Table 9.31). Infants who
received exclusively breast milk feeds also had feeds discontinued for more hours.
In infants who had attained full feeds, feeds were discontinued in smaller proportions of
babies, but for similar reasons. However, feeds were withheld in a larger proportion of
babies for vomiting (6.6%), and during blood transfusion (4.3%). Indomethacin was more
frequently associated with stopping feeds in Canada than in the UK before and after full
feeds were established. Withholding of feeds during transfusion, either before or after infants
had attained full feeds, was confined to four neonatal units in the UK. Figure 9.9 shows the
variation in time for which feeds were withheld between neonatal units. Analysis using a
Kruskal Wallis test showed that this variation was significant (P=0.011).
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Table 9.30: Reasons for temporary discontinuation during feed advancement
UK Canada Total
(n=380) (n==177) (n=557)
No. No. (%) No. No. (%) No. No. (%)
days babies days babies days Babies
Large gastric aspirates 274 141 (37) 146 67 (37.8) 420 208 (37.3)
Bilious gastric aspirates 112 63 (16.6) 122 46 (26) 234 109(19.5)
Abdominal distension 125 40(10.5) 28 16(9) 153 56(10)
Suspected NEC 50 10(2.6) 56 5 (2.8) 106 15 (2.7)
Proven NEC 14 2 (0.5) 52 2(1.1) 66 4(0.7)
Suspected NEC 50 10 (2.6) 56 5 (2.8) 106 15 (2.7)
Blood-stained aspirates 12 9 (2.4) 2 2(1.1) 14 11(2)
Vomiting 45 29 (7.6) 10 6 (3.4) 55 34 (6.1)
No EBM 48 31 (8.1) 1 1 (0.6) 49 32 (5.7)
Suspected/ proven sepsis 16 6(1.6) 42 12(6.8) 58 18 (3.1)
Respiratory distress 27 11 (2.9) 14 5 (2.8) 41 16 (2.9)
Clinical deterioration 69 29 (7.6) 18 11 (6.2) 87 40 (7.2)
Intubation 28 23 (6) 23 18 (10.2) 51 41 (7.4)
Recent extubation 25 20 (5.2) 9 9(5.1) 34 29 (5.2)
Apnoea/ bradycardia 17 14(3.6) 10 5 (2.8) 27 19 (3.4)
Indomethacin 26 11 (2.9) 91 31 (17.5) 117 42 (7.5)
Clinical procedure 13 10(2.6) 17 16(9) 30 26 (4.7)
Blood transfusion 17 11 (2.9) 0 0 17 11(2)
Reason not identified 78 35 (9.2) 37 11 (6.2) 115 46 (8.2)
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Table 9.31: Comparison of the total number of hours for which feeds were
withheld according to the presence of potentially influencing factors
Number of hours of feeds withheld Significance (P value)
Factor present No Yes
Indomethacin 3 (0-25) 52.5 (12.5-109) <0.000005
Significant event 8 (0-44) 73.5 (20-11 1) <0.0005
Sepsis 4 (0-28) 79.5 (25.5-146.5) <0.000005
nCPAP 0(0-19) 18 (3-64) <0.000005
Ventilation 2 (0-17) 30 (8-93) <0.000005
Inotropes 7.5 (0-42) 34 (7-105) <0.0003
Abdominal distension 3 (0-22) 58 (18-121) <0.000005
uvc 1 (0.15.5) 26(5-74) <0.000005
UAC 2 (0-21) 24(4-71.5) <0.000005
Opiate sedation 5 (0-30) 55 (8.5-143.5) <0.000005
Bolus feeding 3 (0-29) 8 (0-48) 0.150
Exclusive EBM 3 (0-35) 12.5 (0-56.5) <0.0005
Figure 9.9: Boxplot to show the variation in length of time for which feeds
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9.6 Maintenance of enteral feeding
Data were collected for each infant from the time of initiation of enteral feeding until two
weeks after attaining full feeds, or until the time of discharge or transfer, if this occurred
earlier. During this time, the majority of infants received a combination of different types of
enteral feed. Although 577 (86%) infants were given some expressed breast milk (either
maternal or donated), only 156 (23.3%) were exclusively fed using EBM. A further 95
(14.2%) infants received mostly EBM. In these infants, breast milk feeds in the first few
days of life were supplemented with formula milk only until the supply of EBM was
adequate for all feeds.
One hundred and eighty-one (27%) infants received EBM initially, but then changed to a
formula. In 144 babies, this was preterm formula and in 10 cases term formula; 27 infants
were first changed from EBM to term formula before finally being given preterm formula. In
a further 27 (4%) infants, the transition from EBM to preterm or term formula was bridged
by the use of hydrolysed protein formula. Other infants who received some EBM were fed
using a combination of milks from the time of feed initiation. The commonest was mixed
feeding with EBM and preterm formula (n=100 (14.9%)). Hydrolysed formula was used to
supplement feeding with EBM in 17 (2.5%) infants.
The remaining infants did not receive any EBM. Thirty-one (4.6%) infants were fed using
preterm formula alone, 3 (0.4%) using term formula alone and nine (1.3%) using a
combination of the two. Hydrolysed protein formula was used together with term or preterm
formula in six (0.8%) infants. Forty-two (6.3%) infants did not receive any enteral feed
during the study period, because of death or early transfer to another hospital; data were
unavailable for the type of feeds in two (0.3%) infants.
9.6.1 Factors influencing type of milk used for maintenance of enteral feeding
9.6.1.1 Birth weight and gestational age
Figure 9.10 shows the type of feed given to infants in different birth weight categories. The
proportions of babies receiving exclusive or early breast milk were highest in the lowest
birth weight group. The proportion of infants receiving mixed feeding rose with increasing
birth weight to approximately twice that of the smallest group. As might be expected, the
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proportion of exclusively formula fed infants was highest in the larger infants and in this
group was 1.5 to 2.0 times higher than in the smaller infants. A chi-square test showed a
significant association between birth weight and type of milk feeds given (%2 =34.19;
P<0.0005). However, no significant association was found between IUGR and type of feed
given (x2 =3.87; P=0.424)
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Figure 9.11 shows the types of milk fed to infants by gestational age band. This shows
similar trends to those seen in the birth weight groups, but the association between gestation
and type of feed fails to reach statistical significance (%2 =16.255; P=0.180). Hydrolysed
formula was used in 15-20% of infants in each gestational age band.
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9.6.2 Variation in clinical practice between centres
Figure 9.12 shows the types of milk fed to infants in each neonatal unit. Although numbers
of babies for each unit were small, there appeared to be differences in practice between units
and countries. There was wide variation in the proportions of babies established on exclusive
breast milk feeds, ranging from 0% to approximately 70%. The use of hydrolysed formula
varied, with three units using it in a large proportion of babies, compared with much smaller
proportions in other units; in some units, no babies received hydrolysed formula. The use of
early preterm or term formula was lowest in units where the use of either EBM or
hydrolysed formula was greatest. However, in units where a high proportion of babies
received hydrolysed formula, only small numbers of infants received EBM, suggesting that
hydrolysed formula may have been used in place of EBM where mothers were unable, or
chose not to express breast milk.
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Figures 9.12, 9.13 and 9.14 show that the pattern of feeding, in this group of infants was
different between the two countries. Early breast milk feeding with subsequent change to
formula feeding appeared to be common in units in the UK. In contrast, in Canadian units
(Units 12, 13, 14), mixed feeding from the outset appeared to be more the norm. A greater
proportion of UK babies received early feeding with EBM, but a larger proportion of
Canadian infants received all or some breast milk during the total time observed. The
proportion of babies established on exclusive breast milk feeds was larger in the Canadian
group.
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9.7 Use of breast milk fortifier
Human milk fortifier was added to feeds for 175/518 (33.8%) infants who survived to reach
full enteral feeds and received any EBM. Of those infants who were exclusively fed on
breast milk once feeding was established, 93/228 (42%) received HMF. There was wide
variation in practice between units, with some adding HMF to all those receiving exclusive
breast milk feeds and other units not using it at all. Comparison with Figure 9.12 suggests
that in some cases, units not using HMF were those where large proportions of babies
changed from EBM to preterm formula feeding rather than continuing exclusive breast¬
feeding.















n (% of those
receiving exclusive
EBM)
1 (n=47) 42 (89) 4 (9.5) 10(21) 1(10)
2 (n=16) 14(87.5) 0 2(12.5) 0
3 (n=5) 4(80) 3(75) 0 0
4(n=26) 23 (88.5) 12 (52) 8(31) 7(67)
5(n=47) 46 (98) 0 19 (40) 0
6(n=36) 31 (86) 5(16) 17 (47) 4(23.5)
7 (n=20) 18 (90) 14 (78) 5(25) 5(100)
8(n=35) 32 (91) 25 (78) 8(23) 8(100)
9(n=15) 15(100) 5(33) 7(47) 4(57)
10(n=48) 48(100) 0 39(81) 0
11(n=9) 7(78) 1 (14.3) 4(44) 1(25)
12(n=65) 59(91) 29 (49) 30 (46) 17 (57)
13(n=103) 98 (95) 47 (48) 55 (53) 31 (56)
14(n=8) 8(100) 7 (87.5) 5 (62.5) 5(100)
15(n=16) 13 (81) 1 (7.7) 1 (6.2) 0
16(n=12) 10(83) 3 (30) 5(42) 3 (60)
17(n=17) 16 (94) 4(25) 6 (37.5) 2(33)
18(n=39) 34 (87) 15 (44) 7(18) 7(100)
Total (n=564) 518(90) 175 (34) 228 (40) 95 (42)
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9.8 Management of gastro-oesophageal reflux
Every type of medication commonly prescribed in the management of gastro-oesophageal
reflux was used in this group of babies (Table 9.33). The use of feed thickeners and
Gaviscon were confined to the UK and metoclopramide was only given in Canadian units.
H2 receptor antagonists and domperidone were used in both countries. Overall, up to 10% of
babies received some form of pharmacological treatment.
Whilst the use of alginates, feed thickeners and prokinetics are generally confined to the
management of gut dysmotility or reflux, H2 receptor antagonists are also used in the
prevention or treatment of gastro-intestinal bleeding associated with the use of drugs known
to cause gastro-intestinal irritation, such as steroids. A total of 46 babies received steroids
during the period of the study and of these, 13 also received H2 receptor antagonists. It is
therefore not possible to be certain of the indication for treatment in these cases.
Table 9.33: Numbers of babies treated with anti-reflux therapies
UK (n=45I) Canada (n=219) Total (n=670)
Feed thickener 12 (2.7) 0 12 (1.8)
Gaviscon 63 (14.0) 0 63 (9.4)
H2 receptor antagonists 53 (11.7) 15 (6.8) 68 (10.1)
Domperidone 15 (3.3) 10 (4.5) 25 (3.7)
Metoclopromide 0 7 (3.2) 7 (1.0)
Proton pump inhibitors 1 (0.2) 0 1 (0.1)
Values arepresented as n (%)
9.9 Necrotising enterocolitis
Proven NEC was defined according to criteria for Bell Stage II or III disease in cases where
reports of radiological investigations were available. Where the diagnosis was based on
clinical features such as abdominal distension, tenderness or bloody stool, infants were
included if the medical records specifically documented on multiple occasions that a
diagnosis ofNEC had been made, even if the report of an x-ray was not available. Although
most infants with a clinical or radiological diagnosis of NEC were treated with triple
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antibiotic therapy for more than one week, this was not universal. However, it was regarded
as supporting evidence of a firm diagnosis.
Since NEC is extremely rare in the first few days of life before enteral feeds are started, it is
appropriate to compare the group who developed the disease with those surviving until a
time at which they might reasonably be considered to be at risk ofNEC. Infants dying during
the first five days of life (n=35) were therefore not included in the following data analysis.
Two of these excluded infants had received enteral feeds totaling <2ml/kg on day 3 or 4 of
life.
9.9.1 Characteristics of Infants with Stage ll/lll NEC
Of the 635 infants surviving more than five days, 28 babies (4.4%) from twelve neonatal
units developed proven NEC. The proportions of babies developing NEC were similar in the
UK (17/421 (4.2%)) and Canada (11/214 (5.4%)) 0.409; P=0.523). Of these, 12 (43%)
had stage II and 16 (57%) had stage III disease. These infants were of lower gestational age
and birth weight than those who did not develop NEC (Table 9.34). There was significantly
more growth restriction among infants with NEC although numbers were very small and this
was not accompanied by a difference in the number of infants with abnormal antenatal
Doppler studies. Infants developing NEC required umbilical catheters for significantly
longer than infants that did not go on to develop the disease. Other potentially relevant
factors were not significantly different between the two groups.
Table 9.35 shows results of a binary logistic regression analysis. Data were missing for the
day of first feed for eight babies, presence ofUVC and UAC for 7 and 6 babies respectively.
CRIB score was unavailable for 51 babies and the time to reach full feeds was missing for 8
babies who died and 45 who were transferred before reaching full feeds. In order to include
those infants who died from NEC before reaching full enteral feed volumes, the time to
either full feeds or death was included in the model. Complete data for 532/635 babies were
available for this analysis, of whom 25 were infants that developed NEC. The remaining 3
infants with NEC, but for whom data were not complete, were excluded. This analysis shows
that infants of lower gestation and those who had a shorter period of MEN had increased
odds of developing NEC; those who took longer to reach full feeds and those who received
indomethacin had decreased odds.
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The proportion of babies developing NEC was highest (15.1%) in infants born at <26 weeks
band and fell with increasing gestational age (Table 9.36). Stage III NEC was confined to
infants of less than 30 weeks of gestation at birth. Although a greater percentage of babies
with NEC weighed <1000g at birth, both Stage II and Stage III disease were seen in babies
in the two larger birth weight groups in similar proportions(Table 9.37). Although univariate
analysis comparing infants developing stage II and stage III NEC (Table 9.38) showed that
infants with stage III NEC progressed from first to full feeds faster than those with stage II
disease, multivariate analysis showed no significant associations in this small group of
babies.







Gestation (weeks) 29 (27-30) 27 (24.25-28) <0.0005
Birth weight (g) 1145 (950-1330) 955 (677-1260) 0.004
CRIB score 1 (1-4) 2(1-7.25) 0.042
Day of first feed 3 (2-4) 4 (2-5) 0.022
Time from first to full feeds (days) 9(6-13) 12 (7-20.25) 0.014
Exclusive EBM 237 (39) 14 (50) 0.155
MEN (days) 2(1-4) 2 (1-4) 0.774
IUGR 199 (32.8) 3 (10.7) 0.025
Abnormal dopplers 70(11.5) 3 (10.7) 1.00
PDA 143 (23.6) 7 (25.0) 1.00
Indomethacin 138 (22.7) 6 (21.4) 0.872
UVC (days) 0 (0-5) 4.5 (0-7) 0.032
UAC (days) 0 (0-4) 4 (0-8) 0.001
Deaths 66/642 (10.3) 9/28(32.1) <0.0005
Values for continuous variables are presented as median (interquartile range);
Values for categorical variables arepresented as n (%>).
Mann Whitney U testfor continuous variables; "/ or Fisher's exact testfor categorical
variables
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Table 9.35: Logistic regression analysis showing characteristics of infants






Gestation (weeks) -0.35 0.70 0.51,0.97 0.033
CRIB score 0.08 1.08 0.89, 1.32 0.432
Day of first feed -0.08 0.92 0.70, 1.21 0.551
Time from first to full feeds or death 0.05 1.051 1.01, 1.10 0.020
(days)
Exclusive EBM 0.23 1.26 0.49, 3.27 0.635
MEN (days) -0.23 0.48 0.64, 0.10 0.048
IUGR -0.87 0.42 0.10, 1.72 0.227
PDA -0.36 0.96 0.26,3.58 0.957
Indomethacin -1.70 0.183 0.04, 0.83 0.028
UVC (days) 0.01 1.01 0.88, 1.14 0.927
UAC (days) 0.04 1.04 0.90, 1.21 0.552
H2 receptor antagonists -0.38 0.68 0.18,2.52 0.567











No proven NEC 56 (84.8) 125 (94.5) 218(96.5) 208 (98.5) 607 (95.7)
Stage II 3 (4.5) 5(4) 1 (0.4) 3(1.5) 12 (18.9)
Stage III 7 (10.6) 2(1.5) 7(3.1) 0 16(2.5)
Total proven NEC 10(15.1) 7 (5.6) 8 (3.7) 3(1.4) 28 (4.4)
Values are presented as n (%>).
Table 9.37: Distribution of Stage II and III NEC by birth weight








No proven NEC 181 (92.3) 204 (97) 222 (97) 607 (95.7)
Stage II 7(3.5) 2(1) 3(1.3) 12(18.9)
Stage III 8(4.1) 4(2) 4(1.7) 16(2.5)
Total proven NEC 15 (7.6) 6 (2.8) 7 (3.0) 27 (4.4)
Values are presented as n (%).
193








Gestation (weeks) 27 (25.25-29.5) 27 (24-28) 0.423
Birth weight (g) 952.50 952.50 0.763
(760-1257.50) (666.5-1240)
CRIB score 2(1-4.25) 3.5 (1-10) 0.503
Day of first feed 4 (3-4.5) 3.5(2-5.75) 0.778
Time from first to full feeds (days) 18(12-21.75) 7(6.75-14) 0.026
Exclusive EBM 5 (41.6) 9 (56.2) 0.146
MEN (no. days) 2 (1-4) 2 (1-4) 0.838
IUGR 2(16.7) 1 (6.2) 0.389
Abnormal dopplers 2 (16.7) 1 (6.2) 0.389
PDA 3(25) 4(25) 0.666
UVC (no. days) 6 (0.5-7) 4 (0-5.5) 0.799
UAC (no.days) 4 (0-7.5) 4 (0.5-8) 0.422
Day of diagnosis of NEC 27 (12.25-42.25) 16 (11.25-21.75) 0.121
Values for continuous variables are presented as median (interquartile range); Values for
categorical variables are presented as n (%).Mann Whitney U test for continuous variables;
f or Fisher's exact testfor categorical variables
9.9.2 Deaths due to NEC
Nine infants (26%) with a diagnosis of proven NEC died, all of whom had stage III disease.
Causes of death were not always recorded in the medical notes and death certificates were
not available. Death due to NEC was therefore defined as death whilst undergoing medical
or surgical treatment for NEC in the presence of ongoing signs of the disease. Eight of the
nine deaths were attributable to NEC. Three deaths were in UK infants and five in Canadian
infants (17.6% and 45% of those with the disease respectively). Although a greater
proportion of babies died ofNEC in Canadian neonatal units, the overall difference in deaths
due to NEC was not statistically significant between the countries (%2 0.2.994; Fisher's exact
test P=0.091). Deaths occurred in all birth weight groups, but were confined to infants of
<30 weeks of gestation. Numbers of deaths from NEC according to gestational age at birth
were 4/10 (40%), 2/7 (28.6%), 2/8 (25%) respectively for babies <26 weeks, 27-28+6 weeks
and 29-30+6 weeks respectively.
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9.9.3 Enteral feeds in babies developing NEC
9.9.3.1 Type of feed
All had received some enteral feed prior to developing the disease. Data for the type of feed
given were available for 27/28 infants developing Stage II or III NEC. All except one had
received some EBM and 14/28 were exclusively breast fed after establishing early feeding
and up until the time of diagnosis ofNEC. Table 9.39 shows the range and combination of
feeds given to babies that then developed NEC.
Table 9.39: Feeds given to babies before diagnosis ofNEC
Type of feed Stage II NEC Stage III NEC Total
Exclusive MEBM 5 8 13
Exclusive MEBM/DEBM 1 1
MEBM, then change to PTF 2 2
MEBM with TF, then change to PTF 2 2
MEBM with HF, then change to PTF 1 1
MEBM then Mixed MEBM/PTF 2 1 3
Mixed MEBM/PTF 1 2 3
MEBM then change to TF 1 1
PTF 1 1
Missing 1 1
Total 12 16 28
PTF: preterm formula; TF: term formula; HF: hydrolysedprotein formula
9.9.3.2 Initiation and advancement of feeds
Infants with NEC started feeds later and took longer to reach full feeds than those without
NEC (Table 9.29). There was no difference in the number of days ofMEN between those
with and without NEC or between those with Stage II and Stage III NEC. However, infants
with Stage III NEC attained full feed volumes more rapidly than those with Stage II disease.
Figure 9.15 shows a graph of the volumes of enteral feed given during the first two weeks of
life to babies with and without proven NEC and indicates that during the first week, those
developing stage III disease were fed at approximately the same rate as those that did not
195
develop NEC. However, infants with Stage II disease had a slower rate of increase. Figure
9.16 shows that this was the case regardless of gestational age, but that in infants of 29-30+6
weeks of gestation, those with either stage II or III disease were fed more rapidly than those
that did not develop NEC.
Figure 9.15: Graph to show median feed volumes in infants with and without
NEC
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Day of life
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Figure 9.16: Graph to show median feed volumes in infants with and without
NEC by gestational age band
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The number of babies with NEC was too small to be able to analyse less common
characteristics. The characteristics of each baby and presence of factors that might influence
the risk of NEC are therefore described in detail in Tables 9.40-9.42. Table 9.40 shows
demographic data, factors present before birth and in the early days of life. Table 9.41
describes feed-related factors and Table 9.42 describes other factors that have less
commonly been associated with NEC in some studies. Eight infants required surgery for
NEC and in these infants. All of these infants had radiological signs ofNEC prior to surgery
and the diagnosis was confirmed by histopathological findings at operation. In sixteen
infants the diagnosis was made in the light of radiological evidence of pneumotosis
intestinalis and in three infants with stage II disease, x-ray reports were not available, but the
diagnosis was evident from medical records, length of treatment with antibiotics and
withholding of feeds. One infant was transferred to another hospital before the diagnosis was
made, but post mortem findings were documented. The day of diagnosis of NEC varied
considerably between babies. Eight infants, four ofwhom died, developed the disease before
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full feeds had been established and the others had spent varying amounts of time on full feed
volumes. Infants who died from NEC did so within 72 hours of the diagnosis being made in
all cases. Only one infant died later and this was attributable to sepsis rather than bowel
disease.
Only three infants received blood transfusions within 72 hours of a diagnosis ofNEC. Two
of these had been established on full feeds for >10 days and the other had recently achieved
full feeds. Data for haemoglobin levels at the time of transfusion were not collected. Seven
infants had received H2 receptor antagonists before developing NEC, but only one within 72
hours of the diagnosis. Only four infants were receiving HMF at the time of developing NEC
and all had stage II disease. In four babies, the development of NEC was temporally related
to reaching full feeds, occurring within 48 hours. Six babies changed from receiving EBM to
either preterm or term formula after reaching full feeds, but in only one was this temporally
related to the diagnosis ofNEC.
There were five infants for whom a significant potentially hypoxic event occurred before the
diagnosis of NEC was made and a further one infant who had had surgical intervention for
spontaneous intestinal perforation before later developing NEC. Of the infants who may
have suffered a hypoxic event, three were within the first 3 days of life and infants
developed NEC before two weeks of age. One case of late NEC appeared to follow on
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The subject of this thesis is a two-part observational study, conducted in the UK and Canada.
A questionnaire survey sent to neonatal clinicians sought to investigate current opinion and
reported practice with respect to early enteral feeding of infants born at less than 30 weeks of
gestation and/or 1501 g birth weight in the UK and Canada. This survey was complemented
by a detailed retrospective review of the medical and nursing records of 695 infants admitted
to fifteen UK and three Canadian neonatal units.
There have been few recent detailed reports relating to opinions about feeding of preterm
infants. Churella et al conducted a US survey in 1983414, but changes in many aspects of
neonatal care limit the relevance of this for current practice. In 1987 and 1994, a telephone
survey of feeding policies for ventilated preterm infants in 22 UK regional neonatal intensive
care units showed fundamental differences between units, in spite of a tendency to more
uniform approach over the time period between surveys415. More recently, Patole and Muller
reported results of a 2001 Australian survey of neonatologists' practice and examined the
response to the presence of risk factors for NEC, again showing uncertainty and variation in
practice190. Holm conducted interviews with 12 medical and nursing clinicians to explore in
detail the reasons behind variation in practice between two UK units416. The most recent
survey was published in 2009 and reported analysis of a 2006 survey of neonatologists,
neonatal nurses and dieticians in the US191. This survey investigated intentions of clinicians
with respect to feeding practice in preterm infants and compared them to published
recommendations available at the time. The authors reported on both parenteral and enteral
nutrition practices and concluded that regimens that were more appropriate were being used
at that time than in previous studies, although the response rate was poor for this survey,
raising concerns about non-response bias as highlighted in the following section of this
discussion. Other surveys have focused on individual areas of feeding417 418 or on maternal
experiences of feeding preterm infants419 420.
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10.1 Strengths and limitations of the survey
This approach of this study is novel in its ability to explore the complex relationship between
available research evidence, clinician opinion and clinical practice. It provided a unique
opportunity for direct comparison of practice between two developed countries providing
care to similar populations of infants in the context ofmodern neonatal intensive care.
Double entry of research data represents the "gold standard" but for financial reasons, it was
not possible to appoint a second researcher for this study. Extensive and detailed data
collection by a single researcher across all included neonatal units in both countries ensured
consistency in the approach to data collection and definitions and completeness of data.
Previous piloting of the methodology1 allowed appropriate amendments to be made to the
dataset and refinement of data collection methods before embarking on the current survey.
The postal survey is the largest of its kind in the UK and Canada and was distributed to all
senior clinicians involved in care of the group of infants of interest. This inclusion of
consultant and attending neonatologists ensured that responses were informed and based on a
high level of clinical experience. The retrospective review included neonatal units that were
representative of the range of neonatal intensive care offered at the current time, in order that
the results might be generalisable to the wider neonatal population. All live-bom babies
meeting the selection criteria, bom during the six-month study period, were eligible to be
included in the study, allowing data collection from birth for both survivors and non-
survivors. To the author's knowledge, the retrospective review represents the largest cross-
sectional survey of its kind and this is the only survey to document contemporaneously both
reported and actual clinical practice.
A number of limitations to both parts of the survey are acknowledged. The use of a postal
survey rather than interviewing of clinicians probably led to poor response rates, in spite of
additional attempts to engage non-responders. The overall response rate of 40.7% is lower
than might be expected. However, further analysis revealed that 78.4% of all valid
responses received were either from tertiary neonatologists or from paediatricians known to
have a special interest in neonatology, whilst responses from general paediatricians with
only limited responsibilities for neonatal care were fewer. The response rate in this subgroup
was 57.3%, which is comparable with response rates to other postal surveys of medical
professionals421"423. An additional 20 responses were excluded from the analysis as these
203
clinicians requested that unit-based responses were considered and declined requests to
complete individual questionnaires. Asch et al examined response rates to postal surveys in
published studies and found that, although response rates were poorly reported in many
studies, those seen in surveys to physicians were the lowest observed with a mean (SD)
response rate of 54 (17)%421. Cummings et al selected a random sample of 5% of articles
published between 1986 and 1995 reporting data from postal questionnaires to doctors423.
They showed an overall average response rate of 61%, which fell to 52% for studies with
more than 1000 observations. This study was updated recently for studies among health
professionals published between 1996 and 2005422. The results suggested that response rates
in doctors had fallen significantly to 57.5% (95% CI: 55.2-59.8%). Previous published postal
surveys specifically related to feeding in preterm infants have reported variable response
rates: Churella et al, 275/702 clinicians (39%)414; Patole and Muller 56/80 (70%)190; Hans et
al 176/775 (23%)191.
A Cochrane systematic review identified a number of ways of increasing response to postal
questionnaires424. These included the use of financial incentives, recorded delivery, follow-
up contact and provision of a second questionnaire, university sponsorship, personalised
questionnaires, the provision of a stamped addressed, rather than franked envelope, first
class mailing, the suggestion of an obligation to respond and the questionnaire being about
an interesting subject. Whilst financial and ethical restrictions prevented the use of first class
postage, recorded delivery or monetary incentives, the remaining methods suggested were
used in this survey. It is likely that limitation on clinicians' time to complete surveys played
a large part in the low response rate seen. However, the increased response rate in clinicians
with a declared interest in neonatal medicine suggests that the degree of interest in neonates,
and therefore in neonatal feeding, may have played a major part. In fact, the desire to be
fully inclusive when distributing the questionnaire may have been detrimental in this respect.
If such a survey was to be repeated in the UK, a more selective approach may be prudent.
Reasons for differences in response rates observed between UK and Canadian clinicians are
speculative, but may be related to the distribution of the questionnaire in Canada by email
rather than by post, or to a lack of a feeling of obligation to complete a survey sent by a non-
Canadian trainee. Poor response rates raise concerns about non-response bias. In this survey,
results are based mainly on responses from those with a specific neonatal interest and may
not represent views of clinicians with only limited roles in neonatal care. It is also likely that
those with an interest in preterm feeding were over-represented, although this information
was not sought. However, since neonatologists in tertiary centres coordinate care for the
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majority of high-risk infants, this may not substantially compromise the validity and
generalisability of the results. The fact that almost 80% of neonatal units surveyed were
represented provides some reassurance, but must be accompanied by the caveat that results
also indicated substantial variation in practice within individual units.
The retrospective review was not a population-based study in that it did not include all
neonatal units in the two countries. Although ideal, this approach would not have been
feasible due to time and cost limitations. A random sample of units in the two countries
would also have been preferable, but would also have been prohibitively challenging for
similar reasons, particularly in Canada where distances between units are great. An
opportunistic approach was therefore adopted, which would allow maximum efficiency of
data collection within financial and time constraints. This may have introduced some
selection bias, as included units were located within two principal areas of the UK and only
one province of Canada. Potential sources of bias may relate to systematic differences in
clinical approach in different areas of the country or differences within the maternal or infant
population due to ethnic, cultural, socio-economic, environmental or genetic differences.
Such elements are likely to be of only modest clinical significance in the UK, where
distances are small and most populations of many areas are cosmopolitan. Within the
practical constraints associated with conducting the study, units in the UK were chosen to
represent urban and rural areas, areas of socioeconomic affluence and deprivation and areas
of ethnic diversity. In contrast, populations of different areas of Canada may be significantly
different in terms of culture and environment. Data collection in one province may therefore
limit the generalisability of the study results to other parts of the country, although
widespread integration and movement of populations, particularly to and within large cities
such as Toronto means that this effect may be less relevant in modem society than in the
past. Similarly, movement of clinicians from one part of Canada to another may lessen the
likelihood of systematic differences in clinical management.
There are major limitations associated with any observational and retrospective study design
when compared with randomised controlled trials, prospective cohort studies or case-control
studies. Crucially, in retrospective reviews, the data collected have been for clinical, rather
than research purposes. The researcher must rely on the availability of medical records and
make assumptions about the accuracy of recording in the records; incomplete data may lead
to bias in the results, depending on the reasons for the unavailability of information. In this
study, medical records were unable to be located for 6/701(0.08%) eligible babies. Some of
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these records were thought to be under investigation for medico-legal reasons. It is possible
that elements of care will have differed substantially in this group from those of babies
whose records were retrieved, but this small proportion is unlikely to significantly influence
the overall results unless all suffered adverse outcomes associated with feeding practice.
This information was not available. Other exclusions occurred prior to analysis because
some infants were not representative of the population of interest and others had excessive
amounts ofmissing or uninterpretable data that might unduly influence study results. These
numbers were also small (25/701 (3.5%)). Clinical entries in medical records were assumed
to be accurate, but unusual entries were verified by cross checking with other entries in notes
or discussion with clinicians. Accurate and complete data were therefore available for all or
most analyses for 96% of eligible infants.
The issue of confounding limits the conclusions that can be drawn from any retrospective
observational study. Whilst attempts were made to obtain information on all potential
confounding factors and to control for these in analysis, there may be some unknown or
unrecognised factors that were not considered. Birth weight and gestation are probably the
most important confounders in this group of babies and these were controlled for mainly by
stratification at the time of analysis. Unequal distribution of confounding factors may also
have influenced results of comparisons between countries or units. Similarly, unequal
numbers of babies in different centres and different countries limits the interpretation of
results. This study can at most suggest associations between independent variables and
outcomes considered and can in no way establish causality. Nevertheless, the observed
associations provide information either to support or question current beliefs and suggest
areas for development of further interventional research.
Additional limitations relate to the content of the clinician questionnaire and data collected
in the retrospective review, both of which restrict interpretation of the data. Clinicians were
asked about clinical practice in relation to feeding in babies of <30 weeks of gestation or
1501 g birth weight. It is clear from the variation seen in responses and in the survey of
practice that this encompassed too wide a range of babies and that practices probably
differed more with gestational age and birth weight than was anticipated. It was not possible
to tease out these differences from the questionnaire responses and this limits the ability to
compare between reported and actual feeding practice. With respect to the retrospective
review, detailed serial data for weight gain were not collected and this makes it impossible to
determine whether different feeding practices have significant effects on growth. It had been
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intended that robust data about weight gain either at discharge or at a given gestational age,
such as 36 weeks would be collected. However, the large number of transfers to other units
prior to discharge from hospital made this impossible. Another important outcome, for which
data were collected, was the occurrence of infection. However, diagnosis of infection is
challenging for a number of reasons. Firstly, signs of sepsis are non-specific in neonates and
so antibiotics are frequently administered for clinical suspicion on infection and then
discontinued if no organisim is identified on culture. Secondly, sampling of blood and other
normally sterile fluids is technically difficult, and the interpretation of culture results is
therefore challenging. Therefore, although the presence of culture-positive sepsis was
included as an independent variable in regression analyses, it was not deemed appropriate to
conduct analyses with sepsis and an outcome variable.
Although this is one of the largest and most detailed surveys to date, the amount of data
collection limited the number of babies that could be included by a single researcher. In turn,
this limited the number of important outcomes that could be detected within the group of
babies. One of the main aims of the study was to document in detail reported and actual
feeding practice in UK and neonatal units and this aim was achieved. However, this
necessitated a 'trade-off between detailed data in this aspect of the study and quantity and
quality of outcome data. Since data for several thousand babies would probably be needed in
an observational study to show robust associations with rare outcomes such as NEC, this
ideal type of study, characterised by detailed data and large numbers of outcomes is probably
not feasible without substantial funding and collaborative effort. Nevertheless, data collected
in this study add to the body of knowledge and serve as a means to highlight areas for further
exploration and to inform design of large randomised controlled trials, which are better able
to determine cause and effect with relatively small numbers of babies.
10.2 The use of feeding guidelines
There have been no published studies reporting information about the use of clinical
guidelines for preterm infant feeding. The North American survey by Hans191 and Australian
survey by Patole190 questioned neonatologists on their clinical practice but neither study
addressed the availability of clinical guidelines for feeding within the units surveyed. The
pilot survey of 15 neonatologists in Scotland1 questioned a single clinician in each unit and it
was assumed that the response would represent the unit. The responses suggested that 8/15
207
(53%) NNUs had written clinical guidelines for some aspect of enteral feeding in preterm
neonates. In contrast, this wider survey asked all neonatal clinicians, with a positive response
from 59%. Although some variation in responses was anticipated for questions that sought
opinions on optimum feeding practice, inconsistency regarding the reporting of availability
of written guidelines was unexpected. However, from more than half of the neonatal units
included in the survey, Yes/No responses from members of the team were conflicting,
implying that substantial numbers of senior clinicians were unaware of the presence of
written guidelines in their own neonatal unit. It is also possible that, in units where a single
clinician responded, the information provided was inaccurate. Explanations for this might
include very recent introduction of guidelines, incomplete dissemination of information
among staff or unwillingness of clinicians to recognise and acknowledge such guidance,
even if it exists.
Preterm infant feeding is one of the few areas of neonatal medicine in which the use of
written guidance and standardised regimens has been examined in relation to outcomes219.
Although there are limitations to the research, it has been suggested that standardised
regimens may be important in reducing NEC. It is perhaps surprising then that the use of unit
guidelines may be as low as 10% for some aspects of feeding and that clinicians' knowledge
of local guidelines is so limited.
However, the inconsistencies in these results may be simply a reflection of the challenges
associated with producing and implementing formal guidelines. Despite the increasing
development of clinical guidelines in all branches of medicine, opinion remains varied with
respect to their effectiveness in changing clinical practice425 426. The success of guideline
implementation depends on widespread and effective dissemination within the clinical
environment and "buy in" or support of all clinicians. In centres where considerable
enthusiasm on the part of one or more clinicians is directed toward the pursuit of excellence
in a particular part of practice, such "champions" may strive more than others to develop and
implement evidence-based guidelines. This is likely to be the case in centres that go on to
examine and publish their experience and this may in part, be responsible for some of the
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positive results reported in studies of feeding regimens " . For areas of practice
where evidence is uncontroversial and robust, successful guideline implementation may be
easier, but in areas such as preterm feeding, where availability of evidence is poor, variation
in opinion is great and results of research inconsistent, it is less simple. Nevertheless,
guidelines can represent an effective way of synthesising evidence, where this exists to guide
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practice, or of reaching consensus on practice methods where it does not426. The widespread
use of standardised guidelines is relatively recent and many established clinicians are more
used to basing decision-making on years of clinical experience. Cabana et al identified seven
barriers to adherence to clinical guidelines427. These were lack of awareness, lack of
familiarity, lack of agreement, lack of self-efficacy, lack of outcome expectancy, inertia of
previous practice and external barriers. Few researchers have investigated the adherence to
clinical guidelines in neonatal medicine. In a retrospective review, Atkinson et al showed
only 54% adherence to a guideline for the use of phototherapy in neonates428. In a survey
(response rate 55%) to assess adherence to the guideline for developmental screening in
infants produced by the American Association of Pediatrics, only 23% reported using a
defined screening tool, as recommended by the guideline, while 71% carried out screening in
a non-standardised way429. It therefore seems likely that, even where guidelines are in place
for feeding of preterm infants, the extent to which they are followed may be variable. It was
not possible to investigate adherence in this study, as copies of neonatal unit feeding
guidelines were not obtained to allow comparison with practice.
10.3 Factors influencing feeding practice
Both the postal and retrospective surveys demonstrated the large number of factors that
appear to be influential in the process of clinician decision-making to allow attainment of
full feeding in vulnerable infants. Some of these factors are more consistent and widespread
in their influence than others and these are discussed below.
10.3.1 Type of feed
EBM is recommended as the feed of choice for preterm infants and there are few
contraindications to its use430. Although evidence from randomised trials is scarce198 the
introduction of enteral feeds as early as the first or second day of life does not appear to
confer any disadvantage and may be protective against NEC and sepsis203 204. In this clinician
survey, more than 90% indicated that their preferred time for introduction of breast milk
would be during the first 48 hours of life. Since this is the large majority of clinicians, it
might reasonably be expected that this would be the intended practice in most neonatal units.
However, in the retrospective survey of practice, less than half of all infants surviving to
receive some enteral feed were fed on day 1 or day 2 of life and almost one third reached
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four or more postnatal days before receiving any milk. Survey respondents indicated that
they might delay initiation of feeds for many different reasons. This was in response to direct
questioning about factors that have been associated with feeding practice in the published
literature. Although more, less or different reasons may have been suggested without these
prompts, it is probable that these responses do, in fact, reflect practice at the time of the
survey.
In the retrospective review, the use of EBM for the first feed was significantly associated
with the timing of feed introduction in all groups and in babies of <1250g birth weight, it
was the most significant factor. Feeding with EBM has been associated with improved short -
and long-term outcomes113"116 143-145 and so expression of breast milk is encouraged as early
as possible. Mothers of preterm infants say that expressing breast milk is an important way
in which they can contribute to their babies' care and some appear to view it as a way of
"compensating" for a baby's premature delivery431. It is suggested that expression of breast
milk should occur on the first day after birth in order to increase the likelihood of
establishing breast-feeding in the long term432. It is nevertheless common for mothers who
intend to breast-feed their premature babies to have trouble in expressing breast milk shortly
after delivery. For some, difficulties can be prolonged for several days, because of either
maternal illness or poor milk supply. Frequently, beginning enteral feeds in a preterm baby is
clinically indicated before the time at which the mother is able to express any or adequate
breast milk. In these circumstances, a decision must be taken whether to wait for maternal
breast milk or to commence feeds with another type ofmilk.
Unexpectedly, in this study, the use of EBM for the first feed was associated with later
introduction of feeds and this may be related to conscious decisions to wait for breast milk.
Of all babies fed within the first 48 hours after birth, only 47% were given maternal breast
milk and a further 8% received DEBM. This implies that, although clinicians aspire to start
feeds at this early stage, in reality it may prove challenging to obtain expressed breast milk
from mothers, or that in some infants the perceived risks of feeding during the first 48 hours,
even with EBM, were greater than the risk of delaying. The randomised controlled ADEPT
Trial in growth restricted infants of <35 weeks of gestation with abnormal antenatal Doppler
studies, currently published in abstract format, reports that of 189 infants recruited to the
early feeding arm (feeds started on day 2 of life), 81% received feeds at the specified time
and 82% received breast milk as the first feed433. Flowever, the proportions of babies that
received MEBM and DEBM are not specified in this preliminary report. The early
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introduction of feeds did not appear to increase the risk of later NEC. It is likely that many of
the infants recruited to this trial would also have had other factors that might lead to delayed
feed introduction. Ronnestad also reports that of 462 infants enrolled in a Norwegian study,
61%, 92% and 96% had started feeds with human breast milk by days 1,2 and 3
respectively201. This suggests that, even in high-risk infants, it is possible both to obtain
breast milk within the first 48 hours and to introduce feeds successfully at this early stage.
An additional factor contributing to the studies' success may be that in neonatal units
participating in research, there may be a heightened awareness of feeding issues leading to a
more proactive approach in encouraging mothers to express breast milk before the first feed.
Challenges in the staffing of both neonatal and midwifery units are well-recognised,
particularly in the UK, and this is likely to mean that fewer personnel and resources can be
devoted as part of routine care to providing prolonged assistance to new mothers to help
them to achieve successful and early expression of breast milk.
Infants starting feeds beyond the first five days of life all received MEBM, while those
starting feeds earlier variably received preterm, term or hydrolysed protein formula. Feeds
used in the absence of breast milk mirrored the reported preferences of clinicians
participating in the postal survey and may reflect their consideration of perceived risks and
benefits of different feeds although the evidence on which to base such a decision is limited.
In infants starting feeds at the end of the first week of life or later, it is likely that this
represents a group of particularly high-risk infants and/or reflects a delay whilst awaiting
MEBM. This is also broadly in line with the views expressed in the survey indicating that
only a minority of clinicians would wait for more than 7 days for MEBM.
In this study, during the build up to full feeds, 64% of infants received EBM as their only
milk or received only very small amounts of other milk during the first two days of life. This
compares favourably with other studies. Hylander reported that 59% received exclusively
breast milk434; Furman reported that in her study, 66% received some maternal breast milk"2
and Meinzen-Derr reported that approximately 30% of infants in a study of glutamine
supplementation were exclusively breast fed for the first 14 days of life119. However, in
Ronnestad's study, 92% of infants were receiving MEBM and 6% DEBM at the time of
attaining full feeds201. The exclusive use of EBM for early feeding was expected to be
associated with more rapid feeding, since this is regarded as the most appropriate feed for
immature babies and is better tolerated. However, analysis of the number of hours for which
feeds were discontinued showed that infants who received exclusively EBM had their feeds
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discontinued for a greater period of time overall, suggesting either poorer feed tolerance or
the presence of other reasons for feed discontinuation. Regression analysis of the time to full
feeds showed differences between the gestational age bands. In infants of 28-29+6 weeks of
gestation, EBM was associated with earlier establishment of full feeds. However, there was
no association with the time to full feeds in infants of <28 weeks of gestation and in infants
of >30 weeks of gestation, was unexpectedly associated with increased time to attain full
feeds. Most (82%) babies in the lowest gestational age group received exclusive EBM,
which may reflect unwillingness of clinicians to use other milks in infants perceived to be at
highest risk ofNEC and this high proportion in a relatively small group may account for the
inability to detect an association. The association with slower feeding in breast-fed babies in
the highest gestational age group is difficult to explain and may be a chance finding.
However, one might speculate that sick infants or those perceived to be at higher risk of feed
intolerance or NEC were preferentially given breast milk, but were also fed more cautiously
than those for whom the risk was thought to be lower. Alternatively, it may represent
differences in clinical practice between centres in the management of more mature infants
and it is interesting to note that within this gestational age group, the effect of the country of
neonatal care was highly significant and increased the significance of exclusive breast milk
feeding in the regression model.
Data for ongoing maintenance feeds and feeding on discharge were unavailable for many
babies who were transferred to other neonatal units before discharge from hospital.
However, from the available data, less than 40% were receiving breast milk at the time of
leaving the neonatal unit surveyed. Most commonly, breast milk feeds were changed to
preterm formula. Schanler's randomised trial of DEBM or preterm formula to supplement
MEBM feeding found that 21% of infants in the DEBM group required a change to preterm
formula because of poor weight gain"8. It was not possible to ascertain the reasons for
change in milk in this study, but it appeared that a change to preterm formula was most
common in units where HMF was not used, suggesting that poor weight gain may have been
the primary reason. However, it is interesting to note that the unit with the highest proportion
of exclusively breast fed babies did not introduce HMF for these babies. This highlights
current uncertainties about the most appropriate way in which to promote growth in low
birth weight infants. Although HMF is widely used, this is not universal and some clinicians
prefer milk substitution or increase in volumes. The timing of introduction of fortifier was
not investigated in this study, but is also likely to be very variable. The use of hydrolysed
formula varied between the birth weight and gestational age groups. Since this type of feed
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tends to be utilized to minimize feed intolerance in ELBW babies this might be expected to
fall with increasing birth weight, but the highest proportion of babies is in the middle group,
which is difficult to explain and suggests that the use of hydrolysed formula may be related
to factors other than birth weight.
10.3.2 Severity of illness
In the retrospective review of feeding records, a number of additional factors were
independently associated with delay in feed initiation, including lower birth weight,
ventilation, acidosis, inotropic support and sedation. Systemic sepsis in preterm infants is
regarded as extremely significant and usually represents serious illness. A definite clinical
suspicion of severe infection in this group of babies can therefore be regarded as a marker of
severity of illness. Established sepsis is often characterised by hypotension and treatment
with inotropic drugs; these three factors are therefore closely related. However, low blood
pressure requiring treatment may occur for reasons other than infection. Canadian clinicians
appeared to be more likely to delay the introduction of feeds in the presence of any of these
three factors. Approximately half of the respondents to the postal survey highlighted the use
of inotropes as an independent reason to delay initiation or slow feed advancement. In
contrast, less than one quarter identified the other factors. Most of these factors in the babies
of <30 weeks of gestation appear to relate to early severity of illness and so may occur
together. The significant association of higher CRIB score with later feed initiation in these
babies supports this hypothesis. It is likely that many acutely unwell babies had feeds
delayed until greater stability was achieved. By the time feeds began to advance therefore, a
number of these factors were probably no longer present. However, continuing or renewed
need for respiratory support is probably a reasonable marker of severity of ongoing or new
illness. The effects of this appeared to influence the rate of advancement of feeds in the least
mature babies, with a greater need for either mechanical ventilation or nCPAP particularly
associated with slower feeding. In larger and more mature babies, ventilation and other
markers of illness were not associated with the time to attain full feeds and this is likely to be
due to smaller numbers of very sick babies in this group. Since these more mature babies
tend to be fed earlier and more rapidly, the relatively greater influence of other factors, such
as feed intolerance, in increasing time to full feeds is perhaps to be expected.
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10.3.3 Opiate sedation
The use of opiate sedation was associated with later initiation of feeding in babies with birth
weight >1250g. In years leading up to this study, the routine use of opiate sedation in very
preterm ventilated infants had become increasingly prominent despite the still sparse
evidence regarding either efficacy or safety435 436. The smallest and least mature babies often
require long periods of ventilation and it is likely that many of these infants would be
receiving sedation. Although this hypothesis was not investigated, it may explain the
inability to detect an association with feeding in these groups. In larger preterm babies,
sedation may be reserved for the sickest infants and the association with later feeding may
reflect this confounding. Although only a small proportion of clinicians in the postal survey
indicated that they would delay feeds solely because of sedation, it was the most highly
significant factor in babies of >1250g and an independent effect is plausible. Opiates are
known to slow gut motility437 and in neonates, this might increase gastric residual volumes, a
factor which was considered important by the majority of clinicians when making decisions
about feed progression. Morphine has been associated with delay in starting feeds in a
secondary analysis of data from the NEOPAIN (Neurologic Outcomes and Pre- emptive
Analgesia In Neonates) Trial of morphine versus placebo in preterm ventilated infants438.
Babies randomised to receive morphine started and achieved full feeds later and there was a
relationship between increasing doses of morphine and later feed initiation. This study also
found a statistically significant effect of opiate sedation on the time to full feeds, but this was
confined to infants of <28 weeks gestation and may be related to a greater ongoing need for
ventilation in this group.
10.3.4 IUGR and abnormal antenatal Doppler studies
Almost three quarters of the clinicians surveyed highlighted abnormal antenatal Doppler
studies and less commonly IUGR as reasons for delaying introduction of feeds. Even larger
proportions would slow the rate of increase in the presence of these factors. This is
unsurprising, since multiple small and large observational studies over many years have
shown an increased risk ofNEC in growth restricted infants88 98 439 and in particular in those
with absent or reversed end diastolic flow antenatally83 94 91. In the light of such studies,
recommendations have been made for cautious feeding in these infants440. In the review of
records, abnormal Doppler studies were related to later introduction of feeds overall
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although this did not reach statistical significance in the models for individual gestational
age bands. Abnormal antenatal Doppler studies were reported more commonly in UK than in
Canadian infants. Whilst the difference may be real, it is more likely that this relates to
inconsistent documentation of results of antenatal Doppler findings in neonatal medical
records and differences in obstetric practice in measuring umbilical vessel Doppler flow.
Variability in reporting was evident in both countries. Since maternal records were not
examined to ascertain the true number of women having this investigation, it is therefore
likely that the actual number may be higher in one or both countries and that the effect of
this on the timing of feed initiation may be greater than suggested. The finding that IUGR
babies started feeds earlier than AGA babies was surprising. However, since the majority of
growth restricted babies were in the highest gestational age band in both countries this may
be subject to confounding by gestational age. Neither IUGR nor abnormal Dopplers was
associated with an increased time to attain full feed volumes. In his prospective feeding trial,
Mihatsch also found no difference in either the time of starting feeds or rate of increase in
growth-restricted babies and concluded that it was unnecessary for special feeding protocols
to be developed for these babies251. However, from the survey of clinicians it seemed that
these were the commonest reasons for developing specific guidelines in both UK and
Canadian neonatal units. The recently completed ADEPT Trial is the first prospective
randomised controlled study to investigate the effects of different timing of introduction of
feeding in preterm growth restricted infants. Infants were fed on the second or sixth day of
life and feeds were increased according to a standardised regimen253 433. Preliminary reports
suggest no difference in adverse outcomes between the groups but early fed babies achieved
full feeds 3 days earlier than those fed late413.
10.3.5 Minimal enteral nutrition
In 1999, Kliegman stated that "gastrointestinal priming must now become the standard of
care for very low birth weight infants"441. Responses to the postal questionnaire indicated
that approximately 40-60% of UK neonatal units and 40-75% of Canadian units used a
defined MEN regimen, although details of these regimens were not sought. This is a
somewhat smaller proportion than indicated in the 2001 Australian190 and 2006 USA191
surveys, in which more than 80% of respondents said that they used MEN in ELBW and
extremely preterm infants. The intended duration of MEN reported in these surveys was
variable, suggesting that infants in these countries may receive MEN for between 0 and 15
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days. MEN was undefined in the American survey. In the Australian survey, three slightly
different definitions were used (encompassing volumes between 1ml and 30ml or
30ml/kg/day) reflecting current uncertainty about optimum practice. In this review of UK
and Canadian practice in 2004, the definition used was <25ml/kg/24 hours prior to attempts
to increase feed volumes; this falls within generally accepted parameters. Sixty-seven
percent of infants received MEN volumes for two or more days and the variation in the
duration of MEN observed was 1-16 days, similar to that reported in the previous survey.
This suggests that inconsistency may be widespread across all countries offering neonatal
intensive care to preterm infants and that clinical practice probably did not change
substantially between 2001 and 2006. It is notable, however, that the practice of MEN
appears to have been widely endorsed and adopted by clinicians despite lack of convincing
evidence of benefit and lack of consistent guidance on how to employ this strategy of
feeding. The endorsement of MEN in principle is clear from the reported intentions of
neonatal clinicians in three separate surveys. However, it is less certain that the results of the
retrospective review reflect a positive stance in clinical practice, as it is impossible to
ascertain how many infants were maintained on MEN volumes by intent and how many by
default because of failure in attempts to increase feeds or concerns about the clinical status
of infants. Without clear guidance based on sound evidence from large studies, decision¬
making is likely to differ between clinicians and to be based on the modest experience of any
individual clinician or neonatal unit of caring for a relatively small number of high-risk
infants.
A longer duration of low volume feeds would be expected to be associated with a longer
time to attain full feeds. The number of days of MEN was highly significantly associated
with slower feed advancement in infants >28 weeks, but did not quite reach statistical
significance in the least mature infants and it is likely that this may be due to smaller
numbers in this group and more consistent use of minimal feed volumes in higher risk
infants.
10.3.6 Signs of intra-abdominal pathology
Concerns about intra-abdominal pathology were not associated with the time of initiation of
feeds. Signs that would have prompted 60-90% of clinicians in the survey to delay feed
initiation were abdominal tenderness, large gastric aspirates, bloody stools and severe
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abdominal distension. Abdominal distension in preterm infants is common, and its
identification is highly subjective and subject to inter-observer variability, so although there
is a highly statistically significant difference in this between the two countries studied, this
finding may not be completely robust. The presence of abdominal signs before feeding
would be likely to indicate early NEC, bowel obstruction or other bowel pathology, but none
of these were recorded as being present in the infants studied. In contrast, and as expected,
the presence of signs of intra-abdominal pathology explained much of the variation in the
time taken for babies to reach full feeds. Variables showing strongest associations in the
entire group of babies were large or bilious aspirates, abdominal distension and Stage I NEC,
all of which are closely related indicators of potential intra-abdominal pathology, and which
substantial numbers of clinicians highlighted in the postal survey. In this analysis, gastric
aspirate volumes of >2ml were regarded as "large", although responses from clinicians to the
survey question indicated that many would have lower or higher thresholds than this for
slowing or discontinuing feeds. It may be that clinicians make judgements based on the
cumulative effects of a number of indicators, or that the significance of gastric aspirate
volumes are more related to the size or gestation of the baby in question. Analysis according
to gestational age bands showed a gradient in the time to full feeds from the most to the least
immature and signs of abdominal pathology were significantly associated with increasing
time to full feeds across all gestational ages. Whilst other factors previously mentioned were
more significant in the lowest gestational age band, the influence of gastric residuals and
abdominal distension became more significant with increasing gestational age and in infants
>30 weeks of gestation, all significant contributors to the regression model were related to
feeding practice or to potential signs of gut pathology. Reasons for this are speculative, but
may include earlier and more rapid feeding in larger and more mature preterm infants with
associated feed intolerance, a relatively lower occurrence of other pathologies such as
respiratory illness in this group or differences in clinical practice between centres. It is also
possible that the effect may be exerted by a small number of unusual infants, although
examination of outliers for all parameters did not reveal any factors that suggested that
exclusion from analysis was necessary.
The importance of gastric residual volumes as a sign of gastrointestinal pathology has been
289 291 293debated" " and it has been suggested that volumes of up to 5ml may not be significant
in indicating feed intolerance290. There is no consensus on what constitutes a significant
residual volume, limited understanding of what it represents and little guidance on the
appropriate management in the presence of large residual volumes442. Nevertheless, the
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presence of gastric aspirates in excess of 2ml was the factor highlighted most consistently by
clinicians in both the UK and Canada as a reason to slow or discontinue feeds. In the review
of infant feeding it was very significantly associated with later attainment of full feeds.
Large or bilious gastric aspirates were the most common reasons for discontinuation of
enteral feeds in infants receiving either advancing or full feed volumes and affected the
largest proportion of infants in the study.
10.3.7 Feed volumes and frequency
Responses to the postal survey indicated wide variation in the volume and frequency of milk
given at the time of feed initiation. The review of clinical practice showed similar variation
that encompassed the range of volumes and frequencies suggested by respondents to the
survey. Standardised regimens that have been reported are few and not all authors have
specified feed volumes and frequency used. Brown and Sweet gave 2, 3 or 4ml sterile water
at 2 hourly intervals, depending on birth weight213; Kamitsuka et al used 3 - 4 ml breast milk
or diluted formula every 3 hours ; Patole et al used 0.5-lml every hour ; Kuzma-O'Reilly
et al suggested "small bolus feedings at intervals of every 3 to 8 hours"218; Spritzer et al are
unclear about volumes and frequency of feeds in their report214. In this survey, the largest
proportion of clinicians (60%) stated that they would use volumes of 0.5-lml and the most
common frequency suggested was hourly (47%). However, variation did not appear to be
strongly related to the influence of birth weight, gestation or severity of illness. In the
absence of published guidance on this aspect of feeding, it seems likely that such variation
results from personal experience or usual practice in units, as well as from consideration of
other risk factors in individual infants and availability of maternal breast milk during the first
few days of feeding.
10.3.8 Other factors
Data for other factors that have less commonly been associated with NEC and differences in
feeding practice were also collected. Others have noted differences in feed tolerance and the
time to achieve full feeds between babies receiving continuous feeds or bolus feeds, although
1 so ton 1H7
study results have been conflicting " . No association was seen in this study, but the
number of babies fed continuously was small. Transpyloric feeding has also been previously
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examined with respect to feed tolerance and weight gain304"306, but in this study, no baby was
fed using this method. Since others have also shown adverse effects with transpyloric
feeding308"312, this finding probably reflects the decreased use of this method in preterm
infants in the light of evidence. However, anecdotal reports suggest that in some centres
transpyloric feeding is still used in babies with refractory feeding tolerance, so it may be that
this survey of a relatively small number of neonatal units does not fully reflect current
practice.
10.4 Feed intolerance and gastro-oesophageal reflux
Clinicians participating in the postal survey were not questioned about their practice with
respect to gastro-oesophageal reflux. However, in the light of reports that, despite a dearth of
evidence of efficacy or safety, drug treatment for this condition was common in neonatal
units3'5 329, data for the use of anti-reflux medications were collected. This confirmed that all
of these medications were prescribed amongst babies in this study. H2 receptor antagonists
were the most commonly prescribed and were used in 10-11% of babies. However, patterns
of prescribing differed between the two countries and details of these differences are
described in a later section.
10.5 Necrotising enterocolitis
Stage II or stage III NEC affected 4.4% of babies in this study. This proportion is in line with
other reports that range from 3% to 18%65 69 245 443. Stage II disease occurred in almost 2% of
babies and Stage III in 2.5%. Mortality among infants who developed NEC was 32%, but
that due directly to NEC was 28.5% compared with 10% in infants who did not develop
NEC. This proportion of deaths also falls within previously reported range of 12-50%64 66 69
443 444
stucjy confirms the most significant findings of other studies, that the rate of
NEC is inversely proportional to gestation at birth and birth weight. It also demonstrates an
association between NEC and increased severity of illness. There was an association
between NEC and IUGR, but not the presence of abnormal Doppler studies although, as
discussed previously, the number of babies with abnormal dopplers may be underestimated
in one or both groups.
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The single factor that has been suggested to reduce the risk of NEC is the use of EBM for
early enteral feeding. A number of studies found that any breast milk was protective and that
increasing proportions of feed given as breast milk increased the protective effect. However,
the results of this study do not support those findings
There was no significant increase in NEC in babies with a PDA or those treated with
indomethacin. In contrast to other studies, NEC was associated with later initiation of feeds
and a longer time to progress to full feeds. Studies examining the relationship between
umbilical catheterisation and NEC have shown variable results, with some showing a strong
association and others no relationship. In this study, on univariate analysis, there was a
significant relationship between increasing duration of umbilical catheterisation with UVC
or UAC, but the relationship was stronger with UAC. Some have suggested that UACs
should be removed after a maximum of 5-7 days or before commencing enteral feeds, but
others have refuted this recommendation. In this study, nine infants were fed with a UAC in
place and seven infants had UACs for eight or more days. In a further 11 babies, UACs were
removed on the first day of feeding. Although this association supports the findings of other
studies, also in common with other studies, numbers of infants were small and this may
represent a Type II error. In a logistic regression analysis including gestational age, infants
of lower gestation and those who had a shorter period ofMEN had significantly increased
odds of developing NEC, while those who took longer to reach full feeds and those who
received indomethacin had decreased odds. The presence of umbilical catheters was not
significantly associated after adjustment for other factors. The association with shorter
duration of MEN supports the findings of Henderson et al187 who showed a similar
relationship in their case-control study. Although more rapid feeding has been proposed as a
factor that increases the risk of NEC, this is not seen in the study. The rate of increase of
feeds was not studied specifically and it may be that this is more related to the occurrence of
NEC than the time to reach full enteral feeds, which also includes the period of minimal
enteral nutrition.
Infants with stage II and III disease were similar in all characteristics except the rate of feed
advancement. Infants who developed stage III NEC had been fed significantly more rapidly
than those with stage II disease and on average achieved full feeds within approximately half
the number of days. This is intriguing and is supportive of others' findings that NEC is
associated with more rapid feed advancement, although few have reported differences
between the stages of NEC. The fact that rate of feed advancement was not more rapid in
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infants with either stage ofNEC compared with those without NEC suggests that this may be
a spurious finding more related to small numbers or outliers. Elowever, it is interesting to
note that, while many researchers are urging caution in the rate of advancement of feeds in
high-risk babies, in this study, 95 (14%) babies of <30 weeks of gestation reached full feeds
by the tenth day of life and 50 (7.5%) advanced to full feed volumes in seven days or less.
The small number of infants developing NEC meant that further analysis with adjustment for
other relevant factors was not appropriate.
10.6 Reported and actual clinical practice
There are few opportunities to determine to what extent clinicians' day-to-day practice
reflects their opinions of optimum practice. Although the retrospective review of practice
involved only a limited number of neonatal units, these were felt to be representative of
practice generally in the UK and Ontario, although perhaps not the whole of Canada. The
postal survey sought opinion from every clinician and in spite of the modest response rate,
most neonatal units were represented suggesting that the responses obtained generally reflect
the variation of opinion within the whole body of neonatologists.
Clinician opinion is influenced by many different factors including awareness of published
evidence, previous personal experience and education, anecdote and, where guidelines are in
place, consensus between fellow clinicians. Whether these opinions translate into practice
that is reflective of the opinion depends on a further large number of factors that are related
to the condition of individual babies, the beliefs and opinions of the babies' parents and
external influences within neonatal units such as availability of staff, equipment and drugs.
Some of these factors, such as the prescription of drugs or the use of different feeds are
within the control of the clinician, but others, such as change in a baby's condition are to
greater or lesser extents, not amenable to change.
In spite of the fact that, in this survey, the use of written guidance was sparse and knowledge
of the availability of guidelines was inconsistent, clinicians were willing to report their usual
practice and personal opinions with respect to feeding of preterm infants. Results indicated
wide variation, but for some areas of practice, agreement of opinions was almost 100%.
Since the fear ofNEC seems to be universally instrumental in guiding feeding practice, it is
not surprising that such agreement was most clearly evident in consideration of signs
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indicative of suspected or proven NEC. Interestingly, for most areas of practice only small
proportions of clinicians identified factors that would influence their decision-making. The
fact that such a wide range of factors was felt to be important by between 3% and 90% of
clinicians shows the broad range of influences on feeding. Although there were differences
in the proportion of clinicians identifying factors as important influences, broadly speaking,
there was a large amount of agreement within the body of clinicians from each country.
Many of these opinions were in fact reflected in the observed clinical practice. Perhaps the
clearest reflection of opinion in practice is seen in the extremes of practice and where
opinion appears to differ significantly between countries. Examples of this are in the
management of feeds in babies receiving indomethacin or blood transfusion, where both
opinion and practice are confined to only one country.
Broad variation in opinion exists, and it appears that this does translate directly into similar
variation in clinical practice. This supports the hypothesis at the start of the study. Where
extremes exist, clinicians do not appear to think and act in isolation, but rather a particular
practice is seen to be part of the practice of a small number of clinicians as part of a whole
spectrum. It is likely that the variation seen does, therefore, represent the differing views and
intentions of clinicians rather than unplanned and unpredictable behaviour. This is reassuring
in that neonatal feeding is subject to some common 'rules' and consistency, although given
the wide variation and lack of evidence, it is sometimes difficult to understand on what basis
these 'rules' are founded.
10.7 Comparison between UK and Canadian practice
This is the first detailed comparison of feeding practice between two countries. Some
interesting differences were seen between the UK and Canadian clinicians, both in the
response to the postal survey and in the observational study of clinical practice.
A number of differences between the two countries were seen for the occurrence at the start
of feeding of a number of factors that might indirectly or directly affect initiation,
advancement or discontinuation of enteral feeds (Table x.x). These differences may reflect
differences in the population of babies or systematic differences in practice. The larger
number of Canadian infants having mechanical ventilation and requiring umbilical catheters
may reflect either greater severity of illness in the Canadian group, or difference in clinical
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management of respiratory disease. Similarly, the difference in PDA may relate either to
lower gestational age or the availability of echocardiography to make the diagnosis. In
contrast, the use of sedation and indomethacin are likely to reflect true differences in clinical
practice between the countries. In particular, the figures for PDA and indomethacin use in
Canada suggest that some infants were treated prophylactically. Although no information
was specifically obtained about indomethacin doses and whether short or prolonged courses
were given, inspection of the data suggests that indomethacin more likely to be given earlier
and for shorter, but sometimes repeated courses in comparison with practice in the UK.
Forty percent of Canadian clinicians reported that they would delay feeds whilst awaiting
breast milk for only 24 hours or less, compared with only 20% of UK clinicians who, on
average, reported that they would be more likely to delay for longer periods of time.
Interestingly however, UK infants were more likely than Canadian infants both to be fed
earlier and to receive EBM as their first feed, suggesting that this intention may be
aspirational rather than feasible in Canada. No Canadian clinician said that they would
preferentially use DEBM in this circumstance, reflecting the lack of availability of banked
donated EBM in Canada compared with the UK. Whilst 3.5% (n=9) of UK clinicians
spontaneously responded that they would be guided by parents' wishes, this was not stated
by any in Canada.
UK clinicians suggested that they were more likely than Canadian clinicians both to delay
feed introduction and slow the rate of advancement for babies with absent or reversed end
diastolic flow. A greater proportion of Canadian clinicians reported that they would delay,
slow or discontinue feeds for babies having pharmacological paralysis and indomethacin
treatment. No Canadian clinician cited blood transfusion as a reason to change feeding
regimens. However, 6% ofUK clinicians surveyed would do this and 9% would discontinue
feeds. Although only small proportions in both countries would be influenced by the use of
sedation, a greater proportion of Canadian than UK clinicians reported delaying and slowing
feeds in sedated infants. Whilst there was agreement with respect to most indicators of
abdominal pathology, a greater proportion would delay, slow or discontinue feeds in the
presence of mild abdominal distension in the UK than in Canada. Larger proportions ofUK
than Canadian clinicians would interrupt enteral feeding in infants displaying signs of
respiratory distress or requiring mechanical ventilation.
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The effect of differences in practice by country of neonatal care was evident in the
retrospective review of medical records. Regression analysis confirmed that Canadian
infants started feeds later than infants in UK units and that this was significant independent
effect, even after controlling for birth weight and other potentially influencing factors. This
was in keeping with the hypothesis. Analysis by gestational age band further explored the
influence of international differences and this suggested that differences in clinical practice
might have exerted a greater effect in more mature infants. In the absence of documented
reasons for delay in initiation of feeds, it is difficult to untangle individual effects that may
represent fundamental differences in practice. Although the effect of country accounted for
only approximately 3% of the variation in timing of feed initiation, this may nevertheless be
a clinically significant effect.
Infants in Canadian centres progressed from first to full enteral feeds significantly more
slowly than UK infants and this was in keeping with expectation. This also showed
significance in the regression model, but again, the largest effect of country was exerted in
the most mature babies although the effect approached statistical significance in the least
mature babies. Contributors to this variation can be identified from examination of the
documented reasons for delaying discontinuing either during minimal or advancing feeds.
The most striking differences between the countries mirror the reports of respondents to the
survey. Feeds were much more likely to be discontinued during indomethacin treatment in
Canadian compared with UK infants both during minimal feeding (46.7% v 3.8%) and
advancing feeds (17.5% v 2.6%). A greater proportion of Canadian infants also had feeds
discontinued for suspected sepsis (6.8 v 1.6). In the UK, clinicians stopped feeds for
abdominal distension during minimal feeding in a larger proportion of babies (24% v 4.4%)
although the proportions stopping feeds for this reason during advancement of feeds was
similar for both countries. No Canadian infant had feeds discontinued during blood
transfusion in contrast with almost 3% ofUK infants. UK clinicians also omitted feeds more
frequently in the absence of breast milk (8% compared with <1% in Canada). Similar
proportions of infants had feeds stopped for respiratory deterioration and neither sedation nor
paralysis was documented as a reason for feeds being stopped in data for either country.
Other factors did not substantially vary between the two countries.
Differences also emerged in patterns of feeding. As anticipated from the results of the
clinician survey, DEBM and hydrolysed protein formula were rarely used for Canadian
infants. In contrast, hydrolysed formula was commonly used in the UK and appeared to be
224
the feed of choice in some units where DEBM was not in use and where MEBM was
unavailable or insufficient. UK infants were more likely than Canadian infants to receive
EBM as their early feeds. However, this did not translate into a high proportion of infants
established on exclusive breast milk feeds as many changed to either mixed feeding or
exclusive preterm formula feeding shortly after attaining full feed volumes. Reasons for this
change were not documented, but since this pattern of feeding was more prominent in units
that did not use HMF in any of their babies, it seems most likely that it was to promote
weight gain. The perceived benefits of this over HMF are unclear, but the practice may have
other disadvantages in addition to the possible increased risk ofNEC. Provision of her breast
milk is often perceived by the mother of a preterm baby as a very basic and positive aspect
of care in an environment where the ability of a mother to care for her baby directly is
limited. Removing this opportunity may have adverse psychological effects on the mother
and send mixed or adverse messages about the importance and adequacy of her breast milk
for her baby.
Unexpectedly, the pattern of feeding in Canadian infants was completely different and
almost the reverse of that in the UK. Although many infants received a small amount of
formula at the start of enteral feeding, EBM was introduced early and the babies then
progressed to establish full feeds with EBM. This led to a greater proportion of Canadian
infants than UK infants establishing exclusive breast-feeding. Mixed feeding with EBM and
preterm formula during the first few days of life was uncommon in the UK. In contrast, a
large proportion of babies in Canadian centres received both types of feed from the outset.
As a result, a greater proportion of Canadian infants overall received some or all breast milk
during their neonatal stay. These differences are intriguing and difficult to explain based on
the limited evidence available for type of feed. One might speculate that maternal and/or
cultural elements play a part in this and it may reflect a greater desire to breast feed in
Canadian women, compared with UK women. Maternal details were not recorded so this
hypothesis cannot be explored. Differences in clinician attitudes might also explain these
differences. If so, this would perhaps suggest that UK clinicians are more focused on the
potential to reduce the risk of NEC or other pathology by early feeding with EBM, whereas
Canadian clinicians aim for the establishment of long-term breast-feeding. It is likely that
both might contribute in part, as may other unidentified reasons, but there is little evidence
that one approach or the other is better or leads to improved short- or long-term outcomes.
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Although infants in both the UK and Canada received treatment for gastro-oesophageal
reflux, patterns of prescribing were very different between the two countries. Gaviscon and
feed thickeners were not used in any Canadian infant, but were used in 14% and 3% of UK
infants respectively. Domperidone and H2 receptor antagonists were used slightly more
commonly in the UK, whereas metoclopramide was given to 3% of Canadian, compared
with no UK infants. Such differences in practice are not easy to explain and cannot simply
be ascribed to differences in availability of evidence or products. Although reasons can only
be speculative, it seems likely that differences emerge due to long-standing local practice or
to varying interpretation of evidence supporting or refuting different practices.
10.8 Implications of variation in clinical practice
The results of this survey confirms the findings of the Scottish pilot survey'2 that extensive
variation in clinical practice exists between and within neonatal units in the UK for almost
every area of enteral feeding and suggests that similar or greater variation exists between and
within different countries. Sources of variation are many and some of this is undoubtedly
related to the diverse and vulnerable population for which neonatologists care. Many of the
differences in practice are likely to have arisen with the rapid advancement of knowledge in
this relatively young specialty. Eagerness to enhance care and improve survival and long-
term outcomes of infants has led to the implementation of many different strategies without
the benefit of a strong evidence base, which would take many years to amass. Research that
has been conducted has struggled to show clear differences between methods, either due, on
many occasions, to small numbers or challenges in study design and methodology. Study
results can be interpreted in different ways and influences on practice are equally varied.
Uncertainty and confusion are common. Neonatal clinicians and teams therefore continue to
practice, in some cases using quite different methods, yet without any clearly demonstrable
differences in overall outcomes. It is difficult, therefore, to suggest that one or other feeding
strategy is optimum, or that another is suboptimal; one must ultimately ask the question of
whether changes and differences in detail of enteral feeding are worth investigating or
whether, in fact, there is little to be gained by manipulation of this kind. However, although
NEC is a rare illness affecting only a minority of an already small population, its devastating
effects are clear and it is one of the most striking inadequacies in our medical knowledge, in
terms of causation, prevention and management. Few clinicians would not consider the
impact of this disease when choosing the method of enteral feeding for a high-risk infant and
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it will continue to dominate clinical practice until our understanding of the disease is clearer.
Similarly, few researchers would pass by an opportunity to improve this understanding in
some way. The search for optimum feeding strategies for preterm infants is likely to
continue and until more robust evidence is produced, variation in practice between
individuals and institutions variation will exert effects on outcomes that are yet to be
effectively elucidated and measured, but that may have highly significant effects on
morbidity or mortality for individual infants or groups of infants.
10.9 Implications for future research
This survey was conducted in 2004, but there is little to suggest that feeding practice has
substantially changed or that large amounts of new evidence have become available since
that time. Indeed, similar questions are still debated today as then and the gaps in our
knowledge persist. The need for further research to guide clinical practice and minimise risk
in the most vulnerable infants remains. Important research questions are best answered with
large randomised controlled trials, yet such trials have been very few in the recent past.
Results from the recent ADEPT Trial433 will be a welcome addition to the body of
knowledge in the UK and this appropriately powered trial should provide useful and robust
information about timing of feed introduction in the highest risk growth restricted infants.
ADEPT began in the UK at around the same time as this survey was conducted and arms of
the study were chosen to reflect reported practice in a regional survey in the UK96. Are these
results, therefore, relevant for clinicians in other countries? This survey would suggest that
perhaps they are not; as this was one area of practice where clinicians from Canada reported
that they would not necessarily respond to the scenario of antenatally diagnosed absent or
reversed end diastolic flow in the same way as those in the UK. Are clinicians likely to
respond to published results of trials by changing their clinical practice? Clinicians in the UK
have invested a great deal of time and effort in supporting and participating in this trial, so
they are likely to seek out and modify practice on the basis of the results if appropriate. This
may not be the case internationally. Time will tell, but the enormous variation in both
opinion and practice, seen between and within units and countries in this survey, does not
suggest universal adherence either to published evidence or even to local guidelines where
either is available.
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Most importantly, for research to be taken seriously and for it to be successful in changing
practice it needs to ask unanswered questions that are important to large numbers of
clinicians and their patients. In addition, it needs to address the most important outcomes and
those that substantially influence clinical practice. The research methods need to be feasible
and the results as generalisable as possible. In no area of neonatology are these research
challenges greater than in enteral feeding. Perhaps one of the greatest challenges in modern
neonatal medicine is the prevention ofNEC. Advances in antenatal care and respiratory care
have led to prolonged survival of some of the highest risk infants, only for significant
numbers to die from the effects of NEC at a stage in their neonatal course when they are
more stable and, to their parents, appear to be "out of danger". We urgently need answers to
the question "How do we prevent or minimise the risk ofNEC in preterm neonates?" and it
is unlikely that any clinician in the world would dispute the importance of this.
However, surveys such as this serve to highlight the difficulties in conducting such research.
A review of the literature has demonstrated inconsistent or insufficient evidence for many
aspects of feeding. The survey of clinicians' feeding intentions indicates lack of awareness
of available evidence to guide practice, differences in opinions between clinicians in the
same neonatal unit, differences between countries and differences between neonatal units
within the same country. Is it surprising, therefore, that the retrospective review of practice
shows wide variation in feeding practice that broadly reflects these highly variable views?
Perhaps at the root of this problem lies the inconsistent and inadequate evidence, produced
by many years of small studies and observational studies (such as this) and inadequately
powered to provide robust answers to important questions. Consistent, however, are reports
of a large number of potential risk factors that may or may not increase the risk of NEC.
There is a need for large, adequately powered and well-designed randomised controlled trials
to examine the real contribution, if any, of many of these risk factors to the development of
NEC.
The main challenge lies in the fact that NEC is not a common disease, and even in the
preterm population can be regarded as a rare outcome. Many studies have included NEC as a
secondary outcome but few, if any have contained sufficient numbers of infants to be able to
detect a true difference in the occurrence of NEC between intervention groups. Surrogate
measures and short-term outcomes such as the time to full feeds, feed tolerance, and
occurrence of sepsis have been used in most studies, apparently to circumvent the challenge
of recruiting several thousand preterm neonates. Yet from the published literature and from
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the work presented in this thesis it seems that the relationship between these surrogate
measures and NEC is far from clear. Whilst these measures may be important in their own
right from a health economic or service provision perspective, these outcomes are not the
outcomes that "drive" clinical practice and the answers provided by such studies will lead
neither to clear guidance to refine practice nor to clear reassurance that change is
unnecessary.
Future trials should be collaborative and preferably international, acknowledging in the
design phase the range and variation in practice that is acceptable to clinicians to produce
trial arms that are relevant for the majority. Only using such methods will there be
widespread "buy-in" to the trials, which is key to the success and will also ensure maximum
impact of significant results in clinical practice after the research is completed. This does not
intend to suggest that this approach is straightforward and a great deal of planning is
required. Nevertheless, such collaboration and planning has proved possible in a number of
parallel trials currently examining oxygen target saturations in preterm infants and for which
a prospective meta-analysis is planned in order to provide sufficient power to answer with
confidence this important question. The UK406, Canada405, the USA and Australia445 are all
involved in this collaborative endeavour. Such an approach might prove helpful in
disentangling some of the most taxing dilemmas in enteral feeding in preterm neonates and
should address the outcome measures of NEC and/or death and neurodisability as the most
important short- and long-term outcomes associated with feeding.
Among potential trials of feeding practice, the effect of the rate of increase of feeds on NEC
is probably one of the most pressing issues to address. Rapid feeding has been implicated in
the causation of NEC by some researchers7 197 205 206 and the findings of this survey suggest
that there may be an association between the rate of feeding and severity of NEC. Others
207 208 * •have found no relationship"" . This survey also suggests that differences between
gestational age bands may warrant stratification of trials according to gestational age or birth
weight. Without such stratification, it would be challenging to determine appropriate arms
for this trial, as caution in the rate of advancement of feeds tends to increase with decreasing
gestation and birth weight. Whilst relatively small differences in rate of feed advancement
may be clinically significant and therefore appropriate to study, it may be challenging to
demonstrate a statistically significant difference in outcomes in the number of babies that
might feasibly be recruited, particularly at the lowest gestational ages. In contrast, widely
separated groups may be less likely to represent the range of usual practice and may
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therefore lack relevance for some clinicians or, more importantly, introduce additional risk at
the extremes of practice.
The timing of introduction of feeds has been addressed in the ADEPT trial of feeding in a
small group of high-risk growth restricted babies433. However, the vast majority of preterm
babies do not fall within this group and yet optimum feeding strategies for this much larger
and still vulnerable group remain unclear. It is unlikely that the results of the ADEPT Trial
are applicable in the wider group, as few clinicians would delay feeds for up to six days in
any but the sickest or highest risk infants. Equally, it appears that some do not routinely
introduce feeds within two days of birth. However, the clinician survey suggested that there
is a preference for earlier feeding among practising neonatologists, although this appears to
be difficult to achieve in practice. Clinical equipoise has probably been lost with respect to
the timing of introduction of feeds, and according to the retrospective review of practice,
feeds were generally given during the first three days of life. If this is universally the case,
any further study of this aspect of feeding is not warranted. Previous studies have suggested
that feeds were routinely started later in the USA188, although the most recent survey
suggests that here too, practice has changed191
The concept of MEN requires further study to determine whether there is any benefit from
this type of feeding. Clarity with respect to the optimum time to introduce MEN, optimum
volumes and optimum duration of MEN is required. Each of these aspects needs to be
studied in its own right, but collaboration between large numbers of units on an international
basis might allow investigation ofmore than one question within the same study framework.
The role ofMEBM is probably now established in routine practice. However, in the absence
of MEBM, other milks are used and although preterm milk has been quite extensively
studied, the appropriate roles of DEBM and hydrolysed protein formula have not been
explored in detail. Yet from this survey, it appears that both are commonly used as
substitutes for MEBM when this is not available. DEBM is currently only available to a
limited number of neonatal units. The introduction of new feeding practices on the basis of
limited evidence may lead to different risks or benefits, which may only be attributed with
certainty to the feeding within the context of a trial. Maintenance of current breast milk
banks and development of further banks should be supported by clear evidence of benefit
from the use of donated milk in high-risk infants and of acceptability to mothers of such
infants. A reasonable counter-argument might be that the considerable funds required to
230
support the processing ofDEBM could be redirected into provision of support for mothers to
begin, establish and maintain breast-feeding of their own infants, as the rates of early breast
milk expression in this study suggest that enhancement of this kind of support may be
needed.
Some neonatal units preferentially introduce preterm formula where babies' weight gain is
poor instead of supplementing MEBM with HMF. This approach has never been subjected to
trial and may have unidentified or unrecognised adverse or beneficial effects, which might
include a change in the risk of NEC. The use of HMF is, in itself controversial and well-
designed studies are required to determine the optimum time of introduction of feeds.
Although data for the timing of introduction of HMF have not been analysed, anecdotally,
most neonatal units introduce fortification of feeds once full milk feed volumes have been
attained. However, this approach is not evidence-based and trials to determine whether
earlier introduction of fortifier may confer benefits for growth without increasing the risk of
NEC.
The management of PDA clearly varies between clinicians, units and countries in the
absence of data from randomised controlled trials. Treatment with indomethacin contributes
enormously to the periods of feed discontinuation in spite of a lack of evidence for
protection against NEC or other bowel pathology with this approach. Similarly, blood
transfusion is managed very differently by different clinicians and centres and also accounts
for a substantial amount ofwithheld feeds in some units. Both of these are common elements
of routine neonatal care and therefore could form the basis of a randomised trial to determine
with certainty whether feed discontinuation is of true benefit or whether the risks of
increased need for central lines and subsequent sepsis might negate any possible benefit.
These suggested trials represent only a small proportion of those that are required, but are
probably the most important and the most likely to produce results that might benefit the
maximum numbers of babies. Other potentially important interventions including the use of
probiotics that are linked to feeding practice, but not addressed in this study are currently
under trial. Alternative methodologies such as large, well-designed prospective cohort
studies provide useful information about important outcomes, but are expensive and time-
consuming. NEC, as a rare outcome, might lend itself to studies using case-control
methodology. However, these are challenging to execute and evidence from these is
generally regarded as somewhat less robust than that from controlled trials.
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10.10 Summary
This study demonstrates that there is wide variation in both opinion and practice among
neonatal clinicians in the UK and Canada for most aspects of feeding in preterm and low
birth weight infants. It is unlikely that such variation is limited to these two countries and in
other parts of the world it may be even more striking. The effects of such variation on
important feed-related outcomes are unknown and require further investigation to define
optimum strategies to maximise benefit in terms of growth, nutrition and long term
neurodevelopmental outcome, whilst minimising the risk of significant morbidity and
mortality associated with NEC and infection. Important research questions remain
unanswered with respect to the rate of advancement of enteral feeds, timing, volume and
duration of MEN and clarification of the relationship between various therapies and NEC.
The most robust way of answering such questions is with large randomised controlled trials
which may need to be organised on an international scale to produce high quality
information to guide clinical practice in the future.
232
REFERENCES
1. Boyle EM. Scottish Neonatal Feeding Survey: A survey of practice in feeding of preterm
and very low birth weight infants in neonatal units in Scotland. University of Edinburgh,
2003.
2. Boyle EM, Menon G, Elton R, Mcintosh N. Variation in feeding practice in preterm and
low birth weight infants in Scotland. Early Hum Dev 2004;77:125-6.
3. Stoll BJ. Epidemiology of necrotizing enterocolitis. Clin Perinatol 1994;21 (2):205-18.
4. Palmer SR, Thomas SJ, Cooke RW, Low DC, Fysh WJ, Murphy JF, et al. Birthweight-
specific risk factors for necrotising enterocolitis. J Epidemiol Community Health
1987;41 (3):210-4.
5. Wilson R, del Portillo M, Schmidt E, Feldman RA, Kanto WP, Jr. Risk factors for
necrotizing enterocolitis in infants weighing more than 2,000 grams at birth: a case-control
study. Pediatrics 1983;71(1): 19-22.
6. Wiswell TE, Robertson CF, Jones TA, Tuttle DJ. Necrotizing enterocolitis in full-term
infants. A case-control study. Am JDis Child 1988; 142(5):532-5.
7. Uauy RD, Fanaroff AA, Korones SB, Phillips EA, Phillips JB, Wright LL. Necrotizing
enterocolitis in very low birth weight infants: biodemographic and clinical correlates.
National Institute of Child Health and Human Development Neonatal Research Network. J
Pediatr 1991; 119(4):630-8.
8. Yu VY, Joseph R, Bajuk B, Orgill A, Astbury J. Perinatal risk factors for necrotizing
enterocolitis. Arch Dis Child 1984;59(5):430-4.
9. Sibbons P, Spitz L, Van Velzen D. The use of animal models in the study of necrotizing
enterocolitis in the newborn. Semin Neonatol 1997;2:281-90.
10. Nankervis CA, Nowicki PT. Role of endothelin-1 in regulation of the postnatal intestinal
circulation. Am JPhysiol Gastrointest Liver Physiol 2000;278(3):G367-75.
11. Nankervis CA, Nowicki PT. Role of nitric oxide in regulation of vascular resistance in
postnatal intestine. Am JPhysiol 1995 ;268(6 Pt l):G949-58.
12. Nankervis CA, Giannone PJ, Reber KM. The neonatal intestinal vasculature:
contributing factors to necrotizing enterocolitis. Semin Perinatol 2008;32(2):83-91.
13. Nankervis CA, Schauer GM, Miller CE. Endothelin-mediated vasoconstriction in
postischemic newborn intestine. Am JPhysiol Gastrointest Liver Physiol 2000;279(4):G683-
91.
233
14. Ito Y, Doelle SM, Clark JA, Halpern MD, McCuskey RS, Dvorak B. Intestinal
microcirculatory dysfunction during the development of experimental necrotizing
enterocolitis. Pediatr Res 2007;61(2): 180-4.
15. van Elburg RM, Fetter WP, Bunkers CM, Heymans HS. Intestinal permeability in
relation to birth weight and gestational and postnatal age. Arch Dis Child Fetal Neonatal Ed
2003;88(l):F52-5.
16. Piena-Spoel M, Albers MJ, ten Kate J, Tibboel D. Intestinal permeability in newborns
with necrotizing enterocolitis and controls: Does the sugar absorption test provide guidelines
for the time to (re-)introduce enteral nutrition? JPediatr Surg 2001;36(4):587-92.
17. Shin CE, Falcone RA, Jr., Stuart L, Erwin CR, Warner BW. Diminished epidermal
growth factor levels in infants with necrotizing enterocolitis. JPediatr Surg 2000;35(2): 173-
6; discussion 77.
18. Otte JM, Kiehne K, Herzig KH. Antimicrobial peptides in innate immunity of the human
intestine. J Gastroenterol 2003;38(8):717-26.
19. Eckmann L. Innate immunity and mucosal bacterial interactions in the intestine. Curr
Opin Gastroenterol 2004;20(2):82-8.
20. Chen H, Xu Z, Peng L, Fang X, Yin X, Xu N, et al. Recent advances in the research and
development of human defensins. Peptides 2006;27(4):931-40.
21. Kliegman RM, Fanaroff AA. Neonatal necrotizing enterocolitis: a nine-year experience.
Am JDis Child 1981; 135(7): 603-7.
22. Meinzen-Derr J, Morrow AL, Hornung RW, Donovan EF, Dietrich KN, Succop PA.
Epidemiology of necrotizing enterocolitis temporal clustering in two neonatology practices.
JPediatr 2009; 154(5):656-61.
23. Wendelboe AM, Smelser C, Lucero CA, McDonald LC. Cluster of necrotizing
enterocolitis in a neonatal intensive care unit: New Mexico, 2007. Am J Infect Control 2009.
24. Frantz ID, 3rd, L'Heureux P, Engel RR, Hunt CE. Necrotizing enterocolitis. J Pediatr
1975;86(2):259-63.
25. Boccia D, Stolfi I, Lana S, Moro ML. Nosocomial necrotising enterocolitis outbreaks:
epidemiology and control measures. Eur JPediatr 2001; 160(6):3 85-91.
26. Gordon PV, Swanson JR, Attridge JT, Clark R. Emerging trends in acquired neonatal
intestinal disease: is it time to abandon Bell's criteria? JPerinatol 2007;27(11):661-71.
27. Sharma R, Hudak ML, Premachandra BR, Stevens G, Monteiro CB, Bradshaw JA, et al.
Clinical manifestations of rotavirus infection in the neonatal intensive care unit. Pediatr
Infect Dis J 2002;21(12): 1099-105.
234
28. Gerber AR, Hopkins RS, Lauer BA, Curry-Kane AG, Rotbart HA. Increased risk of
illness among nursery staff caring for neonates with necrotizing enterocolitis. Pediatr Infect
Dis 1985;4(3):246-9.
29. Sakata H, Yoshioka H, Fujita K. Development of the intestinal flora in very low birth
weight infants compared to normal full-term newborns. Eur JPediatr 1985; 144(2): 186-90.
30. Stark PL, Lee A. The microbial ecology of the large bowel of breast-fed and formula-fed
infants during the first year of life. JMedMicrobiol 1982; 15(2): 189-203.
31. Bjorkstrom MV, Hall L, Soderlund S, Hakansson EG, Hakansson S, Domellof M.
Intestinal flora in very low-birth weight infants. Acta Paediatr 2009;98(11): 1762-7.
32. Kosloske AM. Epidemiology of necrotizing enterocolitis. Acta Paediatr Suppl
1994;396:2-7.
33. Goldmann DA, Leclair J, Macone A. Bacterial colonization of neonates admitted to an
intensive care environment. JPediatr 1978;93(2):288-93.
34. Claud EC, Walker WA. Bacterial colonization, probiotics, and necrotizing enterocolitis.
J Clin Gastroenterol 2008;42 Suppl 2:S46-52.
35. Hoy C, Millar MR, MacKay P, Godwin PG, Langdale V, Levene ML Quantitative
changes in faecal microflora preceding necrotising enterocolitis in premature neonates. Arch
Dis Child 1990;65(10 Spec No): 1057-9.
36. de la Cochetiere MF, Piloquet H, des Robert C, Darmaun D, Galmiche JP, Roze JC.
Early intestinal bacterial colonization and necrotizing enterocolitis in premature infants: the
putative role of Clostridium. Pediatr Res 2004;56(3):366-70.
37. Petrosyan M, Guner YS, Williams M, Grishin A, Ford HR. Current concepts regarding
the pathogenesis ofnecrotizing enterocolitis. Pediatr Surg Int 2009;25(4):309-18.
38. Martin CR, Walker WA. Intestinal immune defences and the inflammatory response in
necrotising enterocolitis. Semin Fetal Neonatal Med 2006; 11(5):369-77.
39. Ewer AK, Al-Salti W, Coney AM, Marshall JM, Ramani P, Booth IW. The role of
platelet activating factor in a neonatal piglet model of necrotising enterocolitis. Gut
2004;53(2):207-13.
40. Hsueh W, Caplan MS, Sun X, Tan X, MacKendrick W, Gonzalez-Crussi F. Platelet-
activating factor, tumor necrosis factor, hypoxia and necrotizing enterocolitis. Acta Paediatr
Suppl 1994;396:11-7.
41. Rabinowitz SS, Dzakpasu P, Piecuch S, Leblanc P, Valencia G, Kornecki E. Platelet-
activating factor in infants at risk for necrotizing enterocolitis. JPediatr 200 l;138(l):81-6.
235
42. Caplan MS, Sun XM, Hseuh W, Hageman JR. Role of platelet activating factor and
tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. JPediatr 1990; 116(6):960-
4.
43. Caplan M, Hsueh W, Kelly A, Donovan M. Serum PAF acetylhydrolase increases during
neonatal maturation. Prostaglandins 1990;39(6):705-14.
44. Furukawa M, Narahara H, Yasuda K, Johnston JM. Presence of platelet-activating
factor-acetylhydrolase in milk. JLipid Res 1993 ;34(9): 1603-9.
45. Morecroft JA, Spitz L, Hamilton PA, Holmes SJ. Plasma interleukin-6 and tumour
necrosis factor levels as predictors of disease severity and outcome in necrotizing
enterocolitis. JPediatr Surg 1994;29(6):798-800.
46. Morecroft JA, Spitz L, Hamilton PA, Holmes SJ. Plasma cytokine levels in necrotizing
enterocolitis. Acta Paediatr Suppl 1994;396:18-20.
47. Jones CA, Cayabyab RG, Kwong KY, Stotts C, Wong B, Hamdan H, et al. Undetectable
interleukin (IL)-IO and persistent IL-8 expression early in hyaline membrane disease: a
possible developmental basis for the predisposition to chronic lung inflammation in preterm
newborns. Pediatr Res 1996;39(6):966-75.
48. Le T, Leung L, Carroll WL, Schibler KR. Regulation of interleukin-10 gene expression:
possible mechanisms accounting for its upregulation and for maturational differences in its
expression by blood mononuclear cells. Blood 1997;89(11 ):4112-9.
49. Moonen RM, Paulussen AD, Souren NY, Kessels AG, Rubio-Gozalbo ME, Villamor E.
Carbamoyl phosphate synthetase polymorphisms as a risk factor for necrotizing
enterocolitis. Pediatr Res 2007;62(2): 188-90.
50. Szebeni B, Szekeres R, Rusai K, Vannay A, Veres G, Treszl A, et al. Genetic
polymorphisms of CD 14, toll-like receptor 4, and caspase-recruitment domain 15 are not
associated with necrotizing enterocolitis in very low birth weight infants. J Pediatr
Gastroenterol Nutr 2006;42(l):27-31.
51. Ahrens P, Kattner E, Kohler B, Hartel C, Seidenberg J, Segerer H, et al. Mutations of
genes involved in the innate immune system as predictors of sepsis in very low birth weight
infants. Pediatr Res 2004;55(4):652-6.
52. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association
of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature
2001 ;411(6837):599-603.
53. Zouali H, Bonnard A, De Lagausie DL, Farnoux C, Aigrain Y, Cezard JP, et al.
CARD15/NOD2 is not a predisposing factor for necrotizing enterocolitis. Dig Dis Sci
2005;50(9): 1684-7.
236
54. Henderson G, Craig S, Baier RJ, Helps N, Brocklehurst P, McGuire W. Cytokine gene
polymorphisms in preterm infants with necrotising enterocolitis: genetic association study.
Arch Dis Child Fetal Neonatal Ed 2009;94(2):F 124-8.
55. Treszl A, Heninger E, Kalman A, Schuler A, Tulassay T, Vasarhelyi B. Lower
prevalence of IL-4 receptor alpha-chain gene G variant in very-low-birth-weight infants with
necrotizing enterocolitis. JPediatr Surg 2003;38(9): 1374-8.
56. Treszl A, Kocsis I, Szathmari M, Schuler A, Tulassay T, Vasarhelyi B. Genetic variants
of the tumour necrosis factor-alpha promoter gene do not influence the development of
necrotizing enterocolitis. Acta Paediatr 2001;90(10): 1182-5.
57. Santulli TV, Schullinger JN, Heird WC, Gongaware RD, Wigger J, Barlow B, et al.
Acute necrotizing enterocolitis in infancy: a review of 64 cases. Pediatrics 1975;55(3):376-
87.
58. Mizrahi A, Barlow O, Berdon W, Blanc WA, Silverman WA. Necrotizing Enterocolitis
in Premature Infants. JPediatr 1965;66:697-705.
59. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal
necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg
1978; 187( 1): 1 -7.
60. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria.
Pediatr Clin North Am 1986;33(1): 179-201.
61. BPSU. Neonatal NEC. In: Lynn R, Nicoll A, Guy M, editors. BPSU 11th Annual Report
1996/7. London: British Paediatric Surveillance Unit (BPSU), 1998.
62. Geffers C, Baerwolff S, Schwab F, Gastmeier P. Incidence of healthcare-associated
infections in high-risk neonates: results from the German surveillance system for very-low-
birthweight infants. JHosp Infect 2008;68(3):214-21.
63. Lee SK, McMillan DD, Ohlsson A, Pendray M, Synnes A, Whyte R, et al. Variations in
practice and outcomes in the Canadian NICU network: 1996-1997. Pediatrics
2000; 106(5): 1070-9.
64. Sankaran K, Puckett B, Lee DS, Seshia M, Boulton J, Qiu Z, et al. Variations in
incidence of necrotizing enterocolitis in Canadian neonatal intensive care units. J Pediatr
Gastroenterol Nutr 2004;39(4):366-72.
65. Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, et al. Association of
H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight
infants. Pediatrics 2006;117(2):el37-42.
66. Holman RC, Stoll BJ, Curns AT, Yorita KL, Steiner CA, Schonberger LB. Necrotising
enterocolitis hospitalisations among neonates in the United States. Paediatr Perinat
Epidemiol 2006;20(6):498-506.
237
67. Horbar JD, Badger GJ, Carpenter JH, Fanaroff AA, Kilpatrick S, LaCorte M, et al.
Trends in mortality and morbidity for very low birth weight infants, 1991-1999. Pediatrics
2002; 110( 1 Pt 1): 143-51.
68. Luig M, Lui K. Epidemiology of necrotizing enterocolitis—Part I: Changing regional
trends in extremely preterm infants over 14 years. J Paediatr Child Health 2005;41 (4): 169-
73.
69. Luig M, Lui K. Epidemiology of necrotizing enterocolitis—Part II: Risks and
susceptibility of premature infants during the surfactant era: a regional study. J Paediatr
ChildHealth 2005;41(4): 174-9.
70. Aschner JL, Deluga KS, Metlay LA, Emmens RW, Hendricks-Munoz KD. Spontaneous
focal gastrointestinal perforation in very low birth weight infants. J Pediatr
1988; 113(2):364-7.
71. Stoll BJ, Kanto WP, Jr., Glass RI, Nahmias AJ, Brann AW, Jr. Epidemiology of
necrotizing enterocolitis: a case control study. JPediatr 1980;96(3 Pt 1):447-51.
72. De Curtis M, Paone C, Vetrano G, Romano G, Paludetto R, Ciccimarra F. A case control
study of necrotizing enterocolitis occurring over 8 years in a neonatal intensive care unit.
Eur JPediatr 1987; 146(4):398-400.
73. Kanto WP, Jr., Wilson R, Breart GL, Zierler S, Purohit DM, Peckham GJ, et al. Perinatal
events and necrotizing enterocolitis in premature infants. Am JDis Child 1987; 141 (2): 167-9.
74. Lui K, Nair A, Giles W, Morris J, John E. Necrotizing enterocolitis in a perinatal centre.
J Paediatr Child Health 1992;28(l):47-9.
75. Guthrie SO, Gordon PV, Thomas V, Thorp JA, Peabody J, Clark RH. Necrotizing
enterocolitis among neonates in the United States. JPerinatol 2003;23(4):278-85.
76. Sharma R, Hudak ML, Tepas JJ, 3rd, Wludyka PS, Marvin WJ, Bradshaw JA, et al.
Impact of gestational age on the clinical presentation and surgical outcome of necrotizing
enterocolitis. JPerinatol 2006;26(6):342-7.
77. Beeby PJ, Jeffery H. Risk factors for necrotising enterocolitis: the influence of
gestational age. Arch Dis Child 1992;67(4 Spec No):432-5.
78. Lubchenco LO, Hansman C, Dressier M, Boyd E. Intrauterine Growth as Estimated from
Liveborn Birth-Weight Data at 24 to 42 Weeks of Gestation. Pediatrics 1963;32:793-800.
79. Van den Berg BJ, Yerushalmy J. The relationship of the rate of intrauterine growth of
infants of low birth weight to mortality, morbidity, and congenital anomalies. J Pediatr
1966;69(4):531-45.
238
80. Dobson PC, Abell DA, Beischer NA. Mortality and morbidity of fetal growth
retardation. Aust N Z J Obstet Gynaecol 1981 ;21 (2):69-72.
81. Starfield B, Shapiro S, McCormick M, Bross D. Mortality and morbidity in infants with
intrauterine growth retardation. JPediatr 1982; 101(6):978-83.
82. Koops BL, Morgan LJ, Battaglia FC. Neonatal mortality risk in relation to birth weight
and gestational age: update. JPediatr 1982; 101 (6):969-77.
83. Hackett GA, Campbell S, Gamsu H, Cohen-Overbeek T, Pearce JM. Doppler studies in
the growth retarded fetus and prediction of neonatal necrotising enterocolitis, haemorrhage,
and neonatal morbidity. Br MedJ (Clin Res Ed) 1987;294(6563): 13-6.
84. Kempley ST, Gamsu HR, Vyas S, Nicolaides K. Effects of intrauterine growth
retardation on postnatal visceral and cerebral blood flow velocity. Arch Dis Child
1991 ;66(10 Spec No): 1115-8.
85. Maruyama K, Koizumi T. Superior mesenteric artery blood flow velocity in small for
gestational age infants of very low birth weight during the early neonatal period. J Perinat
Med 2001;29(l):64-70.
86. Simchen MJ, Beiner ME, Strauss-Liviathan N, Dulitzky M, Kuint J, Mashiach S, et al.
Neonatal outcome in growth-restricted versus appropriately grown preterm infants. Am J
Perinatol 2000;17(4):187-92.
87. Gilbert WM, Danielsen B. Pregnancy outcomes associated with intrauterine growth
restriction. Am J Obstet Gynecol 2003; 188(6): 1596-9; discussion 99-601.
88. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and
mortality among premature neonates. Am J Obstet Gynecol 2004; 191(2):481-7.
89. Pena IC, Teberg AJ, Finello KM. The premature small-for-gestational-age infant during
the first year of life: comparison by birth weight and gestational age. J Pediatr
1988;113(6): 1066-73.
90. Adiotomre PN, Johnstone FD, Laing IA. Effect of absent end diastolic flow velocity in
the fetal umbilical artery on subsequent outcome. Arch Dis Child Fetal Neonatal Ed
1997;76(l):F35-8.
91. Malcolm G, Ellwood D, Devonald K, Beilby R, Henderson-Smart D. Absent or reversed
end diastolic flow velocity in the umbilical artery and necrotising enterocolitis. Arch Dis
Child 1991 ;66(7 Spec No):805-7.
92. Karsdorp VH, van Vugt JM, van Geijn HP, Kostense PJ, Arduini D, Montenegro N, et al.
Clinical significance of absent or reversed end diastolic velocity waveforms in umbilical
artery. Lancet 1994;344(8938): 1664-8.
239
93. Kirsten GF, van Zyl N, Smith M, Odendaal H. Necrotizing enterocolitis in infants born
to women with severe early preeclampsia and absent end-diastolic umbilical artery doppler
flow velocity waveforms. Am JPerinatol 1999; 16(6):309-14.
94. Muller-Egloff S, Strauss A, Spranger V, Genzel-Boroviczeny O. Does chronic prenatal
Doppler pathology predict feeding difficulties in neonates? Acta Paediatr 2005;94(11): 1632-
7.
95. Soregaroli M, Bonera R, Danti L, Dinolfo D, Taddei F, Valcamonico A, et al. Prognostic
role of umbilical artery Doppler velocimetry in growth-restricted fetuses. J Matern Fetal
Neonatal Med 2002; 11(3): 199-203.
96. Dorling J, Kempley S, Leaf A. Feeding growth restricted preterm infants with abnormal
antenatal Doppler results. Arch Dis Child Fetal Neonatal Ed 2005;90(5):F359-63.
97. Kamoji VM, Dorling JS, Manktelow B, Draper ES, Field DJ. Antenatal umbilical
Doppler abnormalities: an independent risk factor for early onset neonatal necrotizing
enterocolitis in premature infants. Acta Paediatr 2008;97(3):327-31.
98. Manogura AC, Turan O, Kush ML, Berg C, Bhide A, Turan S, et al. Predictors of
necrotizing enterocolitis in preterm growth-restricted neonates. Am J Obstet Gynecol
2008; 198(6):638 el-5.
99. Flansen JD, Smith CA. Effects of withholding fluid in the immediate postnatal period.
Pediatrics 1953; 12(2):99-113.
100. Bauman WA. Early feeding of dextrose and saline solution to premature infants.
Pediatrics 1960;26:756-61.
101. Wennberg RP, Schwartz R, Sweet AY. Early versus delayed feeding of low birth
weight infants: effects on physiologic jaundice. JPediatr 1966;68(6):860-6.
102. Smallpeice V. The Immediate Feeding of Babies Weighing 1,000-2,000 G with Breast
Milk. Proc R Soc Med 1964;57:1173-5.
103. Wu PY, Teilmann P, Gabler M, Vaughan M, Metcoff J. "Early" versus "late" feeding of
low birth weight neonates: effect on serum bilirubin, blood sugar, and responses to glucagon
and epinephrine tolerance tests. Pediatrics 1967;39(5):733-9.
104. Flowie PW. Protective effect of breastfeeding against infection in the first and second
six months of life. Adv Exp Med Biol 2002;503:141-7.
105. Pisacane A, Graziano L, Mazzarella G, Scarpellino B, Zona G. Breast-feeding and
urinary tract infection. JPediatr 1992; 120( l):87-9.
240
106. Oddy WH, Holt PG, Sly PD, Read AW, Landau LI, Stanley FJ, et al. Association
between breast feeding and asthma in 6 year old children: findings of a prospective birth
cohort study. BMJ 1999;319(7213):815-9.
107. Saarinen UM, Kajosaari M. Breastfeeding as prophylaxis against atopic disease:
prospective follow-up study until 17 years old. Lancet 1995;346(8982): 1065-9.
108. Anderson JW, Johnstone BM, Remley DT. Breast-feeding and cognitive development:
a meta-analysis. Am J Clin Nutr 1999;70(4):525-35.
109. Henderson G, Anthony MY, McGuire W. Formula milk versus maternal breast milk for
feeding preterm or low birth weight infants. Cochrane Database Syst Rev
2007(4):CD002972.
110. Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Wright LL, Langer JC, et al.
Beneficial effects of breast milk in the neonatal intensive care unit on the developmental
outcome of extremely low birth weight infants at 18 months of age. Pediatrics
2006; 118( 1 ):e 115-23.
111. Tanaka K, Kon N, Ohkawa N, Yoshikawa N, Shimizu T. Does breastfeeding in the
neonatal period influence the cognitive function of very-low-birth-weight infants at 5 years
of age? Brain Dev 2008.
112. Furman L, Wilson-Costello D, Friedman H, Taylor HG, Minich N, Hack M. The effect
of neonatal maternal milk feeding on the neurodevelopmental outcome of very low birth
weight infants. JDev Behav Pediatr 2004;25(4):247-53.
113. Lucas A, Cole TJ. Breast milk and neonatal necrotising enterocolitis. Lancet
1990;336(8730): 1519-23.
114. Dugdale A. Breast milk and necrotising enterocolitis. Lancet 1991 ;337(8738):435-6.
115. Lucas A, Morley R, Cole TJ, Gore SM. A randomised multicentre study of human milk
versus formula and later development in preterm infants. Arch Dis Child Fetal Neonatal Ed
1994;70(2):F 141-6.
116. Lucas A, Morley R, Cole TJ. Randomised trial of early diet in preterm babies and later
intelligence quotient. BMJ 1998;317(7171):1481-7.
117. Furman L, Taylor G, Minich N, Hack M. The effect of maternal milk on neonatal
morbidity of very low-birth-weight infants. Arch Pediatr Adolesc Med 2003 ;157(1):66-71.
118. Schanler RJ, Lau C, Hurst NM, Smith EO. Randomized trial of donor human milk
versus preterm formula as substitutes for mothers' own milk in the feeding of extremely
premature infants. Pediatrics 2005; 116(2):400-6.
241
119. Meinzen-Derr J, Poindexter B, Wrage L, Morrow AL, Stoll B, Donovan EF. Role of
human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. J
Perinatol 2009;29(l):57-62.
120. AAP. Breastfeeding and the use of human milk. American Academy of Pediatrics.
Work Group on Breastfeeding. Pediatrics 1997; 100(6): 1035-9.
121. Wight NE. Donor human milk for preterm infants. JPerinatol 2001;21(4):249-54.
122. McCann JC, Ames BN. Is docosahexaenoic acid, an n-3 long-chain polyunsaturated
fatty acid, required for development of normal brain function? An overview of evidence
from cognitive and behavioral tests in humans and animals. Am J Clin Nntr 2005;82(2):281-
95.
123. Hoffman DR, Boettcher JA, Diersen-Schade DA. Toward optimizing vision and
cognition in term infants by dietary docosahexaenoic and arachidonic acid supplementation:
a review of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids
2009;81 (2-3): 151-8.
124. Bokor S, Koletzko B, Decsi T. Systematic review of fatty acid composition of human
milk from mothers of preterm compared to full-term infants. Ann Nutr Metab
2007;51(6):550-6.
125. Bitman J, Wood L, Hamosh M, Hamosh P, Mehta NR. Comparison of the lipid
composition of breast milk from mothers of term and preterm infants. Am J Clin Nutr
1983 ;38(2):300-12.
126. Luukkainen P, Salo MK, Nikkari T. Changes in the fatty acid composition of preterm
and term human milk from 1 week to 6 months of lactation. J Pediatr Gastroenterol Nutr
1994; 18(3):355-60.
127. Genzel-Boroviczeny O, Wahle J, Koletzko B. Fatty acid composition of human milk
during the 1st month after term and preterm delivery. Eur JPediatr 1997; 156(2): 142-7.
128. Rueda R, Ramirez M, Garcia-Salmeron JL, Maldonado J, Gil A. Gestational age and
origin of human milk influence total lipid and fatty acid contents. Ann Nutr Metab
1998;42(1): 12-22.
129. Kovacs A, Funke S, Marosvolgyi T, Burus I, Decsi T. Fatty acids in early human milk
after preterm and full-term delivery. JPediatr Gastroenterol Nutr 2005;41(4):454-9.
130. Barros MD, Carneiro-Sompaio MM. Milk composition of low birth weight infants'
mothers. Acta Paediatr Scand 1984;73(5):693-4.
131. Lepage G, Collet S, Bougie D, Kien LC, Lepage D, Dallaire L, et al. The composition
of preterm milk in relation to the degree of prematurity. Am J Clin Nutr 1984;40(5): 1042-9.
242
132. Anderson GH, Atkinson SA, Bryan MH. Energy and macronutrient content of human
milk during early lactation from mothers giving birth prematurely and at term. Am J Clin
Nutr 1981 ;34(2):258-65.
133. Gross SJ, Geller J, Tomarelli RM. Composition of breast milk from mothers of preterm
infants. Pediatrics 1981;68(4):490-3.
134. Schanler RJ, Oh W. Composition of breast milk obtained from mothers of premature
infants as compared to breast milk obtained from donors. JPediatr 1980;96(4):679-81.
135. Wojcik KY, Rechtman DJ, Lee ML, Montoya A, Medo ET. Macronutrient analysis of a
nationwide sample of donor breast milk. JAm Diet Assoc 2009; 109(1): 137-40.
136. Koenig A, de Albuquerque Diniz EM, Barbosa SF, Vaz FA. Immunologic factors in
human milk: the effects of gestational age and pasteurization. J Hum Lact 2005;21(4):439-
43.
137. Gross SJ. Growth and biochemical response of preterm infants fed human milk or
modified infant formula. NEngl JMed 1983;308(5):237-41.
138. Svenningsen NW, Lindroth M, Lindquist B. A comparative study of varying protein
intake in low birthweight infant feeding. Acta Paediatr Scand Suppl 1982;296:28-31.
139. Tyson JE, Lasky RE, Mize CE, Richards CJ, Blair-Smith N, Whyte R, et al. Growth,
metabolic response, and development in very-low-birth-weight infants fed banked human
milk or enriched formula. I. Neonatal findings. JPediatr 1983; 103(1):95-104.
140. McGuire W, Anthony MY. Donor human milk versus formula for preventing
necrotising enterocolitis in preterm infants: systematic review. Arch Dis Child Fetal
Neonatal Ed 2003 ;88( 1):F 11-4.
141. Brooke OG, Wood C, Barley J. Energy balance, nitrogen balance, and growth in
preterm infants fed expressed breast milk, a premature infant formula, and two low-solute
adapted formulae. Arch Dis Child 1982;57(12):898-904.
142. Tudehope DI, Mitchell F, Cowley DM. A comparative study of a premature infant
formula and preterm breast milk for low birthweight infants. Aust Paediatr J
1986;22(3): 199-205.
143. Lucas A, Gore SM, Cole TJ, Bamford MF, Dossetor JF, Barr I, et al. Multicentre trial
on feeding low birthweight infants: effects of diet on early growth. Arch Dis Child
1984;59(8):722-30.
144. Lucas A, Morley R, Cole TJ, Gore SM, Davis JA, Bamford MF, et al. Early diet in
preterm babies and developmental status in infancy. Arch Dis Child 1989;64( 11): 1570-8.
243
145. Lucas A, Morley R, Cole TJ, Gore SM, Lucas PJ, Crowle P, et al. Early diet in preterm
babies and developmental status at 18 months. Lancet 1990;335(8V04): 1477-81.
146. Morley R, Lucas A. Randomized diet in the neonatal period and growth performance
until 7.5-8 y of age in preterm children. Am J Clin Nutr 2000;71(3):822-8.
147. Jadcherla SR, Berseth CL. Acute and chronic intestinal motor activity responses to two
infant formulas. Pediatrics 1995;96(2 Pt 1):331 -5.
148. Wisen O, Hellstrom PM, Johansson C. Meal energy density as a determinant of
postprandial gastrointestinal adaptation in man. ScandJ Gastroenterol 1993;28(8):737-43.
149. Grulee CG, Sanford HN. The influence of breast and artificial feeding on infantile
eczema. JPediatr 1936;9:223-25.
150. Saarinen KM, Juntunen-Backman K, Jarvenpaa AL, Klemetti P, Kuitunen P, Lope L, et
al. Breast-feeding and the development of cows' milk protein allergy. Adv Exp Med Biol
2000;478:121-30.
151. Juvonen P, Mansson M, Andersson C, Jakobsson I. Allergy development and
macromolecular absorption in infants with different feeding regimens during the first three
days of life. A three-year prospective follow-up. Acta Paediatr 1996;85(9): 1047-52.
152. Chirico G, Gasparoni A, Ciardelli L, De Amici M, Colombo A, Rondini G.
Immunogenicity and antigenicity of a partially hydrolyzed cow's milk infant formula.
Allergy 1997;52(l):82-8.
153. de Seta L, Siani P, Cirillo G, Di Gruttola M, Cimaduomo L, Coletta S. [The prevention
of allergic diseases with a hypoallergenic formula: a follow-up at 24 months. The
preliminary results]. Pediatr Med Chir 1994; 16(3):251 -4.
154. Halken S, Hansen KS, Jacobsen HP, Estmann A, Faelling AE, Hansen LG, et al.
Comparison of a partially hydrolyzed infant formula with two extensively hydrolyzed
formulas for allergy prevention: a prospective, randomized study. Pediatr Allergy Immunol
2000; 11(3): 149-61.
155. Maggio L, Zuppa AA, Sawatzki G, Valsasina R, Schubert W, Tortorolo G. Higher
urinary excretion of essential amino acids in preterm infants fed protein hydrolysates. Acta
Paediatr 2005;94(l):75-84.
156. Mallet E, Henocq A. Long-term prevention of allergic diseases by using protein
hydrolysate formula in at-risk infants. JPediatr 1992; 121(5 Pt 2):S95-100.
157. Marini A, Agosti M, Motta G, Mosca F. Effects of a dietary and environmental
prevention programme on the incidence of allergic symptoms in high atopic risk infants:
three years' follow-up. Acta Paediatr Suppl 1996;414:1-21.
244
158. Nentwich I, Michkova E, Nevoral J, Urbanek R, Szepfalusi Z. Cow's milk-specific
cellular and humoral immune responses and atopy skin symptoms in infants from atopic
families fed a partially (pHF) or extensively (eHF) hydrolyzed infant formula. Allergy
2001;56(12):1144-56.
159. Oldaeus G, Anjou K, Bjorksten B, Moran JR, Kjellman NI. Extensively and partially
hydrolysed infant formulas for allergy prophylaxis. Arch Dis Child 1997;77( 1 ):4-10.
160. Picaud JC, Rigo J, Normand S, Lapillonne A, Reygrobellet B, Claris O, et al.
Nutritional efficacy of preterm formula with a partially hydrolyzed protein source: a
randomized pilot study. JPediatr Gastroenterol Nutr 2001 ;32(5):555-61.
161. Szajewska H, Albrecht P, Stoitiska B, Prochowska A, Gawecka A, Laskowska-Klita T.
Extensive and partial protein hydrolysate preterm formulas: the effect on growth rate, protein
metabolism indices, and plasma amino acid concentrations. J Pediatr Gastroenterol Nutr
2001;32(3):303-9.
162. Tsai YT, Chou CC, Hsieh KH. The effect of hypoallergenic formula on the occurrence
of allergic diseases in high risk infants. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi
1991 ;32(3): 137-44.
163. Vandenplas Y, Hauser B, Van den Borre C, Sacre L, Dab I. Effect of a whey
hydrolysate prophylaxis of atopic disease. Ann Allergy 1992;68(5):419-24.
164. Vandenplas Y, Hauser B, Blecker U, Suys B, Peeters S, Keymolen K, et al. The
nutritional value of a whey hydrolysate formula compared with a whey-predominant formula
in healthy infants. JPediatr Gastroenterol Nutr 1993; 17( 1 ):92-6.
165. von Berg A, Koletzko S, Grubl A, Filipiak-Pittroff B, Wichmann HE, Bauer CP, et al.
The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life:
the German Infant Nutritional Intervention Study, a randomized double-blind trial. JAllergy
Clin Immunol 2003; 111(3):533-40.
166. Willems R, Duchateau J, Magrez P, Denis R, Casimir G. Influence of hypoallergenic
milk formula on the incidence of early allergic manifestations in infants predisposed to
atopic diseases. Ann Allergy 1993 ;71 (2): 147-50.
167. Riezzo G, Indrio F, Montagna O, Tripaldi C, Laforgia N, Chiloiro M, et al. Gastric
electrical activity and gastric emptying in preterm newborns fed standard and hydrolysate
formulas. JPediatr GastroenterolNutr 2001;33(3):290-5.
168. Mihatsch WA, Hogel J, Pohlandt F. Hydrolysed protein accelerates the gastrointestinal
transport of formula in preterm infants. Acta Paediatr 2001;90(2):196-8.
169. Lucas A, Adrian TE, Christofides N, Bloom SR, Aynsley-Green A. Plasma motilin,
gastrin, and enteroglucagon and feeding in the human newborn. Arch Dis Child
1980;55(9):673-7.
245
170. Hughes CA, Dowling RH. Speed of onset of adaptive mucosal hypoplasia and
hypofunction in the intestine of parenterally fed rats. Clin Sci (Lond) 1980;59(5):317-27.
171. Lucas A, Bloom SR, Aynsley-Green A. Gut hormones and 'minimal enteral feeding'.
Acta Paediatr Scand 1986;75(5):719-23.
172. Berseth CL. Neonatal small intestinal motility: motor responses to feeding in term and
preterm infants. JPediatr 1990; 117(5):777-82.
173. Berseth CL. Effect of early feeding on maturation of the preterm infant's small intestine.
JPediatr 1992;120(6):947-53.
174. Berseth CL, Nordyke C. Enteral nutrients promote postnatal maturation of intestinal
motor activity in preterm infants. Am JPhysiol 1993;264(6 Pt 1):G1046-51.
175. Dunn L, Hulman S, Weiner J, Kliegman R. Beneficial effects of early hypocaloric
enteral feeding on neonatal gastrointestinal function: preliminary report of a randomized
trial. JPediatr 1988; 112(4):622-9.
176. McClure RJ, Newell SJ. Randomised controlled trial of trophic feeding and gut
motility. Arch Dis Child Fetal Neonatal Ed 1999;80(l):F54-8.
177. McClure RJ, Newell SJ. Randomised controlled study of clinical outcome following
trophic feeding. Arch Dis Child Fetal Neonatal Ed 2000;82(l):F29-33.
178. McClure Rf, Newell SJ. Randomized controlled study of digestive enzyme activity
following trophic feeding. Acta Paediatr 2002;91(3):292-6.
179. Meetze WH, Valentine C, McGuigan JE, Conlon M, Sacks N, Neu J. Gastrointestinal
priming prior to full enteral nutrition in very low birth weight infants. J Pediatr
GastroenterolNutr 1992; 15(2): 163-70.
180. Mosqueda E, Sapiegiene L, Glynn L, Wilson-Costello D, Weiss M. The early use of
minimal enteral nutrition in extremely low birth weight newborns. J Perinatol
2008;28(4):264-9.
181. Saenz de Pipaon M, VanBeek RH, Quero J, Perez J, Wattimena DJ, Sauer PJ. Effect of
minimal enteral feeding on splanchnic uptake of leucine in the postabsorptive state in
preterm infants. Pediatr Res 2003;53(2):281-7.
182. Schanler RJ, Shulman RJ, Lau C, Smith EO, Heitkemper MM. Feeding strategies for
premature infants: randomized trial of gastrointestinal priming and tube-feeding method.
Pediatrics 1999;103(2):434-9.
183. van Elburg RM, van den Berg A, Bunkers CM, van Lingen RA, Smink EW, van Eyck
J, et al. Minimal enteral feeding, fetal blood flow pulsatility, and postnatal intestinal
246
permeability in preterm infants with intrauterine growth retardation. Arch Dis Child Fetal
Neonatal Ed 2004;89(4):F293-6.
184. Troche B, Harvey-Wilkes K, Engle WD, Nielsen HC, Frantz ID, 3rd, Mitchell ML, et
al. Early minimal feedings promote growth in critically ill premature infants. Biol Neonate
1995;67(3): 172-81.
185. Bombell S, McGuire W. Early trophic feeding for very low birth weight infants.
Cochrane Database Syst Rev 2009(3):CD000504.
186. Weiler HA, Fitzpatrick-Wong SC, Schellenberg JM, Fair DE, McCloy UR, Veitch RR,
et al. Minimal enteral feeding within 3 d of birth in prematurely born infants with birth
weight < or = 1200 g improves bone mass by term age. Am J Clin Nutr 2006;83( 1): 155-62.
187. Henderson G, Craig S, Brocklehurst P, McGuire W. Enteral feeding regimens and
necrotising enterocolitis in preterm infants: a multicentre case-control study. Arch Dis Child
Fetal Neonatal Ed 2009;94(2):F 120-3.
188. Berseth CL, Bisquera JA, Paje VU. Prolonging small feeding volumes early in life
decreases the incidence of necrotizing enterocolitis in very low birth weight infants.
Pediatrics 2003; 111(3):529-34.
189. Menon G, Boyle EM, Embleton ND, Mcintosh N. Introduction of enteral feeds in
preterm infants. Pediatrics 2004; 114(l):327-8.
190. Patole S, Muller R. Enteral feeding of preterm neonates: a survey of Australian
neonatologists. JMatern Fetal Neonatal Med 2004;16(5):309-14.
191. Hans DM, Pylipow M, Long JD, Thureen PJ, GeorgieffMK. Nutritional practices in the
neonatal intensive care unit: analysis of a 2006 neonatal nutrition survey. Pediatrics
2009; 123( 1):51 -7.
192. Berseth CL. Gestational evolution of small intestine motility in preterm and term
infants. JPediatr 1989; 115(4):646-51.
193. Berseth CL, Nordyke CK, Valdes MG, Furlow BL, Go VL. Responses of
gastrointestinal peptides and motor activity to milk and water feedings in preterm and term
infants. Pediatr Res 1992;31(6):587-90.
194. Slagle TA, Gross SJ. Effect of early low-volume enteral substrate on subsequent
feeding tolerance in very low birth weight infants. JPediatr 1988; 113(3):526-31.
195. LaGamma EF, Ostertag SG, Birenbaum H. Failure of delayed oral feedings to prevent
necrotizing enterocolitis. Results of study in very-low-birth-weight neonates. Am JDis Child
1985; 139(4):3 85-9.
247
196. Ostertag SG, LaGamma EF, Reisen CE, Ferrentino FL. Early enteral feeding does not
affect the incidence of necrotizing enterocolitis. Pediatrics 1986;77(3):275-80.
197. McKeown RE, Marsh TD, Amarnath U, Garrison CZ, Addy CL, Thompson SJ, et al.
Role of delayed feeding and of feeding increments in necrotizing enterocolitis. J Pediatr
1992; 121(5 Pt l):764-70.
198. Davey AM, Wagner CL, Cox C, Kendig JW. Feeding premature infants while low
umbilical artery catheters are in place: a prospective, randomized trial. J Pediatr 1994; 124(5
Pt l):795-9.
199. Khayata S, Gutcher G, J B. Early versus late feeding of low birth weight (LBW)
infants:Effect on growth and hyperbilirubinaemia. Pediatric Research 1987;21:431A.
200. Sisk PM, Lovelady CA, Dillard RG, Gruber KJ, O'Shea TM. Early human milk feeding
is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. J
Perinatol 2007;27(7):428-33.
201. Ronnestad A, Abrahamsen TG, Medbo S, Reigstad H, Lossius K, Kaaresen PI, et al.
Late-onset septicemia in a Norwegian national cohort of extremely premature infants
receiving very early full human milk feeding. Pediatrics 2005;115(3):e269-76.
202. Bombell S, McGuire W. Delayed introduction of progressive enteral feeds to prevent
necrotising enterocolitis in very low birth weight infants. Cochrane Database Syst Rev
2008(2):CD001970.
203. Simmer K. Editorial - Nutrition of the preterm infant. Best Practice Guidelines on
nutrition of preterm infants. Early Hum Dev 2007;83(10):629.
204. Simmer K. Aggressive nutrition for preterm infants—benefits and risks. Early Hum Dev
2007;83(10):631-4.
205. Book LS, Flerbst JJ, Jung AL. Comparison of fast- and slow-feeding rate schedules to
the development of necrotizing enterocolitis. JPediatr 1976;89(3):463-6.
206. Goldman HI. Feeding and necrotizing enterocolitis. Am JDis Child 1980; 134(6):553-5.
207. Rayyis SF, Ambalavanan N, Wright L, Carlo WA. Randomized trial of "slow" versus
"fast" feed advancements on the incidence of necrotizing enterocolitis in very low birth
weight infants. J Pediatr 1999; 134(3):293-7.
208. Caple J, Armentrout D, Huseby V, Halbardier B, Garcia J, Sparks JW, et al.
Randomized, controlled trial of slow versus rapid feeding volume advancement in preterm
infants. Pediatrics 2004; 114(6): 1597-600.
248
209. Kennedy KA, Tyson JE, Chamnanvanakij S. Rapid versus slow rate of advancement of
feedings for promoting growth and preventing necrotizing enterocolitis in parenterally fed
low-birth-weight infants. Cochrane Database Syst Rev 2000(2):CD001241.
210. McGuire W, Bombell S. Slow advancement of enteral feed volumes to prevent
necrotising enterocolitis in very low birth weight infants. Cochrane Database Syst Rev
2008(2):CD001241.
211. Salhotra A, Ramji S. Slow versus fast enteral feed advancement in very low birth
weight infants: a randomized control trial. Indian Pediatr 2004;41(5):435-41.
212. Wiedmeier SE, Henry E, Baer VL, Stoddard RA, Eggert LD, Lambert DK, et al. Center
differences in NEC within one health-care system may depend on feeding protocol. Am J
Perinatol 2008;25(1):5-11.
213. Brown EG, Sweet AY. Preventing necrotizing enterocolitis in neonates. JAMA
1978;240(22):2452-4.
214. Spritzer R, Koolen AM, Baerts W, Fetter WP, Lafeber HN, Sauer PJ. A prolonged
decline in the incidence of necrotizing enterocolitis after the introduction of a cautious
feeding regimen. Acta Paediatr Scand 1988;77(6):909-11.
215. Kamitsuka MD, Horton MK, Williams MA. The incidence of necrotizing enterocolitis
after introducing standardized feeding schedules for infants between 1250 and 2500 grams
and less than 35 weeks of gestation. Pediatrics 2000;105(2):379-84.
216. Patole S, McGlone L, Muller R. Virtual elimination of necrotising enterocolitis for 5
years - reasons? MedHypotheses 2003;61(5-6):617-22.
217. Premji SS, Chessell L, Paes B, Pinelli J, Jacobson K. A matched cohort study of feeding
practice guidelines for infants weighing less than 1,500 g. Adv Neonatal Care 2002;2(1):27-
36.
218. Kuzma-O'Reilly B, Duenas ML, Greecher C, Kimberlin L, Mujsce D, Miller D, et al.
Evaluation, development, and implementation of potentially better practices in neonatal
intensive care nutrition. Pediatrics 2003;111(4 Pt 2):e461-70.
219. Patole SK, de Klerk N. Impact of standardised feeding regimens on incidence of
neonatal necrotising enterocolitis: a systematic review and meta-analysis of observational
studies. Arch Dis Child Fetal Neonatal Ed 2005;90(2):F147-51.
220. Patole SK, Kadalraja R, Tuladhar R, Almonte R, Muller R, Whitehall JS. Benefits of a
standardised feeding regimen during a clinical trial in preterm neonates. Int J Clin Pract
2000;54(7):429-31.
221. Schanler RJ. The use of human milk for premature infants. Pediatr Clin North Am
2001;48(1):207-19.
249
222. Butte NF, Garza C, Johnson CA, Smith EO, Nichols BL. Longitudinal changes in milk
composition of mothers delivering preterm and term infants. Early Hum Dev 1984;9(2): 153-
62.
223. Atkinson SA, Radde IC, Anderson GH. Macromineral balances in premature infants fed
their own mothers' milk or formula. JPediatr 1983; 102( 1 ):99-106.
224. Maggio L, Costa S, Gallini F. Human milk fortifiers in very low birth weight infants.
Early Hum Dev 2009;85(10 Suppl):S59-61.
225. Schanler RJ, Shulman RJ, Lau C. Feeding strategies for premature infants: beneficial
outcomes of feeding fortified human milk versus preterm formula. Pediatrics 1999; 103(6 Pt
1): 1150-7.
226. Carey DE, Rowe JC, Goetz CA, Horak E, Clark RM, Goldberg B. Growth and
phosphorus metabolism in premature infants fed human milk, fortified human milk, or
special premature formula. Use of serum procollagen as a marker of growth. Am JDis Child
1987;141(5):511-5.
227. Venkataraman PS, Blick KE. Effect of mineral supplementation of human milk on bone
mineral content and trace element metabolism. JPediatr 1988; 113(1 Pt 2):220-4.
228. Modanlou HD, Lim MO, Hansen JW, Sickles V. Growth, biochemical status, and
mineral metabolism in very-low-birth-weight infants receiving fortified preterm human milk.
JPediatr Gastroenterol Nutr 1986;5(5):762-7.
229. Nicholl RM, Gamsu HR. Changes in growth and metabolism in very low birthweight
infants fed with fortified breast milk. Acta Paediatr 1999;88( 10): 1056-61.
230. Ronnholm KA, Perheentupa J, Siimes MA. Supplementation with human milk protein
improves growth of small premature infants fed human milk. Pediatrics 1986;77(5):649-53.
231. Kashyap S, Schulze KF, Forsyth M, Dell RB, Ramakrishnan R, Heird WC. Growth,
nutrient retention, and metabolic response of low-birth-weight infants fed supplemented and
unsupplemented preterm human milk. Am J Clin Nutr 1990;52(2):254-62.
232. Greer FR, McCormick A. Improved bone mineralization and growth in premature
infants fed fortified own mother's milk. J Pediatr 1988; 112(6):961-9.
233. Gross SJ. Bone mineralization in preterm infants fed human milk with and without
mineral supplementation. JPediatr 1987; 11 l(3):450-8.
234. Zuckerman M, Pettifor JM. Rickets in very-low-birth-weight infants born at
Baragwanath Hospital. SAfr MedJ 1994;84(4):216-20.
250
235. Pettifor JM, Rajah R, Venter A, Moodley GP, Opperman L, Cavaleros M, et al. Bone
mineralization and mineral homeostasis in very low-birth-weight infants fed either human
milk or fortified human milk. JPediatr GastroenterolNutr 1989;8(2):217-24.
236. Faerk J, Petersen S, Peitersen B, Michaelsen KF. Diet and bone mineral content at term
in premature infants. Pediatr Res 2000;47(1): 148-56.
237. Polberger SK, Axelsson IA, Raiha NC. Growth of very low birth weight infants on
varying amounts of human milk protein. Pediatr Res 1989;25(4):414-9.
238. Wauben IP, Atkinson SA, Grad TL, Shah JK, Paes B. Moderate nutrient
supplementation ofmother's milk for preterm infants supports adequate bone mass and short-
term growth: a randomized, controlled trial. Am J Clin Nutr 1998;67(3):465-72.
239. Lucas A, Fewtrell MS, Morley R, Lucas PJ, Baker BA, Lister G, et al. Randomized
outcome trial of human milk fortification and developmental outcome in preterm infants. Am
JClin Nutr 1996;64(2): 142-51.
240. Kuschel CA, Harding JE. Multicomponent fortified human milk for promoting growth
in preterm infants. Cochrane Database Syst Rev 2004(1):CD000343.
241. Moody GJ, Schanler RJ, Lau C, Shulman RJ. Feeding tolerance in premature infants
fed fortified human milk. JPediatr Gastroenterol Nutr 2000;30(4):408-12.
242. McClure RJ, Newell SJ. Effect of fortifying breast milk on gastric emptying. Arch Dis
Child Fetal Neonatal Ed 1996;74(l):F60-2.
243. Gathwala G, Shaw C, Shaw P, Yadav S, Sen J. Human milk fortification and gastric
emptying in the preterm neonate. Int J Clin Pract 2008;62(7): 1039-43.
244. Yigit S, Akgoz A, Memisoglu A, Akata D, Ziegler EE. Breast milk fortification: effect
on gastric emptying. JMatern Fetal Neonatal Med 2008;21(11):843-6.
245. Hallstrom M, Koivisto AM, Janas M, Tammela O. Frequency of and risk factors for
necrotizing enterocolitis in infants born before 33 weeks of gestation. Acta Paediatr
2003 ;92( 1): 111-3.
246. Book LS, Herbst JJ, Atherton SO, Jung AL. Necrotizing enterocolitis in low-birth-
weight infants fed an elemental formula. JPediatr 1975;87(4):602-5.
247. De Curtis M, Candusso M, Pieltain C, Rigo J. Effect of fortification on the osmolality
of human milk. Arch Dis Child Fetal Neonatal Ed 1999;81(2):F141-3.
248. Agarwal R, Singal A, Aggarwal R, Deorari AK, Paul VK. Effect of fortification with
human milk fortifier (HMF) and other fortifying agents on the osmolality of preterm breast
milk. Indian Pediatr 2004;41(l):63-7.
251
249. Sullivan S, Schanler RJ, Kim JH, Patel AL, Trawoger R, Kiechl-Kohlendorfer U, et al.
An exclusively human milk-based diet is associated with a lower rate of necrotizing
enterocolitis than a diet of human milk and bovine milk-based products. J Pediatr
2010; 156(4):562-7.
250. Robel-Tillig E, Vogtmann C, Bennek J. Prenatal hemodynamic disturbances —
pathophysiological background of intestinal motility disturbances in small for gestational age
infants. EurJPediatr Surg 2002; 12(3): 175-9.
251. Mihatsch WA, Pohlandt F, Franz AR, Flock F. Early feeding advancement in very low-
birth-weight infants with intrauterine growth retardation and increased umbilical artery
resistance. JPediatr GastroenterolNutr 2002;35(2): 144-8.
252. Murdoch EM, Sinha AK, Shanmugalingam ST, Smith GC, Kempley ST. Doppler flow
velocimetry in the superior mesenteric artery on the first day of life in preterm infants and
the risk of neonatal necrotizing enterocolitis. Pediatrics 2006; 118(5): 1999-2003.
253. Feaf A, Dorling J, Kempley S, McCormick K, Mannix P, Brocklehurst P. ADEPT -
Abnormal Doppler Enteral Prescription Trial. BMC Pediatr 2009;9:63.
254. Cochran WD, Davis HT, Smith CA. Advantages and complications of umbilical artery
catheterization in the newborn. Pediatrics 1968;42(5):769-77.
255. Castor WR. Spontaneous perforation of the bowel in the newborn following exchange
transfusion. Can MedAssoc J 1968;99(19):934-9.
256. Touloukian RJ, Kadar A, Spencer RP. The gastrointestinal complications of neonatal
umbilical venous exchange transfusion: a clinical and experimental study. Pediatrics
1973 ;51 (1 ):36-43
257. Rand T, Weninger M, Kohlhauser C, Bischof S, Heinz-Peer G, Trattnig S, et al. Effects
of umbilical arterial catheterization on mesenteric hemodynamics. Pediatr Radiol
1996;26(7):435-8.
258. Wigger HJ, Bransilver BR, Blanc WA. Thromboses due to catheterization in infants
and children. JPediatr 1970;76( 1): 1 -11.
259. Tyson JE, deSa DJ, Moore S. Thromboatheromatous complications of umbilical arterial
catheterization in the newborn period. Clinicopathological study. Arch Dis Child
1976;51(10):744-54.
260. Bunton GL, Durbin GM, Mcintosh N, Shaw DG, Taghizadeh A, Reynolds EO, et al.
Necrotizing enterocolitis. Controlled study of 3 years' experience in a neonatal intensive care
unit. Arch Dis Child 1977;52(10):772-7.
261. Smith MF, Borriello SP, Clayden GS, Casewell MW. Clinical and bacteriological
findings in necrotising enterocolitis: a controlled study. J Infect 1980;2(1):23-31.
252
262. Kliegman RM, Hack M, Jones P, Fanaroff AA. Epidemiologic study of necrotizing
enterocolitis among low-birth-weight infants. Absence of identifiable risk factors. J Pediatr
1982;100(3):440-4.
263. Barrington KJ. Umbilical artery catheters in the newborn: effects of catheter design
(end vs side hole). Cochrane Database Syst Rev 2000(2):CD000508.
264. Harris MS, Little GA. Umbilical artery catheters: high, low, or no. J Perinat Med
1978;6( 1): 15-21.
265. Mokrohisky ST, Levine RL, Blumhagen JD, Wesenberg RL, Simmons MA. Low
positioning of umbilical-artery catheters increases associated complications in newborn
infants. NEngl JMed 1978;299(11):561-4.
266. Wesstrom G, Finnstrom O, Stenport G. Umbilical artery catheterization in newborns. I.
Thrombosis in relation to catheter type and position. Acta Paediatr Scand 1979;68(4):575-
81.
267. UACTSG. Relationship of intraventricular hemorrhage or death with the level of
umbilical artery catheter placement: a multicenter randomized clinical trial. Umbilical Artery
Catheter Trial Study Group. Pediatrics 1992;90(6):881-7.
268. Kempley ST, Bennett S, Loftus BG, Cooper D, Gamsu HR. Randomized trial of
umbilical arterial catheter position: clinical outcome. Acta Paediatr 1993;82(2): 173-6.
269. Lehmiller DJ, Kanto WP, Jr. Relationships of mesenteric thromboembolism, oral
feeding, and necrotizing enterocolitis. JPediatr 1978;92(1):96-100.
270. Tiffany KF, Burke BL, Collins-Odoms C, Oelberg DG. Current practice regarding the
enteral feeding of high-risk newborns with umbilical catheters in situ. Pediatrics 2003; 112(1
Pt l):20-3.
271. McGrady GA, Rettig PJ, Istre GR, Jason JM, Holman RC, Evatt BL. An outbreak of
necrotizing enterocolitis. Association with transfusions of packed red blood cells. Am J
Epidemiol 1987; 126(6): 1165-72.
272. Bednarek FJ, Weisberger S, Richardson DK, Frantz ID, 3rd, Shah B, Rubin LP.
Variations in blood transfusions among newborn intensive care units. SNAP II Study Group.
JPediatr 1998; 133(5):601-7.
273. Mally P, Golombek SG, Mishra R, Nigam S, Mohandas K, Depalhma H, et al.
Association of necrotizing enterocolitis with elective packed red blood cell transfusions in
stable, growing, premature neonates. Am JPerinatol 2006;23(8):451-8.
274. Krimmel GA, Baker R, Yanowitz TD. Blood Transfusion Alters the Superior
Mesenteric Artery Blood Flow Velocity Response to Feeding in Premature Infants. Am J
Perinatol 2008.
253
275. Bell EF, Strauss RG, Widness JA, Mahoney LT, Mock DM, Seward VJ, et al.
Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in
preterm infants. Pediatrics 2005; 115(6): 1685-91.
276. Kirpalani H, Whyte RK, Andersen C, Asztalos EV, Heddle N, Blajchman MA, et al.
The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial
of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth
weight infants. JPediatr 2006;149(3):301-07.
277. Whyte RK, Kirpalani H, Asztalos EV, Andersen C, Blajchman M, Heddle N, et al.
Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to
restrictive or liberal hemoglobin thresholds for blood transfusion. Pediatrics
2009; 123( 1 ):207-13.
278. McCumin D, Clyman RI. Effects of a patent ductus arteriosus on postprandial
mesenteric perfusion in premature baboons. Pediatrics 2008; 122(6):e 1262-7.
279. van de Bor M, Verloove-Vanhorick SP, Brand R, Ruys JH. Patent ductus arteriosus in a
cohort of 1338 preterm infants: a collaborative study. Paediatr Perinat Epidemiol
1988;2(4):328-36.
280. Dollberg S, Lusky A, Reichman B. Patent ductus arteriosus, indomethacin and
necrotizing enterocolitis in very low birth weight infants: a population-based study. JPediatr
Gastroenterol Nntr 2005;40(2): 184-8.
281. Milner ME, de la Monte SM, Moore GW, Hutchins GM. Risk factors for developing
and dying from necrotizing enterocolitis. JPediatr Gastroenterol Nutr 1986;5(3):359-64.
282. Coombs RC, Morgan ME, Durbin GM, Booth IW, McNeish AS. Gut blood flow
velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin.
Arch Dis Child 1990;65(10 Spec No): 1067-71.
283. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF. Effects of
indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with
patent ductus arteriosus. JPediatr 1999; 135(6):733-8.
284. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality
and morbidity in preterm infants. Cochrane Database Syst Rev 2002(3):CD000174.
285. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term
effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med
2001;344(26): 1966-72.
286. Grosfeld JL, Chaet M, Molinari F, Engle W, Engum SA, West KW, et al. Increased risk
of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with
indomethacin. Ann Surg 1996;224(3):350-5; discussion 55-7.
254
287. Fujii AM, Brown E, Mirochnick M, O'Brien S, Kaufman G. Neonatal necrotizing
enterocolitis with intestinal perforation in extremely premature infants receiving early
indomethacin treatment for patent ductus arteriosus. JPerinatol 2002;22(7):535-40.
288. O'Donovan DJ, Baetiong A, Adams K, Chen A, Smith EO, Adams JM, et al.
Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and
surgical ligation in premature infants with patent ductus arteriosus. J Perinatol
2003;23(4):286-90.
289. Malhotra AK, Deorari AK, Paul VK, Bagga A, Singh M. Gastric residuals in preterm
babies. J Prop Pediatr 1992;38(5):262-4.
290. Mihatsch WA, von Schoenaich P, Fahnenstich H, Dehne N, Ebbecke H, Plath C, et al.
The significance of gastric residuals in the early enteral feeding advancement of extremely
low birth weight infants. Pediatrics 2002;109(3):457-9.
291. Cobb BA, Carlo WA, Ambalavanan N. Gastric residuals and their relationship to
necrotizing enterocolitis in very low birth weight infants. Pediatrics 2004;113(1 Pt 1):50-3.
292. Bertino E, Giuliani F, Prandi G, Coscia A, Martano C, Fabris C. Necrotizing
enterocolitis: risk factor analysis and role of gastric residuals in very low birth weight
infants. JPediatr Gastroenterol Nutr 2009;48(4):437-42.
293. Neu J, Zhang L. Feeding intolerance in very-low-birthweight infants: what is it and
what can we do about it? Acta Paediatr Suppl 2005;94(449):93-9.
294. Kairamkonda VR, Deorukhkar A, Bruce C, Coombs R, Fraser R, Mayer AP. Amylin
peptide is increased in preterm neonates with feed intolerance. Arch Dis Child Fetal
Neonatal Ed 2008;93(4):F265-70.
295. Aynsley-Green A, Adrian TE, Bloom SR. Feeding and the development of
enteroinsular hormone secretion in the preterm infant: effects of continuous gastric infusions
of humanmilk compared with intermittent boluses. Acta Paediatr Scand 1982;71(3):379-83.
296. de Ville K, Knapp E, Al-Tawil Y, Berseth CL. Slow infusion feedings enhance
duodenal motor responses and gastric emptying in preterm infants. Am J Clin Nutr
1998;68( 1): 103-8.
297. Toce SS, Keenan WJ, Eloman SM. Enteral feeding in very-low-birth-weight infants. A
comparison of two nasogastric methods. Am JDis Child 1987;141(4):439-44.
298. Akintorin SM, Kamat M, Pildes RS, Kling P, Andes S, Hill J, et al. A prospective
randomized trial of feeding methods in very low birth weight infants. Pediatrics
1997;100(4):E4.
299. Silvestre MA, Morbach CA, Brans YW, Shankaran S. A prospective randomized trial
comparing continuous versus intermittent feeding methods in very low birth weight
neonates. JPediatr 1996;128(6):748-52.
255
300. Dollberg S, Kuint J, Mazkereth R, Mimouni FB. Feeding tolerance in preterm infants:
randomized trial of bolus and continuous feeding. JAm Coll Nutr 2000;19(6):797-800.
301. Rojahn A, Lindgren CG. Enteral feeding in infants <1250 g starting within 24 h post¬
partum. Eur JPediatr 2001;160(10):629-32.
302. Dsilna A, Christensson K, Alfredsson L, Lagercrantz H, Blennow M. Continuous
feeding promotes gastrointestinal tolerance and growth in very low birth weight infants. J
Pediatr 2005; 147( l):43-9.
303. Premji S, Chessell L. Continuous nasogastric milk feeding versus intermittent bolus
milk feeding for premature infants less than 1500 grams. Cochrane Database Syst Rev
2003(1):CD001819.
304. Rhea JW, Chazzawi O, Weidman W. Nasojejunal feeding: an improved device and
intubation technique. JPediatr 1973; 82(6): 951-4.
305. Cheek JA, Jr., Staub GF. Nasojejunal alimentation for premature and full-term newborn
infants. JPediatr 1973;82(6):955-62.
306. Wells DH, Zachman RD. Nasojejunal feedings in low-birth-weight infants. J Pediatr
1975;87(2):276-9.
307. Caillie MV, Powell GK. Nasoduodenal versus nasogastric feeding in the very low
birthweight infant. Pediatrics 1975;56(6): 1065-72.
308. Roy RN, Pollnitz RB, Hamilton JR, Chance GW. Impaired assimilation of nasojejunal
feeds in healthy low-birth-weight newborn infants. JPediatr 1977;90(3):431-4.
309. Drew JH, Johnston R, Finocchiaro C, Taylor PS, Goldberg HJ. A comparison of
nasojejunal witn nasogastric feedings in low-birth-weight infants. Aust Paediatr J
1979; 15(2):98-l 00.
310. Pereira GR, Lemons JA. Controlled study of transpyloric and intermittent gavage
feeding in the small preterm infant. Pediatrics 1981 ;67(l):68-72.
311. Laing IA, Lang MA, Callaghan O, Hume R. Nasogastric compared with nasoduodenal
feeding in low birthweight infants. Arch Dis Child 1986;61 (2): 138-41.
312. Macdonald PD, Skeoch CH, Carse H, Dryburgh F, Alroomi LG, Galea P, et al.
Randomised trial of continuous nasogastric, bolus nasogastric, and transpyloric feeding in
infants of birth weight under 1400 g. Arch Dis Child 1992;67(4 Spec No):429-31.
313. Misra S, Macwan K, Albert V. Transpyloric feeding in gastroesophageal-reflux-
associated apnea in premature infants. Acta Paediatr 2007;96(10): 1426-9.
256
314. Malcolm WF, Smith PB, Mears S, Goldberg RN, Cotten CM. Transpyloric tube feeding
in very low birthweight infants with suspected gastroesophageal reflux: impact on apnea and
bradycardia. JPerinatol 2009;29(5):372-5.
315. Dhillon AS, Ewer AK. Diagnosis and management of gastro-oesophageal reflux in
preterm infants in neonatal intensive care units. Acta Paediatr 2004;93(l):88-93.
316. Leape LL, Flolder TM, Franklin JD, Amoury RA, Ashcraft KW. Respiratory arrest in
infants secondary to gastroesophageal reflux. Pediatrics 1977;60(6):924-8.
317. Herbst JJ, Minton SD, Book LS. Gastroesophageal reflux causing respiratory distress
and apnea in newborn infants. JPediatr 1979;95(5 Pt l):763-8.
318. Menon AP, Schefft GL, Thach BT. Apnea associated with regurgitation in infants. J
Pediatr 1985; 106(4):625-9.
319. Jolley SG, Halpern CT, Sterling CE, Feldman BH. The relationship of respiratory
complications from gastroesophageal reflux to prematurity in infants. J Pediatr Surg
1990;25(7):755-7.
320. de Ajuriaguerra M, Radvanyi-Bouvet MF, Huon C, Moriette G. Gastroesophageal
reflux and apnea in prematurely born infants during wakefulness and sleep. Am J Dis Child
1991;145(10):1132-6.
321. Peter CS, Sprodowski N, Bohnhorst B, Silny J, Poets CF. Gastroesophageal reflux and
apnea of prematurity: no temporal relationship. Pediatrics 2002; 109(1):8-11.
322. Di Fiore JM, Arko M, Whitehouse M, Kimball A, Martin RJ. Apnea is not prolonged
by acid gastroesophageal reflux in preterm infants. Pediatrics 2005; 116(5): 1059-63.
323. Bhat RY, Rafferty GF, Flannam S, Greenough A. Acid gastroesophageal reflux in
convalescent preterm infants: effect of posture and relationship to apnea. Pediatr Res
2007;62(5):620-3.
324. Mitchell DJ, McClure BG, Tubman TR. Simultaneous monitoring of gastric and
oesophageal pH reveals limitations of conventional oesophageal pEl monitoring in milk fed
infants. Arch Dis Child 2001;84(3):273-6.
325. Grant L, Cochran D. Can pH monitoring reliably detect gastro-oesophageal reflux in
preterm infants? Arch Dis Child Fetal Neonatal Ed 2001;85(3):F155-7; discussion F57-8.
326. Wenzl TG, Skopnik H. Intraluminal impedance: an ideal technique for evaluation of
pediatric gastroesophageal reflux disease. Curr Gastroenterol Rep 2000;2(3):259-64.
327. Wenzl TG, Schenke S, Peschgens T, Silny J, Heimann G, Skopnik H. Association of
apnea and nonacid gastroesophageal reflux in infants: Investigations with the intraluminal
impedance technique. Pediatr Pulmonol 2001;31(2): 144-9.
257
328. Corvaglia L, Zama D, Gualdi S, Ferlini M, Aceti A, Faldella G. Gastro-oesophageal
reflux increases the number of apnoeas in very preterm infants. Arch Dis Child Fetal
Neonatal Ed 2009;94(3):F 188-92.
329. Malcolm WF, Gantz M, Martin RJ, Goldstein RF, Goldberg RN, Cotten CM. Use of
medications for gastroesophageal reflux at discharge among extremely low birth weight
infants. Pediatrics 2008; 121 (l):22-7.
330. Huang RC, Forbes DA, Davies MW. Feed thickener for newborn infants with gastro-
oesophageal reflux. Cochrane Database Syst Rev 2002(3):CD003211.
331. Orenstein SR, Magill HL, Brooks P. Thickening of infant feedings for therapy of
gastroesophageal reflux. JPediatr 1987; 110(2): 181-6.
332. Vandenplas Y, Hachimi-Idrissi S, Casteels A, Mahler T, Loeb H. A clinical trial with
an "anti-regurgitation" formula. Enr J Pediatr 1994; 153(6):419-23.
333. Vanderhoof JA, Moran JR, Harris CL, Merkel KL, Orenstein SR. Efficacy of a pre-
thickened infant formula: a multicenter, double-blind, randomized, placebo-controlled
parallel group trial in 104 infants with symptomatic gastroesophageal reflux. Clin Pediatr
(Phila) 2003;42(6):483-95.
334. Wenzl TG, Schneider S, Scheele F, Silny J, Heimann G, Skopnik H. Effects of
thickened feeding on gastroesophageal reflux in infants: a placebo-controlled crossover
study using intraluminal impedance. Pediatrics 2003;111(4 Pt l):e355-9.
335. Clarke P, Robinson MJ. Thickening milk feeds may cause necrotising enterocolitis.
Arch Dis Child Fetal Neonatal Ed 2004;89(3):F280.
336. Corvaglia L, Ferlini M, Rotatori R, Paoletti V, Alessandroni R, Cocchi G, et al. Starch
thickening of human milk is ineffective in reducing the gastroesophageal reflux in preterm
infants: a crossover study using intraluminal impedance. JPediatr 2006;148(2):265-8.
337. Birch JL, Newell SJ. Gastrooesophageal reflux disease in preterm infants: current
management and diagnostic dilemmas. Arch Dis Child Fetal Neonatal Ed 2009;94(5):F379-
83.
338. Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium
alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH
monitoring in infants and children. Eur JPediatr 1987; 146(2): 156-8.
339. Forbes D, Hodgson M, Hill R. The effects of gaviscon and metoclopramide in
gastroesophageal reflux in children. J Pediatr GastroenterolNutr 1986;5(4):556-9.
340. Miller S. Comparison of the efficacy and safety of a new aluminium-free paediatric
alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Curr
Med Res Opin 1999; 15(3): 160-8.
258
341. Sorbie AL, Symon DN, Stockdale EJ. Gaviscon bezoars. Arch Dis Child
1984;59(9):905-6.
342. Hewitt GJ, Renham ES. A complication of Gaviscon in a neonate - "the Gavisconoma".
Aust PaediatrJ 1976; 12(l):47-8.
343. Managing gastro-oesophageal reflux in infants. Drug Ther Bull 2009;47(12): 134-7.
344. Keady S. Update on drugs for gastro-oesophageal reflux disease. Arch Dis Child Educ
Pract Ed 2007;92(4):epl 14-8.
345. Del Buono R, Wenzl TG, Ball G, Keady S, Thomson M. Effect of Gaviscon Infant on
gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Arch
Dis CM<i2005;90(5):460-3.
346. Cresi F, Savino F, Marinaccio C, Silvestro L. Gaviscon for gastro-oesophageal reflux in
infants: a poorly effective treatment? Arch Dis Child 2006;91(1):93.
347. Euler AR, Byrne WJ, Meis PJ, Leake RD, Ament ME. Basal and pentagastrin-
stimulated acid secretion in newborn human infants. Pediatr Res 1979; 13(1 ):36-7.
348. Hyman PE, Clarke DD, Everett SL, Sonne B, Stewart D, Harada T, et al. Gastric acid
secretory function in preterm infants. JPediatr 1985; 106(3):467-71.
349. Kelly EJ, Brownlee KG, Newell SJ. Gastric secretory function in the developing human
stomach. Early Hum Dev 1992;31(2): 163-6.
350. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the
preterm infant: a systematic review of RCTs. BMC Pediatr 2001; 1:1.
351. Kuusela AL, Ruuska T, Karikoski R, Laippala P, Ikonen RS, Janas M, et al. A
randomized, controlled study of prophylactic ranitidine in preventing stress-induced gastric
mucosal lesions in neonatal intensive care unit patients. Crit Care Med 1997;25(2):346-51.
352. Cothran DS, Borowitz SM, Sutphen JL, Dudley SM, Donowitz LG. Alteration of
normal gastric flora in neonates receiving ranitidine. JPerinatol 1997; 17(5):383-8.
353. Carrion V, Egan EA. Prevention of neonatal necrotizing enterocolitis. J Pediatr
Gastroenterol Nutr 1990; 11(3):317-23.
354. Bianconi S, Gudavalli M, Sutija VG, Lopez AL, Barillas-Arias L, Ron N. Ranitidine
and late-onset sepsis in the neonatal intensive care unit. JPerinat Med 2007;35(2): 147-50.
355. Zhang W, Kukulka M, Witt G, Sutkowski-Markmann D, North J, Atkinson S. Age-
dependent pharmacokinetics of lansoprazole in neonates and infants. Paediatr Drugs
2008;10(4):265-74.
259
356. Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind
placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J
Pediatr 2003;143(2):219-23.
357. Putnam PE. And the winner is...unhappy coexistence. JPediatr 2003; 143(2): 147-8.
358. Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid
gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J
Pediatr Gastroenterol Nutr 2007;44(l):41-4.
359. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter,
double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of
proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux
disease. JPediatr 2009; 154(4):514-20 e4.
360. Ariagno RL, Kikkert MA, Mirmiran M, Conrad C, Baldwin RB. Cisapride decreases
gastroesophageal reflux in preterm infants. Pediatrics 2001;107(4):E58.
361. Dubin A, Kikkert M, Mirmiran M, Ariagno R. Cisapride associated with QTc
prolongation in very low birth weight preterm infants. Pediatrics 2001; 107(6): 1313-6.
362. Sankaran K, Yeboah E, Bingham WT, Ninan A. Use of metoclopramide in preterm
infants. Dev Pharmacol Ther 1982;5(3-4): 114-9.
363. Meadow WL, Bui KC, Strates E, Dean R. Metoclopramide promotes enteral feeding in
preterm infants with feeding intolerance. Dev Pharmacol Ther 1989; 13(l):38-45.
364. Kimball AL, Carlton DP. Gastroesophageal reflux medications in the treatment of
apnea in premature infants. JPediatr 2001; 138(3):355-60.
365. Wheatley E, Kennedy KA. Cross-over trial of treatment for bradycardia attributed to
gastroesophageal reflux in preterm infants. JPediatr 2009; 155(4):516-21.
366. Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux
disease in infants: a systematic review. Pediatrics 2006; 118(2):746-52.
367. Hyams JS, Leichtner AM, Zamett LO, Walters JK. Effect of metoclopramide on
prolonged intraesophageal pH testing in infants with gastroesophageal reflux. J Pediatr
GastroenterolNutr 1986;5(5):716-20.
368. Putnam PE, Orenstein SR, Wessel HB, Stowe RM. Tardive dyskinesia associated with
use ofmetoclopramide in a child. JPediatr 1992; 121(6):983-5.
369. Grill BB, Hillemeier AC, Semeraro LA, McCallum RW, Gryboski JD. Effects of
domperidone therapy on symptoms and upper gastrointestinal motility in infants with
gastroesophageal reflux. JPediatr 1985; 106(2):311-6.
260
370. Bines JE, Quinlan JE, Treves S, Kleinman RE, Winter HS. Efficacy of domperidone in
infants and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr
1992; 14(4):400-5.
371. Carroccio A, Iacono G, Montalto G, Cavataio F, Soresi M, Notarbartolo A.
Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in
children with gastroesophageal reflux. A double-blind randomized study versus placebo.
ScandJ Gastroenterol 1994;29(4):300-4.
372. Cresi F, Marinaccio C, Russo MC, Miniero R, Silvestro L. Short-term effect of
domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal
impedance and pH monitoring. JPerinatol 2008;28(11):766-70.
373. Flegar B, Alatas S, Advani N, Firmansyah A, Vandenplas Y. Domperidone versus
cisapride in the treatment of infant regurgitation and increased acid gastro-oesophageal
reflux: a pilot study. Acta Paediatr 2009;98(4):750-5.
374. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of
domperidone in an infant. Pediatr Cardiol 2005;26(5):720-3.
375. Djeddi D, Kongolo G, Lefaix C, Mounard J, Leke A. Effect of domperidone on QT
interval in neonates. JPediatr 2008;153(5):663-6.
376. Gunlemez A, Babaoglu A, Arisoy AE, Turker G, Gokalp AS. Effect of domperidone on
the QTc interval in premature infants. JPerinatol', 30(l):50-3.
377. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology
1993; 105(6): 1886-99.
378. Ng PC, So KW, Fung KS, Lee CH, Fok TF, Wong E, et al. Randomised controlled
study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants.
Arch Dis Child Fetal Neonatal Ed 2001;84(3):F177-82.
379. Costalos C, Gounaris A, Varhalama E, Kokori F, Alexiou N, Kolovou E. Erythromycin
as a prokinetic agent in preterm infants. JPediatr GastroenterolNutr 2002;34(l):23-5.
380. Nuntnarumit P, Kiatchoosakun P, Tantiprapa W, Boonkasidecha S. Efficacy of oral
erythromycin for treatment of feeding intolerance in preterm infants. J Pediatr
2006;148(5):600-5.
381. Oei J, Lui K. A placebo-controlled trial of low-dose erythromycin to promote feed
tolerance in preterm infants. Acta Paediatr 2001;90(8):904-8.
382. ElHennawy AA, Sparks JW, Armentrout D, Huseby V, Berseth CL. Erythromycin fails
to improve feeding outcome in feeding-intolerant preterm infants. J Pediatr Gastroenterol
Nutr 2003;37(3):281-6.
261
383. Aly H, Abdel-Hady H, Khashaba M, El-Badry N. Erythromycin and feeding intolerance
in premature infants: a randomized trial. JPerinatol 2007;27(l):39-43.
384. SanFilippo A. Infantile hypertrophic pyloric stenosis related to ingestion of
erythromycine estolate: A report of five cases. JPediatr Surg 1976; 11(2): 177-80.
385. Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L, et al. Infantile
hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review
and cohort study. Lancet 1999;354(9196):2101-5.
386. Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and
other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J
Pediatr 2001; 139(3):380-4.
387. Bell EF. Preventing necrotizing enterocolitis: What works and how safe? Pediatrics
2005;115(1): 173-74.
388. Schanler RJ. Probiotics and necrotising enterocolitis in premature neonates. Arch Dis
ChildFetal Neonatal £J2006;91(6):F395-F97.
389. Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for
preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010;125(5):921-30.
390. Bin-Nun A, Bromiker, R., Wilschanski, M., Kaplan, M., Rudensky, B., Caplan, M.,
Hammerman, C. Oral probiotics prevent necrotizing enterocolitis in very low birth weight
neonates. JPediatr 2005;147(2):192-6.
391. Costalos C, Skouteri, V., Gounaris, A., Sevastiadou, S., Triandafilidou, A.,
Ekonomidou, C., Kontaxaki, F., Petrochilou, V. Enteral feeding of premature infants with
Saccharomyces boulardii. Early Hum Dev 2003;74(2):89-96.
392. Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF. Probiotics feeding in
prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm
infants. A prospective double-blind study. Biol Neonate 2002;82(2): 103-8.
393. Kitajima H, Sumida Y, Tanaka R, Yuki N, Takayama H, Fujimura M. Early
administration of Bifidobacterium breve to preterm neonates: randomised control trial. Arch
Dis Child Fetal Neonatal Ed 1997;76(2):F101-F07.
394. Lin HC, Su, B.H., Chen, A.C., Lin, T.W., Tsai, C.H., Yeh, T.F., Oh, W. Oral probiotics
reduce the incidence and severity of necrotizing enterocolitis in very low birth weight
infants. Pediatrics 2005; 115(1): 1-4.
395. Lin HC, Hsu CH, Chen HL, Chung MY, Hsu JF, Lien RI, et al. Oral probiotics prevent
necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized,
controlled trial. Pediatrics 2008;122(4):693-700.
262
396. Manzoni P, Mostert M, Leonessa ML, Priolo C, Farina D, Monetti C, et al. Oral
supplementation with Lactobacillus casei subspecies rhmnosus prevents enteric colonization
by Candid species in preterm neonates: a randomized study. Clin Infect Dis
2006;42( 12): 1735-42.
397. Mohan R, Koebnick C, Schildt J, Schmidt S, Mueller M, Possner M, et al. Effects of
Bifidobacterium lactis Bbl2 supplementation on intestinal microbiota of preterm infants: a
double-blind, placebo-controlled, randomized study. J Clin Microbiol 2006;44(11):4025-31.
398. Rouge C, Piloquet H, Butel MJ, Berger B, Rochat F, Ferraris L, et al. Oral
supplementation with probiotics in very-low-birth-weight preterm infants: a randomized,
double-blind, placebo-controlled trial. Am J Clin Nutr 2009;89(6): 1828-35.
399. Samanta M, Sarkar M, Ghosh P, Ghosh J, Sinha M, Chatterjee S. Prophylactic
probiotics for prevention of bnecrotizing enterocolitis in very low birth weight newborns. J
Trop Pediatr 2009;55(2): 128-31.
400. Stratiki Z, Costalos C, Sevastiadou S, Kastanidou O, Skouroliakou M, Giakoumatou A,
et al. The effect of a Bifidobacter supplemented bovine milk on intestinal permeability of
preterm infants. Early Human Dev 2007;83(9):575-79.
401. Garland SM, Jacobs SE, Tobin JM. A cautionary note on instituting probiotics into
routine clinical care for premature infants. Pediatrics 2010;126(3):e741.
402. Millar M, Wilks M, Fleming P, Costeloe K. Should the use of probiotics in the preterm
be routine? Arch Dis Child Fetal Neonatal Ed 2010.
403. Beattie LM, Hansen R, Barclay AR. Probiotics for preterm infants: Confounding
features warrant caution. Pediatrics 2010;125(3):e742-e43.
404. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine
therapy for apnea ofprematurity. NEngl JMed 2006;354(20):2112-21.
405. clinicaltrials.gov. Canadian Oxygen Trial (COT), 2010.
406. NPEU. BOOST-II UK: Benefits ofOxygen Saturation Targeting, 2010.
407. Patole S. Strategies for prevention of feed intolerance in preterm neonates: a systematic
review. JMatern Fetal Neonatal Med 2005;18(l):67-76.
408. Patole S, Rao S, Doherty D. Erythromycin as a prokinetic agent in preterm neonates: a
systematic review. Arch Dis ChildFetal Neonatal Ed 2005;90(4):F301-6.
409. de Silva A, Jones PW, Spencer SA. Does human milk reduce infection rates in preterm
infants? A systematic review. Arch Dis Child Fetal Neonatal Ed 2004;89(6):F509-13.
263
410. Putnam PE. Stop the PPI express: they don't keep babies quiet! J Pediatr
2009;154(4):475-6.
411. Swyer PR. The regional organisation of special care for the neonate. Pediatr Clin North
Am 1970; 17(4):761 -76.
412. CPS. Levels of neonatal care: Position statement (FN 2006-02). Paediatr Child Health
2006;11(5):303-06.
413. DH. Report of the review of neonatal intensive care services review group, 2003.
414. Churella HR, Bachhuber WL, MacLean WC, Jr. Survey: methods of feeding low-birth-
weight infants. Pediatrics 1985;76(2):243-9.
415. McClure RJ, Chatrath MK, Newell SJ. Changing trends in feeding policies for
ventilated preterm infants. Acta Paediatr 1996;85(9): 1123-5.
416. Holm PA. Early enteral feeding in the preterm infant: an exploration of differencies in
views and policies. Journal ofNeonatal Nursing 2004; 10(2):41-44.
417. Dodrill P, McMahon S, Donovan T, Cleghorn G. Current management of transitional
feeding issues in preterm neonates born in Queensland, Australia. Early Hum Dev
2008;84(10):637-43.
418. Bimbaum R, Limperopoulos C. Nonoral feeding practices for infants in the neonatal
intensive care unit. Adv Neonatal Care 2009;9(4): 180-4.
419. Flacking R, Ewald U, Starrin B. "I wanted to do a good job": experiences of'becoming
a mother' and breastfeeding in mothers of very preterm infants after discharge from a
neonatal unit. Soc Sci Me<72007;64(12):2405-16.
420. Sweet L. Birth of a very low birth weight preterm infant and the intention to breastfeed
'naturally'. Women Birth 2008;21(1): 13-20.
421. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in
medical journals. J Clin Epidemiol 1997;50( 10): 1129-36.
422. Cook JV, Dickinson HO, Eccles MP. Response rates in postal surveys of healthcare
professionals between 1996 and 2005: an observational study. BMC Health Serv Res
2009;9:160.
423. Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician
questionnaires. Health Serv Res 2001;35(6): 1347-55.
424. Edwards P, Roberts I, Clarke M, DiGuiseppi C, Pratap S, Wentz R, et al. Methods to
increase response rates to postal questionnaires. Cochrane Database Syst Rev
2007(2):MR000008.
264
425. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential
benefits, limitations, and harms of clinical guidelines. BMJ 1999;318(7182):527-30.
426. McClave SA. "Do you feel misguided by all these guidelines"? JPEN J Parenter
Enteral Nutr 2009;33(4):358-60.
427. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don't
physicians follow clinical practice guidelines? A framework for improvement. JAMA
1999;282( 15): 1458-65.
428. Atkinson LR, Escobar GJ, Takayama JI, Newman TB. Phototherapy use in jaundiced
newborns in a large managed care organization: do clinicians adhere to the guideline?
Pediatrics 2003;111(5 Pt l):e555-61.
429. Sand N, Silverstein M, Glascoe FP, Gupta VB, Tonniges TP, O'Connor KG.
Pediatricians' reported practices regarding developmental screening: do guidelines work? Do
they help? Pediatrics 2005; 116(1): 174-9.
430. Gartner LM, Morton J, Lawrence RA, Naylor AJ, O'Hare D, Schanler RJ, et al.
Breastfeeding and the use of human milk. Pediatrics 2005;115(2):496-506.
431. Lee T-Y, Lee T-T, Kuo S-C. The experiences of mothers in breastfeeding their very
low birth weight infants. Journal ofAdvancedNursing 2009;65(12):2523-31.
432. Spatz D. Ten steps for promoting and protecting breastfeeding for vulnerable infants.
Journal ofPerinatal andNeonatal Nursing 2004; 18:385-96.
433. Leaf A, Dorling J, Kempley S, McCormick K, Mannix P, Brocklehurst P. When should
feeds be started in the high-risk preterm infant? - The Abnormal Doppler Enteral
Prescription Trial (ADEPT). Pediatric Academic Societies Annual Meeting. Vancouver,
2010.
434. Hylander MA, Strobino DM, Dhanireddy R. Human milk feedings and infection among
very low birth weight infants. Pediatrics 1998;102(3):E38.
435. Bellu R, de Waal KA, Zanini R. Opioids for neonates receiving mechanical ventilation.
Cochrane Database Syst Rev 2008(1):CD004212.
436. Anand KJ, Hall RW, Desai N, Shephard B, Bergqvist LL, Young TE, et al. Effects of
morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN
randomised trial. Lancet 2004;363(9422): 1673-82.
437. Bueno L, Fioramonti J. Action of opiates on gastrointestinal function. Baillieres Clin
Gastroenterol 1988;2(1): 123-39.
265
438. Menon G, Boyle EM, Bergqvist LL, Mcintosh N, Barton BA, Anand KJ. Morphine
analgesia and gastrointestinal morbidity in preterm infants: secondary results from the
NEOPAIN trial. Arch Dis Child Fetal Neonatal Ed 2008;93(5):F362-7.
439. Aucott SW, Donohue PK, Northington FJ. Increased morbidity in severe early
intrauterine growth restriction. JPerinatol 2004;24(7):435-40.
440. Yu VY, Upadhyay A. Neonatal management of the growth-restricted infant. Semin
Fetal Neonatal Med 2004;9(5):403-9.
441. Kliegman R. Experimental validation of neonatal feeding practices. Pediatrics
1999; 103(2):492.
442. Jadcherla SR, Kliegman RM. Studies of feeding intolerance in very low birth weight
infants: definition and significance. Pediatrics 2002; 109(3):516-7.
443. Walther FJ, Verloove-Vanhorick SP, Brand R, Ruys JH. A prospective survey of
necrotising enterocolitis in very low birthweight infants. Paediatr Perinat Epidemiol
1989;3(1):53-61.
444. Llanos AR, Moss ME, Pinzon MC, Dye T, Sinkin RA, Kendig JW. Epidemiology of
neonatal necrotising enterocolitis: a population-based study. Paediatr Perinat Epidemiol
2002;16(4):342-9.
445. BOOST II: Benefits of oxygen saturation targeting.
266
APPENDICES
Appendix 1 List of abbreviations
Appendix 2 UK and North American Neonatal Feeding Survey
Clinician Questionnaire
Appendix 3 Retrospective review of medical records - Dataset






ADEPT Abnormal Doppler Enteral Prescription Trial
AEDF Absent end diastolic flow
ALP Alkaline phosphatase
ANNP Advanced neonatal nurse practitioner
BAPM British Association of Perinatal Medicine
BPD Bronchopulmonary dysplasia
BPSU British Paediatric Surveillance Unit
BSID Bayley Scales of Infant Development
CARD15 Caspase recruitment domain 15
COREC Central Office for Research Ethics Committees
CPS Carbamoyl phosphate synthetase
DEBM Donor expressed breast milk
DHA Docosahexanoic acid
EBM Expressed breast milk
EGF Epidermal growth factor
ELBW Extremely low birth weight
ET-1 Endothelin -1
GOR Gastro-oesophageal reflux
HIV Human immunodeficiency virus
HMF Human milk fortifier
ICD-9-CM International Classification of Diseases 9th revision,
Clinical Modification
IL Interleukin
IUGR Intrauterine growth restriction
LBW Low birth weight
LCPUFAs Long chain polyunsaturated fatty acids
MEBM Maternal expressed breast milk
MEN Minimal enteral nutrition
Mil Multichannel intraluminal impedance
MMC Migrating motor complexes
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MREC Multicentre Research Ethics Committee
NEC Necrotising enterocolitis
NICHD National Institute of Child Health and Development
NNU Neonatal unit
NO Nitric oxide
NOD 2 Nucleotide oligomerization domain 2
PAF Platelet activating factor
PAF-AH Platelet activating factor acetylhydrolase
PDA Patent ductus arteriosus
PN Parenteral nutrition
REDF Reversed end diastolic flow
RT Respiratory therapist
SIP Spontaneous intestinal perforation
SMA Superior mesenteric artery
SNP Single nucleotide polymorphism
TLRS Toll-like receptors
TNF a Tumour necrosis factor - alpha
UAC Umbilical arterial catheter
UVC Umbilical venous catheter
VLBW Very low birth weight
VON Vermont Oxford Network
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UKNEONATALF EDINGS RVEY-ClinicianQuestionn ire
Thankyouforagreeingtcompletet isquestionnaire.Ple sre dthefollowi gbri fn t scar fullybea swer gthques i n : (i)Allquestionsrefertoinfan sbornwithi thweig t1500glesand/ogestati alagf29compl tweeks(i .Utwe ks +6days)orless. (ii)Feeding/fe dsreferstoANYvolumegivenent rally,wh th raspartogutprimi gmin alent ralfe d ngr me/troph c feedingregimen,orasvolumesintendedpr vidnutrition. A.GeneralInformation Al.pproximatelyhowmanybabiesf<1500girthweightor29co plet dweeks'g tati narloo ed afterpeyeaonyourne nataluni ?
babies









Bl.Doesyourne natalu ithavewritt nguid linesthinitiatiofent ralfe ds?Y/N B3.Doesyourne natalu ithavespecificguid linesf rthinitiationeep rticulars bgro psfbabi s?Y/N
IfNo=>QuestionB5
B4.Forwhichparticularsubgroupsofbabiesdyh vespeci icproto olsfthinitiationfeeds?(Ples fy) B5.WhenbreastmilkisavailableAND,nyouropinio .,th res ecificcontra nd cationbeginn ge t lfe d ,w ndyo considertbehoptimalimef rintroducingen e le d ? (.Pleasecirclon fthefoll wing) (1)Day1(ie.ofdeliver ) (ii)Day2 (hi)Day3-4 (IV)Day5-7 (v)>7days B6.Ifamotherwis stexpresbr astilkndhbyiseadyt rtnteralfe d ,howlo gwouy u waitforbreasmilkefo est tinge dithan thertypfilk? 273
NextPage[
B7.Ifbreastmilkisnoav i able,whichtypeofiliniti llygi eninfant<1500gbi thw ightr29 completedweeksgestationony urn onataluni ? (Pleasecirclonefthefoll wing) (i)Termformula (ii)Pretermformula (iii)Hydrolysedproteinformula (iv)OtherPleasesp cify) B8.Whatistheusualtartingvolumeandfrequ ncyoen eralfe dsiy rneon t lu it? C.ProgressiontFullEnt raleeds CI.Doesvourne natalu ithavewritteng idelineothra finc ease teralfeeds?Y/N C2.Doesyourne natalu ithavespecificg idelineforthratfinc easfeepart cu arsubgro psfY/N babies?
IfNôQuestionD1
C3.




D.iscontinuationfFeedsb foreullEn erali gstablish d
Dl.
Doesyourneonatalu ithavewritt ncriterifthemporarydisc ntinu tionfentds?
Yes/No
D2.
Inyoure natalu it,whichmembe sofstaffostftenkedecisionsab uis onti uingfeeds? (Pleasecirclallth tpply) (a)Nurse (b)Middlegradedoctor (c)SHO (d)Consultant (e)ANNP
E.Factorsinfluencingfeedinpracti e
Pleaseansw rquestionsn mber dEl,2nd3oth xt2p gebyicki gox sfALLrtpply. Pleaseconsid rwheththpresencefchfa torsINSOLATIONuldinflu ncyo rc i e.
NextPage[
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El.Whichoft efactorslistedbel w leadyoutDELAYSTARTING enteralfe ds?
(1)Historyofabsentenddia tolicfl w (2)Historyofreversednddiastolicfl w (3)Evidenceofperi atalasphyxia (4)PresenceofUVC (5)PresenceofUAC (6)PositionfUAC (7)Hypotension (8)Suspectedsystemicpsis (9)Sedation (10)NasalCPAP (11)Respiratorydiseasenotventilated) (12)Acidosisspecifylevel) (13)Pharmacologicalp ralysis (14)Failuretopassmeconium (15)Polycythemia
E2.Whichoft efactorsbel wl ady u
toSLOWTHERATOFINCREASE offeeds?
(1)Historyofabsentenddia tolicfl w (2)Historyofreversednddia tolicfl w (3)Evidenceofperi atalasphyxia (4)PresenceofUVC (5)PresenceofUAC (6)PositionfUAC (7)Hypotension (8)Suspectedsystemicpsis (9)Sedation (10)NasalCPAP (11)Respiratorydiseasenoventila ed) (12)Acidosisspecifylevel (13)Pharmacologicalparalysis (14)Failuretopassmeconium (15)Polycythemia
E3.Whichoft efactorslistedbel w leadyoutDISCONTINUEenteral feeds?




(17)Mechanicalventilation (18)IncreasingFiC>2 (19)Treatmentwithindomethacin (20)Useofinotropes (21)Mildabdominaldistension (22)Severeabdominaldistension (23)Bloodysto ls (24)Abdominaltenderness (25)Largeaspiratesspecifyvolume) (26)Biliousaspirates (27)Vomiting (28)Recentextubation{sp cifytime) (29)Bloodtransfusion (30)Otherpleasesp cify)
(17)Mechanicalventilation (18)IncreasingFi02 (19)Treatmentwithindomethacin (20)Useofinotropes (21)Mildabdominaldistension (22)Severeabdominaldistension (23)Bloodysto ls (24)Abdominaltenderness (25)Largeaspiratesspecifyvolume) (26)Biliousaspirates (27)Vomiting (28)Recentextubation{sp cifytime) (29)Bloodtransfusion (30)Otherpleasesp cify)




NORTHAME ICANEONATALF DINGSU VEY-ClinicianQuestionn ire
Thankyouforagreeingtcompletehisquest onnaire.Plear adfoll wbri fn t sc r ullyef rnsw ringque ion : (i)Allquestionsrefertoinfantsbornwi hirtig tf1500grle d/ges ationalge29c mpletede k( .U +6days)orless. (ii)Feeding/fee sr ferstoANYv lumegivent ally,wh th rapa tfr ingmini allf r g meroph c feedingregimen,orasvolu esint ndedprov dnutr t on. C.GeneralInformation Al.pproximatelyhowmanybabiesf<1500girthwe ghr29c mpletedeeks'gest tionarlo k d afterpeyeaonoune atalunit?
babies
A2.Isparenteralnutri ionavailablefobab syoure nat lunit?
Yes/No
A3.Isdonor(thirdparty)bre stmilkav ilablef youne na alunit?
Yes/No






Doesvourne natalu ithavewritt nguid linesthinitiatiofent ralfe s?Y/N
B3.
Doesyourne natalu ithavespecificguid linesf rthinitiationeep rtic lars bgroupsfY s/N babies?IfNôQuestionB5
B4.
Forwhichparticularsubgroupsfbab esdyoh vepe ificro ocolfothiniti t needs?(Plea fy)
B5.
Whenbreastmilkisav ilableAND,nvouropinion,thereoec ficcontra ndicatiobegin i ge t lfe dwhdy considertbeheoptimalimef rintr ducingen e le ? (Pleasecirclon fthefol wing) (i)Day1ie.ofdelivery) (vi)Day2 (vii)Day3-4 (viii)Day5-7 (ix)>7days
B6.
Ifamotherwish stexpresbr astilkndhbyisreadyt rnteralfe d ,howlo gwouly u waitforbre smilkefo esta tinge dsithanoth rtypfilk? 279
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or<29completedweeksgestationnyourn ataluni ? (Pleasecirclon fthefoll wing)
jg—
(v)Termformula (vi)Thirdpartydonorbre stmilk (vii)Pretermformula (viii)Hydrolysedproteinformula (ix)OtherPleasesp cify)




Doesyourne natalu ithavewritt nguidelinesthra finc eaen er lfe s?Y/N
C2.
Doesyourne natalu ithavesp cificguidelinesf rthratinc eae dparti ul rs bgroupsY/N babies?
IfNoQuestionD1
C3.
Forwhichparticularsubgroupsfbab esdyohavepe ificrotocolfthr tincreaseeeds?(Pleasp cify) 280
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Dl.
Doesyourne natalu ithavewritt ncriterifthempo rydisc nt nu tionfen lds?
Yes/No
D2.
Inyourne natalu it,whichmembe sofsta fostftenkdecisionsab uis onti uingfeeds? (Pleasecirclallth tpply) (f)Nurse-RN (g)NeonatalDietician-Nutritionist (h)Fellow (i)Res dent (j)AttendingNeonatologist (k)NeonatalursePractition r
E.Factorsinfluencingfeedinpracti e
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jeli. wnicn 01mrnctors nsteo oeroleadyoutDELAYSTARTING enteralfe ds?
jez. wmen oi factors orrcrw feaoyoutSLOWTHERATOF INCREASEoffeeds?






























































































• Study ID number




• Gestation at birth
• Birth Weight
• 5 minute Apgar score
• Age at hospital discharge
Other early / antenatal issues:
• Prolonged rupture of membranes
• Congenital abnormality
• Antenatal steroids
• Timing of first dose of surfactant
• Absent / reversed / reduced end diastolic flow
• Asphyxia
• Intrauterine growth restriction
• Polycythaemia (Hct > 0.7)
• CRIB score (severity of illness)
Overview feeding data:
• Day of first enteral feed
• Volume of first enteral feed
• Type ofmilk started
• Feeding method (bolus / continuous)
• Day of starting parenteral nutrition
• Day attaining full enteral feeds (150ml/kg/day)
Lines / infection:
• Umbilical arterial catheter (UAC) - insertion and removal
• Umbilical venous catheter (UVC) - insertion and removal
• Percutaneous intravenous central catheter (P1CC) - insertion and removal
• Total days on antibiotics
Outcomes:
• Day of diagnosis of necrotising enterocolitis (NEC)
• Bell stage NEC
• Weight at discharge
• Number of days antibiotic treatment for suspected / proven NEC




Associated illness / severity:
• Hypotension
• Inotropes
• Respiratory support (ventilation / CPAP)
• Increasing oxygen requirement




• Patent ductus arteriosus
Feeding data:
• Volume of enteral feed (ml/day)
• Volume of enteral feed (ml/kg/day)
• Feed interval
• Availability of expressed breast milk
• Type ofmilk
• Route of feeding
• Use of human milk fortifier
• Use of feed thickener
• Use of Gaviscon
• PN / route of administration of PN
Gut related outcomes:
• Passage of stool
• Use of glycerin suppositories
• Abdominal distension (mild / severe)
• Bloody stool
• Abdominal tenderness
• Abdominal x ray findings
• Presence of Intramural gas on x ray
• Bowel perforation
• Gastric residuals (bilious/ large)
• Feed discontinuation (no. hours)
Drugs:
• Indomethacin / ibuprofen
• Caffeine





• Presence of UVC
• Presence / position of UAC
• Presence ofPICC
• Blood culture and result
• CSF culture and result
• Antibiotics given (with or without Metronidazole)
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LETTERS OF APPROACH TO CLINICIANS
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UK NEONATAL FEEDING SURVEY
Neonatal Unit
Simpson Centre for Reproductive Health





Name and address of
Consultant Neonatologist will be inserted here
Dear Dr
I am conducting a UK wide survey of feeding practice in preterm and very low birth weight
infants. The Multicentre Research Ethics Committee has approved this proposal. The
results from the survey will form the basis ofmy PhD thesis.
This survey will consist of two parts:
1. A questionnaire to consultant neonatologists aiming to document current opinion
and intentions with respect to enteral feeding.
2. A retrospective review ofmedical records in selected neonatal units to document
current feeding practice throughout the United Kingdom.
I invite you to take part by completing the attached questionnaire, which I expect to take
approximately 10-15 minutes of your time. I enclose an information sheet outlining the
background to the study.
Please return the completed questionnaire to me in the stamped addressed envelope
provided.
I may contact your hospital unit again with a view to arranging a convenient time to
conduct a retrospective review ofmedical records. Information about this part of the study
will be sent separately.
Thank you very much for your help. I hope that a high response rate will allow me to
generate high quality observational data that will inform the design ofmuch-needed
interventional trials to identify optimum strategies for feeding of vulnerable infants.
Yours sincerely,
Elaine M Boyle MBChB, MD, MSc
Specialist Registrar in Academic Neonatology
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UK NEONATAL FEEDING SURVEY
Neonatal Unit
Simpson Centre for Reproductive Health





Name and address ofconsultant
neonatologist will be inserted here
Dear
We would like to conduct a survey of feeding practice your neonatal unit, as part of a UK
wide survey of feeding in very preterm and low birth weight babies. This will take the form
of a retrospective review of medical and nursing records.
Background
It seems, from the published literature and from personal experience, that there is a huge
variation in practice in the enteral feeding of very preterm and small infants. A recent small
pilot survey of practice in Scotland confirms this and the results have been presented at
national and international meetings. Current practice encompasses major differences in the
introduction and rate of increase of feeds, the type of feeds given and the time taken to
reach full enteral feeds. Serious but conflicting clinical risks accompany the extremes of
practice in this area. With fast feed introduction, potential risks are poor gut tolerance of
feeds with gastric distension, gastro-oesophageal reflux and aspiration and necrotizing
enterocolitis. Conversely, with slow introduction of feeds, risks include regression of gut
architecture and integrity, line and gut related sepsis.
Research to date has failed to define the safest and most effective strategies for infant
feeding. There is a need for a large randomised controlled trial to answer this question.
Before embarking upon such a study, it is essential to document the range of clinical
opinion and current practice in order to establish the degree of clinical uncertainty in this
area and to determine what strategies would be acceptable to clinicians taking part in an
intervention trial.
The Survey
A review of medical records will be carried out to document current feeding practice in
infants with birth weight <1500g or <30 weeks gestation admitted to UK neonatal units
within a 6 month period.
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To maintain confidentiality, all data will be anonymised. Centres and infants will be
identifiable only by study number. No comparisons will be made between particular
centres. The Multicentre Research Ethics Committee has approved the proposal. Since
there will be no local researchers, there will be no requirement for approval from each
individual Local Research Ethics Committee though they will be informed about the
research. Permission will be sought from the Research and Development Department of
your hospital. I enclose a copy of the letter we would send to the trust, with your approval.
Appropriate people to be contacted might be the Caldicott Guardian to discuss issues of
confidentiality and the Human Resources Department to facilitate arrangements for an
outside researcher.
1 plan to visit each neonatal unit myself to perform the case note reviews. The development
of this survey and results will form the basis ofmy thesis for the degree of PhD.
I hope that you will agree that this is an important area of research and consider your unit
taking part. If you consent to your unit taking part in the survey, I will make arrangements
to visit at a mutually convenient time.
I would be grateful if you would return the enclosed form to me or preferably contact me
by phone or email, indicating whether you are willing for your unit to be included in the
survey and suggesting possible contact names at your hospital.
Thank you for your interest,
Yours sincerely,
Elaine M Boyle MBChB, MD, MSc
Specialist Registrar in Academic Neonatology
Direct line: 0131 242 2578
Mobile: 07989 595220
email: elaine.boyle@luht.scot.nhs.uk
290
